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DNA vaccination is a novel means of expressing antigens in vivo for the generation of humoral
and cell-mediated immune responses. DNA vaccines elicit protective immunity in mice; however,
DNA vaccination in outbred species requires optimisation. Dendritic cells (DC) are unique in that
they are the only cells capable of stimulating naive T cells, the major requirement of successful
vaccination. Lack of efficacy of DNA vaccines may be due to inefficient targeting of DC. One
strategy to improve DNA vaccines is to use cytokine gene adjuvants to recruit DC, such as GM-
CSF and IL-3.
The aim of the work carried out in this thesis was to investigate the effects of GM-CSF and IL-3
after gene-gun vaccination. Initial studies focused on the histological effects of GM-CSF and IL-3
in ovine skin. GM-CSF induced a linear increase in IL-lp transcripts from 1-24 hours concomitant
with pronounced neutrophilic infiltration and micro-abscess formation by 24 hours. Maximal GM-
CSF and IL-3 mRNA expression was evident at approximately 4 hours, whereas IL-ip and TNF-a
transcripts remained highly elevated up to 96 hours. Infiltration of DC, coordinately with a rise in
MHC class II DRa expression in perivascular regions, was observed 72-96 hours after GM-CSF
administration. Recruitment of eosinophils and neutrophils was evident 24-48 hours after
administration of IL-3, whereas infiltates of B cells and DC were observed at 24 and 72 hours,
respectively.
Subsequent work characterised DC draining skin before and after GM-CSF administration by
means of cannulation of the pseudoafferent lymphatics. Two sub-populations of afferent lymph
DC (ALDC) were isolated based on differential expression of SIRPa as described in both cattle
and rats. Ovine SIRPa+ ALDC constitutively express high levels of IL-ip, IL-18 and IL-10
mRNA. Conversely, SIRPa ALDC do not express IL-10 but express high levels of IL-12p40.
SIRPa+ ALDC may contain Langerhans' cells since both ATPase and langerin were detected. Both
subpopulations express Toll like receptor 3 (TLR3) and TLR9, whereas SIRPa" ALDC uniquely
express TLR4 (+/- CD14). Gene-gun vaccination with pGM-CSF resulted in increased cytokine
transcripts in both ALDC subpopulations and an upregulation of surface MHC class Ila, CD lb,
CD40, CD86 and CD 11c. These studies have extended the knowledge of GM-CSF and IL-3 as
adjuvants and highlight the use of the cannulation model to further decipher the immune
mechanisms of adjuvants. This work has demonstrated that GM-CSF not only recruits DC into
skin but also activates DC, possibly as a result of increased expression of "danger signals"
including IL-1|3 and TNF-a.
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1.1.1 A brief history of DNA vaccines
Vaccination is undoubtedly one of the major triumphs of medicine and is the most
commonly employed immunological intervention. Current effective vaccines protect hosts
primarily via neutralising antibodies. There are however many infections for which there are
no effective vaccines and which continue to challenge immunologists. Vaccines that do not
work satisfactorily and do not induce long-term protection include vaccinations against most
parasitic infections, tuberculosis (TB), leprosy and a plethora of viruses including human
immunodeficiency virus (HIV), dengue, herpes and papilloma viruses. These infections have
in common that neutralising antibodies alone are not sufficient to eliminate or control the
infection (reviewed in Zinkernagel, 2003). Efficient control of these infectious agents
requires T cell-mediated effector mechanisms in addition to protective antibodies, since
these infections are essentially inaccessible to antibodies once intracellular infection is
established. In addition, many of these infections persist in tissues where antibodies cannot
permeate, for instance in epithelial tissue (papilloma virus) or in granulomas (Mycobacteria).
DNA vaccination was first proposed in a report by Wolff and colleagues in 1990, which
demonstrated that purified plasmid DNA was stably expressed following intramuscular
injection in mice (Wolff et al., 1990). Tang and colleagues (Tang et al., 1992) subsequently
demonstrated that expression ofplasmid DNA induced a humoral immune response that was
specific for the encoded antigen. Two independent reports generated much excitement in the
vaccine field in 1993; mice were protected from a lethal challenge of influenza A virus
following intramuscular vaccination with plasmids encoding either haemaglutinin (Fynan et
al., 1993) or nucleoprotein (Ulmer et al., 1993). Ofparamount interest was the demonstration
of an induction of nucleoprotein-specific cytotoxic CD8+ T cells (CTL), which conferred
protection from a heterologous strain of influenza virus.
DNA vaccines have since been demonstrated to be an effective means of inducing protective
cell-mediated immune responses and humoral immune responses in many animal models of
infectious disease (Table 1.1) and some neoplasms (reviewed in Gurunathan et al., 2000).
Substantial interest into DNA vaccines has been generated and research has rapidly
progressed from the laboratories to clinical trials for several human diseases, ranging from
HIV (Mwau et al., 2004), Human Papilloma Virus (HPV) (Klencke et al., 2002) and malaria
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(Wang et al., 1998; Wang et al., 2001), to prostate (Mincheff et al., 2000) and colorectal
cancer (Conry et al., 2002).
1.1.2 Principles of DNA vaccination
DNA vaccines are composed of backbone plasmid DNA into which a gene encoding a
protective antigen is inserted. Expression of the gene is under the control of a viral
eukaryotic promoter (usually the immediate early gene of cytomegalovirus (CMV)),
followed by an mRNA termination/polyadenylation sequence, thus enabling expression of
the gene in mammalian cells. In addition, the plasmid contains an antibiotic resistance gene
to aid in vitro manipulation and selection. Since the first few publications, a range of
methods have been employed to deliver plasmids (reviewed in Donnelly et al., 2003);
however, plasmid DNA is traditionally injected either intramuscularly or intradermally.
Alternatively, plasmid DNA is coated onto microscopic gold particles and bombarded into
tissue using a gene-gun pressurised with helium or C02 resulting in efficient transfection of
host cells (Williams et al., 1991). This method proved to be by far the most efficient method
of DNA immunisation in one study, where administration of only 0.4pg of DNA vaccine in
mice resulted in 95% survival after challenge with a lethal dose of influenza virus (Fynan et
al, 1993). It is of interest to note that the route of administration of DNA vaccines strongly
influences the T helper 1 (Thl)-type or Th2-type immunity and is discussed in more detail in
Section 1.2.4.
Regardless of the method employed to administer the plasmid DNA, transfection of cells
ensues and the cell machinery then performs DNA transcription, translation of mRNA and
production of the immunogenic polypeptide, which may then be processed via the
transporters associated with antigen processing (TAP)-dependent, endogenous-processing
pathway (major histocompatibility complex (MHC) class I presentation pathway), resulting
in the presentation of MHC class I-peptide complexes on the cell surface, thereby enabling
recognition by antigen-specific MHC class I-restricted CTL (Section 1.2). This essentially
mimics the presentation of antigens during a natural intracellular infection. Alternatively,
soluble or secreted antigen may be phagocytosed by antigen presenting cells (APC) and gain
entry into the MHC class II exogenous pathway, thus enabling the induction of humoral
immunity, where antigen-specific CD4+ T helper (Th) cells promote immunoglobulin (Ig)
secretion by primed B cells. Importantly, plasmid DNA encoding immunogenic antigens also
results in the production of proteins with native post-translational modifications and
conformation. Release of intact polypeptides by transfected cells into the extracellular milieu
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may result in the production of immunologically relevant neutralising antibodies, since the Ig
receptor of B cells directly recognises complex folded proteins.
1.1.3 Advantages of DNA vaccines
A major drawback of most current vaccine formulations is the apparent failure in the
generation ofCD8+ T cell responses. Current vaccine formulations, including protein subunit
and heat-killed vaccines, generate neutralising antibodies through adaptive humoral
responses. Live, attenuated vaccines can induce robust cellular immune responses, but there
is concern over the reversion to virulence or indeed causing disease in immunocompromised
individuals. Genetic immunisation with DNA represents a novel vaccination strategy that
overcomes several limitations imposed by conventional vaccines. Expression of plasmid
DNA by the host cell machinery essentially mimics an intracellular infection and strong cell
mediated immune responses (interferon (IFN)-y-secreting T cells) are indeed well
documented for a number of infectious agents in mice (Table 1.1). Importantly, DNA
vaccines are also capable of inducing strong humoral immunity (IgG-secreting B cells). A
recent report which involved intramuscular vaccination ofmice with a plasmid encoding the
spike glycoprotein of the severe acute respiratory syndrome (SARS) coronavirus illustrates
this well (Yang et al., 2004). A spectrum of immune responses were elicited after DNA
vaccination, including an expansion of virus-specific CD4+ and CD8+ T cells and antibody;
however, donor immune T cells were unable to reduce pulmonary viral replication in
recipient animals, whereas passive transfer of purified IgG from immunised mice provided
immune protection comparable to that observed in DNA vaccinated animals. The
mechanisms by which DNA vaccines induce immunity are described in detail in Section 1.2.
An added advantage of DNA vaccines is their intrinsic immunostimulatory capacity, owing
to the presence of unmethylated cytidine-phosphate-guanosine (CpG) dinucleotides (Sato et
al., 1996), a feature of prokaryotic DNA. CpG motifs can directly stimulate leukocytes to
produce pro-inflammatory cytokines such as interleukin (IL)-6, IL-12 and IFN-y (Hartmann
et al., 1999; Klinman et al., 1996) via interaction with toll like receptor (TLR) 9 (TLR9)
(Hemmi et al., 2000) (Section 1.4.4.2). CpG motifs could therefore be considered to be a
built-in adjuvant, alerting the immune system to the presence of a potential pathogen.
Genetic immunisation exhibits several other advantages over traditional vaccines. For
instance, DNA vaccination is highly versatile; current molecular biology techniques enable
easy manipulation of plasmid vectors to include virtually any gene or indeed several genes
(termed bicistronic plasmids) under the control of the same or different promoters. In
addition, DNA is relatively cheap to manufacture and can be produced at large scale in
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bacteria. Furthermore, DNA is stable and resists extreme temperatures and could potentially
be lyophilised prior to being distributed. This is of great significance since it would impact
the requirement of cold chain storage and would thus facilitate storage, transport and
distribution of vaccines in third world countries, where cold chain storage can be
problematic.
Table 1.1 DNA vaccines induce protective immunity for a number of intracellular infectious
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1.2 Mechanisms of immunity following DNA vaccination
1.2.1 Role of tissue resident somatic cells
The mechanisms underlying DNA vaccination are complex and are yet to be fully
elucidated. The introduced plasmid and encoded antigen(s) have been detected
predominantly in resident keratinocytes and occasionally in fibroblasts after intradermal
vaccination (Eisenbraun et al., 1993; Hengge et al., 1996; Raz et al., 1994; Williams et al,
1991) and in myocytes after intramuscular injection (Wolff et al, 1990; 1992b). Tissue-
resident (somatic) cells take up naked DNA by an unidentified mechanism and this is
followed by expression of the antigen encoded within the DNA plasmid vector. Monolayers
of keratinocytes do not however take up naked DNA (Hengge et al, 1996), suggesting that
these cells must be in an organised epidermis for DNA uptake to occur. The process of how
naked uncomplexed DNA is internalised by cells is. intriguing and still not understood.
Uptake ofDNA may involve either potocytosis by caveolae (Wolff et al., 1992a), or even the
formation of semi-permanent membrane vesicles for uptake of extracellular molecules via a
nonendocytic pathway (Dowty et al., 1995).
1.2.2 Role of bone-marrow derived APC
Although plasmid DNA immunisation provides an effective means of inducing CTL
responses to an expressed antigen, the mechanism by which CTL precursors are activated
was something of a mystery. Since resident somatic cells are the principal cell type
transfected after intramuscular (myocytes) and intradermal (keratinocytes and fibroblasts)
DNA vaccination, it is not surprising that strong CTL responses were initially believed to be
induced by these cells. Somatic cells are however deemed unlikely to be directly responsible
for the induction of immunity following DNA vaccination. Although fibroblasts (Pober et
al., 1984) and myocytes (Karpati et al., 1988; Stan et al., 2001) are known to be facultative
APC due to inducible expression ofMHC class II, they are incapable of stimulating naive T
cells due to the lack of expression of costimulatory molecules (CD40, CD80 and CD86).
Stimulation of naive T cells requires that they receive (at least) 2 signals; signal 1 is
delivered via the T cell receptor by peptides presented on MHC molecules, whereas signal 2
is delivered by costimulatory molecules to the CD28 receptor on the T cell. Resident
somatic cells do not therefore account for the potent T cell responses generated by DNA
vaccination.
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Substantial evidence has accumulated to suggest that professional bone marrow-derived
APC play a pivotal role in the induction of immunity following DNA vaccination. Evidence
to support the role of APC has been demonstrated in transplantation studies involving bone
marrow chimeric mice, where mice are lethally irradiated and reconstituted with the bone
marrow of an MHC disparate donor. These studies have shown that the induction of a CTL
response is restricted to the MHC haplotype of the bone marrow-derived APC and not
restricted to the haplotype of transfected somatic cells, after both intramuscular (Corr et al.,
1996; Doe et al., 1996; Ulmer et al., 1996) and gene-gun administration of plasmid DNA
(Iwasaki et al., 1997).
The evidence that bone marrow-derived APC are indeed responsible for the induction of
immunity after DNA vaccination, rather than resident somatic cells, encouraged researchers
to look more closely into the role of a family of potent APC known as dendritic cells (DC).
DC are unique in that they are the only APC capable of stimulating nai've T cells (Steinman,
1991), which is the major requirement of successful primary vaccination. DC are
strategically positioned at all major portals of entry, notably forming networks underlying
major body surfaces such as the skin, trachea and intestine (Table 1.2). A key feature of the
lifecycle of DC is their ability to acquire antigens in peripheral tissues (as immature DC) and
traffic from their tissue of residence, through afferent lymphatic vessels into lymphoid
organs where they present processed peptides to recirculating T cells, clearly distinguishing
DC from tissue resident somatic cells (reviewed in Banchereau and Steinman, 1998). DC are
highly equipped to stimulate nai've T cells due to a high density of antigen presentation
molecules (10-100 fold greater expression ofMHC class I and class molecules than on other
APC), costimulatory molecules (CD40, CD80, CD83, CD86) and accessory molecules
(ICAM-1, ICAM-3 and LFA-3); experimentally only one DC is required to stimulate 100-
3000 T cells (Stockwin et al., 2000). DC can therefore be regarded as sentinels of the
immune system, poised ready for potential invading pathogens in the periphery and
conveying information with cells of the adaptive immune system.
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Table 1.2 Examples of DC in vivo. DC represent a trace population of cells in all tissues.
Follicular DC are distinct from the other DC subsets listed, these cells are involved in the
retention of immune complexes and have a unique role in the stimulation of B cells and
maintenance of B cell memory.
DC subset location
Langerhans' cell epidermis, mucosal lining of trachea
interstitial DC dermis, heart, lungs, liver and other
organs
veiled DC afferent lymph
interdigitating DC T cell-rich areas of lymphoid tissue
thymic DC thymus
follicular DC follicles of lymph nodes and spleen
1.2.3 Role of dendritic cells following DNA vaccination
1.2.3.1 DNA vaccination targets dendritic cells
Delivery of DNA via intradermal injection and via the gene-gun targets the skin, a highly
immunocompetent site, which harbours two populations of immature DC. One population
consists of numerous and readily accessible Langerhans' cells (LC) which are scattered in
the outermost layers (epidermis) of skin with densities of -1000 cells/mm2 in mice
(Bergstresser et al., 1980). A second population of DC is the dermal DC population (a type
of interstitial DC), which are quite distinct from LC (reviewed in Lappin et ah, 1996). Unlike
interstitial DC, LC are completely absent in muscle. Surgical ablation experiments suggest
that there may be a different contribution of local tissue antigen expression, depending on
how DNA vaccines are administered Excision of an injected muscle bundle within minutes
of DNA inoculation did not affect the magnitude or longevity of the humoral and CTL
responses, possibly due to injected plasmid entering the lymphatic or circulatory systems. By
contrast, excision of the epidermal site of the skin up to 24 hours after gene gun
bombardment completely abrogated the antibody response in the majority of mice (Torres et
ah, 1997). Klinman and colleagues also demonstrated complete abrogation of an immune
response in mice whose injection site (skin) was removed immediately after gene-gun
immunisation (Klinman et ah, 1998); however, low level primary IgG responses were
induced if the skin was left in place for 5 hours. Interestingly, IFN-y production in spleen
cells was observed in naive littermates grafted with transfected skin within 5 hours of
vaccination, suggesting that primary immunity is induced by transfected migratory skin cells.
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1.2.3.2 Dendritic cells generate immunity following DNA vaccination
Several groups have successfully demonstrated that DC induce immunity in mice after DNA
vaccination. For instance, Bot and co-workers (Bot et al., 2000) removed skin from the ears
of mice after intradermal vaccination with a plasmid encoding nucleoprotein of influenza
virus (containing a dominant murine class I/Kd restricted epitope) and then employed a skin
explant culture system to isolate migratory MHC class II+ DC. Importantly, adoptive transfer
of migratory MHC class II+ epidermal DC into nai've animals induced remarkably potent
priming of virus-specific CTL. Further convincing evidence that DC are pivotal in the
induction of immunity after DNA vaccination came from experiments where lymph node
DC from DNA vaccinated mice were adoptively transferred into syngeneic nai've mice and
induced strong CTL activity (Bouloc et al., 1999). Porgador and colleagues elegantly
demonstrated the role of DC in the induction of CTL responses following gene-gun
bombardment (Porgador et al., 1998). This involved delivery of gold beads coated with a P-
galactosidase (P-gal) encoding plasmid, followed by the isolation of different lymph node
cell populations and incubation with CD8+ T cells specific for a P-gal-derived determinant
presented by Kb. DC expressing the DNA-encoded antigen were rare, yet depletion of DEC-
205+ DC eliminated up to 70% of the presentation activity, whereas depletion of
macrophages and B cells had no effect. Although DC were well demonstrated to induce
immunity after DNA vaccination, the mechanism(s) by which DC come into contact with the
plasmid/encoded antigen remained unanswered. For instance, were directly transfected DC
responsible for the induction of immunity after vaccination, or were T cells primed with DC
which had taken up antigen released from transfected somatic cells?
1.2.3.3 Transfected DC induce immunity after DNA vaccination
There is convincing evidence that resident DC are directly transfected by plasmid DNA after
vaccination. Plasmid DNA has been detected in DC isolated from lymph node and skin after
intramuscular and intradermal vaccination (Casares et al., 1997). Fluorescently-labelled,
skin-derived DC have not only been found to contain gold beads in the draining lymph node
(DLN), but also to express green fluorescent protein (GFP), after gene-gun administration of
plasmid encoding GFP (Condon et al., 1996). Furthermore, antigen-specific mRNA has been
detected in migratory LC after gene-gun vaccination of human skin organ cultures; LC were
then demonstrated to efficiently present a peptide derived from the melanoma antigen
(MART-1) to MART-1-specific CTL (Larregina et al., 2001b). Priming of CD4+ T cells by
directly transfected DC has also been demonstrated in vivo (Akbari et al., 1999). Moreover,
as few as 500 in vitro transfected DC are capable of inducing both strong humoral and cell-
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mediated immune responses in vivo (Timares et al., 1998), suggesting that direct transfection
of DC is largely responsible for the generation of immunity after DNA vaccination.
1.2.3.4 Dendritic cells gain access to antigen from non-bone-marrow derived
cells (cross-priming)
Although it has been demonstrated that a small number of DC are directly transfected
following DNA vaccination, an alternative mechanism whereby DC gain access to antigen is
by uptake of secreted protein synthesised by transfected skin or muscle cells. DC have
indeed been shown to acquire antigen from transfected myoblasts and cross-present this
antigen to antigen-specific CD4+ T cells (Casares et al, 1997). In addition, DC have a unique
ability to channel exogenous antigen into the MHC class I presentation pathway. This
property is termed "cross-priming" and enables DC to present exogenous antigen on both
MHC class II and class I molecules (Brossart and Bevan, 1997; Shen et al., 1997). Two
routes for the exogenous MHC class I pathway have been described, a TAP-independent
pathway in which Ag is hydrolysed in endosomes, and a phagosome-to-cytosol pathway, that
is TAP dependent (reviewed in Banchereau et al., 2000). Cross-priming may occur by direct
transfer ofMHC class I-associated peptide on the surface of transfected somatic cells to DC,
or secreted antigen may be taken up by DC by micropinocytosis. Alternatively, chaperone:
peptide complexes may be taken up by a receptor-mediated mechanism (Kumaraguru et al.,
2000), or DC may acquire antigen by phagocytosis of apoptotic cells via av(35 and CD36 and
cross present the antigen to CD8+ T cells (Albert et al., 1998). Transfected somatic cells
could therefore be regarded as antigen-producing "factories", secreting antigen into the
extracellular milieu or releasing the antigen upon dying. And importantly, DC are well
equipped to stimulate both CD4+ and CD8+ T cells, which is imperative since CTL responses
to both intramuscular and intradermal DNA vaccination are highly dependent upon the
generation of CD4+ T cell help via a class II MHC-dependent pathway (Maeckcr et al.,
1998).
The unique ability of DC to channel exogenous antigen into the MHC-I presentation
pathway explains how transplantation of stably transfected myoblasts into chimeric mice
induces a protective antibody and CTL response that is restricted to the haplotype of the
recipient mice bone marrow cells (Ulmer et al, 1996). However, cross-priming was not
found to make a substantial contribution to CD8+ T cell priming in Porgador's study
(Porgador et al, 1998), where instead a predominant role of directly transfected DC in
antigen presentation to CD8+ T cells was highlighted, since removal of directly transfected
lymph node DC from mice reduced presentation by 60-70% 24 hours after gene-gun
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bombardment with a plasmid-encoding human CD4 and P-gal. The relative contribution of
secreted and non-secreted antigen in the induction of T cell priming after DNA vaccination
has been investigated by Rush and colleagues (Rush et al., 2002), where fluorescently
labelled ovalbumin (OVA)-specific TCR transgenic T cells were adoptively transferred into
mice, followed by vaccination with DNA vectors encoding cell-associated or soluble
secreted OVA. DNA vectors encoding cell-associated OVA resulted in greater CD8+ T cell
division, whereas vectors encoding soluble secreted OVA (targeted to the classical secretory
pathway) enhanced division of CD4+ T cells and to a lesser extent, CD8+ T cells, suggesting
that although secreted antigen can access the MHC class I-processing pathway (by cross-
priming), it is less efficiently presented to CD8+ T cells than cell-associated forms.
Plasmid DNA is rapidly disseminated throughout the body via blood (Nichols et al., 1995)
and lymph (Mena et al., 2001; Watkins et al., 1999), and can even reach remote areas such as
lymph nodes (Akbari et al, 1999) where plasmid DNA could be taken up and expressed by
resident lymph node DC. It is also possible that migratory DC internalise plasmid DNA
during transit. Collection of lymph following intradermal vaccination with a construct
encoding GFP revealed that plasmid DNA was present in lymph fluid within one hour of
injection (Watkins et al, 1999) and approximately 1% of afferent lymph DC (ALDC)
contained GFP protein, with fluorescence peaking 2^4 hours after-vaccination; however,
PCR analysis of the afferent lymph cell (ALC) pellets failed to demonstrate the presence of
the GFP plasmid. Alternatively, DC migrating from the periphery could transfer their
captured antigens to other DC in the lymph node for presentation to T cells. Such transfer
could occur by phagocytosis of the antigen-loaded DC (Inaba et al., 1998) or by the release
of antigen-bearing vesicles (exosomes) derived from DC lysosomal compartment (Thery et
al., 1999).
1.2.4 The method of delivery of DNA affects the type of immune
response induced
The method employed to deliver plasmid DNA has long been known to affect the type of
immune response induced. This has made it difficult to compare the immunogenicity of
various vaccines where different routes of administration have been employed. DNA vaccine
efficacy is strongly influenced by the route of vaccination in mice and there is evidence that
this may also be the case in large outbred animals. Production of IgG2a is a hallmark of Thl-
type immunity, reflecting IFN-y enhanced Ig isotype switching to IgG2a, whereas Th2
responses favour the generation of the IgGl subclass (Stevens et al., 1988). Studies in mice
have shown that DNA vaccines injected intramuscularly elicit strong CTL responses and
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humoral responses characterised by serum IgG2a (indicating a predominant Thl response).
Conversely, gene-gun-mediated DNA immunization is often characterised by lower CTL
activity and predominant IgGl (Th2-type response) (Feltquate et ah, 1997). Furthermore,
injection ofDNA into the skin induces higher CTL activity than when DNA is administered
by gene-gun vaccination (Bouloc et al, 1999).
Differences in the Th response after DNA vaccination have been partly attributed to the
amount of DNA used in the delivery system. Gene-gun vaccination uses small amounts of
DNA (typically 0.5-2pg/shot), whereas intramuscular injection generally requires more
plasmid (~10pg) and so it has been speculated that a Thl-biased immune response is
promoted following intramuscular injection, since more CpG motifs would be available to
stimulate innate immune cells including DC to produce Thl polarising cytokines. In
agreement with this, Th2 immunity to hepatitis B surface antigen primed by gene-gun
mediated DNA vaccination can be shifted towards Thl-type immunity by codelivery of CpG
motif-containing oligodeoxynucleotides (Zhou et al., 2003). The intramuscular route was
indeed reported to be more effective than gene-gun or intradermal DNA vaccination in sheep
and resulted in better protection of animals following challenge with live Corynebacterium
pseudotuberculosis (De Rose et al., 2002). This was suggested to be due to a more
pronounced Thl response characterised by elevated IgG2 responses.
The induction of strong CTL responses after intramuscular injection may also be due to the
relatively inefficient cellular uptake of DNA by myocytes. Based on reporter gene
expression, DNA plasmid injection into mouse muscle produces only picogram amounts of
protein in muscle cells (Wolff et al, 1990). Importantly, the level of antigen expression can
have important consequences in terms of activating CD4+ and CD8+ T cells. Recent data
indicate that CD8+ and CD4+ T cells are fundamentally different in their requirements for
activation and clonal expansion (Foulds et al., 2002). In contrast to humoral responses, only
a very small amount of antigen, when presented in the context of a DC, is sufficient to prime
and sustain strong CTL responses and is not influenced by the duration of antigen
presentation. In contrast, CD4+ cells require repeated antigen exposure and increased
amounts of antigen for the survival of proliferating cells.
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1.3 Optimisation of DNA vaccines
1.3.1 General introduction
DNA vaccination is in many cases hampered by poor efficacy in species other than mice;
clinical trials in humans have so far been largely disappointing (reviewed in Donnelly et al,
2003). A recurring observation in clinical studies reported in the literature so far is that
antibody responses induced by DNA vaccination are relatively low compared with those
induced by direct injection of proteins with adjuvants. Whilst CTL are required to control
and eliminate an infection once it has become established, neutralising antibodies are
necessary in order to prevent establishment of the infection (reviewed in Zinkernagel, 2003).
It has been proposed that although plasmid DNA may persist for some time (Williams et al,
1991), the levels of antigen produced may be insufficient to induce adequate antibody
production (Foulds et al, 2002). Results of the first human trial of a malaria vaccine showed
no antibody response in any volunteer despite the induction ofCTL responses in the majority
of vaccinees (Wang et al, 1998). Interestingly, Whitton and colleagues, have designed a
DNA vaccine which induced a CTL response, but did not induce antibodies and argue that
this is due to a lack of release of intact protein (Whitton et al., 1999). Furthermore, DNA
vaccines designed to express a correctly folded immunogen can induce a highly specific
antibody response (Benvenuti and Burrone, 2001). Increasing antigen expression and
designing plasmids which ensure some of the immunogen is released intact and correctly
folded, may hold the key to enhanced antibody responses generated by DNA vaccines.
The evaluation ofDNA vaccines in outbred animals has been particularly challenging due to
the high cost, the absence of well-characterised populations and the limited number of
immunological reagents. Few studies have focused on veterinary species and while results
obtained in laboratory animals can be extrapolated to veterinary species, this is not always
relevant. Indeed experiments in large out-bred animals suggest that DNA vaccines are not
nearly as immunogenic as they are in rodents (reviewed in Babiuk et al., 2003). Drew and
colleagues have directly compared the immunogenicity of DNA vaccines encoding Taenia
ovis host-protective antigens in both mice and sheep (Drew et al., 2000). DNA vaccines were
immunogenic in mice and generated significant titres of antigen-specific antibody after
intramuscular injection, whereas vaccination of sheep generated significantly lower titres of
specific antibody. It has been suggested that the transfection efficiency ofmyocytes is lower
in larger animals than in mice, resulting in low antigen expression (Han et al., 2000).
Promisingly, in vivo electroporation has been successfully utilised to enhance transfection of
ovine myocytes and resulted in enhanced humoral immunity, possibly due to an increased
release of intact protein (Scheerlinck et al., 2004).
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Despite considerable effort expended in improving DNA vaccine delivery, only minute
amounts of antigen are available for immune induction following DNA vaccination in large
animals, particularly with regard to gene-gun vaccination. Experiments conducted by Braun
and colleagues (Braun et al., 1999), demonstrated that mice can be readily immunised with
the gene-gun; yet in cattle, a secondary immunisation was required for seroconversion, even
after receiving 10-100 times as much plasmid. Booster vaccinations are commonly employed
by researchers and yet still cannot guarantee protection. For instance, only partial protection
against foot-and-mouth disease virus challenge has been demonstrated after gene-gun
vaccination of swine, even with administration of booster vaccines (Benvenisti et al., 2001).
Furthermore, vaccination of large animals generally requires milligram doses ofDNA, which
is unfavourable from both safety and economic viewpoints.
1.3.2 Strategies employed to enhance efficacy of DNA vaccines
It has been speculated that the lack of efficacy of DNA vaccines may be due to the fact that
the delivery conditions do not efficiently target resident DC, resulting in inadequate access
of antigens to these cells. In addition, insufficient activation of DC (Section 1.4) or possibly
even ineffective targeting of a particular DC subset may account for the lack in efficacy of
DNA vaccines. Evidently there is a requirement to further optimise DNA vaccines before
this technology can be applied to humans and livestock. One method is to employ a "prime-
boosting" strategy. The basic prime-boost strategy involves priming the immune system to a
target antigen delivered by one vector (plasmid DNA) and then selectively boosting this
immunity to a protective level by re-administration of the antigen in the context of a second
and distinct vector (reviewed in Woodland, 2004), such as live-attenuated or killed vaccines.
Heterologous prime-boost strategies gaining most interest use DNA vaccine priming
followed by boosting with a recombinant vaccinia virus.
Researchers have also focused on modifying plasmid vectors to enhance protein expression,
for instance by including introns in the gene (Rush et al, 2002) or by targeting antigen to
MHC class II- or I-processing pathways (Gurunathan et al, 2000). Methods to improve DNA
uptake have also been investigated and include administration of cationic lipids and even the
application of electric currents after intramuscular injection of DNA (reviewed in Donnelly
et al, 2003). Other methods include inducing apoptosis in transfected cells and promoting
phagocytosis of transfected cells (Gurunathan et al, 2000). Enhancement of the immune
response to DNA vaccines has been achieved by co-administration of immunomodulatory
genes including cytokines (Section 1.3.3), chemokines (including RANTES and MlP-la),
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costimulatory molecules (CD80, CD86 and CD40), heat-shock proteins (Hsps) such as Hsp
70, and the complement protein C3d (reviewed in Sasaki et al., 2003).
1.3.3 Cytokines as molecular adjuvants
Strategies involving the combination of DNA immunisation and molecular adjuvants are
under intense investigation. The magnitude and direction (humoral or cellular) of the
immune response can be manipulated upon administration of DNA vaccines containing
cytokine genes as molecular adjuvants. For instance, inclusion of genes encoding the Thl-
polarising cytokines IL-12, IFN-y (Chow et al., 1998; Kim et al., 1998) and IL-18 (Kim et
al., 2001) as molecular adjuvants have been shown to skew the immune response towards the
Thl phenotype and to induce potent CTL responses following DNA vaccination. In contrast,
co-injection of the IL-4 gene enhances development of antigen specific Th2 cells and
increases production of IgGl, whereas Thl differentiation and IgG2a production are
suppressed (Chow et al, 1998; Kim et al, 1998). Another method to enhance the immune
response is to employ genetic cytokine adjuvants to recruit DC to the site of inoculation.
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and IL-3 are both potent
cytokines known to cause the growth and differentiation of immature haematopoietic cells
and have been implicated in the development of DC.
1.3.3.1 GM-CSF and IL-3 biology
GM-CSF and IL-3 are haematopoietic cytokines that share several common features. Both
cytokines stimulate the proliferation, differentiation, and activation of haematopoietic cells
in the bone marrow (reviewed in Martinez-Moczygemba and Fluston, 2003). Part of the
overlap in function of these cytokines can be explained by their use of a common signalling
component in their receptors. Receptors for GM-CSF and IL-3 consist of two subunits,
where an a subunit is specific for each cytokine and a p unit is common to both cytokines
(reviewed in Bagley et al., 1997). IL-3 is expressed predominantly by activated T cells, mast
cells, and natural killer (NK) cells. The expression of IL-3 in mice and humans is co-
regulated with that of GM-CSF in both T cells and NK cells; however, IL-3 expression is not
readily detected in macrophages, fibroblasts or endothelial cells, all of which express GM-
CSF (Mclnnes et al., 1993).
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1.3.3.2 GM-CSF and IL-3 are used to propagate DC in vitro
DC are found in virtually all tissues and DC precursors (pre-DC) circulate in the blood and
seed tissues. Large-scale preparation of DC is however hampered by their low frequency in
blood (DC constitute only 1-2% of circulating leukocytes) and their relative scarcity in
tissues. Furthermore, the isolation of DC from tissues is difficult and requires extensive
purification procedures including enzymatic digestion of the collagenase matrix (Steinman et
al., 1974). Alternatively, human DC can either be generated from the CD34+ progenitor pool
contained in cord blood (Caux et al., 1996a) and in peripheral blood (Romani et al., 1994). In
addition, DC can be propagated in vitro using CD14+ blood monocytes (Zhou and Tedder,
1996). Murine DC can be propagated from either mouse bone marrow or blood according to
methods established by Inaba and co-workers (Inaba et al., 1992a; Inaba et al., 1992b). In
vitro culture systems generate large numbers of DC and have enabled researchers to study
these rare and enigmatic cells.
DC of lymphoid and myeloid origin were originally proposed in both mice and in humans,
although the precise origin of these subsets in vivo is not clear as both common myeloid and
lymphoid progenitors can give rise to both "myeloid" (CD8a~) and "lymphoid" (CD8a+) DC
in mice (Manz et al., 2001; Traver et al., 2000). GM-CSF is used extensively for the in vitro
generation of myeloid DC ("DC1") from human monocytes (Sallusto and Lanzavecchia,
1994) and from pluripotent progenitors (Caux et al., 1992b; Santiago-Schwarz et al., 1992).
GM-CSF is also used to generate myeloid DC from mouse bone marrow (Inaba et al, 1992a)
and blood (Inaba et al, 1992b) and is essential for the viability and function of cultured
murine epidermal LC (Witmer-Pack et al., 1987). Both murine thymic pre-DC (Saunders et
al., 1996) and human plasmacytoid DC (pDC), also referred to in the literature as "DC2"
(and proposed to be of lymphoid origin) (Grouard et al., 1997; Kohrgruber et al., 1999;
Olweus et al., 1997) show a dependence on IL-3 rather than GM-CSF for survival and
development into mature DC. In addition, foetal liver tyrosine kinase 3 ligand (Flt-3L), a
stromal cell product, is used to propagate murine plasmacytoid-type DC (Gilliet et al., 2002).
In terms of DC development in vivo, it may be an oversimplification to assume that one type
of DC relies exclusively on one cytokine and not on another. It is likely that GM-CSF and
IL-3 (and other growth factors such as Flt-3L) have overlapping functions in vivo. Although
GM-CSF is an important cytokine for the generation of myeloid-related DC in vitro,
examination of mice deficient in GM-CSF or in GM-CSF receptor (GM-CSFR((3)) indicates
that DC development in lymphoid tissues is not dramatically affected (Vremec et al., 1997).
Furthermore, myeloid DC can be propagated from bone marrow cells obtained from GM-
CSFR knockout mice, if supplied with Flt-3L and IL-6 (Hikino et al., 2000). Such flexibility
in the DC system is further demonstrated by the finding that LC (proposed to be of myeloid
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origin) can be propagated from cord blood CD34+ haematopoietic progenitor cells with IL-3
in conjunction with TNF-a (Caux et al., 1996b) or TGF-p (Mollah et ah, 2003). IL-3 in
combination with IL-4 has also been used to generate human myeloid "DC1" which
preferentially induce a Th2 response (Ebner et ah, 2002). Conversely, human "lymphoid"
DC can be generated from early human thymic T-precursors supplied with a GM-CSF based
cytokine mix (Kelly et ah, 2001).
1.3.3.3 Administration of GM-CSF and IL-3 in vivo: expansion of DC
Both GM-CSF and IL-3 increase the recycling and maturation of haematopoietic progenitors
in the bone marrow. For this reason GM-CSF (and to a lesser extent IL-3) are well
documented as immunotherapeutic agents clinically exploited to augment regimens for
cancer therapy and bone marrow transplantation (reviewed in Armitage, 1998). For instance,
GM-CSF is well documented to increase antibody-dependent cell-mediated cytotoxicity
towards tumour cells and this is believed to be due to enhancement of the generation and
function of DC. GM-CSF has pleiotropic effects in vivo, including upregulation of MHC
class II antigen expression on macrophages and DC, induction of inflammation at the
inoculation site and mobilisation and maturation of DC. Indeed GM-CSF is often exploited
specifically to expand DC in humans, for instance, to mobilise DC in breast cancer patients
undergoing autologous stem cell transplantation (Avigan et ah, 1999) and also to generate
autologous tumour DC vaccines in vitro (Nestle et ah, 1998).
Although flexibility has been demonstrated with regard to the type of DC propagated in vitro
with different cocktails of cytokines (Section 1.3.3.2), it cannot be disputed that GM-CSF
favours the outgrowth of myeloid DC in vitro. Not surprisingly, expansion of myeloid DC
has also been documented after in vivo administration of recombinant GM-CSF. Systemic
administration of GM-CSF and IL-4 preferentially expands and matures myeloid pre-DCl
into DC1 (human leukocyte antigen (HLA)-DR+/CD 1 lc+) in patients with advanced
metastatic cancer (Kiertscher et ah, 2003). DC were found to express higher levels of HLA-
DR, CDllc and CD80 than pre-treatment cells and Mixed Leukocyte Reaction (MLR)
activity was comparable to that of monocyte-derived DC (MoDC) generated in vitro from
the patients' pre-treatment blood using GM-CSF and IL-4. Administration of recombinant
GM-CSF in humans has also been reported to expand S100+, Factor XIIIa+ myeloid DC after
intradermal injection into melanoma skin metastases (Nasi et ah, 1999) and to significantly
increase S100+ DC in tumour DLN in breast cancer patients (Pinedo et ah, 2003). There are
few reports on the administration of recombinant GM-CSF in outbred species other than
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humans, although a significant increase in dermal MHC class II+ CD1 DC was observed in
skin after intradermal injection of recombinant GM-CSF in sheep (Haig et al., 1995a).
Studies in mice have also revealed the ability of GM-CSF to augment the immune response.
For instance, injection of irradiated tumour cells genetically engineered to secrete murine
GM-CSF stimulated potent and long-lasting anti-tumour immunity, requiring both CD4+ and
CD8+ T cells (Dranoff et al., 1993). A later study demonstrated that injection of tumour cells
co-transduced with GM-CSF and CD40 resulted in a marked infiltration of DC into tumours
with enhanced capacity to take up and present endogenous tumour-associated antigens and
prime tumour-specific CD8+ T cells (Chiodoni et al., 1999). Expansion of splenic DC with
enhanced allostimulatory capacity in MLR (Hanada et al., 1996) and enhanced uptake and
processing of particulate antigen (Storozynsky et al., 1999) has also been described after
injection ofmice with tumour cells transfected with GM-CSF. Expansion of splenic DC with
enhanced antigen uptake and presentation was also reported after injection of tumour cells
transfected with IL-3 (Storozynsky et al, 1999), although a proportion of the DC infiltrate
had some macrophage-like characteristics, including expression of Mac-1. Indeed, IL-3 has
been well demonstrated to enhance presentation of particulate antigen presentation by APC
and to prime tumour-specific CTL (Lord et al., 1998; Yeh et al., 1998).
Preferential expansion of the myeloid subset (CDllc+ CDllbbr,ght) and not lymphoid-related
DC (CDllc+ CD11 hdull/ ) in mouse spleen has been documented following subcutaneous
administration of a polyethylene glycol-modified form of recombinant GM-CSF (Daro et al.,
2000; Pulendran et al., 1999) and unmodified recombinant GM-CSF (O'Keeffe et al., 2002;
Parajuli et al., 1999). In addition, expanded DC isolated from GM-CSF-treated mice
captured and processed antigen more efficiently than DC from Flt-3L-treated mice but were
equally efficient at stimulating allogeneic and antigen-specific T cell proliferation in vitro
(Daro et al, 2000). Preferential expansion of myeloid CDllc+ DEC 205 DC was also
reported following adenoviral-mediated GM-CSF over-expression in the liver (Pillarisetty et
al., 2003). Interestingly, GM-CSF does not appear to skew the cytokine profiles of DC, but
instead may augment cytokine production. This is illustrated by the finding that the
preferentially expanded myeloid DC subset in mice (which was originally described as "Th2
inducing"; section 1.4.4.2) contain more abundant IL-10 transcripts after administration of
recombinant GM-CSF; whereas IL-12p40 mRNA expression is increased in the isolated
CD8a+ lymphoid DC subset (which has a capacity to express high levels of IL-12p70;
section 1.4.4.2) (Parajuli et al., 2001). Furthermore, GM-CSF expanded myeloid DC induced
antigen-specific CD4+ transgenic T cells to secrete large amounts of the Th2 cytokines IL-4
and IL-10 when restimulated in vitro (Pulendran et al, 1999). Myeloid DC also induced Thl-
associated cytokines (IFN-y and IL-2) in antigen-specific CD4+ transgenic T cells in mice
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primed with OVA-peptide pulsed DC; however, GM-CSF treatment significantly increased
IgGl titres and failed to stimulate IgG2a in one strain ofmouse. It was proposed that the Th2
cytokines mitigated the effects of IFN-y, thus favouring an IgGl response.
1.3.3.4 GM-CSF as a molecular adjuvant
GM-CSF has received considerable interest as a molecular adjuvant, whilst IL-3 has not as
yet been investigated. Much interest has focused on the use of GM-CSF to overcome poorly
immunogenic antigens, such as those associated with intracellular infection and cancer.
Furthermore, GM-CSF is well documented to augment the primary antibody response
(reviewed in Warren and Weiner, 2000). While the mechanism for the adjuvant effects of
GM-CSF has not been completely elucidated, it seems likely that the ability of GM-CSF to
attract immature DC into the tissues following inoculation enhances the ability of the
coadministered DNA vaccine to be presented by DC. Infiltration of CDllc+ (myeloid)
immature DC at the inoculation site of GM-CSF DNA injection has been postulated as a
mechanism by which immune responses are enhanced in mice after both intramuscular
(Haddad et al., 2000; Ou-Yang et ah, 2002) and intradermal vaccination (Bowne et ah,
1999).
Plasmid GM-CSF (pGM-CSF) was first shown to enhance both B cell and Th cell activity
after coadministration with plasmid DNA encoding the glycoprotein of rabies virus (Xiang
and Ertl, 1995). It was suggested that a significant increase in levels of neutralising antibody
conferred protection following challenge with virus. pGM-CSF administration has
subsequently been shown to augment antigen-specific antibody responses to hepatitis C virus
core protein (Geissler et ah, 1997; Ou-Yang et al, 2002), HIV (Kim and Weiner, 1997),
herpes simplex virus type-2 (Sin et ah, 1998; Sin et ah, 1999) and Plasmodium yoelii (Wang
et al, 1998). There are however some discrepancies in the predominant isotype induced by
GM-CSF, since induction of antigen-specific IgGl antibodies (a hallmark of Th2-type
immunity) have been documented (Burger et ah, 2001; Harrison et ah, 2002; Kim and
Weiner, 1997; Liu et ah, 1998a; Sin et al, 1998), whereas others have demonstrated the
induction of IgG2a antibodies (Sakai et ah, 1999; Sun et ah, 2002), a hallmark of Thl-type
immunity. The balance of activation and expansion of DC subsets by GM-CSF plasmid
DNA injection might be one of the factors implicated in different Th responses.
pGM-CSF enhances CTL responses to a number of infections, including hepatitis C
(Geissler et al, 1997; Ou-Yang et al, 2002), and the envelope gene of HIV (Moore et ah,
2002). CTL activity was significantly increased in mice co-injected with pGM-CSF and a |3-
gal plasmid (Burger et al, 2001); although interestingly an IgGl response was induced. Most
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CTL responses require Thl polarising cytokines (IL-2 and IFN-y) for their induction;
however, CTL can be primed by DC in the absence of CD4+ T cells (Schlecht et al., 2001).
Some evidence suggests that the adjuvant effect of GM-CSF might also be related to
enhanced phagocytosis or pinocytic uptake of antigen by DC (Lutz et ah, 1996). Increased
antigen uptake in conjunction with increased MHC and costimulatory molecule expression
may result in a more effective CD8+ T cell priming capacity. Furthermore, Sin and
colleagues (Sin et al, 1998) demonstrated that although GM-CSF coinjection induced a
dramatic increase in IgGl levels as compared to IgG2a levels, Th cell proliferation and
secretion of Thl-polarising cytokines were significantly increased, thus an overall increase
in either isotype should be interpreted with some degree of caution. Others have reported
some enhancement of CTL activity by GM-CSF, which was less potent than other plasmid-
encoded cytokines such as IL-2 (Geissler et al, 1997), IL-12 or IFN-y (Chow et al, 1998).
Conversely, others found that GM-CSF has little effect on induction of CTL activity when
used as a plasmid adjuvant (Kim et al, 1998). The differences in the findings among these
studies are significant and may reflect differences in expression vectors, assays employed
and the antigen(s) of choice.
The induction of a predominantly humoral or cellular immune response may also be an
inherent property of the antigen after DNA vaccination. This is illustrated by work
conducted by Moore and colleagues (Moore et al, 7002) where in the absence ofGM-CSF, a
strong CTL response was elicited in response to plasmid encoding the envelope gene ofHIV,
whereas a strong humoral immune response was elicited to the nef gene. The predominance
of a cellular or humoral response was not reversed by GM-CSF in this study; instead GM-
CSF enhanced the already biased immune response, such that env-specific IFN-y producing
CD4+ Thl cells and a strong CTL response were induced.
Bicistronic plasmids contain two genes under the control of the same or separate promoters.
Bicistronic plasmids expressing GM-CSF and an antigen have been shown to further
augment immunity. Co-administiation of a GM-CSF plasmid and a plasmid encoding gpl20
of HIV led to a marginal increase in gpl20-specific CD4+ T cell response (Barouch et al.,
2002); however, immunization with a bicistronic plasmid led to a dramatic augmentation of
CD4+ T cell responses. Bicistronic plasmids are more effective at inducing immunity to
melanoma (Sun et al, 2002); hepatitis C (Lee et al., 1998), and Mycobacterium tuberculosis
(Kamath et al., 1999). These data suggest that by linking antigen and GM-CSF expression
closely in vivo, a more conductive microenvironment is provided for the uptake and
presentation of antigen by DC. The optimal induction of immune responses through APC
may require close proximity of the antigen and appropriate signals that allow for maturation
and migration of antigen loaded APC, as demonstrated by the fact that priming of a distant
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injection site with pGM-CSF 5 days prior to exposure to plasmid encoding [3-gal antigen did
not enhance the IgG response to P-gal, whereas injection at the same site enhanced antibody
production (Burger et al, 2001). It is puzzling why the timing of administration of pGM-CSF
can influence the Th response (Kusakabe et al., 2000). Injection of pGM-CSF 3 days before
vaccination with a HIV-antigen encoding plasmid induced a Th2 response in mice.
Conversely, injection of pGM-CSF 3 days after DNA vaccination induced a Thl response.
There are limited studies where pGM-CSF has been employed as a molecular adjuvant in
outbred species. In marked contrast to the enhanced serological responses observed in mice
after DNA vaccination with pGM-CSF, Nobiron and co-workers found no evidence of
increased antibody titres in cattle vaccinated with constructs expressing the E2 envelope
glycoprotein of bovine viral diarrhoea virus plus pGM-CSF, than in animals vaccinated with
the E2-encoding plasmid alone (Nobiron et al., 2003). Similarly, pGM-CSF did not
significantly affect the neutralizing antibody levels to dengue virus type 1 in Aotus monkeys;
however, pGM-CSF administration in combination with immunostimulatory sequences and
the DNA vaccine afforded 100% protection to animals challenged 6 months after vaccination
(Raviprakash et al., 2003). Co-delivery of pGM-CSF in conjunction with a protein boost
significantly enhanced the antibody response to EG95 of Echinococcus granulosus in sheep
(Scheerlinck et al., 2001). The mechanisms involved in the induction of immunity after
pGM-CSF administration are however, poorly defined and require further attention if pGM-
CSF is to be fully exploited in DNA vaccination.
1.3.3.5 GM-CSF is a potent inducer of inflammation
GM-CSF is not only a potent growth factor for DC, but it is also a major inducer of
inflammation and localised inflammation at the injection site has been well documented
(Warren and Weiner, 2000). Conventional adjuvants such as Freund's adjuvant (widely used
to augment antibody responses in experimental animals), cause marked inflammation at the
site of inoculation and act by inducing DC maturation, resulting in an upregulation of MHC
and costimulatory molecules, a release of cytokines and an upregulation of chemokine
receptor CCR7 (Medzhitov and Janeway, Jr., 1999). Adjuvants could therefore be interpreted
to "trick" DC into responding as though an active infection is taking place, therefore
promoting DC migration and maturation to the DLN and interaction with naive T cells. DC
are highly flexible cells and it is now becoming apparent that the environment in which an
immature DC first encounters antigen will shape the way in which that DC functions. To
understand the implications of GM-CSF as an adjuvant, this necessitates a closer
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examination of the role of DC as immunological sentinels and how inflammatory signals in
the periphery affect the biology of DC and ultimately the instruction of T cells.
1.4 Dendritic cells and inflammation
1.4.1 In wfro-generated DC require inflammatory stimuli to
become mature DC
In most culture systems DC exist in two functionally and phenotypically distinct states,
immature and mature (reviewed in Mellman and Steinman, 2001). Immature cells are adept
at endocytosis and express relatively low levels of surface MHC class I and II products and
costimulatory products (CD80 and CD86). Abundant MHC class II molecules are
synthesised, but they are mainly sequestered intracellularly in late endocytic compartments.
Immature DC are remarkable fluid phase endocytic cells; to date they are the only cells
found to perform fluid phase macropinocytosis constitutively (Sallusto et al., 1995). Thus,
immature DC in culture are active in antigen uptake but do not present antigen efficiently to
T cells.
The addition of exogenous factors, for example, proinflammatory cytokines such as TNF-a
and IL-ip, or microbial products such as lipopolysaccharide (LPS), (a feature of Gram
negative bacteria); CpG motifs, or dsRNA (RNA viruses) can convert these cells into a
mature phenotype, characterised by high surface expression of MHC and costimulatory
molecules and a reduced capacity for antigen uptake but now with an exceptional capacity
for T cell stimulation (reviewed in Stockwin et al, 2000). This transition (often referred to as
"activation") is accompanied by a dramatic cytoplasmic reorganisation highlighted by a
redistribution of MHC class II from intracellular compartments to the plasma membrane.
The cells extend long dendritic cell processes (membrane folds) that increase opportunities
for T cell capture and interaction.
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1.4.2 Ex-vivo isolated Langerhans' cells become activated by
inflammatory stimuli
Defined maturational stages of DC have also been described in DC isolated from tissues;
early studies demonstrated that when DC were isolated from lymphoid tissue, a terminally
differentiated population of DC was obtained, characterised by high surface expression of
MHC class II, but low rates of MHC biosynthesis (reviewed in Watts, 1997). As a result,
these DC stimulated T cells that could recognise the existing surface MHC-peptide
complexes, but they were poor at capturing and presenting newly offered antigens.
Conversely, analyses of DC isolated from peripheral tissues and studied immediately ex vivo
suggested that DC exist as immature cells that can be roused by various stimuli. For instance,
freshly isolated epidermal LC are phagocytic and endocytic (Reis e Sousa et al., 1993) and
can acquire and process protein antigens, but are poor at presenting antigen to responsive T
lymphocytes (Romani et al., 1989). After culture, they become weakly endocytic and lose
the ability to process native antigens, but develop potent immunostimulatory capacity
(Schulerand Steinman, 1985).
Skin explant models are useful tools which have helped to define the migratory pathways of
cutaneous DC. Briefly, skin patches are explanted and LC are challenged with an antigen or
some form of stimulus and migration of DC into the tissue culture medium is observed.
Following culture with inflammatory mediators such as LPS, TNF-a or IL-ip (reviewed in
Banchereau et al, 2000), LC downregulate E-cadherin expression and loosen their
connections with surrounding keratinocytes (Tang et al., 1993), invade the lymphatic vessels
in the dermis and end up in the culture medium (Lukas et al., 1996). Migrated LC are of a
mature phenotype, as illustrated by their potent ability in MLR due to high surface
expression of MHC class II and costimulatory molecules. Thus, in vitro cultured murine
epidermal LC more closely resemble terminally differentiated cells isolated from lymphoid
tissues, capable of forming clusters with resting T cells, whereas fresh LC are of an
immature phenotype (Schuler and Steinman, 1985).
1.4.3 In vivo exposure of skin to inflammatory mediators causes
DC migration and maturation
Cumberbatch and co-workers have conducted several in vivo studies in which they have
demonstrated that intradermal injection of recombinant TNF-a, (Cumberbatch and Kimber,
1992), IL-ip (Cumberbatch et al., 1997a; Cumberbatch et al., 1997b; Cumberbatch et al.,
1997c) and IL-18 (Cumberbatch et al., 2001) reduce the number of LC in murine epidermis
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and increase the number of DC in DLN. Subcutaneous application of LPS to mice also
results in a loss of LC in the epidermis; emigrating DC become visible in lymph vessels and
accumulate in T cell rich areas of lymphoid organs draining the site of exposure (Roake et
al., 1995). CpG motifs (Ban et ah, 2000) and heat shock proteins (Binder et ah, 2000) have
also been demonstrated to promote LC maturation and migration. There is even evidence
that inflammatory cytokines cause LC migration in humans; intradermal administration of
TNF-a resulted in a dose-dependent reduction in the frequency of CDla+ HLA-DR+
epidermal LC (Cumberbatch et ah, 1999).
1.4.4 DC are activated by "danger signals"
Inflammatory signals have therefore been well documented to cause profound changes in DC
function, namely to cause DC maturation and en masse migration to the DLN. DC are
capable of detecting a plethora of microbial and inflammatory stimuli and such DC-
activating stimuli have been termed "danger signals". Danger signals were proposed as part
of a model of immunity that suggests that the immune system responds to danger, rather than
to those that are simply foreign (Matzinger, 1994). Danger signals consist of molecules or
molecular structures, released or produced by cells undergoing stress or abnormal cell death
and induce APC to become activated, upregulate costimulatory molecules and thus to initiate
immune responses.
DC are remarkably plastic cells and their subsequent response appears to depend on the
nature of the stimulus. Such plasticity is demonstrated by studies that have been conducted
using murine DC (Gallucci et ah, 1999) and human DC (Sauter et ah, 2000) where cells,
killed by acute necrotic death activated resting DC, whereas cells dying by physiological
apoptotic death did not. Matzinger and colleagues (Matzinger, 1994) have argued that since
apoptotic bodies are normally seen to be a natural part of cell death they are not normally
seen as "danger signals". Although "resting" DC are indeed capable of engulfing apoptotic
bodies and presenting them, this does not result in activation. Conversely, necrotic cells are
often a feature of infection, where cell death is uncontrolled and results in the release of
Hsps, which can maturate DC (Basu et ah, 2000). In this way, Matzinger has proposed that
only pathological death stimulates the immune system; physiological apoptotic death, which
happens continuously in the body is neutral and may indeed be anti-inflammatory (Fadok et
ah, 1998). Danger signals can be divided into two large subclasses according to their source;
endogenous signals are products of the host organism and exogenous signals are products or
components of pathogens.
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1.4.4.1 Endogenous danger signals
The activation of DC in response to infection can occur either indirectly or directly by
inflammatory mediators (Table 1.3). Importantly, IL-ip and TNF-a are regarded as primal
danger signals induced in keratinocytes by inflammatory stimuli (Zepter et al., 1997). In
mice, IL-ip is produced almost exclusively by epidermal LC (Heufler et ah, 1992; Schreiber
et ah, 1992). Furthermore, a substantial proportion ofmurine LC express IL-1R1, the signal-
transducing receptor for IL-1 (Cumberbatch et ah, 1998) and are therefore poised ready to
detect this cytokine and amplify the immune response by acting as a positive feedback
signal. In addition, activated cells of the immune system express TNF-a and IL-1 p, thus
amplifying the immune response further. A study conducted by Perales et ah, (Perales et ah,
2002) demonstrated that pGM-CSF administration induced high levels of TNF-a, IL-1 ft, IL-
6, RANTES, MlP-la and MCP-1 in skin, later followed by expression of precursor Thl
cytokines, IL-12 and IL-18, concomitant with IFN-y production. Local production of GM-
CSF protein also resulted in the early recruitment of polymorphonuclear cells (PMN) and
later recruitment of mononuclear cells, including DC. GM-CSF is thus a potent inducer of
"danger" which is likely to have profound effects on DC biology.
IFNs are also examples of endogenous danger signals. Virtually all cells can produce type-1
IFNs upon viral infection. Indeed Matzinger and colleagues have argued that alarm signals
produced by virally infected tissues are sufficient to activate DC. Importantly, apoptotic
bodies produced as a consequence of viral infection have been demonstrated to activate
immature DC in the presence of IFN-a (Matzinger, 1994). Keratinocytes exposed to a mimic
of viral double-stranded RNA produce cytokines (type I IFNs, TNF-a and IL-18) that induce
DC to produce Thl-polarising cytokines. CD40L has also been proposed to be an
endogenous danger signal and is commonly employed to maturate DC in vitro (Caux et ah,
1994) and LC migration is stimulated following systemic treatment with an anti-CD40
monoclonal antibody (mAb) (Jolles et ah, 2002). CD40L is upregulated on activated T cells
and this requires previous activation of DC; however, CD40L is also expressed by activated
platelets (Henn et ah, 1998). Under normal conditions, platelets and tissue-resident DC do
not come in contact with each other, but in injured and bleeding tissue, the platelet-expressed
CD40L may serve as an early source ofDC stimulation (Gallucci and Matzinger, 2001).
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Table 1.3 Examples of endogenous danger signals which activate DC and other innate
immune cells. (ATP, adenosine triphosphate; UTP, uridine triphosphate.)
endogenous danger signal source reference
uric acid crystals necrotic cells Schnurr et al (2000); Shi et al (2003)
ATP and UTP
IL-ip, TNF-a, distressed/infected cells Sallusto et al (1995)
CD40L T cell signals
activated platelets
Caux et al (1994); Flenn et al (1998)
Hsps necrotic cells Asea et al (2000); Singh-Jasuja et al
(2000)
metalloproteinase-9 matrix-proteolytic enzyme Kobayashi et al (1999)
Type 1 IFN (IFN-o/p) virally infected cells
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1.4.4.2 Exogenous danger signals: PAMP-dependent DC activation
DC are also activated directly by conserved molecular signatures of potential pathogens, the
so-called pathogen-associated molecular patterns (PAMP). Cells of the innate immune
system, including DC, possess pattern-recognition receptors (PRR) that recognise PAMP
from viruses, bacteria, fungi and protozoa (Table 1.4). Direct contact with many pathogens
leads to the maturation of DC, which is characterised by an increase in antigen presentation,
upregulation of costimulatory molecules, and subsequent stimulation of naive T cells in
lymphoid organs (Banchereau and Steinman, 1998). C-type lectins constitute a major class
of PRR and activation of DC may occur following their engagement with carbohydrate
structures on pathogens. Dectin-1 acts as a PRR for p-glucan and could play an important
role in DC activation by yeasts (Brown et ah, 2003). DC-specific ICAM-3-grabbing
nonintegrin (DC-SIGN/CD209) is another example of a C-type lectin and importantly recent
studies demonstrate that DC-SIGN is a universal pathogen receptor that recognises gpl20 of
HIV, Ebola, cytomegalovirus, Mycobacteria, Helicobacterpylori, Lcishmania mcxicana and
Schistosoma mansoni (reviewed in Geijtenbeek and van Kooyk, 2003); however, some
pathogens have exploited binding to this receptor to further dissemination (HIV) or inhibit
the immunostimulatory function of DC (M tuberculosis). Some C-type lectins may act as
endocytic receptors as has been discovered with DEC-205, concentrating potential pathogens
for antigen presentation and recognition by PRR (Engering et al., 2002).
Recognition of pathogens is largely dependent on TLR
TLR were only discovered recently, yet they are undoubtedly the best-studied PPR.
Although LPS, peptidoglycan, unmethylated DNA and other microbial products were long
known to be the primary targets of innate immune recognition, researchers puzzled as to how
each molecule triggered a response. It is now known that the TLR are the principle signalling
molecules through which mammals sense infection. Each TLR recognises a restricted subset,
of molecules produced by microbes. Cells of the innate immune system may express any of
10 distinct TLR thereby allowing recognition of, and reaction to, a broad range of PAMP.
More recently, TLR 11-13 have been isolated in mice, although little is known as yet with
regard to the microbial ligands involved (O'Neill, 2004).
The responsiveness to a given PAMP has been linked to the expression of a particular TLR
(reviewed in Athman and Philpott, 2004). For instance, the recognition of RNA viruses
involves TLR3, which recognises dsRNA that is present either as part of viral genomic
structures (for example, reovirus) or is generated during viral replication (Alexopoulou et al.,
2001). More recently TLR7 has been shown to recognise single-stranded (ss) RNA viruses in
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Table 1.4 Examples of exogenous danger signals. DC-SIGN is a C-type lectin which may
function as PRR and alert DC to the presence of a pathogen; however, this molecule has
also been exploited as a means of pathogen dissemination in HIV and M. tuberculosis
pathogenesis (Geijtenbeek and van Kooyk, 2003).
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mice (Diebold et al., 2004; Heil et al., 2004; Lund et al., 2004) whereas TLR8 has been
implicated in recognition of ss RNA oligonucleotides in humans (Heil et al, 2004).
Importantly, ss RNA species are only recognized as "danger signals" if they are present in
the endosomal compartment. TLR9 recognises CpG motifs present in viral, fungal and
bacterial DNA (Table 1.4). Initially, TLR2 was reported to have a role in sensing LPS
(Kirschning et al., 1998; Yang et al., 1998). This later turned out to be due to a
peptidoglycan contaminant in the LPS used; TLR2 is now known to be implicated in the
recognition of bacterial peptidoglycan (Yoshimura et al., 1999). Beutler's group later
identified TLR4 as the receptor of LPS (Poltorak et al., 1998), since mice with mutations in
the TLR4 gene were resistant to the effects of LPS. Others have made similar findings
(Chow et al., 1999; Qureshi et al., 1999). LPS is now known to be recognised by a receptor
complex composed of TLR4, CD 14 and MD-2 (reviewed in Miyake, 2004).
Most microbial ligands for TLR have similar effects on DC; engagement of TLR results in
recruitment of an adaptor protein (MyD88) to the receptor complex and this activates
intracellular signalling via the Toll-IL-1 receptor pathway, resulting in activation of nuclear
factor-xB (NF-tcB) (Medzhitov et al., 1998), although a MyD88-independent signalling
pathway that mediates NF-kB activation is suggested following ligation of TLR4 with LPS
(Akira et al., 2000). Engagement of TLR results in DC activation and helps to induce
differentiation into professional APC, by increasing surface expression of MHC-peptide
complexes and co-stimulatory molecules CD80 and CD86, as well as the production of
proinflammatory cytokines including TNF-a, IL-6 and IL-12 (reviewed in Takeda et al.,
2003) all ofwhich have a profound effect on T cell priming and differentiation.
Engagement of PPR affects cytokine production by DC and subsequent Th
differentiation
DC are not only responsible for priming and sustaining the expansion of naive T cells, but
also to direct T cell effector differentiation. DC determine the type of immune response that
is initiated, primarily by affecting the cytokine environment in which the T cells respond.
Immune responses dominated by CD4+ T cells producing IFN-y and B cells secreting IgG2a
antibody are termed Thl responses; those dominated by CD4+ T cells producing IL-4 and IL-
10 and B cells secreting IgGl are termed Th2 responses. At the individual T cell level,
considerable heterogeneity of cytokine profiles can be seen with T cell clones, raising the
possibility that the Thl and Th2 phenotypes may represent two polar extremes of all possible
single cell phenotypes (Kelso, 1995). In general, the production of IL-12 by DC has been
shown to bias nai've T cells towards a Thl type (IFN-y-producing) response (Heufler et al.,
1996; Macatonia et al., 1995; Seder et al., 1993). Conversely, the absence of IL-12 and
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presence of IL-6 and IL-10 have been implicated in skewing naive T cells toward Th2-type
(IL-4-producing) responses (Liu et al., 1998b; Rincon et al., 1997).
DC subsets were originally suggested to be pre-programmed to direct the differentiation of
CD4+ T cells into either IFN-y-producing Thl cells or IL-4-producing Th2 cells. Evidence
for this hypothesis came from studies of DC derived from humans and mice which identified
a number of different sub-populations that varied in their ability to stimulate T cells and
influence the bias of the T cell response (Liu et al., 2001). Based on in vitro studies with
human blood DC, the DC1 and DC2 dichotomy was proposed to describe the capacity of
MoDC ("DC1") to produce high levels of IL-12 after activation and to preferentially induce
the generation of Thl cells, whereas pDC ("DC2") were found to have a strong capacity to
generate Th2 cells (Rissoan et al., 1999). In the mouse, the best studied DC subpopulations
are found in the CDllcbnght fraction of spleen and comprise at least three subsets defined on
the basis of CD4 and CD8a expression: CD8a+ CD4 "lymphoid" DC and "myeloid" DC
(CD8a CD4+ and CD8of CD4 DC) (Vremec et al., 2000). Moser and colleagues reported
that immunisation of mice with antigen-pulsed CD8a+ DC led to Thl priming, whereas
immunisation with CD8a" DC induced a Th2 response (Maldonado-Lopez et al., 1999;
Maldonado-Lopez et al., 2001). In parallel studies, Pulendran showed that both CD8a+ and
CD8of DC populations induced Thl development (Pulendran et al, 1999), but that only the
CD8a (myeloid) subset promoted Th2 differentiation. This led to the proposal that DC
represented lineage-committed cells, where each population has a precommitted role in vivo.
More recent experiments have now led to an alternative hypothesis about DC, which
demonstrate that the induction of a distinct Th phenotype by DC ultimately depends on the
"environmental education" of DC in the periphery and may not therefore be dependent on
the type of DC. DC are remarkably plastic cells capable of responding to a plethora of
pathogens and pathogen by-products by engagement with their PPR and tailoring their
cytokine profile accordingly. For instance, following ligation of TLR7 with a TLR7 agonist,
murine myeloid DC (CD8of CDllc+ CDllb+) express high levels of IL-12 and TNF-a
(Doxsee et al., 2003). Indeed, both murine lymphoid and myeloid DC have the ability to
produce either IL-12p70 or IL-10 depending on the nature of the stimulus. Both subsets can
direct increased Thl development in response to stimuli known to elicit IL-12 production
(including purified protein from M. tuberculosis) and both subsets can suppress Thl
development and allow Th2 cells to expand upon-exposure to IL-10-inducing microbial
agents (heat-killed yeast or zymosan particles) (Manickasingham et al., 2003). Furthermore,
Boonstra and co-workers have shown that mouse myeloid and pDC cultured from bone
marrow precursors and ex vivo splenic DC subsets can induce the development of both Thl
and Th2 effector cells depending on the dose of antigen; high antigen doses induced Thl
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development whereas low antigen doses induced Th2 cell development, regardless of the DC
subset (Boonstra et al., 2003). Such flexibility has also been demonstrated in the human
system, where human pDC ("DC2") activated by influenza virus and CD40L are capable of
driving potent Thl polarisation (Fonteneau et ah, 2003). Viral infection can also switch non-
pDC into high IFN producers (Diebold et ah, 2003). Therefore, although certain DC subsets
may be intrinsically more prone to induce Thl or Th2 differentiation, this property can be
either strengthened or overridden by PRR signals from microbes (perhaps due to the
chemistry of the antigen). The response of DC may also depend on the local cytokine milieu
in which the immature DC resides, the dose of the pathogen and other such environmental
cues.
Fluang and colleagues (Huang et ah, 2001) have further illustrated the plasticity of DC in
their ability to respond to infection and direct adaptive immunity by measuring gene
expression profiles of human myeloid DC after exposure to a range of microorganisms and
molecular components. A core response was elicited, including a rapid decline in expression
of genes associated with phagocytosis and pathogen recognition, a transient increase in the
expression of cytokines and chemokines, followed by induction of antigen processing and
presentation genes. Pathogen-specific programs of gene expression were also observed. E.
coli exposure resulted in rapid upregulation of most innate immune genes and at later time
points, genes that regulate adaptive immune responses, including T cell-stimulating genes
and a subset of chemokines that attract naive Th2 Th cells. The adaptive response to
influenza included upregulation of IFN-a/(3 and IFN-inducible chemokines genes, which
may induce migration of nai've Thl cells. Such plasticity has even been demonstrated with
the same pathogen; studies with the fungus Candida albicans showed that myeloid DC
stimulated a protective Thl response following ingestion of yeasts, whereas ingestion of
hyphae induced a non-protective Th2 response (d'Ostiani et al., 2000), demonstrating that the
diverse functions of DC in immune regulation are dictated by the instructions they received
during innate immune responses to different pathogens.
DC are therefore equipped with the capacity to sense diverse pathogens and elicit tailored,
pathogen-specific immune responses through ligation of conserved receptors, ultimately
affecting cytokine expression and the subsequent bias in the T cells responses that they
induce. Different stimuli are likely to trigger qualitatively different states of maturation,
suggesting that DC "decode" environmental signals via TLR or other receptors, allowing the
development of mature DC capable of polarising T cell responses, or inducing tolerance (in
the absence of "danger"). DC are therefore responsible for ensuring that the specificity of the
innate immune system, which distinguishes between many classes of potential pathogens, is
translated into an equally specific class of adaptive immune response. Inflammation induced
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by PAMP is sufficient to activate DC; however, Reis e Sousa argues that direct PRR
triggering, but not indirect activation, allows DC to differentiate between classes of pathogen
and that the main function of DC-exposed PPR may not be to activate a DC to become
immunogenic APC, but rather to convey information about the nature of the insult, thus to
allow DC to direct an appropriate class of immune response (Reis e Sousa, 2004).
TLR expression by DC subsets
What has also become apparent from recent studies is that different DC subsets can express
distinct TLR repertoires, suggesting that DC may have an inherent ability to recognise
different pathogens. A major dichotomy in TLR expression has been observed in human
blood DC subtypes, where myeloid DC and myeloid pre-DC (monocytes) express all TLR
investigated with the exception of TLR7 and TLR9, which are preferentially expressed by
both pDC and plasmacytoid pre-DC (Jarrossay et al., 2001). In accordance with their TLR
expression, these DC/pre-DC subsets were found to respond to their respective ligands. For
instance, only pDC and their precursors responded to CpG-oligodeoxynucleotides, whereas
only monocytes and myeloid DC responded to the TLR2 and TLR4 ligands, peptidoglycan
and LPS. In the murine system, pDC, like their human counterparts, express high levels of
TLR9 but selectively lack TLR3 and TLR4 (Boonstra et al, 2003). In addition, both cultured
and ex v/vo-derived splenic pDC enhance CD4+ T cell proliferation and induce Thl cell
development when activated with CpG, but not with LPS. However, it should be noted that
in mice TLR9 expression is not restricted to pDC, since it is also expressed by non-
plasmacytoid spleen DC, which respond to CpG-containing oligonucleotides by producing
IL-12 (Edwards et al., 2003).
It is possible that DC are equipped with specialised functions in vivo. Of the number of DC
subtypes identified in recent years, the pDC is characterised for its potent ability to secrete
high levels of type I IFNs in response to viruses in both humans (Siegal et al., 1999) and in
mice (Brawand et al., 2002) and thus an innate antiviral role has been proposed. Although
non-pDC in mice can be induced to secrete IFNs, pDC are the major producers of IFNa/p in
response to most viruses. Furthermore, expression of IFNs by murine pDC has been shown
to regulate multiple DC responses, limiting viral replication and IL-12 production in other
DC (Dalod et al., 2003). Recently, pDC have been shown to recognise the CpG-rich dsDNA
genome of the herpes simplex virus type 1 and type 2 via the TLR9/MyD88 pathway (Krug
et al., 2004; Lund et al., 2003). Furthermore, murine pDC have been found to recognise
ssRNA viruses (vesicular stomatitis virus and influenza virus) through TLR7, resulting in
upregulation of costimulatory molecules and production of IFN-a (Lund et al, 2004),
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whereas TLR8 has been implicated in the recognition of ss viruses by human pDC and
production of IFN-a (Heil et al, 2004).
Selective expression of TLR9 and DNA vaccine efficacy
As has already been highlighted (Section 1.3.1), DNA vaccination is less successful in
outbred species than in murine models of infectious disease and thus understanding the
immunology of DNA vaccination is imperative. One possible contributing factor as to why
DNA vaccines are more effective in mice may be due to different expression patterns of
TLR9. Both TLR2 (Kawai et al., 2002) and TLR4 (Song et al., 2002) are expressed by
murine resident keratinocytes, whereas TLR9 is not constitutively expressed in skin;
however, Liu and colleagues (Liu et al., 2003) have demonstrated that the physical trauma of
intradermal vaccination induces TLR9 expression to levels comparable with that of plasmid-
injected skin. Although TLR9 expressing cells were not clearly identified, the authors
suggest that TLR9 expression was the result of infiltration by blood leukocytes that express
TLR9, rather than de novo synthesis by resident skin cells. Thus physical damage alone to
the skin results in infiltration of TLR9 expressing cells, which may then be responsive to the
injected DNA at the site of injection. It is possible, although not yet proven, that differences
in vaccine efficacy could be partly attributed to differences in TLR9 expression by DC
subsets. It is interesting to speculate that TLR9 expression in several murine DC subsets,
including LC (Mitsui et al., 2004), but its unique expression in human blood pDC, may help
to explain the apparent lack of efficacy of DNA vaccines in humans. Spies and colleagues
have, however, negated a dominant role of CpG-DNA/TLR9 interactions in long-term
vaccination protocols (Spies et al., 2003), since priming and expansion of OVA-specific
CTL were reported to be equal in wildtype and TLR9 knockout (TLR9~/_) and MyD88 L
mice after vaccination with a plasmid containing a transcription unit for OVA.
Selective expression of TLR by DC subsets may however imply that there is some degree of
inflexibility in the DC system, where some DC are uniquely sensitive to some pathogens but
perhaps not to others. Experiments by Manickasingham and colleagues (Manickasingham et
al, 2003) demonstrate that whilst murine splenic DC subsets can be skewed into polarising
either Thl or Th2 immune responses ex vivo following exposure to different pathogens,
subtle differences between the populations were evident. In particular, priming with CD8a+
DC generally increased the frequency of Thl cells developing under neutral conditions while
both subsets ofCD8a DC tended to promote Th2 differentiation. The authors concluded that
although not very pronounced, these biases agree overall with the results by Maldonado-
Lopez (Maldonado-Lopez et al, 1999; Maldonado-Lopez et al, 2001) and Pulendran
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(Pulendran et al, 1999), where murine DC subsets propagated in vitro and transferred into
mice directed the development of distinct Th populations in vivo.
1.5 Accessing migratory DC
1.5.1 Danger signals are not mandatory for DC migration
The current and popularly cited lifecycle of DC has immature DC strategically placed
encountering antigen in the periphery (antigen capturing mode) and upon exposure to
various inflammatory stimuli (danger signals), DC become activated, resulting in their
migration and maturation en route to the DLN, whereupon stimulation of T cells takes place
(Banchereau and Steinman, 1998). While valuable in general terms, this view is too simple
for describing the real DC system in vivo. Whilst it is evident that inflammatory and
microbial stimuli activate DC and can result in en masse migration to DLN, such signals are
not mandatory for migration. A paper by Geissmann and colleagues (Geissmann et al., 1999)
challenged DC researchers to re-examine the widely accepted idea that migration of LC in
response to inflammatory stimuli is coupled to and follows their maturation. Lymph nodes
from patients with dermatopatic lymphadenopathy1 contained LC with characteristic LC
markers (CDla and langerin) but none showed expression of the maturation markers CD83
and CD86. In addition, the group showed that cultures of LC (derived from monocytes co
cultured in IL-4, GM-CSF and TGF-(f) did not become CD83+ even when exposed to TNF-a
or E. coli, although these inflammatory stimuli were sufficient to induce expression of CCR7
and migratory responses to CCR7 chemotactic ligands, indicating that LC migration and
maturation can be independently regulated.
1.5.1.1 Access to genuine migratory dendritic cells by cannulation of the
afferent lymphatics
Highly informative animal models with regard to the study of the phenotype of migratory
lymph DC are those in which afferent lymph is sampled from cannulating lymphatic ducts
after the ablation of lymph nodes. Peripheral afferent lymph is known to contain a small
number (1-10%) of cells with veiled or dendritic morphology. Cannulation of the afferent
lymphatics provides direct access to ex vivo DC migrating from tissue to the regional lymph
node in which they act. This has been carried out in several animal species, including sheep
1 A pathological disorder marked by excessive accumulation of nonproliferative LC in lymph
nodes that drain a chronically inflamed site.
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(Hall, 1967) and cattle (Emery et al., 1987), where afferent lymph draining the skin is
collected, and also in rats (Pugh et al., 1983), where intestinal lymph is obtained. It has long
been known from such models that DC migrate constitutively from peripheral tissues in the
absence of any overt antigenic or inflammatory stimuli (Pugh et al, 1983; Smith et al., 1970).
Furthermore, it is not possible to study all aspects of DC biology by investigating cells
derived and maintained in vitro and it has been suggested that in v/7ro-derived DC might be
deficient in some important immunological functions and that they might not accurately
represent the DC population(s) naturally developed and maintained in vivo (Morse et al.,
2002). A study conducted by MacPherson and co-workers illustrates this well; rat bone-
marrow-derived DC (BMDC) expressed some, but not all markers expressed by splenic DC
and lymph-derived DC. BMDC also functionally differed from ex v/vo-derived DC as APC,
as they were only relatively weak stimulators of an allogeneic MLR in comparison to splenic
and lymph-derived DC (Powell et al., 2003).
DC are highly flexible cells and isolation of DC from tissues is likely to modify their
phenotype and function. The isolation of DC from tissues is difficult and requires extensive
purification procedures. For instance, the isolation of epidermal LC requires mechanical
disruption and enzymatic treatment. Disruption of the epidermis has been reported to induce
DC maturation (Inaba et al., 1986; Schuler and Steinman, 1985). Perhaps the greatest
advantage of investigating the function of ALDC is that they have not been subjected to
enzymatic treatment, or extensive periods of culture, which could modify these highly plastic
cells. Cannulation of the afferent lymphatics therefore provides access to DC, which
resemble more closely DC in vivo.
Constitutive migration of DC from peripheral tissues to DLN has been proposed to maintain
tolerance to self- or harmless foreign antigens, although the factors which control such
steady-state migration are yet to be elucidated. DC in the steady-state flux have indeed been
found to capture antigens against which immunity is normally avoided, including
environmental proteins found in the respiratory tract and digestive tracts (Vermaelen et al.,
2001), as well as self-antigens derived from tissues exhibiting constitutive cell turnover
(Huang et al., 2000). Conceivably, the capture of proteins in the steady-state (in the absence
of microbial or endogenous danger signals) allows DC to maintain tolerance to self and
normal environmental constituents, so they are of a mature enough phenotype to present the
self-antigen on their cell surface, but do not have sufficiently high costimulatory molecule
expression, thus inducing tolerance (due to absence of signal 2). The finding that DC of an
immature phenotype are present in lymphoid tissues supports this (Wilson et al., 2003).
34
To further complicate matters, DC directly isolated ex vivo from afferent lymph draining the
skin or intestine are highly heterogeneous and are of different maturational stages. Whilst
ALDC stimulate proliferative responses in allogeneic CD4+ and CD8+ T cells in vitro
(Howard et al., 1996) and prime CD4+ T cells in vivo (McKeever et ah, 1992), consistent
with the idea that migratory DC are mature, the notion that all migratory DC have lost
characteristics normally "restricted" to immature DC is in fact wrong. For instance, ALDC
are indeed capable of endocytosis as demonstrated by the observation that ovine ALDC can
acquire soluble protein antigen in vivo or in vitro and present the material directly to
autologous T cells in an antigen-specific manner (Bujdoso et ah, 1989). Furthermore, antigen
uptake occurs rapidly in the presence of specific antibodies, suggesting that ALDC may
concentrate antigen on their surface efficiently via FcR (Harkiss et ah, 1990) and this has
been shown to augment antigen presentation and CD4+ T cell proliferation in in vitro
secondary responses (Coughlan et ah, 1996).
It cannot be denied that inflammatory stimuli induce DC maturation and migration and result
in an accumulation of DC in the DLN; however, these factors are not solely responsible for
the migration of DC. Cannulation models enable researchers to assess real changes to DC
following administration of a stimulus. For instance, after systemic administration of LPS,
the flux of intestinal DC emigration from the gut via lymph increases 8-15 fold
(MacPherson et ah, 1995). Importantly, the relative proportion of the less mature DC
population does not change after LPS treatment, suggesting that the migration-enhancing
effects of LPS may not entirely stem from its maturation-inducing properties. In vivo
antigenic stimulation in primed animals has been shown to have profound effects on the
quantitative expression of MHC class II, similar to the relative increase induced by
exogenous stimuli on mouse epidermal LC (Schuler and Steinman, 1985). In addition, the
capacity of ALDC to enhance in vitro lymphocyte proliferation correlates directly with
increased MHC class II expression, but not with CD1 expression (Hopkins et ah, 1989).
Origin of ALDC
Afferent lymph veiled cells (ALVC) and lymph node DC have been isolated with antigen on
their cell surface following skin painting with dinitrofluorobenzene (DNFB) (Lens et ah,
1983) and fluorescein isothiocyanate (FITC) (Macatonia et ah, 1987), demonstrating that
ALDC are involved in the transport of antigens to the lymph node by migration through the
afferent lymphatics to the paracortical areas of the lymph node, where they develop into
interdigitating DC and present antigen to naive T cells. The origin of ALDC and their
relationship to other DC, such as epidermal LC, has however been a subject of active
investigation (Bujdoso et al, 1989; Gliddon et ah, 2004; Knight, 1984). Evidence from these
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studies suggests that ALDC contain cells (or subpopulations) which have originated from LC
and/or dermal DC. Cells with Birbeck granules (a unique feature of epidermal LC) have been
found in afferent lymph and T-cell areas of lymph nodes following skin sensitisation
(Silberberg-Sinakin et al., 1976).
ALDC and MyD-1 (SIRPa) expression
ALDC can be further characterised based on the differential expression of the myeloid
restricted molecule, MyD-1 (CD 172). Perhaps the studies carried out with murine and
human DC will reveal similar findings. MyD-1 was initially described in the bovine system
where it was shown to be expressed on bovine monocytes, macrophages, granulocytes and a
subset ofALVC (Brooke et ah, 1998; McKeever et al., 1991). MyD-1 is also expressed on a
subpopulation of rat (Liu et ah, 1998c), and ovine ALDC (Bailey, 2003) and on human
myeloid cells (Seiffert et ah, 1999). MyD-1 is a type 1 glycoprotein belonging to the Ig
superfamily comprising 3 extracellular Ig-like domains with several glycosylation sites, a
transmembrane region consisting of a single hydrophobic stretch of 22 amino acids, and at
least 4 possible tyrosine phosphorylation sites including one or more putative
immunoreceptor tyrosine-based inhibition motifs (ITIMS) within the cytoplasmic tail
(Brooke et al, 1998). MyD-1 is a member of the signal regulatory protein (SIRP) family
(Vely and Vivier, 1997) and will now be referred to in the text as SIRPa. SIRPs are a family
of transmembrane glycoproteins that are involved in the negative regulation of receptor
tyrosine kinase signalling pathways (Ostman and Bohmer, 2001).
Studies in which COS-7 cells were transfected with the cDNA encoding the SIRPa molecule
showed that this molecule mediated binding ofCD4+ T cells (Brooke et al, 1998). The ligand
for SIRPa is now known to be the integrin-associated protein, CD47 (Vernon-Wilson et ah,
2000). CD47 is a widely distributed molecule expressed on a variety of haematopoietic cells
including monocytes and T cells (Mawby et ah, 1994), although it is expressed at
significantly higher levels on T cells (Latour et ah, 2001). Importantly, soluble CD47 mAb
exerts inhibitory functions in allogeneic MLR (Reinhold et ah, 1997; Waclavicek et ah,
1997). Early experiments demonstrated that ligation of the SIRPa molecule with mAb
inhibited antigen-specific T cell responses. For instance, the proliferation of resting memory
bovine CD4+ T cells to OVA-pulsed monocytes in vitro was significantly reduced in the
presence ofmAb to SIRPa (Brooke et al, 1998). SIRPa mAb have also been demonstrated to
strongly inhibit T cell proliferation in both MLR and anti-CD3 assays (Patel et ah, 2002).
More recently, ligation of SIRPa on human APC was found to induce suppression ofPAMP-
induced TNF-a secretion by DC by ~50%, suggestive of a possible role of SIRPa in the
regulation of the innate immune system (Smith et ah, 2003). Importantly, inhibition of TNF-
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a production by DC resulted in the inhibition of subsequent T cell activation induced by
either CD3 or allogeneic APC. Furthermore, anti-SIRPa treatment resulted in tyrosine
phosphorylation of SIRPa and inhibition of the PI-3-kinase signalling pathway, resulting in
cellular retention of TNF-a. These data strongly suggest that SIRPa may act to suppress
aberrant induction of TNF-a and inflammation. These data are also in agreement with those
described by Latour and colleagues (Latour et al, 2001), where CD47-Fc potently suppressed
TNF-a release by MoDC stimulated by Staphylococcus aureus. The latter study also
highlighted the ability of CD47 and its receptor SIRPa to deliver a bidirectional negative
signal to both T cells and DC, since not only was a decrease in IL-12 production by DC
observed, but also an inhibition of IL-12 responsiveness in CD3 activated PBMC.
Rat ALDC
Two functionally different DC populations have been isolated from rat intestinal lymph,
distinguished by the differential expression of SIRPa, the target of the 0X41 mAb (Adams
et al., 1998), and CD4 (Liu et al, 1998c). Both populations (SIRPa+/OX41+ CD4+ DC and
SIRPa /OX4C CD4" DC) express similar levels ofMHC class II, ICAM-1, CDllb, CDllc
and 0X62; however, OX41 DC stain more strongly for both CD80 and invariant chain. The
0X41+ population (which comprise 50-60% of ALDC) display short, fine pseudopodia and
stain weakly for non-specific esterase (NSE). Conversely, OX41" DC possess long
pseudopodia and stain strongly for NSE and also contain many cytoplasmic inclusions.
Furthermore, these phenotypic differences are still evident after overnight culture.
Surprisingly, OX41+ ALDC are more potent APC than OX41 ALDC exemplified by a more
robust activity in MLR, for sensitised T cells in vitro and naive T cells in vivo. Furthermore,
OX41+ ALDC continue to process and present antigen in vitro, whereas 0X41 ALDC
cannot present native antigen. It is interesting to speculate about these populations, do they
represent distinct DC lineages or are they the result of differentiation modulated by different
micro environmental stimuli?
A later study conducted revealed that the cytoplasmic inclusions described earlier in 0X41~
ALDC contain apoptotic DNA (Huang et al, 2000). Two approaches were undertaken to
show that this population also contained intestinal intraepithelial cell (IEC) remnants. Firstly,
OX417CD4 ALDC were positive for IEC-restricted cytokeratins. The second approach
identified the origin ofNSE (of which more than 80% of intestinal ALDC stain positive) and
demonstrated that IECs and OX41 ALDC contained NSE variants with identical mobilities,
suggesting that NSE reactivity in OX41 ALDC derives from endocytosed apoptotic IEC.
Furthermore, NSE+ DC were identified in T cell areas of mesenteric lymph node (MLN).
These data elegantly show that 0X41 DC constitutively endocytose and transport fragments
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of apoptotic gut epithelial cells to the T cell area ofmesenteric lymph nodes. It has therefore
been suggested that this pathway of self-antigen transport could be involved in the
maintenance ofperipheral self-tolerance (Huang and MacPherson, 2001).
Two phenotypically distinct subsets of DC with different T cell stimulatory activities have
been also been isolated in rat spleen based on SIRPa expression (Voisine et al., 2002). In
contrast to data obtained from ALDC, freshly isolated splenic SIRPa+ DC were of an
intermediate maturity (moderate expression of CD80) whereas SIRPa DC were immature,
although DC could be matured by overnight culture. Furthermore, unlike lymph-derived
SIRPa+ DC, splenic SIRPa+ DC induced only slightly higher proliferation of allogeneic
naive CD4+ T cells than splenic SIRPa DC. SIRPa DC were comparatively poor at
inducing allogeneic naive CD8+ T cell proliferation and IFN-y secretion (even after
overnight culture) unless an additional maturational stimulus such as CD40L was
administered. In addition, freshly isolated SIRPa" DC produced large amounts of the
proinflammatory cytokines IL-12 and TNF-a and promoted differentiation of IFN-y-
secreting CD4+ T cells. SIRPa+ DC also induced differentiation of Thl cells despite a low
production of IL-12, suggesting an IL-12-independent Thl-priming capacity; yet only
SIRPa+ DC induced allogeneic CD4+ T cells to produce the Th2 cytokine IL-13. Based on
the high IL-12 production, the low capacity to stimulate CD8+ T cells, the large size,
spontaneous maturation and poor viability in vitro, the authors propose that rat splenic
SIRPa CD4 DC are the equivalent ofmurine splenic CD8+ ("lymphoid") DC.
Bovine ALDC
Two major populations have been defined on the basis of expression of a number of antigens
in bovine afferent lymph (Howard et al., 1997; Howard and Hope, 2000); the major
population (approximately 80% of DC in afferent lymph) expresses SIRPa. The smaller and
more homogeneous SIRPa" population expresses an antigen recognised by the mAb CC81,
high levels of CD1 la and the bovine WC10 antigen (that has now been identified as CD26).
The SIRPa+ population lacks expression of CD26 and the antigen recognised by the mAb
CC81 present on the minor population.
Howard and colleagues have investigated the way in which the SIRPa+ and SIRPa" ALDC
populations interact with T cells in vitro (Howard et al, 1997). Although both DC
populations were capable of taking up the soluble protein antigen OVA and stimulating
memory T cells from OVA-immune cattle, SIRPa+ DC were more effective than SIRPa" DC
at presenting inactivated respiratory syncytial virus (RSV) antigen to T cells from RSV-
immune cattle. The SIRPa" population was also relatively ineffective at stimulating CD8+ T
cells in an allogeneic model, as was reported with rat splenic SIRPa" DC (Liu et al, 1998c).
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A similar disparity in the stimulation of CD8+ lymphocyte proliferation has also been
reported for subsets of murine splenic DC (Kronin et al, 1996). Interestingly, differences in
the induction of CD8+ T cells by bovine ALDC was not due to differences in surface
expression of costimulatory molecules (CD80, CD86 and CD40), but rather due to a
difference in IL-la synthesis; supernatant from SIRPa+ ALDC significantly enhanced
SIRPa ALDC to stimulate the proliferation of allogeneic CD8+ T cells and this stimulatory
capacity was blocked upon addition of an anti-IL-la mAb (Hope et al., 2001).
Further investigation revealed differences in the expression of cytokine transcripts by bovine
SIRPa+ and SIRPa ALDC that may have significant effects on the T cell response (Stephens
et al., 2003). A quantitative approach was adopted in order to measure cytokine transcripts
from freshly sorted DC. Notably, the SIRPa" population contained more numerous
transcripts of IL-12p40, whereas transcripts for IL-la, IL-1p, IL-6 and IL-10 were more
numerous in the SIRPa"1" ALDC population. In general, SIRPa+ DC expressed 2-3 fold more
IL-ip and IL-6 transcripts than SIRPa" DC sorted from the same afferent lymph sample. The
authors propose that high levels of expression of IL-12 in the SIRPa" DC (and expression of
CD26) would promote a strong Thl biased immune response; however, low levels of IL-la
would result in a poor induction of CD8+ T cell immune responses. Conversely, presentation
by the SIRPa+ population would be expected to promote a more intense CD8+ T cell
response, but the lower levels of IL-12 and higher levels of IL-10 in this population may
result in an immune response that has less of a Thl bias. In mice the presence of IL-6 and
IL-10 during T cell stimulation has been linked to the generation of Th2 immune responses
(Liu et al, 1998b; Rincon et al, 1997), whereas in cattle and humans, IL-10 has a down-
regulatory effect, reducing the proliferation of both Thl- and Th2-type clones (Brown and
Estes, 1997; Del Prete et al., 1993). It has therefore been proposed that IL-10 production may
imply an anti-inflammatory role for this subpopulation of ALDC or indeed for a subset of
cells within it.
The model in which human myeloid pre-DC 1 mature into DC 1 secreting high levels of IL-
12, while "lymphoid" pre-DC2 mature into cells secreting low levels of IL-12 would suggest
that SIRPa" DC are the equivalent of myeloid DC1, whereas SIRPa+ DC are related to the
"lymphoid" DC2 subset. This does not appear to be the case as the Myd-l/SIRPa antigen is
"myeloid" restricted. It is interesting to note that surface expression of CD8 has been
observed on SIRPa ALDC in both cattle and sheep (Bailey, 2003), although it appears
equally unlikely that this subpopulation is the equivalent of the lymphoid (CD8a+) DC subset
found in mice, since SIRPa" ALDC also express myeloid-restricted antigens. It is possible
that CD8 expression is a consequence of adsorption of this molecule from neighbouring cells
rather than endogenous expression of CD8.
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1.6 Aims of the project
1.6.1 Characterisation of immunohistological events following
administration of pGM-CSF and pll_-3
GM-CSF is an attractive molecular adjuvant, since this cytokine not only recruits DC, but
also acts as a danger signal by causing inflammation at the inoculation site and such
inflammatory signals likely modulate DC function and phenotype. Whilst GM-CSF has
attracted considerable attention as a molecular adjuvant, the mechanisms by which GM-CSF
exerts its effects are still to be fully elucidated; in particular there is little information with
regard to the kinetics of expression of proinflammatory mediators which activate DC. IL-3
has not as yet been investigated as a molecular adjuvant and since IL-3 has been implicated
in DC development and is chemotactic for a variety of cells (including eosinophils and
neutrophils), the resulting inflammatory response may have profound affects upon DC
phenotype and function. Plasmid DNA itself has important adjuvant effects by ligation with
TLR9 expresssed by DC and other cells of the immune system. Understanding which signs
are both necessary and sufficient to convert DC into the immunostimulatory APC that prime
appropriate effector T cells will hold the key to improved strategies for vaccination (Reis e
Sousa, 2004).
There is a surprising paucity of published material that describes the immunohistological
characteristics following gene-gun vaccination with pGM-CSF. Better characterisation of the
inflammatory events after administration of cytokine gene adjuvants may help to better
understand the mechanisms involved in DNA vaccination. The aim of the first part of the
project was therefore to determine the effects in ovine skin after gene-gun bombardment
with pGM-CSF or pIL-3 and to compare the inflammatory events with a control plasmid. An
investigation into the cell types recruited to the site of DNA vaccination was required, with
particular interest with regard to the time-frame in which DC infiltrate the skin. In order to
determine the kinetics of plasmid expression and the expression of proinflammatory
cytokines in the skin, including TNF-a, IL-ip and IL-18, a quantitative RT-PCR method was
developed.
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1.6.2 Characterisation of ovine ALDC in the steady-state
Ovine ALDC have been partially characterised based on expression of SIRPa (Bailey,
2003); however little is known about the cytokine expression of these subsets in the steady-
state flow. Further characterisation of ALDC subsets is required in order to accurately assess
any changes in cytokine expression after cytokine gene administration. Expression of Thl-
polarising cytokines (IL-12p40 and IL-18), a Th2-polarising cytokine (IL-10) and
proinflammatory cytokines (TNF-a and IL-1 (!) required investigation (by quantitative RT-
PCR). In addition, no information is as yet available with regard to expression of TLR by
ALDC in any species and an investigation into these receptors may further our understanding
of the inherent functions of SIRPa+ and SIRPa" ALDC subsets in vivo. The origin of SIRPa+
and SIRPa ALDC and how they equate to human and murine DC is still under debate,
although evidence suggests that SIRPa"1" ALDC contain cells derived from epidermal LC
(Gliddon et al, 2004). Further analysis of each population is imperative to address this
further, including an investigation into the expression of langerin and CD la transcripts (LC-
specific transcripts) in addition to morphological and ultrastructural analysis.
1.6.3 Characterisation of ALDC after cytokine gene administration
The second part of the project involved investigation of the effects of pGM-CSF on DC
trafficking from the skin to the DLN via the afferent lymphatics. Cannulation of the afferent
lymphatics of sheep provides a unique method to investigate DC in their closest possible
form and therefore may help to understand the immune mechanisms underlying the effects of
GM-CSF as a molecular adjuvant. It was hypothesised that pGM-CSF would act upon pre-
DC recruited from the blood and/or resident immature DC in the skin (epidermal LC and/or
dermal DC) after gene-gun bombardment and this may be reflected by an increase in DC
numbers in the lymph when compared to those collected prior to DNA vaccination.
Furthermore, upregulation of proinflammatory cytokines in the skin is hypothesised to cause
DC maturation. Therefore, analysis of antigen presentation molecules (CD1 and MHC class
II), costimulatory molecules (CD80, CD86 and CD40), accessory molecules (CD2 and LFA-
3) and the [l-intcgrin CDllc was carried out, since an increase in surface expression of these
molecules is indicative of DC maturation and enhanced T cell stimulatory capacity. In
addition, expression of a range of genes involved in T helper cell polarisation was
investigated in purified ALDC populations by quantitative real-time RT-PCR and compared
to expression profiles of DC obtained during the steady-state flux. These experiments were
designed to decipher if pGM-CSF has the potential to influence the type and the magnitude
of the immune response generated to a particular antigen.
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2 Materials and Methods
Unless otherwise stated all chemicals were of analytical grade where available and supplied
by BDH or Sigma-Aldrich. Life Technologies supplied plastic ware for tissue culture
purposes.
The companies supplying the reagents used in this work are referred to in the text.
The compositions of all solutions can be found in Appendix I.
All company addresses are listed in Appendix II.
2.1 Cell culture
2.1.1 Recovery of cells from liquid nitrogen
Cells were recovered from liquid nitrogen by thawing in a 37°C water bath. Pre-warmed
wash medium (outlined below) was slowly added to equilibrate the osmotic pressure. The
cells were then centrifuged at 400 x g for 7 minutes in a bench centrifuge. This was followed
by resuspension of the cell pellet in 5ml of tissue culture medium. Cells were seeded into
25cm2 culture flasks.
2.1.2 Culturing cells
All cells were cultured in a humidified 5% C02 incubator (Heraeus) at 37°C and fed every
2-3 days with tissue culture medium (outlined below).
2.1.2.1 Sheep skin fibroblasts
A primary culture of sheep skin (SSk) fibroblasts was derived from a tissue biopsy
(Laurence Dickson, Department of Veterinary Pathology, University of Edinburgh). SSk
fibroblasts were cultured in Dulbecco's Modified Eagles Medium (DMEM, produced in-
house) and supplemented with a 2mM final concentration of L-glutamine (L-glu), 100
units/ml (U/ml) of penicillin/streptomycin (pen/strep) and 5% v/v foetal calf serum (FCS) in
75cm2 flasks.
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2.1.2.2 Baby hamster kidney cells
Baby hamster kidney cells (BHK-21) (Macpherson and Stoker, 1962) were maintained in
Glasgow's Modified Eagle's medium supplemented with 10% v/v tryptose phosphate broth
(Life Technologies, Paisley) and 10% v/v new bom calf serum, L-glu (2mM), pen/strep (100
U/ml).
2.1.2.3 Hybridoma cell lines
B hybridoma monoclonal cell lines were maintained in RPMI-1640, 20% v/v FCS, 2mM L-
glu (2mM) and sodium pyruvate (ImM). Hybridoma cells grew as non-adherent aggregates
and were passaged every 2-3 days. Once the cells were established in culture, FCS content
in the culture medium was reduced by half with each passage and replaced with Ultradoma
PF serum free medium (BioWhittaker).
2.1.3 In vitro stimulation of peripheral blood mononuclear cells
Blood was collected by jugular venipuncture into hcparinised containers (5U/ml). The
mononuclear fraction was isolated by overlaying the blood onto an equal volume of Ficoll-
Hypaque (density 1.077, Sigma), followed by centrifugation at 1600 x g for 30 minutes at
room temperature (rt). No brake was applied on deceleration. The mononuclear layer was
collected from the interface and washed twice in prewarmed Hank's balanced salt solution
(HBSS) at 300 x g for 5 minutes at rt.
Peripheral blood mononuclear cells (PBMC) were resuspended at 2 x 106 cells/ml in RPMI
1640 (Life Technologies) supplemented with 10% FCS, 2-mercaptoethanol (2-ME), L-glu
(2mM), pen/strep (100 U/ml). A 75cm2 flask was then seeded with 8ml of cell suspension.
LPS derived from Salmonella typhimurium (Sigma) was added to the cell suspension at a
final concentration of lpg/ml and cells were stimulated for 24-48 hours at 37°C.
Alternatively, concanavalin A (Con A, Sigma) was added to the cell suspension at a final
concentration of lOgg/ml and cells were stimulated for 24-48 hours.
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2.1.4 Counting cells
A lOjxl volume of cell suspension was mixed with lOpl of 0.5% (weight/volume (w/v))
trypan blue in phosphate buffered saline (PBS, Appendix I). A 10|ll aliquot of the mixture
was placed on a haemocytometer (Weber Improved Neubauer, Merck). Cells were counted
using a light microscope (Leitz). The cells that excluded the dye (viable cells) were counted.
2.1.5 Freezing cells
Approximately 107 cells were centrifuged at 400 x g for 7 minutes in a bench centrifuge,
followed by two washes with wash medium at 400 x g for 7 minutes. The cells were then
resuspended in 1 ml of freezing medium (90% FCS, 10% dimethylsulfoxide (DMSO)) in a
cryotube (Nunc, Life Technologies), which was placed overnight at -70°C. The cells were
then transferred to a liquid nitrogen tank (Jencons).
2.2 Immunochemistry
2.2.1 Monoclonal antibodies
The monoclonal antibodies (mAb) used in this thesis are listed in Table 2.1 and Table 2.2.
This illustrates their isotype, specificity and source for both immunolabelling (Table 2.1) and
flow cytometric analysis (Table 2.2). mAb were obtained from in-house stocks (John
Hopkins, University of Edinburgh), with the exception of IL-A24 and WC6 (European
Collection of Cell Cultures); IL-A156, IL-A159 and IL-A190 (kind gifts from Dr. Jan
Naessens, International Livestock Research Institute, Nairobi) and CC20 (Moredun Research
Institute, Scotland). mAb specificity was confirmed by flow cytometric analysis and
reactivity with PBMC or ALC.
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Table 2.1 mAb used in immuno(histo)chemistry. A panel of mAb was used in the detection of
cells in paraffin wax embedded tissues (lymph node and skin biopsies) and on frozen
sections (cryostats) and on cytospins of cell preparations. (CD, cluster of differentiation; WC-
1, workshop cluster 1; IAH, Institute of Animal Health; Ig LC, Ig light chain; AF, ascitic fluid;
SS, saturated supernatant; ov, ovine; bov, bovine.)
mAb antigen reactivity reference
VPM 54 SS MHC class II DRa DC, macrophages, Dutia et al (1995)
B cells, activated T cells
IAH-CC20 AF CD lb DC Howard et al (1993)
IAH-CC14 AF CDlb DC MacHugh et al (1988)
SBU-T6 SS CD1 DC/B cells MacKay et al (1988b)
VPM 5 SS CD1 DC Budjoso et al (1989)
OM1 CDllc DC, macrophages, Gupta et al (1993)
B cells
IL-A53 SS WC6 DC Dutia etal (1993b)
IL-A24 SS SIRPa SIRPa+ DC & monocytes Brooke et al (1998); Ellis
etal (1988)
VPM 67 SS CD 14 monocytes & macrophages Hopkins and Gupta (1996)
VPM 65 SS CD 14 monocytes & macrophages Gupta et al (1996)
VPM 30 SS 28 kD ovine pan B cell (hi) Naessens and Howard
activated T cells (lo) (1991)
VPM 8 Ig LC B cells Yirrell et al (1991)
73B SS CD45RA B cells, Dutia et al (1993c)
T cell subset,
IAH CC15 SS WC-1 y8 T cells Clevers et al (1990)
SBU-T8 SS CD8 CD8 T cells Maddox et al (1985)
SBU-T4 SS CD4 CD4 T cells Maddox et al (1985)
36F SS CD2 ap T cells MacKay et al (1988a)
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Table 2.2 mAb used in two-colour flow cytometry. Isotype and original references are listed.
Some mAb recognise antigens that have no established CD homologue but have been given
workshop cluster (WC) numbers at the International Ruminant Leukocyte Workshops
(Howard et al., 1991; Parsons et al., 1993). SIRPa is the ruminant homologue of human
signal regulatory protein-a (Brooke et al, 1998). (m, murine; r, rat; bio, biotinylated mAb.)
mAb specificity isotype reference
SW73.2
SW73.2-bio
MHC class II DRp &
DQp
rIgG2a Hopkins et al (1986)
VPM 54 MHC class II DRa IgGl Dutia et al (1995)
IL-A24 SIRPa mlgGl Ellis et al (1988); Brooke et al
IL-A24-bio (1998)
IL-A53 WC6 mIgG2a Dutia et al (1993b)
IL-A53-bio
CC14-bio CDlb mlgG MacHughet al(1988)
IL-A159 CD80 mlgG J. Naessens (personal
communication)
IL-A190 CD86 mlgG J. Naessens (personal
communication)
IL-A156 CD40 mlgG J. Naessens (personal
communication)
VPM 5 CDlb mlgM Bujdoso et al (1989)
OM1 CDllc mlgGl Gupta et al (1993)
IAH-CC6 CD2 mIgG2a MacKay et al (1988a)
2.2.1.1 Purification of Ig from ascitic fluid and saturated supernatant
Ig from ascitic fluid (AF) or hybridoma supernatant (SS) was purified by ammonium
sulphate precipitation according to the method of Hudson and Hay (Hudson and Hay, 1989).
Briefly, Ig was precipitated with ammonium sulphate (pH 6-7) at 50% saturation (w/v) for
30 minutes (AF) or 20 minutes (saturated supernatants (SS)) at rt. The preparations were
centrifuged at 10,000 x g for 20 minutes. The precipitate was washed twice with 50%
saturated ammonium sulphate, re-dissolved in PBS and extensively dialysed into PBS for 12
hours at 4°C. The protein concentration was determined by spectrophotometry OD2go, where
an absorbance reading of 1.35 is equivalent to lmg/ml protein. mAb were stored at -20°C in
the presence of 0.01% sodium azide.
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When new mAb preparations were used, Ig content was analysed by fractionating the
proteins by polyacrylamide gel electrophoresis (PAGE) and visualised by Coomassie Blue
staining (Section 2.2.5.2) or Immunoblotting (Section 2.2.5.3).
2.2.1.2 Biotinylation of monoclonal antibodies
Igs were either extensively dialysed in 0.1 M NaHC03 (pH 8.3), or a buffer exchange into
0.1 M NaHC03 was carried out using a Sephadex G 25 (PD-10) column (Amersham). The
concentration of Ig was adjusted to 1 mg/ml by dilution in 0.1M NaHC03 prior to
biotinylation. Biotinylation was carried out by incubating Ig for 5 hours with biotin (biotin-
amido caproate N-hydroxysuccinimide ester) in DMSO (2.5 mg/ml) at a biotin to protein
ration of 75pg: 1 mg. Biotinylated (bio) Ig was then extensively dialysed against PBS, 0.01%
sodium azide, pH 7.2 for 12 hours at 4°C before a final 3 hour dialysis against PBS-azide
containing 20% glycerol. Biotinylated mAb were stored at -80°C.
2.2.2 Preparation for immunohistochemistry
2.2.2.1 Paraffin wax embedded tissue
Prefemoral lymph nodes were removed from Suffolk sheep during routine cannulation
surgery to obtain a source of material on which mAb could be applied to test for reactivity
against a variety of cell types. The tissue was placed on a petri dish and lymphoid tissue was
dissected from the surrounding fibrous connective tissue with a sterile scalpel. Lymph nodes
were fixed in zinc salts fixative (ZSF; Appendix I) for 6-8 hours at rt and then trimmed and
fixed in fresh ZSF for 24—72 hours (Gonzalez et al., 2001).
Skin samples from shaved skin were removed using a disposable biopsy-punch (6mm x
5mm; Stiefler) immediately at post-mortem. Connective tissue and hair was trimmed.
Biopsies were then fixed in either (i) ZSF (as described above), or (ii) 4% paraformaldehyde
(in PBS, 0.22pm filtered, pFI 7.2) for 24-48 hours at 4°C.
Following fixation, tissues were trimmed and subjected to an automated process through
increasing concentrations of ethanol, isopropanol and xylene, prior to embedding in low
temperature paraffin wax. Biopsies were sectioned at 5pm, mounted on treated glass slides
(Superfrost Plus, Menzel-Glaser, Germany) and allowed to dry overnight at 37°C. Neil
Mclntyre, Andrew Dawson and Sharon Moss at Easter Bush Veterinary Centre (EBVC),
Midlothian, Scotland, processed and sectioned all tissues and stained skin sections with
haematoxylin and eosin (H & E).
47
2.2.2.2 Frozen tissue
Skin biopsies were snap-frozen at -70°C in a mixture of dry ice and isopentane and stored at
-80°C until sectioned.
2.2.2.3 Cytospins
Cytospins of single cell suspensions from lymph were prepared by spinning lOOpl of cell
suspension (1 x 106 cells/ml) onto pre-chilled silane-prep™ microscope slides (Sigma) at
300 revolutions per minute (rpm) for 3 minutes using a Cytopsin-2 (Shandon). Cytospins
were fixed in ice-cold acetone for 5 minutes, air-dried and then stored at -20°C until stained.
Cytospins were also prepared from purified ALDC populations (approximately 25,000-
100,000 cells/ml) and either fixed in acetone (for subsequent immunostaining) or air-dried
(ATPase staining) prior to storage at -20°C. Cytospins were stained with Gurr® Giemsa's
stain solution (improved R66, BDH) for 15 minutes. After staining, cytospins were washed
in tap water, rinsed briefly in dH20 and dried. ATPase staining was carried out with Neil
Mclntyre (EBVC).
2.2.3 Immunohistochemistry
2.2.3.1 Immunostaining of paraffin-wax embedded tissue
Immunohistochemical labelling was carried out using a Dako Envision Horseradish
Peroxidase (HRP) kit, based on a published method (Gonzalez et al, 2001). Slides were
dewaxed by immersion in Clearene (Surgipath) for 15 minutes and gradually hydrated
through graded alcohols. Slides were then washed twice in distilled water (dll20) and
immersed in Tris Buffered Saline (TBS; Appendix I). Two initial blocking steps were carried
out:
(i) Endogenous peroxidase activity was quenched with a peroxidase block
(supplied in the kit) for 5 minutes at rt
(ii) Non-specific tissue antigens were "blocked" by incubating the sections with
25% normal goat serum (NGS) for 30 minutes at rt in a humidity chamber.
Sections were incubated with mAb (Table 2.1) overnight at 4°C in a humidity chamber after
which they were rinsed once and then washed three times in TBS containing 0.1% Tween-20
(TBST) with gentle agitation. The secondary antibody (HRP-conjugated goat anti-mouse
antibody) was applied for 30 minutes at rt and sections were washed 3 times in TBST.
Conjugate binding was detected by adding the substrate chromagen (3,3'-diaminobenzadine;
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DAB (Sigma)) and colour was allowed to develop for 7-8 minutes. Finally, tissue sections
were rinsed in dH20 and counter-stained with haematoxylin, rinsed in tap water, dehydrated
and mounted.
TBST was used to wash the tissue sections between each stage of the labelling procedure and
TBS was used to prepare NGS and antibody dilutions. Omission of the primary antibody was
used to provide a negative control.
2.2.3.2 Antigen retrieval
After blocking of endogenous peroxidase, PFA-fixed tissues were subjected to trypsin
treatment (trypsin tablets, Sigma) for 15-30 minutes at 37°C. Slides were washed twice in
TBST and then blocked for 30 minutes in 25% NGS. Staining was then carried out as
already described.
2.2.3.3 Immunochemical labelling of cytospins and cryostats
Cryostats and cytospins were allowed to reach rt, air dried for 5-10 minutes, rehydrated in
PBS and washed in TBS. After rehydration, a hydrophobic barrier was drawn around
sections using a Pap-pen (Zymed Laboratories Inc.) and slides were again air dried for 3
minutes. Blocking of endogenous peroxidase and non-specific antigens and the staining
procedure was carried out as described in Section 2.2.3.1 with the exception that incubation
with primary antibody was carried out for 1 hour at rt. Haematoxylin was used as a
counterstain.
2.2.3.4 Double Immunochemical labelling of cytospins
Detection of primary antibody was carried out as described in Section 2.2.3.1. After
incubation with DAB substrate, slides were rinsed twice in dH20 and then once in TBST,
blocked for 30 minutes in 25% NGS and then incubated with a second mAb for 1 hour.
Slides were washed three times in TBST and a secondary biotinylatcd antibody (ABC kit,
Vector Laboratories) was then applied for 30 minutes. Slides were washed and ABC-AP
reagent was added to sections and incubated for 30 minutes. Slides were washed again and
Vector Blue alkaline phosphatase was added and colour was allowed to develop for up to 20
minutes.
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2.2.3.5 Immunofluorescent staining of transfected cells
Transfected SSk fibroblasts or BHK cells were harvested 16 hours post-transfection (Section
2.3.8.1) by rinsing the cells with sterile PBS (sPBS) followed by rinsing in 500pl versene
EDTA solution (BioWhittaker™) until cells detached. Cells were transferred into 1.5ml
Eppendorf tubes, washed twice in sPBS and then resuspended in 20pl sPBS. Cells were
spotted onto a multiwell slide (BDH), air-dried and fixed in ice-cold methanol/acetone for 30
seconds. Prior to immunostaining, cells were permeabilised by immersion in 0.1% Triton-X.
Non-specific binding was prevented by incubating slides in blocking solution (25% NGS in
sPBS) for 10 minutes at rt. Primary antibody (2H11; 1:200 in blocking solution) was then
added to the cells and incubated for 1 hour at rt. Primary antibody was removed by washing
slides three times in PBS. Secondary antibody (TRITC-conjugated goat anti-mouse IgG) was
added and incubated for 1 hour. Cells were washed in PBS, slides were mounted with anti-
fade mounting solution (Dako) and visualised by fluorescent microscopy.
2.2.4 Flow cytometry
2.2.4.1 Cell preparation
Pseudoafferent lymph was obtained from chronic cannulation of the prefemoral efferent and
pseudoafferent lymphatics (Hall, 1967; Hopkins et al., 1986). Lymph was collected into
sterile plastic bottles containing 400U of heparin, 1000U penicillin, lmg streptomycin. In
experiments evaluating cytokine expression of DC, all buffers were supplemented with
actinomycin D (final concentration lpg/ml, Sigma) in order to prevent de novo transcription.
Collections were performed at 24-hour intervals to record lymph volume and cell counts.
Animals were allowed at least six days post-operative recovery and the lymph was assessed
for erythrocyte and PMN contamination by flow cytometric light scatter profiles.
2.2.4.2 Single colour flow-cytometry
ALC were collected by centrifugation at 300 x g for 5 minutes at 4°C. Cells were washed
twice in ice-cold FACS buffer (PBS, 2% bovine serum albumin (BSA), 0.05% sodium azide,
pH 7.2) and then resuspended in blocking buffer (FACS buffer containing 10% NGS) at a
concentration of 1 x 107 cells/ml for 30 minutes on ice. Cells were dispensed into FACS
tubes (50pl/tube) and incubated for 15 minutes at 4°C with 25pl of primary mAb
(biotinylated or non-biotinylated mAb; (Table 2.2) diluted appropriately in FACS blocking
buffer. Unbound antibody was removed by washing twice with 2.5ml ice-cold FACS buffer.
Biotinylated primary mAb were detected following incubation with 3.5pl streptavidin-
50
phycoerythrin (SA-PE, Sigma) in the dark for 15 minutes at 4°C. Non-biotinylated mAb
were detected following incubation in the dark for 15 minutes with 25pi of FITC conjugated
anti-mouse Ig (Sigma) diluted 1:1000 in FACS buffer. Cells were washed twice in FACS
buffer and re-suspended in 2% paraformaldehyde prior to analysis.
Normal mouse serum (NMS; 1:500) was used as a negative control to assess non-specific
binding. Biotinylated NMS (1:100) was used to assess background staining where
biotinylated mAb were used.
2.2.4.3 Two-colour flow-cytometry
For double staining (using antibodies of the same isotype), cells were first incubated with the
mAb to be labelled with FITC. Cells were washed and incubated with FITC-antiglobulin
conjugate. After washing, cells were incubated with the second biotinylated antibody (Table
2.2) for 15 minutes at 4°C and washed twice. The second biotinylated mAb was detected
with SA-PE in the dark for 15 minutes. Cells were washed and prepared for flow cytometric
analysis as above.
2.2.4.4 Flow cytometer settings
The immunofluorescence studies described were carried out using the Becton Dickinson
(BD) FACScan flow cytometer and data were analysed using the Cell Quest software. Data
were obtained by analysis of 5000-10,000 cells (events) from each sample. Different cell
populations were distinguished by gating using appropriate linear photomultiplier tube
(PMT) voltage amplifications for forward scatter (FSC) and side scatter (SSC) parameters.
FSC and SSC parameters define cell size and complexity respectively. ALDC have high FSC
and SSC (Figure 2.1). Fluorescence measurements were made on homogenous populations
of cells by setting gates on dot plots. For two-colour flow cytometry analysis, compensation
settings were determined to overcome the spectral overlap from FITC and SA-PE
fluorochromes. The appropriate %FL1-FL2 and %FL2-FL1 PMT voltage compensation was
used. Cells were single stained for MHC class II with mAb VPM 54 (DRa) (detected with
anti-Ig-FITC) or SW73.2 (DRfi DQ(3) biotin conjugate (detected with SA-PE).
Compensation thresholds for FL1 and FL2 were adjusted so that fluorescent cells were in
line with quadrants set with negative controls and parallel to the axis (Figure 2.2).
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Figure 2.1 Gate criteria used in flow cytometry. Cell populations were defined by light scatter
properties and gates were positioned around homogeneous populations of cells. ALDC were
defined by high FSC and high SSC (R1). Lymphocytes were defined by low to medium FSC
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Figure 2.2 Compensation settings for two-colour flow cytometry. ALC were resuspended at
I x 107 cells/ml and then single-stained with either (a) VPM 54 supernatant (anti-MHC class
II DRa) or (b) biotinylated SW73.2 (anti-MHC class II DRp DQP) diluted 1:1500.
Compensation settings were finely adjusted until single stained cells were contained in either
FL1 (VPM 54) or FL2 (SW73.2) quadrants and aligned with the centre of the unstained cell
population (c).
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2.2.4.5 Titration of mAb
mAb used in flow cytometry experiments were titrated on ALC to establish optimal working
concentrations. The optimal dilution of the primary antibody was that which gave strongest
specific fluorescence and lowest background staining of the negative population. A normal
histogram distribution was considered to be mAb-binding saturation (Figure 2.3c).
Gated Events: 5000
Total Events: 53527




































Figure 2.3 Titration of anti-CD1b mAb (VPM 5) on ALC. ALC were resuspended at 1 x 107
cells/ml and stained with (a) negative control (NMS) diluted 1:100 in FACS buffer. Note that
< 1% of (background) staining is evident. VPM 5 diluted (b) 1:75, (c) 1:100, (d) 1:250 and (e)
1:500. 5000 events were counted in the DC (R1) gate (Figure 2.1). A normal histogram
distribution is evident in (c).
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2.2.4.6 Enrichment of ALDC for cell sorting
ALDC were enriched by centrifugation through OptiPrep™ (Axis-shield) based on a
published method for isolating blood monocytes (Graziani-Bowering et al., 1997). The
OptiPrep™ solution was allowed to reach rt and mixed well prior to use.
ALC were collected by centrifugation at 300 x g for 5 minutes at 4°C. The cells were then
washed and resuspended in 0.22pm filtered Buffer B (sPBS, ImM EDTA, 0.5% BSA) at 2 x
107 cells/ml. The method is summarised in Figure 2.4. To a 2.5ml volume of cell suspension,
lml of OptiPrep™ was added and gently mixed. Using a sterile pastette, the lymph-
OptiPrep™ mixture was carefully overlaid with 4ml of a 1.078 g/ml lymphocyte-specific
density layer (OptiPrep™ was diluted in sPBS containing ImM EDTA). This layer was
overlaid with 10 ml of a 1.068 g/ml solution, which was then overlaid with lml sPBS. Care
was taken to prevent mixing of layers. The lymph/OptiPrep™ mixture was centrifuged at
600 x g for 25 minutes at rt with a swing-out rotor; no brake was applied on deceleration.
Cells were collected from the interphase of the 1.068g/ml layer and sPBS (fraction 1) and
were washed with 5ml of sPBS and centrifuged at 200 x g for 5 minutes at rt. The
supernatant was removed and the cells were washed again in 20ml ice-cold FACS buffer at
300 x g for 5 minutes at 4°C. Cells were then resuspended in either (i) blocking buffer (for
subsequent staining for cell sorting) or (ii) sPBS for cytospin preparations. DC were enriched

















Figure 2.4 Schematic representation of the DC isolation procedure from afferent lymph
using OptiPrep™. The diagram illustrates the set-up of the lymph/OptiPrep™ mixture and
the various density layers and the banding patterns of the cells following a 25 minute spin at


























Figure 2.5 Enrichment of DC from afferent lymph. DC were enriched by centrifugation with
Optiprep™ (Section 2.2.4.6, Figure 2.4). Unfractionated lymph and the enriched DC-fraction
were washed twice in FACS buffer and resuspended at 5 * 106 cells/ml. Cells were fixed in
2% paraformaldehyde and flow cytometry analysis was carried out. DC comprise
approximately 9% in unfractionated lymph (a), and are enriched to approximately 48%
following centrifugation in OptiPrep™ (b).
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Figure 2.6 Immunoperoxidase stained cytospins of unfractionated lymph and DC-enriched
fractions, (a) Unfractionated lymph immunolabelled with SBU-T6 (pan anti-CD1) and
counterstained with haematoxylin (original magnification, *80); (b) DC-enriched fraction
(fraction 1) immunolabelled with SBU-T6 (original magnification, *80); (c) double
immunolabelled DC (fraction 1) stained with VPM 54 (MHC class II DRa, brown cells) and
SBU-T6 (blue cells) (original magnification, *250); (d) DC-enriched fraction (fraction 1)
stained with SBU-T6 (original magnification, *250).
2.2.4.7 Immunolabelling of ALDC for cell sorting
Two subpopulations of ALDC were easily distinguished based on expression of SIRPa
(mAb IL-A24) and MHC class II expression (mAb SW73.2) (Figure 2.7a), whereas
populations were not as easily defined after staining with IL-A24 and biotinylated CC14
(anti-CDlb; Figure 2.7b) or after staining with IL-A24 and a biotinylated WC6 (anti-DEC
205; Figure 2.7c). IL-A24 and biotinylated SW73.2 were therefore used for all subsequent
cell sorting experiments.
Immunolabelling prior to cell sorting was carried out essentially as described for
immunolabelling of ALC. Briefly, the enriched DC-fraction (following centrifugation with
OptiPrep™) was washed in sPBS and resuspended in FACS blocking buffer. Cells were
counted and dispensed into FACS tubes (2 x 106- 8 x 106 cells/tube). Cells were centrifuged
at 300 x g for 5 minutes at 4°C and resuspended in a total volume of 500pl blocking buffer
(containing actinomycin-D) for 30 minutes on ice. Sequential staining was then carried out
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using 250(0.1 of each of the antibodies diluted appropriately in FACS buffer. Undiluted tissue
culture IL-A24 supernatant (anti-SIRPa) and biotinylated SW73.2 (anti-MHC class II (3,
diluted 1:1500) were used to stain cells (Figure 2.7a). Half of the recommended volume of
SA-PE was used to detect the biotinylated mAb. After each stage, cells were washed twice in
3.75ml ice-cold FACS buffer. Cells were stored in FACS buffer containing actinomycin-D























































Figure 2.7 Double immunolabelling of ALDC. Enriched DC were immunolabelled with mAb
IL-A24 (anti-SIRPa) followed by (a) biotinylated SW73.2 (anti-MHC class Hp), (b) biotinylated
CC14 (anti-CD1b) and (c) biotinylated WC6 (anti-DEC-205).
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2.2.4.8 Fluorescence activated cell sorter settings
DC populations were purified using fluorescent activated cell sorting (FACS)
(FACSvantage, Becton Dickinson). PMT voltage settings for FSC and SSC parameters, and
compensations defining fluorochrome light emittance were determined for each experiment,
as described in Section 2.2.4.4. Samples were analysed and sorted using a sheath pressure of
9 psi, analysing approximately 20,000 cells per second (2 cells were analysed per drop). The
flow rate of cells analysed was similar in each experiment. This enables the software to
discern individual cells for analysis and sorting. At higher flow rates, or where cell
resolution was not achievable, cells were 'aborted'. The abort rate was consistently 5-10%
of cells analysed. Samples that were sorted at abort rates higher than 10% were discarded.
2.2.4.9 Electron microscopy of FACS-sorted DC
FACS-sorted DC were centrifuged at 10,000 x g for 3 minutes and the supernatant carefully
removed. Cells were washed once in sPBS and centrifuged as above. Approximately 1ml of
3% glutaraldehyde (in 0.1M cacodylate buffer) was added to the pellet and cells were fixed
for 2-3 hours at 4°C with occasional agitation. Cells were again centrifuged and 1ml of
fixative was slowly added to the pellet. Care was taken so as not to disturb the cell pellet and
cells were stored overnight at 4°C in fixative. Further processing of samples was carried out
by Steve Mitchell (Division of Veterinary Biomedical Sciences, University of Edinburgh).
This involved post-fixing the cells in osmium tetroxide in 0.2M cacodylate buffer, followed
by several washes. Cells were than gradually dehydrated in ethanol, propylene oxide and
epoxy resin and finally embedded in resin until sectioned.
2.2.5 Detection of protein
2.2.5.1 Sodium dodecyl sulphate (SDS)-PAGE
Proteins were fractionated by SDS-PAGE. Samples were boiled for 5 minutes in an equal
volume of double strength sample buffer (Appendix I), then vortexed for 30 seconds and
centrifuged at 10,000 x g for 3 minutes at rt. The samples were separated by electrophoresis
under reducing conditions using a 12% acrylamide resolving gel and a 4% acrylamide
stacking gel (Appendix 1) at a constant 140V for approximately 80 minutes until the dye
front reached the bottom of the gel. This was performed at rt in a gel electrophoresis tank
(Biorad) containing running buffer (Appendix I). Following electrophoresis, the gel was
either stained in Coomassie blue or prepared for Western Blotting. Biorad low range
molecular weight markers (range 20.5-111 kDa) were run on each gel.
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2.2.5.2 Coomassie blue staining
Gels were stained for 30 minutes in Coomassie blue (0.1% Coomassie Brilliant Blue R-250
in 10% methanol, 10% acetic acid), then rinsed briefly in tap water and transferred to
Coomassie blue destain (20% methanol and 10% acetic acid) and left overnight or until
bands were clearly visible.
2.2.5.3 Detection of purified mAb by Western blotting
Following SDS-PAGE separation, the proteins were transferred to a polyvinylidene fluoride
(PVDF) membrane (Roche) using a semi-dry electroblotter (Trans-Blot SD, Biorad).
Transfer was performed in transfer buffer (Appendix I) for 1 hour at a constant current of
120mA. Following transfer, non-specific sites on the membrane were blocked in a solution
of 0.2% Tween-20 (Sigma) and 5% w/v dried milk (Cadbury's Marvel) in PBS overnight at
rt. Blots were washed 5 times over 30 minutes in wash buffer (PBS, 0.1% Tween-20) and
then incubated with 1:1000 dilution of FIRP-conjugated rabbit anti-mouse antibody (Dako)
followed by washing. Conjugate binding was detected by adding the substrate chromagen
(3,3'-diaminobenzadine; DAB) (Sigma) and colour was allowed to develop for 7-8 minutes.
2.2.5.4 Detection of IL-3 by Western blotting
This was carried out as essentially as already described with the exception of the following.
After blocking, the membrane was cut into several strips. Each strip was then incubated with
a primary anti-IL-3 antibody diluted in wash buffer (1:200 dilutions of the following AF:
2H11 H6 clone 2; 2H11, 3F7 D4, 2H11 and neat hybridoma supernatant, 5A6/F9) for 2
hours and washed as above. Detection of bound antibody was carried out by incubating blots
for 1 hour at rt in a 1:1000 dilution ofHRP-conjugated rabbit anti-mouse antibody (Dako).
ECL was also used to provide increased sensitivity in development of membranes probed
with anti-IL-3 antibodies (as recommended by the manufacturer). All steps were carried out
as described above with the exception ofwashes being carried out in a solution of PBS, 0.5%
Tween-20 (PBST) for 45 minutes.
2.2.5.5 Detection of GM-CSF by sandwich ELISA
This was carried out according to a published method (Entrican et al., 1996). Recombinant
GM-CSF and anti-GM-CSF mAb were obtained from Dr Gary Entrican (Moredun Research
Institute, Scotland). Flat-bottomed 96 well ELISA plates (Immulon, Dynex) were coated
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with 50M-1 per well of 8D8 affinity mAb at a concentration of lpg/ml in 0.1M carbonate
buffer (pH 9.6; Appendix I) and incubated at 4°C overnight. Plates were washed twice with
PBST and then blocked for 30 minutes rt with 1 OOpl per well PBST containing 3% BSA and
0.05% Tween-20. The plates were then washed twice with PBST. GM-CSF standards and
tissue culture supernatants were prepared by dilution in 3%BSA/PBS/Tween-20. 50pl of the
GM-CSF standards and the test samples (supematants from transfected cells) were loaded.
The plates were incubated for 1-1.5 hours at rt and then washed six times with PBST. 50pl
of the affinity purified monoclonal 3C2-peroxidase conjugate (diluted 1:500 in PBST) was
loaded into each well and then incubated for 1 hour at rt and washed six times in PBST.
50pl/well TMB Microwell Peroxidase substrate (Sigma) was added to each well and colour
was allowed to develop for approximately 10 minutes. The reaction was stopped by adding
50|Lil/well 0.1M Hydrochloric acid. The optical density (OD) was measured using a Dynex
ELISA reader equipped with a 450nm filter. Blank wells contained all reagents with the
exception of sample/GM-CSF standard; supernatant was added to these wells.
2.3 Molecular biology section
2.3.1 Handling of RNA and DNA and molecular biological
techniques
Many of the methods used in handling DNA or RNA were based on methods given in
"Molecular Cloning: A Laboratory manual" (Sambrook et al., 1989). All restriction enzymes
and buffers were obtained from New England Biolabs (NEB).
2.3.2 Measurement of DNA/RNA concentration
The amount of DNA or RNA present in the sample is directly proportional to the amount of
UV radiation absorbed by the sample. The concentration of nucleic acid was determined by
spectrophotometry (GeneQuant II, Amersham Pharmacia Biotech). Absorbance was
measured at wavelengths of 260 and 280nm.
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DNA concentration = Absorption at 260nm (A260) x 50 x dilution factor,
RNA concentration = Absorption at 260nm (A260) x 40 x dilution factor,
where an A260 of 1.0 is equivalent to 50mg/ml of DNA and 40mg/ml of RNA. The purity of
DNA was calculated as a ratio of OD26o/OD28o. A value greater than 1.8 (DNA) and 1.9
(RNA) indicates that the sample is free of protein contamination.
2.3.3 RNA isolation
Precautions were taken to preserve the integrity ofRNA transcripts throughout the following
procedures. Particular emphasis was placed on avoiding contamination with ribonucleases
(RNases). Bench surfaces and pipettes were thoroughly cleaned with 70% ethanol, followed
by removal of RNases with RNaseZAP® (Sigma) in combination with molecular grade water
(Sigma). Sterile disposable plastic ware was used and gloves were changed frequently.
Molecular grade water was used for all elution steps and preparation of wash solutions.
Molecular grade ethanol was used for all wash steps.
2.3.3.1 Isolation of total RNA from tissue
Total RNA was isolated from skin biopsies and spleen samples using the RNeasy® Mini kit
(Qiagen®), which allows the purification of up to lOOpg RNA from animal cells and tissues.
Immediately post-mortem, biopsies were removed using a sterile biopsy-punch and then
placed into 1ml RNA/ater™ (Sigma). Tissue was stored in RNA/a/er™ overnight at 4°C and
then removed from RNA/ater™ into fresh 1.5ml Eppendorf tubes and stored at -80°C until
RNA extraction was performed.
Homogenisation of tissues
Skin biopsies and spleen samples were removed from -80°C storage and allowed to reach rt.
Each biopsy was placed onto a sterile Petri dish and finely chopped into small pieces using
two sterile scalpels. The shreds of tissue (no more than 30mg) were then carefully placed
into a clean 1.5ml Eppendorf tube, to which 350pl of lysis buffer (supplied with the kit) was
added. Lysis buffer contained the RNase inhibitor 2-ME. The tissue was homogenised using
a motorised pestle and mortar until the sample was uniformly homogenised. Following
homogenisation in lysis buffer, 550pl of nuclease-free water was added followed by 1 Oul
proteinase K (20mg/ml; Sigma). The contents were thoroughly mixed and incubated for 15
minutes at 55°C in a hot-block. Genomic DNA was sheared by complete homogenisation
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with a 20-gauge needle (0.9mm diameter). To avoid contamination between samples,
separate pestles were used for each biopsy. Pestles were autoclaved and soaked in
RNaseZAP® (Sigma) and nuclease-free water overnight prior to use.
RNA extraction from tissue
Briefly, homogenates were centrifuged at 10,000 x g for 3 minutes at rt. The supernatants
were dispensed into Qiagen® mini spin columns and all steps thereafter were carried out as
outlined in the manufacturer's instructions. All samples were treated with DNase (Qiagen®
DNase kit) on the spin column membranes.
2.3.3.2 Removal of plasmid DNA from skin biopsy RNA samples
Further treatment ofRNA samples extracted from DNA vaccinated skin sites was required in
order to remove remaining plasmid DNA not completely removed by the on-membrane
DNase step (Qiagen® kit). Complete removal of plasmid DNA was essential prior to
quantitative RT-PCR analysis of gene expression in skin (Section 2.6.2). Further removal of
plasmid DNA in RNA samples was carried out in solution with DNase and restriction
enzymes.
Removal of plasmid DNA from RNA
To remove plasmid DNA containing the GM-CSF insert, lOpl reactions were prepared as
follows. To a 0.6ml Eppendorf tube, 6pl of RNA (0.5-7pg total RNA), lpl 10 x BSA
(NEB), lpl RQ1 buffer (Promega), 1 pi (1 U) of RQ1 DNase and 1 pi (20 U) Pst-1 were
added and gently mixed. Removal of plasmid containing the IL-3 insert was carried out as
described above, with the exception that (i) 7pi of RNA was treated in each reaction (ii) BSA
was omitted and (iii) lpl Hinf-1 (10 U) was used instead of Pst-1.
Approximately lOpg of total RNA was treated in this manner for each individual biopsy;
multiple reactions were prepared for each sample. All treatments were incubated at 37°C for
1.5 hours. Tubes were gently mixed halfway through the incubation. Following treatment of
RNA to remove plasmid DNA, tubes were briefly centrifuged to collect the contents. DNase
was inactivated by addition of lpl RQ1 Stop Solution (Promega). DNase was further
inactivated by heating at 65°C for 10 minutes. Tubes were then immediately place on ice for
5 minutes and the contents collected by centrifugation. RNA samples from the same biopsy
were pooled and volumes adjusted to a total volume of 1 OOpl in nuclease-free water.
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RNA clean-up
To remove any reagents which may interfere with downstream applications,
DNase/restriction enzyme treated RNA samples were purified using the Qiagen® RNA mini
spin columns as described by the manufacturer's instructions ("RNA clean-up procedure").
RNA was eluted in 30pl of nuclease-free water.
2.3.3.3 RNA isolation from cells in suspension
Total RNA was isolated from cells in suspension using the SV Total RNA kit (Promega). No
more than 5 x 106 cells were used for each extraction.
Harvesting of cells
In vitro stimulated PBMC. Following 24-48 hour in vitro stimulation, non-adherent PBMC
and culture medium were removed from the flask(s). Cells were collected by centrifugation
at 300 x g for 5 minutes at 4°C. Cells were then washed twice in sPBS to remove FCS.
Adherent cells were rinsed in sPBS followed by the addition of 0.5ml of pre-warmed trypsin
(in-house) until cells detached. PBMC were washed as above and combined with the
adherent-cell fraction and stored on ice until lysis was carried out.
Transfected fibroblasts. Approximately 48 hours after transfection, fibroblasts were
harvested by trypsin treatment, washed twice in sPBS and stored on ice until extraction was
performed.
FACS-sorted ALDC. ALDC populations purified by FACS were transported on ice and were
temporarily stored in FACS buffer containing actinomycin D (lpg/ml final concentration).
Cells were collected by centrifugation at 300 x g for 5 minutes at 4°C and washed once in
2ml ice-cold sPBS.
Cell lysis and RNA extraction
Cells were counted prior to RNA extraction (with the exception of FACS-sorted ALDC).
Prior to cell lysis, cells were collected by centrifugation at 300 x g. Supernatants were
carefully aspirated and any residual liquid was allowed to drain onto tissue paper. 175pl of
SV RNA lysis buffer (Promega) was added to the cell pellets and mixed by vigorous
vortexing. Genomic DNA was sheared by homogenisation through a 20-gauge needle. Total
RNA was isolated using the SV Total RNA kit as described by the manufacturer. All
samples were subjected to DNase treatment on the membrane (supplied with the kit).
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2.3.3.4 Concentration of RNA
RNA was concentrated under vacuum with a Savant DNA 110 Speed Vac Concentrator
System. Eppendorf lids were pierced several times using a sterile needle. The rotor was
thoroughly cleaned with ethanol and RNaseZAP® prior to use. RNA samples were
concentrated by spinning at ambient temperature under vacuum until the correct volume was
obtained for reverse transcription.
2.3.4 First strand cDNA synthesis using reverse transcriptase
RNA was reverse transcribed using an oligo dT primer to give a heterogeneous population of
cDNA templates, which were subsequently used as the starting template for RT-PCR. The
presence of undegraded genomic material was tested for each RNA sample. Briefly, 1 pg of
RNA2 was diluted in nuclease-free water to give a final volume of 13pl. 500ng of Oligo-
(dT)i5 (Promega) was added to the RNA and incubated at 70°C for 5 minutes, followed by
cooling on ice to allow annealing of the primer. Contents were collected by brief
centrifiigation and lOpl of the reaction mix (Table 2.3) was added to each tube.
The reactions were gently mixed and lpl (50U) ofMMLV-RT (Promega) added. To test for
the presence of undegraded genomic DNA, 1 pi of nuclease-free water was added instead of
the RT enzyme. Reactions were then incubated for 10 minutes at 40°C, followed by 50
minutes at 42°C. The cDNA was heated for 15 minutes at 70°C to inactivate the RT enzyme.
Table 2.3 RT master reaction mix. 10pl of the mix was added to the
RNA/Oligo dT prior to the addition of the RT enzyme.
reagent company volume
5 x M-MLV (H-) reaction buffer Promega 5 pi
RNase block ribonuclease inhibitor Invitrogen 0.5 pi
(40U/pl)
100 mM dNTPs Biogene 1.25 pi
Nuclease-free water Sigma 3.25 pi
2
When available. RNA yields from purified ALDC populations after a 24-hour collection of
lymph were low (average yield 0.5pg RNA from SIRPcf ALDC; range 0.2pg-2.5pg).
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2.3.5 Reverse transcriptase polymerase reaction (RT)-PCR
RT-PCR was carried out essentially as described by (Sambrook et al, 1989). GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) RT-PCR was performed on all samples to
confirm the presence of amplifiable cDNA on each occasion. Each RNA sample was tested
for the presence of undegraded genomic material (-RT reactions). For every run, appropriate
positive and negative controls were included. Sterile dH20 was always included as a control
for DNA contamination.
2.3.5.1 Safe PCR Practice
Care was taken throughout the preparation of PCR reactions to avoid contamination of
samples with amplified products, or unwanted DNA. Gloves were worn and changed
regularly, and sterile tubes and aerosol resistant tips were used throughout the procedure. All
PCR reagents were aliquoted and stored in smaller volumes.
2.3.5.2 Primer design for conventional RT-PCR
The primer pairs for all genes were designed from gene sequences deposited in GenBank
(Table 2.4) and designed using Netprimer33. Primers were checked for secondary structures
using Premier Biosoft4. Parameters for the design of primers for quantitative real-time RT-






Table 2.4 GenBank accession numbers of sequences used to design primers. (*, human and
murine sequences were aligned and primers were designed from homologous regions; f.























Amplification was carried out in a final volume of 50pl for the RT-PCR using 2gl of cDNA
synthesised from lpg of total RNA from the RT reaction. Briefly, the reaction mixture was
prepared by combining the following reagents to a total volume of 50pi in thin-walled PCR
tubes. Each reaction mixture consisted of 2pl template (cDNA or lOng plasmid DNA); 1 x
(Promega) PCR buffer (50mM KC1, lOmM Tris-HCl (pH 9.0), 1.5mM MgCl2); 20pmol of
each oligonucleotide primer (Sigma-Genosys); 200pM each dNTP (Biogene) and 2.5 U Taq
(Thermus aquaticus strain YT1) DNA polymerase. The reaction conditions for each primer
pair were optimised (Table 2.5)
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Table 2.5 Primers used for conventional RT-PCR. (R: reverse primer, F: forward primer, ov:
ovine, bov: bovine, hu: human; por: porcine, *: Langerin primers were designed from
homologous regions of aligned human and murine cDNA sequences)





ovGAPDH F: AAG GCA GAG AAC GGG AAG
R: AGT GAT GGC GTG GAC AGT
366bp 55 25
ovGAPDH F: GGT GAT GCT GGT GCT GAG TA
R: TCA TAA GTC CCT CCA CGA TG
265bp 57 25
ovGM-CSF F: GTC CTC AAG AGG ATG
R: GTC AAG GAG CCC GTG
300bp 57 30
ovIL-3 F: CAA GAC AGA ATC CGC CCT GC
R: AGG AGC CTT CTG GAC TCG GA
192bp 57 30
bovTLR3 F: ATA GGG ATT GGG TCT GGA A
R: TTT CTG CTC CTT CTG ATG CT
139bp 58 40
bovTLR4 F: GTT TCA AGG GTT GCT GTT CT
R: TGT TTC AGA GTG GAA TGC TG
15 lbp 58 40
bovTLR9 F: TGC TGT CCT ACA ACC ACA TT
R: GCG GAA CCA ATC TTT CTC TA
239bp 55 40
huCDla F: TGC TGT TTT TGC TAC TTC CA
R: TTC CTG AGA CCT TTC CAG AG
384bp 53 40
langerin* F: GTC GTG TGG ACA ACA TCA G
R: GGC ACT ATA CCA GGT CTT TG
400bp 53 40
porCCR7 F: ACA TCC TCT TCC TCC TGA CC
R: GAA AGC CCA CCA CCA TCT
387bp 55 40
2.3.5.4 Amplification
PCR amplification was carried out in a Hybaid Sprint Thermocycler. The oligonucleotide
primer pairs used for conventional RT-PCR are shown in Table 2.5. Optimisation of the
cycle number and annealing temperature for each primer pair was carried out. All RT-PCR
programs followed a similar thermal cycling profile, as described below:
An automatic "hot-start" was employed for PCR, to prevent mispriming and amplification of
non-specific products. The DNA template was initially denatured at 94°C for 3 minutes prior
to the addition of Taq polymerase. The reaction mixture was then cycled as follows:
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(i) 1 cycle of denaturation at 94°C for 1 minute
(ii) 1 cycle of annealing at *°C (Table 2.5) for 1 minute
(iii) 1 cycle of extension at 72°C for 1 minute
(iv) *cycles (Table 2.5) of denaturation (1 minute), annealing (1 minute) and
extension (1 minute) with 15-second increments per cycle
(v) 1 cycle of final extension at 72°C for 10 minutes.
2.3.5.5 Agarose gel electrophoresis
Preparation of agarose gels
The range of efficient separation of DNA in agarose gels of different concentrations is
shown in Table 2.6. The appropriate amount of Biogene® agarose (Table 2.6) was dissolved
in 1 x Tris acetate buffer (TAE, Appendix I) and heated in the microwave until the agarose
was completely dissolved. 1 pg/ml of Ethidium Bromide (Promega) was added to the gel
solution to visualise the DNA. The molten gel was poured into the appropriate casting tray
and allowed to set.
Table 2.6 Percentage of agarose for optimal resolution of DNA.
efficient range of






The cast gel was submerged in 1 X TAE. Samples were mixed with 6 x loading buffer
(Promega) and loaded into the wells. For DNA fragments between lOObp-lkb, lOObp or lkb
(Promega) DNA ladders were used. For DNA fragments >1 kb, EcoRl/Hindlll digested
lambda DNA markers (Promega) were used, lpg of markers were run on each gel.
Electrophoresis was carried out at 70mA until sufficient separation of the DNA was
achieved. The DNA was visualised and photographed using a UV Gel Documentation
System. (Ultra Violet Products).
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2.3.6 Quantitative real-time RT-PCR
The strategy employed for quantitative real-time RT-PCR and optimisation of this technique
is discussed in Section 2.5.
Quantitative real-time RT-PCR was performed according to the instructions outlined in the
LightCycler®-FastStart DNA Master SYBR Green I instruction manual (Roche). Capillaries
were pre-chilled prior to loading with samples. Cycling was performed in 20pl reaction
volumes containing 2pi template, 13.4ill nuclease-free water, lpM of each of the (internal)
oligonucleotide primers, 2pi of LightCycler®-FastStart Master SYBR Green I (containing
Taq polymerase with reaction buffer, dNTP mix, SYBR Green dye and ImM MgCF) and
2.4pl5 of additional MgCl2 (4mM final concentration of MgCl2). The capillaries were then
centrifuged for 30 seconds and loaded into the LightCyclcr®.
The cycling conditions are summarised in Table 2.7. Briefly, a hotstart was performed at
94°C for 10 minutes to activate Taq polymerase enzyme. Annealing temperatures for all
primer pairs was 57°C and reactions were carried out for 30-40 cycles followed by melting
curve analysis.
Table 2.7 Cycling conditions, optimised according to guidelines in the Roche handbook. All











1 95 600 20 none
(amplification) 40
1 95 5 20 none
2 57 10 7.999 none
3 72 30 12 single
(melting curve) 1
1 95 5 20 none
2 62 15 20 none
3 95 0 0.1 continuous
(cooling) 1
1 40 30 20 none
5
MgCI2was titrated and 4mM was the optimum concentration for all primers tested.
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2.3.7 DNA Extraction and cloning methods
2.3.7.1 Purification of DNA
DNA from PCR reactions, which was subsequently to be cloned, was purified by excising
the relevant band from the gel and subjecting it to a commercially available purification kit
(QIAquick Gel Extraction Kit, Qiagen®). The solutions and protocol were supplied with the
kit.
Alternatively PCR products and restriction enzyme digests were directly purified using
Qiagen® spin columns (Qiagen® PCR Purification kit) according to the manufacturer's
instructions.
2.3.7.2 Cloning of PCR products
Cloning of PCR products was carried out using a commercially available kit, pGEM®-T Easy
Vector Systems (Promega), which utilises the nontemplate-dependent activity of Taq
polymerase which adds a single deoxyadenosine ('A') to the 3' ends of PCR products. The
supplied, linearised vectors have a single 3' deoxythymidine ('T') residue, which allows the
PCR inserts to ligate efficiently with the vector.
The pGEM®-T Easy vectors contain a multiple cloning region with the a-peptide coding
region of the enzyme (3-galactosidase fused to the lacZ gene. Insertional inactivation of the
a-peptide allows recombinant clones to be directly identified by colour screening on IPTG-
X-Gal plates.
2.3.7.3 Ligation reactions
25-50ng of vector pGEM®-T Easy was ligated to the insert in the range of 3:1 to 10:1
(insert: vector). For subcloning of cytokine-gene constructs, 70-100ng of vector pEGFP-Nl
vector was ligated to the insert at 1:1, 1:3 and 3:1 molar ratios. Reactions were carried out in
a lOpl reaction containing vector and insert, 5 pi 2 x rapid ligation buffer (Promega) and 3 U
of T4 DNA ligase (Promega) and incubated at 4°C for 16 hours. Appropriate controls were
included to assess ligase, transformation efficiency and religation of the vector.
2.3.7.4 Transformation of competent cells
2pl of the ligation reaction was added to 50pl of JM109 or DH5a (Promega) "High
Efficiency" competent cells and incubated on ice for 20 minutes. The cells were heat-
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shocked for 45 seconds at 42°C and then placed back on ice for a further 2 minutes. 950pl of
SOC medium (Appendix I) was added to the cells and incubated at 37°C for 1.5 hours in a
shaking incubator. pGEM®-T Easy transformed cells (lOOjil) were plated onto 1.5% agar in
Luria Bertoni (LB) medium (Appendix I) containing ampicillin (50pg/ml), 200pM IPTG and
0.004% X-Gal in DMF. The plates were incubated at 37°C overnight and then placed at 4°C
to allow colour development. Single white colonies were transferred into 10ml LB medium
supplemented with (10pg/ml) ampicillin and shaken at 37°C for 16 hours. pEGFP-Nl
transformed cells were spread onto plates containing kanamycin (50pg/ml), and incubated at
37°C overnight. Single colonies were transferred to 10ml LB medium supplemented with
kanamycin (50pg/ml).
2.3.7.5 Preparation of plasmid DNA
Preparation of plasmid DNA was performed according to published methods (Bimboim and
Doly, 1979; Ish-Horowicz and Burke, 1981). Briefly, 1.5ml overnight cultures were pelleted
at 12,000 x g for 2 minutes and resuspended in 50mM glucose, 25mM Tris-Cl (pH 8.0),
lOmM EDTA (pH 8.0). Cells were then lysed in 0.2M NaOH, 1% SDS for 5 minutes at 4°C.
Precipitation of bacterial DNA was carried out by addition of 5M potassium acetate,
incubation on ice for 10 minutes, followed by high-speed centrifugation for 3 minutes. The
supernatant was then phenol/chloroform extracted, precipitated with isopropanol, washed in
ethanol and resuspended in 50pl Tris-EDTA (TE) buffer (Appendix I). Ribonuclease
(RNase) was then added to a final concentration of 40pg/ml to remove contaminating RNA
(Sigma).
Plasmid DNA for sequencing was isolated using Qiagen® spin columns (mini kit) according
to the manufacturer's instructions. In order to remove contaminating LPS, the Endofree
Maxi kit (Qiagen®) was used to purify plasmid DNA used for in vivo experiments and in
vitro transfection work.
2.3.7.6 Endonuclease restriction digest
DNA restrictions were carried out for 2^1 hours at 37°C using commercially (NEB)
available restriction endonucleases. 3-10 U of enzyme were used to digest 2^4-pg ofDNA in
a 20pl volume of the recommended buffer. Restriction endonuclease buffers were supplied
at 10 x concentration. pGEM®-T Easy clones were screened for the presence of inserts by
restriction digest with EcoRl. For enzymes with incompatible buffer requirements,
sequential digests were carried out (cloning of pEGFP-Nl constructs). Following digestion,
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inserts were analysed by running lOpl of the restriction digest on an agarose gel alongside
uncut plasmid.
2.3.7.7 SAP treatment
Following digests of pEGFP-Nl vector DNA, the 5' end of the linearised plasmid was
dephosphorylated to help prevent religation by addition of 1 U of shrimp alkaline
phosphatase (SAP) (Roche) and the manufacturer's buffer for 15 minutes at 37°C.
Inactivation of SAP was achieved by heat inactivation at 70°C for 20 minutes.
2.3.7.8 Blunt-ending
DNA fragments for blunt ended-cloning were prepared using the Klenow fragment of E.coli
DNA Polymerase I (Roche) to "fill in" recessed 3' ends. Following restriction endonuclease
digest, DNA fragments were incubated at 20°C for 20 minutes with 33pM of each dNTP
(Biogene) and a further lpl of 10 x BamHl buffer (NEB) and 2U of Klenow in a total
volume of 30pi.
Mungbean nuclease (Promega) was also used to generate blunt-ends with fragments
containing 5' overhangs. Buffers containing 100-400 mM NaCl (inhibit Mungbean nuclease
activity) were firstly removed using the High Pure PCR Purification kit (Roche). lOpg DNA
(in Tris-Cl, pH 8.0), 60 U of Mungbean nuclease, 0.001% Triton X-100 in 1 x reaction
buffer were then incubated in a total volume of 50pl for 37°C for 10 minutes. Mungbean
nuclease was inactivated by adding lOpl ofTris-Cl (pH 8.0, Appendix I).
2.3.7.9 Sub-cloning of cytokine genes & preparation of gene gun cartridges
The pEGFP-Nl plasmid encoding a red shifted variant of GFP under the control of a
cytomegalous virus (CMV) immediate early (IE) promoter was obtained from Clontech
(Figure 2.8). The Multiple Cloning Site (MCS) is between the immediate early (IE) promoter
of CMV and the EGFP coding sequences. The vector backbone contains an SV-40 early
promoter, a neomycin resistance cassette and polyadenylation signals from the herpes
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Figure 2.8 Restriction Map and Multiple Cloning Site (MCS) of the
4.7kb pEGFP-N1 plasmid (Clontech).
Cloning of GM-CSF into pEGFP-Nl
GM-CSF was sub-cloned into the Smal site of PBS +/- phagemid vector (Bluescribe) by Dr
Colin Mclnnes (Moredun Research Institute, Roslin, Midlothian). GM-CSF was excised
from the Bluescribe vector as a 520bp Hindlll-Hindlll fragment and subsequently blunt-
ended with Mungbean nuclease (Promega), followed by restriction enzyme digest with
BamFIl. pEGFP-Nl was linearised with Notl and blunt-ended with Mungbean nuclease.
BamFll digest was then carried out in order to remove the GFP gene. GM-CSF6 was sub-
cloned into the BamHl and blunt-ended Notl site of pEGFP-Nl. A control non-functional
version of GM-CSF (NF-GM-CSF) was generated as follows. GM-CSF was excised from
the Bluescribe vector as a 550bp BamHl-EcoRl fragment (Figure 2.9) and cloned into the
3'-5' orientation of the vector by cloning into the EcoRl-BamFll sites of pEGFP-Nl.
6
Sub-cloning of functional GM-CSF into pEGFP-N1 was carried out by Dr Anton Gossner









Figure 2.9 Analysis of plasmid constructs by restriction endonuclease digest. Each plasmid
was incubated with restriction enzymes for 2-4 hours at 37°C. DNA was then subjected to
gel electrophoresis and visualised by UV.
Lane 1 100bp ladder
Lane 2 BamH1 and Sac1 digest of plL-3
Lane 3 EcoR1 and Nhe1 digests of plL-3
Lane 4 EcoR1 and Nhe1 digests of NF-IL-3
Lane 5 BamH1 and EcoR1 digest of NF-GM-CSF
Lane 6 Nhe1 and Xmn1 digest of NF-GM-CSF
Lane 7 Nhe1 and Xmn1 digest of pGM-CSF
Lane 8100bp ladder
Cloning of IL-3 into pEGFP-Nl
IL-3 was sub-cloned into the Smal site of PBS +/- phagemid vector (Bluescribe) by Dr
Colin Mclnnes. IL-3 was removed from the Bluescribe vector by sequential digest with
BamHl and Sacl restriction enzymes and the 650bp fragment was cloned into the Sacl-
BamHl site of pEGFP-Nl (Figure 2.9). A non-functional version of IL-3 (NF-IL-3) was
constructed as follows. IL-3 was excised from pEGFP-Nl by sequential digest with BamEIl
and Sacl. Following restriction endonuclease digest, 3' recessed ends were filled in by
Klenow enzyme, followed by Kpnl digest. IL-3 was cloned into pEGFP-Nl following
linearization ofpEGFP-Nl with Hindlll, treatment with Klenow enzyme and Kpnl digest.
Removal of GFP gene from pEGFP-Nl constructs
The GFP gene was removed from the plasmids by restriction digest with BamHl and Notl
followed by gel extraction of the remaining backbone plasmid DNA and treatment with
Klenow enzyme to "fill-in" recessed ends.
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Preparation of plasmid DNA coated gold beads
Plasmid DNA for all in vivo experiments was isolated from transformed E.coli using the
EndoFree® Plasmid Mega kit (Qiagen®) in order to remove contaminating
immunostimulatory endotoxin from plasmid preparations. The kit enables the purification of
up to 2.5mg endotoxin-free ultrapure plasmid DNA. Endotoxin-free plasticware and
glassware were always used after the removal of endotoxin. Plasmid DNA was analysed by
UV spectrophotometry to assess the purity of plasmid DNA. Restriction enzyme digest was
carried out to confirm the presence and orientation of cytokine genes and was subsequently
sequenced by Mr. Ian Bennett.
DNA coated gold beads were prepared by firstly mixing lOOpl 0.05M spermidine with 20mg
1.0pm gold beads (Biorad). lOOpg of purified plasmid DNA was added to the mix and
precipitated onto the gold beads by the drop-wise addition of lOOpl 1M CaCl2, whilst slowly
vortexing the mixture. The beads were washed 5-6 times in 1ml 100% cthanol (centrifuging
at 1800 x g for 15 seconds in-between washes) and then resuspended in 2.4ml ethanol
containing 0.05mg/ml polyvinylpyrrolidone (PVP). The DNA-coated beads were then bound
to the inner surface of gold-coat tubing as recommended by the manufacturer.
2.3.8 In vitro transfection
2.3.8.1 Electroporation
Cells were maintained as described in Section 2.1. Cells were "split" the day before
transfection (1:2 SSk fibroblasts and 1:10 BHK cells) and were in log-phase of growth at the
time of transfection. Tissue culture medium was removed and the cells were rinsed in sPBS
and then harvested by adding 0.25ml of pre-warmed trypsin (in-house) to a T75 flask and
cells were observed until they started to detach. Cells were washed once in DMEM by
centrifugation at 300 x g for 5 minutes and resuspended at 2.5 x 106 cells/ml in DMEM.
800pl cell suspensions (2 x 106 cells) were then incubated with lOpg of each plasmid
construct or mock transfected (no plasmid) for 2 minutes on ice. Cell suspensions were
transferred into sterile electroporation cuvettes (Equibrio). Transfections were performed
using an Easyjet electroporator using the following parameters: 280mV, 1050pF, and 99mQ.
Cell suspensions were immediately transferred into 10ml medium. 10ml of each cell
suspension was then added to 2 wells of a 6-well plate and incubated for 48 hours at 37°C.
The culture medium was replenished after overnight culture.
Following an incubation of 48 hours, supernatants were removed and concentrated using
Amicon spin columns (Millipore) according to the manufacturer's instructions. Trypsin was
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used to remove adherent cells. Cells were washed in sPBS, counted and RNA extraction was
performed (Section 2.3.3.3).
2.3.8.2 Transfection of ovine fibroblasts by gene-gun
The efficacy of the plasmid-coated gold particles was evaluated by firing gold particles into
SSk cells. A Helios (Biorad), helium powered gene gun was used to fire the gold particles
into a 6-well plate containing near confluent SSk cells according to the manufacturer's
protocol. Briefly, the medium was firstly removed and the cells were washed with sPBS.
Each well received one of the plasmid-containing cartridges at 15psi. Fresh DMEM (10%
FCS) was replaced into each of the wells and the cells were incubated at 37°C, 5% C02.
After 48 hours cells were harvested for RNA extraction (2.3.3.3).
2.3.9 DNA sequencing of double-stranded DNA templates
Cloned DNA was sequenced using the LICOR 4000L automated sequencer (MWG Biotech),
and the Sequitherm Excel™ II kit (Cambio). Primers were purchased from MWG Biotech
(sequences shown below). Sequencing was kindly performed by Mr. Ian Bennet (Department
ofVeterinary Pathology, University of Edinburgh).
Sequencing primer Sequence (5'-3')
pGEM®-T Easy Ml3 primer
pEGFP-C 17 ATGGGCGTGGATAGCGGTTTGACTC
2.4 Gene-gun vaccination of sheep
Prior to DNA vaccination, the skin on the flanks of sheep was prepared by firstly clipping
the wool, followed by cleaning the skin with Hibitane scrub and warm water and shaving
any remaining wool. The skin was then washed in absolute ethanol and vaccine sites were
drawn on the skin with a marker pen. On each day of vaccination, skin was cleaned again
with Hibitane scrub and closely shaved. For biopsy experiments, three replicates (0.5-1.0|ig
plasmid DNA/shot) of each cytokine construct or non-fuctional control plasmid were
administered by gene-gun at a pressure of 500psi (optimal pressure for delivery of gold
particles to the epidermal-dermal junction). 5mm x 6mm biopsies were removed by punch-
7 Also used to sequence inserts sub-cloned into pEGFP-N1 (position 390 for both plasmids)
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biopsy immediately at post-mortem (Stiefler). Table 2.8 lists the details of each biopsy
experiment carried out.
DNA vaccination of cannulated sheep was carried out essentially as described with the
exception that 5 replicates of plasmid DNA were administered to the skin in the drainage
area of the cannula. Lymph was collected every 24 hours and lymph volumes were carefully
recorded. To prevent de novo cytokine expression, actinomycin-D was added to bottles prior
to lymph collection (Section 2.2.4.1).
Table 2.8 In vivo experiments carried out where various plasmid constructs were
administered to the flank of sheep over a time-course and biopsies removed at post-mortem.
Note that in the preliminary biopsy experiment (A), pEGFP-N1 served as a control and that
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2.5 Development of a quantitative RT-PCR method
2.5.1 Introduction to quantitative RT-PCR
The analysis of cytokine profiles is crucial in the characterisation of immune responses and
in the identification of functional properties of immune cell subpopulations. Tissue biopsy
samples are often too small to allow the detection of cytokine protein and quantitative
systems for the detection of ruminant cytokine proteins are still being developed. The
detection of mRNA by RT-PCR analysis is a useful and sensitive method often employed to
investigate the cytokine milieu in inflammatory lesions. Traditional RT-PCR methods rely
on end-point analysis and are at best semi-quantitative. Quantitative RT-PCR is a novel
method that enables simple and rapid measurement of fluorescent PCR product accumulation
during the log-linear reaction phase. The fluorescence generated is proportional to the
amount of product present. The cycle number at which the level of fluorescence rises above
a background threshold value is inversely proportional to the log of the initial number of
template copies (Higuchi et al., 1993).
The use of hybridisation probes in quantitative RT-PCR is now well established. Probes
require both synthesis and optimisation of a specific probe for each gene of interest and this
can be expensive. An alternative method to monitor DNA amplification employs the high
affinity double-stranded DNA (dsDNA) binding dye SYBR Green I. SYBR Green has
negligible fluorescence in the absence of dsDNA but has large fluorescence enhancement
upon binding to dsDNA. The major advantage of this technique is that SYBR Green can be
used with any primer pair, provided that no products other than the specific one of interest
are amplified.
Aim
To develop and optimise a method for quantitative RT-PCR for a universally expressed
housekeeping gene, GAPDH and several cytokine genes (GM-CSF, IL-3, IL-ip, IL-10, IL-
12, IL-18 and TNF-a) using the DNA-binding fluorescent dye SYBR green.
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2.5.2 Strategy
2.5.2.1 Overview of quantitative real-time RT-PCR strategy
Briefly, two sets of primers were designed from available ovine and bovine (IL-18) cytokine
cDNA sequences in order to perform nested PCR. RNA was extracted from in vitro
stimulated PBMC (Section 2.1.3) and reverse transcribed. Conventional RT-PCR was then
carried out using the external primers to generate primary (1 °) PCR products for each of the
genes of interest. 1 ° PCR products were purified and serial dilutions were prepared. Internal
primers and SYBR green were then used to amplify serial dilutions of 1° PCR product to
create a standard curve on the LightCycler®. Once standard curves had been generated,
quantitative RT-PCR was carried out on cDNA samples to amplify target species. In
addition, one or more of the diluted 1 ° PCR products (standards) were included and acted as
reference point(s) on the imported standard curve.
2.5.2.2 Generation of standards by conventional RT-PCR
A source ofmaterial was required to provide standards of each cytokine in order to generate
standard curves. IL-12p40 and IL-18 could not be detected in freshly isolated PBMC (results
not shown). PBMC were therefore stimulated using either LPS from S. typhimurium or Con
A (Section 2.1.3). LPS induces IL-18 mRNA expression after binding CD14 (and TLR4) on
human blood monocytes in vitro (Manigold et ah, 2000). Con A is a lectin and a well known
T cell mitogen and stimulation of PBMC with Con A results in detectable expression of
several cytokines, including IL-12p40 and IL-12p35 (De Rose et al., 2000). After PBMC
stimulation, RNA was extracted and reverse transcribed. External primers (Section 2.5.5)
were tested on cDNA obtained from either LPS or Con A-stimulated PBMC. Both IL-12p40
and IL-18 primers generated gene fragments after either form of stimulation (results not
shown). GM-CSF, IL-3, IL-10, TNF-a and IL-ip were amplified from cDNA derived from
Con A stimulated PBMC. 20pl of each 1 ° PCR product was then fractionated by agarose gel
electrophoresis and confirmed to be the correct size. The remaining 30pl was then purified
by PCR-clean-up reaction (Qiagen® PCR Purification kit). Serial 1:10 dilutions were
prepared in nuclease-free water and aliquots were stored at -20°C.
Prior to quantitative PCR, internal primers were tested for specificity by conventional nested
PCR. 2pl of each of the 1:100 and 1:1000 dilutions of each 1° PCR product were amplified
for 30 cycles at 37°C. Following secondary amplification, 20pl of each sample was
fractionated by agarose gel electrophoresis. The remaining 30pl of PCR reaction was
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purified (Qiagen® spin column) and cloned into pGEM®-T Easy (Section 2.3.7.2) and
sequenced (Appendix III).
2.5.2.3 Generation of a standard curve with 1° PCR products
Serial 1:10 dilutions of 1° PCR products (diluted in nuclease-free water) were used to
construct standard curves on the LightCycler®. Quantitative RT-PCR was performed
(Section 2.3.6) using specific internal primers (Table 2.11). 2pi of each of the standards (1°
PCR products; 10 3—10 I0) were run in duplicate on the LightCycler® alongside a negative
control (nuclease-free water). The cycling conditions are summarised in Table 2.7. An
example of an amplification plot, a standard curve and a melting curve is shown in Figure
2.10. Standard curves were automatically constructed by the LightCycler® software (second
derivative method, Section 2.5.3), where the error can be reduced by manual deletion of
standards. Standard curves were generated for each of the cytokine genes and also for the
housekeeping gene GAPDH.
Melting curve analysis was carried out for every LightCycler® experiment carried out in
order to assess the extent of primer-dimerisation and that specific product had accumulated
in the target samples. This is essential, since SYBR Green binds non-specifically to all
dsDNA species. Melting curve analysis was performed after the amplification stage of the
program and involved raising the temperature successively through 1 °C steps and comparing
the melting temperature of specific product (diluted standards) with the melting temperature
of each sample and a no-template control. Primer-dimers are easily distinguished from
specific product since they melt at a lower temperature due to their small size (approximately
25bp). Specific products show one sharp and fully overlapping melting peak indicating the
specificity of primers designed from partial sequences (Figure 2.10c). In addition, products
were analysed by gel electrophoresis to confirm that the amplicon of the correct size was
obtained (results not shown).
2.5.2.4 Quantification of cytokine transcripts by real-time RT-PCR
RNA was extracted from skin biopsies and purified DC populations and reverse transcribed
(sections 2.3.3 and 2.3.4). Conventional GAPDH RT-PCR was first performed to confirm
that amplifiable material was present and that genomic DNA had been degraded. cDNA
samples were diluted 1:100 in nuclease-free water and 2pl of diluted cDNA was subjected to
quantification, alongside at least one standard (diluted 1° PCR product) for the gene of
interest. For quantification, a standard curve was then imported at the end of a sample run.
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Standard(s) included on that particular run served as reference points on the standard curve
and the LightCycler® software calculated crossover threshold (Ct) values for each of the
cDNA samples. Quantitative analysis of cytokine cDNA was performed in comparison to the
universally expressed housekeeping gene GAPDH and allowed for corrections of variations
in different numbers of cells in the starting material; differences in the efficiencies of RNA
extraction, and in the reverse transcription procedure.
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Figure 2.10 Generation of a standard curve using 1° PCR products, (a) PCR amplification of
IL-18 1° PCR standards over eight orders of magnitude (diluted 10~3-1CT10) as a graph of
cycle number versus fluorescence intensity (cDNA samples (diluted 1:10 and 1:100) derived
from stimulated PBMC were also included); (b) standard curve as a graph of *log
concentration versus cycle number obtained by second derivative maximum method. Note
that *log concentration refers to the log of arbitrary (arb.) units assigned to each standard in
the dilution series; (c) melting curve analysis of products where -d (F1)/dT refers to the rate
of change of fluorescence. Note that the amplicons generated from the dilution series of 1°
PCR products melt at the same temperature (approximately 81 °C.), whereas no product or
primer-dimer is evident in the no-template control (flat green line).
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2.5.3 Data analysis
Data analysis was performed by the LightCyler® software (version 3.5). Two methods of
quantification are available.
(i) fit points
(ii) second derivative maximum
The fit-points method requires manual adjustment of the noise band or crossing line to
exclude non-informative background fluorescence data from quantitative analysis, whereas
the second derivative maximum method is automated. The second derivative maximum
method was chosen for all data analysis as this method gives rise to a lower coefficient of
variability (Cv) value and is thus more reliable for gene quantification. Furthermore, unlike
the fit points method, this method is not subjected to input variations of bias. The standard
curve was generated by the LightCycler® software based on the values of crossing points (Ct
values) and the log value of the standard concentration. The relative values for target
abundance in each experimental sample were then extrapolated from the standard curve.
Standard curves were imported into all amplification programs where only one or two
standards could be included due to the large number of samples to be analysed (a maximum
of 32 capillaries can be analysed on the LightCyler®). When possible, several standards were
included with cDNA samples so that standard curves could be generated for that particular
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Figure 2.11 Overview of quantitative RT-PCR method using diluted 1° PCR products
generated from in vitro stimulated PBMC as standards.
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2.5.4 Normalisation of data
Variations in the starting material were normalised by calculating a normalisation
coefficient. The concentration of GAPDH (arbitrary units) was calculated for each cDNA
sample by importing the GAPDH standard curve after each run was completed. The mean
value (excluding the Ct values of the included standard(s)), was then calculated from all
cDNA samples analysed on that run. To obtain a normalisation coefficient, the following
equation was applied:
normalisation coefficient = GAPDH Ct value of sample / mean Ct
Gene expression of the target gene (after importation of the standard curve for that gene) was
then normalised against GAPDH (see example in Table 2.9) by applying the following
equation:
expression of target gene = Ct value of sample / normalisation coefficient
Table 2.9 Normalisation of gene expression with the housekeeping gene GAPDH
GAPDH normalisation GM-CSF normalised GM-CSF
sample concentration coefficient concentration concentration
1 2 0.53 4 7.6
2 4 1.1 8 7.3
3 8 2.1 10 4.8
4 4 1.05 2 1.9
5 1 0.26 12 46.2
2.5.5 Primer Design
A database search for ovine mRNA sequences was performed (Table 2.4). PCR primers were
designed by both Oligo 6 (Cambio) and Netprimer3. The parameters used to design primers
for use on the LightCycler® are summarised in Table 2.10. Stringent parameters were used
for primer design since SYBR green binds to all double stranded species. Specificity of
primer sequences was confirmed by the Fasta3-Nucleic acid-EMBL database program8.




the following programs (i) Premier Biosoft and (ii) Primer-finder software with 10T Oligo
Analyser9.
Table 2.10 Parameters chosen for the design of internal primers for use in
quantitative RT-PCR (min, minimum; max, maximum; opt, optimum).
parameter design
GC content min: 40%, opt: 50%, max: 60%
primer Tm min: 55°C, opt: 57°C, max: 60°C
primer size min: 18, opt: 20, max: 22
max self complementarity 3.00
min 3' self complementarity 2.00
amplicon size min: 250 opt: 300 max: 400
All (internal) primers intended for use in quantitative RT-PCR were designed with an
annealing temperature of 57°C. Roche recommend that PCR products generated on the
LightCycler® do not exceed more than 900bp and are not smaller than lOObp (Roche real¬
time PCR course, 2002); thus amplicon sizes were designed to be approximately 190-300bp.
Internal primer sequences and amplicon size are listed in Table 2.11. The parameters for the
design of external primers were generally not as stringent as the parameters used in the
design of internal primers, since they were only intended to generate material (1° PCR




Table 2.11 Internal Primers used for quantitative real-time RT-PCR. All internal primers were
designed with an annealing temperature of 57°C. 40 rounds of amplification were carried out
for most LightCycler® assays. 25-30 cycles were first employed to determine the specificity
of the primers by conventional PCR using 1° PCR products.
gene primer sequence 5' —> 3' product size
GAPDH F: GGT GAT GCT GGT GCT GAG TA
R: TCA TAA GTC CCT CCA CGA TG
265bp
GM-CSF F: GAT GGA TGA AAC AGT AGA AGT CG
R: CAG CAG TCA AAG GGA ATG AT
261 bp
IL-3* F: CAA GAC AGA ATC CGC CCT GC
R: AGG AGC CTT CTG GAC TCG GA
192bp
1L-I2p40 F: TCA GAC CAG AGC AGT GAG GT
R: GCA GGT GAA GTG TCC AGA AT
243bp
IL-18 F: GAG CAC AGG CAT AAA GAT GG
R: TGA ACA GTC AGA ATC AGG CAT A
241 bp
IL-10 F: CTG TTG ACC CAG TCT CTG CT
R: ACC GCC TTG CTC TTG TTT
250bp
TNF-a F: GAA TAC CTG GAC TAT GCC GA
R: CCT CAC TTC CCT ACA TCC CT
238bp
IL-ip F: CCT TGG GTA TCA GGG ACA A
R: TGC GTA TGG CTT TCT TTA GG
317bp
*
Note that another set of primers was designed for ovine IL-3 (shown below) and
successfully amplified specific IL-3 product where cDNA generated from stimulated
PBMC was used. Problems were however encountered with this set of primers where
cDNA samples generated from pIL-3 vaccinated biopsies were used, since the part of the
sequence where the reverse primer binds is not present in the pIL-3 construct.
F: TGA AGT CTG AAG CCC AGT TC
R: ATT CCC AAG TCC CCA TCT TA
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Table 2.12 External primers used for conventional RT-PCR. Primers were used for the first-
round of amplification of ovine GAPDH, GM-CSF, IL-3, IL-10, IL-12, IL-18, TNF-a and IL-1p
to generate standards for use on the LightCycler®. *IL-3 external primers were also used as
internal primers due to problems encountered with the original primers.





GAPDH F: AAG GCA GAG AAC GGG AAG
R: AGT GAT GGC GTG GAC AGT
366bp 55 25
GM-CSF F: GCT TCT CCT GGG CAC TGT
R: GCC TGC TTC ACT TCT GGA C
425bp 55 30
IL-3* F: CAA GAC AGA ATC CGC CCT GC
R: AGG AGC CTT CTG GAC TCG GA
192bp 57 30
IL-12p40 F: CTG GTT TTC CCT GGT TTT G
R: CTG CTG CTT TTG ACA CTG AA
452bp 54 40
IL-18 F: TCA GAT CAC GTT TCC TCT CC
R: GAT GGT TAC AGC CAG ACC TC
348bp 55 40
IL-10 F: TAC CCA CTT CCC AGC CAG
R: CGT TGT CAT GTA GGA TTC TAT GTA G
432bp 58 30
TNF-a F: CAC TGA CGG GCT TTA CCT C
R: TCC TTG GTG ATG GTT GGT
548bp 58 40
IL-lp F: CAA AAA TCC CTG GTG CTG
R: CTG TGT TCT TCC CTT CCC TT
518bp 55 30
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2.6 Optimisation of method for quantification of GM-CSF
and IL-3 transcripts after DNA vaccination
2.6.1 Introduction
Quantitative real-time RT-PCR was required in order to quantify the kinetics of expression
of GM-CSF and IL-3 mRNA in skin after DNA vaccination with plasmid constructs
containing these cytokines. Each construct was administered by gene-gun vaccination to the
skin on the flank of sheep. Each skin sample was removed at post-mortem using a sterile
biopsy punch and bisected. RNA was extracted from one half of each biopsy and reverse
transcribed.
2.6.2 Standard DNase treatment incompletely removes plasmid
DNA
cDNA samples obtained from pGM-CSF vaccinated skin were initially analysed by
quantitative real-time RT-PCR alongside control (-RT) samples. It was evident that plasmid
DNA was not completely degraded by DNase digestion, since specific product was detected
in the control -RT samples by melting curve analysis (Figure 2.12). Quantitative PCR is a
highly sensitive method and can detect even low levels of undegraded plasmid DNA and
thus it was necessary that further treatment was carried out on all RNA samples in order to
accurately assess the kinetics of GM-CSF and IL-3 mRNA expression in skin. Initial
unsuccessful attempts to degrade contaminating plasmid DNA involved extended incubation
with DNase and doubling the volume of DNase added to the spin column membranes;
plasmid DNA was however still present following such treatment (results not shown).
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standard 1CH
standard 1CH
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water
Figure 2.12 Plasmid DNA is incompletely removed with conventional DNase treatment. RNA
was extracted from biopsies vaccinated with pGM-CSF or NF-GM-CSF and reverse
transcribed, (a) cDNA samples were analysed by quantitative RT-PCR. Control (-RT)
samples containing 1pg RNA were included in order to assess the presence of undegraded
plasmid DNA; (b) specific product was detected in -RT samples which had been confirmed
by GAPDH RT-PCR not to contain genomic DNA. Plasmid DNA was thus present in samples
tested. Specific product was observed in cDNA samples obtained from normal skin
(endogenous GM-CSF expression), whereas no transcripts were present in the no-template
control.
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2.6.3 Removal of plasmid DNA in RNA samples by restriction
enzyme and DNase treatment
2.6.3.1 Introduction
Since DNase incubation on the spin column membranes was unsuccessful in eliminating
plasmid DNA, alternative methods were required. It is possible that DNase was not gaining
sufficient access to plasmid DNA on the spin column membrane and treatment of RNA
samples in solution with DNase is necessary for complete degradation of plasmid DNA.
Additionally, a restriction enzyme which cuts the GM-CSF (or IL-3) insert would
theoretically prevent PCR amplification of these fragments and such linearisation of plasmid
DNA may further aid removal of plasmid by DNase. Removal of plasmid DNA was
therefore attempted with DNase alone and also in combination with a restriction enzyme.
The restriction enzymes Pst-1 and Hinf-1 were chosen from pGM-CSF and pIL-3 sequences;
Pst-1 cuts the GM-CSF insert 3 times whereas Hinf-1 cuts the IL-3 insert 5 times. Prior to
treatment of RNA containing pGM-CSF or pIL-3, it was necessary to assess the buffer
requirements of both restriction enzymes and DNase, since all enzymes are supplied with
their own buffers and may have stringent buffer requirements. Reaction mixes containing
2pg pGM-CSF or pIL-3 were prepared and incubated for 1 hour at 37°C. Pst-1 and Hinf-1
were active in the DNase supplied buffer and DNase was active in either of the buffers
supplied with the restriction enzymes (Figure 2.13). Undigested plasmid is not shown on this
gel image, however in previous experiments undigested plasmid was verified to contain only
plasmid and no other DNA fragments. In the reactions containing pGM-CSF, a fragment of
<250bp is evident (expected size is 175bp), the other smaller fragments (expected sizes of
24bp and 32bp) cannot be observed. In the reactions containing pIL-3, at least 9 DNA
fragments are evident. Hinf-1 cuts the pEGFP-Nl backbone 13 times and some of these
fragments can be observed. For example, fragments corresponding to lOOObp (expected size
lOlObp) and 800bp (expected sizes 804 and 782bp) can clearly be observed, whereas the
smaller fragments (~130bp and less) could be generated from either the backbone or the IL-3
insert. From this experiment, it appeared that plasmid DNA could indeed be degraded with
DNase in combination with either enzyme and that DNase was not affected by the addition
of BSA (required for optimal Pst-1 activity).
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Figure 2.13 Compatibility of buffer requirements for the enzymes Pst-1, Hinf-1 and DNase.
Reaction mixes were prepared containing either plasmid and incubated for 1 hour at 37°C.
Restriction enzymes are sufficiently active in either of the supplied NEB buffers or the DNase
buffer (RQ1, Promega). DNase completely degrades pGM-CSF and plL-3 when incubated in
the supplied RQ1 buffer and also in both NEB buffers, with or without BSA supplementation.
Undigested plasmids are not shown on this gel image.
Lane 1, 1kb ladder;
(to test for degradation of pGM-CSF)
Lane 3, Pst-1 in supplied buffer (NEB) & BSA supplementation
Lane 5, Pst-1 in DNase buffer (RQ1)
Lane 7, DNase in Pst-1 supplied buffer (NEB)
Lane 9, DNase in RQ1 buffer
Lane 10, DNase in RQ1 buffer + BSA supplementation
Lane 11, DNase in RQ1 buffer + Pst-1 + BSA
(to test for degradation of piL-3)
Lane 13, Hinf-1 in supplied buffer (NEB)
Lane 15, Hinf-1 in DNase buffer (RQ1)
Lane 17, DNase in Hinf-1 buffer (NEB)
Lane 19, DNase in RQ1 buffer
Lane 20, DNase in RQ1 buffer + Hinf-1
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2.6.3.2 pGM-CSF spiking experiment
To avoid wasting precious RNA samples obtained from biopsy experiments, a spiking
experiment was designed in order to identify the optimum way of eliminating plasmid DNA
(Figure 2.14). Briefly, following homogenisation of a (non-vaccinated) skin sample, lpg of
plasmid DNA (pGM-CSF) was added to the homogenate. lpg of plasmid DNA was chosen
as this is approximately equivalent to the amount of DNA administered with one shot using








RNA extraction (Qiagen® RNeasy ® Mini kit)
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DNase treatment + Pst-1 (pGM-CSF) /






run cDNA samples (-RT) on LightCycler®
to confirm degradation of pDNA
Figure 2.14 Schematic representation of the plasmid spiking experiment. This was carried
out to investigate what methods were required to remove residual plasmid DNA remaining
from the initial DNA vaccination procedure.
Spiked RNA samples were then treated with DNase alone and with DNase in combination
with Pst-1 for 1 hour at 37°C (Section 2.3.3.2). Following treatment, RNA samples were
purified and lpg of each sample was then reverse transcribed or control (-RT) reactions
were prepared (to ascertain the extent of plasmid DNA degradation). cDNA and control (-
RT) samples were then analysed by quantitative RT-PCR. Although DNase in solution
removes the majority of plasmid DNA, DNase in combination with Pst-1 restriction enzyme
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was the most effective treatment and all spiked plasmid DNA containing the GM-CSF insert
was removed in this manner (Figure 2.15).
temperature (°C)
cDNA from normal skin
cDNA from normal skin
GM-CSF standard (1CM)
GM-CSF standard (10-4)
untreated GM-CSF spiked sample
untreated GM-CSF spiked sample
DNase treated GM-CSF spiked sample
DNase & Pst-1 treated GM-CSF spiked sample
DNase & Pst-1 treated GM-CSF spiked sample
DNase treated GM-CSF spiked sample
untreated RNA from vaccinated biopsy -RT
untreated RNA from vaccinated biopsy -RT
water
Figure 2.15 Pst-1 in combination with DNase removes pGM-CSF in spiked RNA samples,
(a) Amplification of untreated RNA (-RT) samples after gene-gun vaccination with pGM-CSF
and in normal skin homogenates spiked with pGM-CSF results in accumulation of product by
approximately 27 cycles, whereas substantially less product is present in samples treated
with DNase (-35 cycles) or DNase in combination with Pst-1 (-39 cycles), (b) Although
DNase treatment in solution substantially reduces plasmid DNA, trace copies of plasmid are
still present as illustrated in the melting curve analysis, where specific product melts at the
same temperature as specific product (GM-CSF standards and spiked samples), whereas no
specific product can be observed in the DNase/Pst-1 treated samples.
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A further experiment was carried out to assess if DNase on the membrane was actually
required. RNA was extracted from spiked skin homogenates, which were either treated with
DNase on the spin column membranes for 15 minutes, or processed without this step. DNase
treatment on the membrane followed by further removal of plasmid by DNase and restriction
enzyme treatment in solution appeared to be the most effective method of ensuring complete
removal of plasmid DNA (Figure 2.16).
temperature (°C)
GM-CSF standard (10-2)
DNase on membrane +RT
no DNase on membrane +RT
— DNase on membrane -RT
no DNase on membrane -RT
water
cycle number
Figure 2.16 DNase treatment on membranes followed by DNase and Pst-1 treatment in
solution is required for complete degradation of plasmid DNA. Homogenates from normal
skin were spiked with pGM-CSF and RNA was extracted. Spiked samples were either
subjected to on membrane DNase treatment, or this step was omitted from the procedure,
(a) Amplification of pGM-CSF in samples treated with and without the additional DNase
treatment; (b) melting curve analysis shows that specific product is still observed in the
sample where the DNase step was omitted. No Specific product is observed in the sample
treated with both DNase on the membrane followed by Pst-1 and DNase treatment in
solution (-RT). GM-CSF transcripts are evident in the +RT sample and are due to
endogenous expression of GM-CSF in skin (normal skin homogenate was spiked with pGM-
CSF).
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2.6.3.3 Overview of the procedure for the removal of plasmid DNA
from pGM-CSF vaccinated biopsy samples
RNA was extracted from biopsy samples using the Qiagen® spin columns which included the
on-membrane DNase step. Plasmid DNA was further removed from each RNA sample by
incubation in solution with DNase and Pst-1 enzymes for 1-1.5 hours at 37°C (as multiple
lOpl total volumes/sample). RNA was then purified and reverse transcribed. Conventional
GAPDH RT-PCR was performed in order to assess that there was amplifiable material after
such extensive treatment of the RNA and that all genomic DNA had been degraded
sufficiently (an example is shown in Figure 2.17). -RT samples (diluted 1:10 in nuclease-
free water) were then analysed on the LightCycler® to assess that plasmid DNA had been
completely removed. For instance, in Figure 2.18a, detectable product is evident after
approximately 32-44 cycles of amplification in 3 out of 16 cDNA samples. However, only 2
out of 16 cDNA samples still contain pGM-CSF, as shown by the melting curve (b) where 2
samples melt at the same temperature as the GM-CSF standard. Products were also subjected
to agarose gel electrophoresis to confirm the results obtained from the melting curve analysis
(c). An overview of the strategy employed to remove pGM-CSF (and pIL-3) is illustrated in
Figure 2.19.
If-RT samples contained specific product, samples were then subjected to further enzymatic
treatment to remove residual plasmid DNA. If the RNA yield was low from the first round of
treatment, the original RNA sample was treated instead, or residual RNA from the first
round of treatment was pooled with the original sample and aliquots of the mix were then
used for treatments. RNA was again reverse transcribed and GAPDH conventional RT-PCR
carried out. -RT samples were run onto LightCyler® and assessed for presence of plasmid
DNA. Importantly, cDNA samples were only analysed by quantitative RT-PCR once all
RNA samples had been validated to be free of residual plasmid DNA.
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250 bp
(b) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Figure 2.17 Extensive DNase/Pst-1 treatment of RNA samples obtained from pGM-CSF
vaccinated skin does not cause degradation of RNA. Conventional GAPDH RT-PCR was
carried out on each of the DNase/Pst-1 treated RNA samples where RT enzyme was either
added (a) or omitted (b) prior to quantitative RT-PCR. (16 samples from biopsy experiment C
are shown). Lane 1, 1kb ladder, lanes 2-17, samples obtained from pGM-CSF vaccinated
skin; lane 18, water; lane 19, positive control (1:1000 diluted plasmid containing GM-CSF
insert). After extensive treatment of RNA to remove plasmid DNA, transcripts are still present















2 4 6 20 22 24 26 30 32 34 36 38
cycle number
640 660 68.0 700 72X) 74.0 76.0 78.0 800 82 0 840 86 0 880 000 020 040
temperature (°C)
23456789 10 11 12 131415 16 17 18 19 20
250bp■
Figure 2.18 Validation of-RT samples to be free of residual plasmid DNA. DNase and Pst-1
treated samples from biopsy experiment C (Table 2.8) were reverse transcribed and
quantitative RT-PCR using GM-CSF specific primers were used to amplify target species,
(a) Detectable product is evident after approximately 32-44 cycles of amplification in 3 out of
16 -RT samples, (b) Only 2 out of 16 -RT samples still contain pGM-CSF where 2 samples
(*) melt at the same temperature as the GM-CSF standard (t) and (c) where LightCycler®
products were subjected to electrophoresis and specific product (~250bp) is present in lanes
10 and 16. Lanes 1 and 20, 1kb ladder; lanes 2-17, -RT samples from pGM-CSF vaccinated
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/ undegraded plasmid in
treated RNA samples
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to check pDNA has
been removed
| fully degraded plasmid in
▼ treated RNA samples
run cDNA samples
on LightCycler®
Figure 2.19 Strategy for preparation of biopsy RNA samples for
quantitative real-time RT-PCR.
2.6.3.4 Removal of plL-3
Homogenates from normal skin were spiked with 2pg pIL-3 and RNA was extracted. RNA
samples were then treated in solution with DNase and Hinf-1 for 1 hour at 37°C. In addition,
RNA extracted from pIL-3 vaccinated skin biopsies was treated to remove plasmid DNA.
All RNA samples were purified and reverse transcribed. cDNA and control samples were
then analysed by quantitative RT-PCR. Hinf-1 and DNase treatment substantially reduced the
amount of pIL-3 in the spiked sample (Figure 2.20). A slightly longer incubation time is
required to remove 2pg pIL-3. In the DNase/Hinf-1 treated samples from pIL-3 vaccinated
skin biopsies, trace amounts of plasmid were present in one sample, whereas complete
removal of plasmid DNA was achieved in the other sample. Hinf-1 and DNase therefore
provides an effective means of removing pIL-3.
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IL-3 standard (1CH)
DNase & Hinf-1 treated IL-3 spiked RNA sample
untreated spiked sample
DNase & Hinf-1 treated sample (1) from IL-3 vaccinated skin (+RT)
DNase & Hinf-1 treated sample (2) from IL-3 vaccinated skin (+RT)
DNase & Hinf-1 treated sample (1) from IL-3 vaccinated skin (-RT)
DNase & Hinf-1 treated sample (2) from IL-3 vaccinated skin (-RT)
water
14 1« 18 20 22 24 20 28
cycle number
74*.0 70O 78J0 00.0 02.0 840
temperature (°C)
Figure 2.20 DNase in combination with Hinf-1 efficiently removes plL-3. Plasmid DNA
containing IL-3 insert was subjected to treatment with DNase in combination with the
restriction enzyme Hinf-1 and was efficiently degraded. cDNA and -RT samples were
amplified for 40 cycles on the LightCycler™ (a) and melting curve analysis performed (b).
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2.7 Statistical analysis
Statistical analyses were performed using the GraphPad Prism package. For comparison of
gene expression in different skin samples vaccinated at the same time (control plasmid vs.
cytokine construct), the unpaired Student t-test was employed, whereas the two-tailed
Student t-test was used to compare gene expression over the time-course of each experiment.
The two-tailed Student t-test was also used to analyse gene expression in ALDC obtained
from the same lymph sample and samples obtained from different animals. Where indicated
in the text, the Wilcoxon Signed Rank test was also used as an extra sensitivity analysis to
analyse data obtained from different animals (lymph experiments only). A p value of < 0.05
was considered statistically significant for all statistical analyses.
102
3 Immunopathology of gene gun delivered
pGM-CSF and plL-3
3.1 Introduction
The efficacy of DNA vaccines in humans and livestock is generally poor (reviewed in
Babiuk et al., 1999). Several administrations of plasmid DNA, or strategies such as "prime-
boosting", are generally required for seroconversion (Woodland, 2004). The reason for this
apparent lack of efficacy in outbred species, when compared to the success of DNA
vaccination in murine models of infectious disease, is not yet known. It is known that DC
play a pivotal role in the induction of immunity after DNA vaccination; both directly
transfected DC and DC that have taken up antigen from other cells induce immunity after
DNA vaccination in mice (as outlined in Chapter 1). It has been suggested that DNA
vaccines are not targeted efficiently to resident DC within the skin or muscle after delivery in
larger species. In these species DNA vaccination requires optimisation and various methods
are currently under intense investigation (Sasaki et al, 2003).
One method to enhance the immunogenicity of DNA vaccines is to use genetic cytokine
adjuvants that expand and maturate DC at the site of inoculation. GM-CSF and IL-3 are both
cytokines known to cause the growth and differentiation of immature haematopoietic cells
and to some extent have overlapping roles in the development of DC in vitro and possibly in
vivo. The use of IL-3 as a vaccine adjuvant has not as yet been reported and merits
investigation of its adjuvant properties. Conversely, GM-CSF has been actively researched
as a molecular adjuvant and shown to significantly enhance both humoral and cell-mediated
immune responses, due to the recruitment of DC to the site of plasmid administration
(Scheerlinck et al, 2001); although the exact mechanisms by which GM-CSF elicits such
effects in vivo require further clarification. In particular, the ability of GM-CSF to act as a
"danger signal" and induce proinflammatory cytokine expression in the skin requires further
investigation, since the tissue microenvironment can influence the phenotype and functional
responses of DC and thus the overall bias of the immune response.
There is a paucity of published material that describes the histological characteristics of skin
after gene-gun administration of cytokine genes in outbred species (Mwangi et al., 2002).
Better characterisation of the inflammatory events after administration of molecular
adjuvants may help to improve DNA vaccine technology in large animals. The research
described in this chapter involves characterisation of the effects of pGM-CSF and pIL-3 in
ovine skin after gene-gun administration and comparison of inflammatory events with
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control plasmid(s). It was of particular interest to this study to determine if DC infiltrated
ovine skin after pGM-CSF and pIL-3 administration. It was hypothesised that GM-CSF and
IL-3 would act upon pre-DC recruited from the blood after DNA vaccination with these
constructs, and/or resident epidermal LC and dermal DC.
At present, there is also limited information with regard to the kinetics of mRNA expression
of plasmid constructs after gene-gun vaccination. Armengol (Armengol et al., 2004) showed
that plasmid DNA can persist for up to 2 years after intramuscular injection in mice with
protein being expressed indefinitely. Conversely, it has been reported that expression of
protein is lost by one week after gene-gun vaccination, consistent with the sloughing of the
epidermal target site (Boyle and Robinson, 2000; Braun et al, 1999). It is crucial to our
understanding of molecular adjuvants that the kinetics of expression of plasmid-encoded
genes and other cytokines (TNF-a, IL-ip and IL-18), which have been implicated in both the
activation and the migration of DC, are investigated. Analysis of the expression of
proinflammatory mediators after pGM-CSF or pIL-3 administration may provide useful
insight into the adjuvant potential of cytokine gene adjuvants, since DC activated in an
inflammatory environment containing high levels of "danger signals" could be anticipated to
present antigen in a non-tolerogenic fashion due to upregulation of costimulatory molecules
(CD80 and CD86). In addition, an understanding of the kinetics of cytokine gene expression
and the induction of proinflammatory genes may help to understand the time-frame during
which activation ofDC takes place.
In addition, cellular responses are induced as a consequence of the physical insult of the gold
particles alone and such damage results in the release of pro-inflammatory cytokines; IL-ip
and TNF-a are inducible products of keratinocytes in response to injury (Luger et al., 1996).
These proinflammatory cytokines act upon the local blood vessels in the skin, increasing
their permeability and allowing innate immune cells to enter the skin in response to
inflammatory cytokines. Secretion of immunomodulatory factors in response to gene-gun
delivery and indeed DNA itself (due to CpG motifs) may act in concert with the GM-
CSF/IL-3 and could have significant qualitative and quantitative effects on the immune
response generated. Quantitative real-time RT-PCR was therefore employed in this study as




(i) To characterise the histopathology of gene gun delivered plasmid DNA
(ii) To characterise the immunopathology of gene gun delivered pGM-CSF and
pIL-3
(iii) To determine the kinetics of expression of plasmid DNA and inflammatory
cytokines (TNF-a, IL-ip and IL-18) in the skin after vaccination
3.3 Cloning and in vitro expression of GM-CSF and IL-3
3.3.1 Cloning of cytokine genes
GM-CSF and IL-3 were individually cloned into the multiple cloning site of pEGFP-Nl
vector (Figure 2.8). Non-functional GM-CSF (NF-GM-CSF) and IL-3 (NF-IL-3) were also
cloned into pEGFP-Nl by insertion into the 3'-5' orientation of the vector, in order to
determine that the biological effects elicited in vivo after gene-gun bombardment were
indeed due to the biological activity of each cytokine. Analysis of constructs was carried out
by restriction endonuclease digest (Figure 2.9) after sub-cloning into pEGFP-Nl. In addition,
all clones were sequenced and verified to contain cytokine genes in the correct orientation. It
was necessary to clone NF constructs as it is now well established that regions of stimulatory
sequences within prokaryotic DNA (CpG motifs) activate DC via TLR9 (Hemmi et al, 2000)
and thus it is vital that the backbone DNA is identical to enable comparison of inflammatory
events following vaccination with plasmids containing different cytokine genes. pEGFP-Nl
was chosen as a suitable vector as it contains the immediate/early promoter from
cytomegalovirus (CMV), which results in high expression levels in vivo (Galvin et al., 2000).
3.3.2 In vitro expression of GM-CSF and IL-3 mRNA in SSk
fibroblasts.
It was necessary to determine ifGM-CSF and IL-3 were expressed by ovine skin fibroblasts
following in vitro transfection with pGM-CSF and pIL-3. Fibroblasts were transfected with
10-20gg of each plasmid by electroporation (Section 2.3.8.1). Cells were harvested
approximately 48 hours after transfection and RNA was extracted. GAPDH RT-PCR was
then carried out to ascertain that all genomic material was degraded by the DNase step
included in the RNA extraction procedure and that amplifiable material was present in each
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sample. Amplifiable material was present in each of the samples and genomic DNA was
fully degraded (Figure 3.1).
cDNA samples obtained from GM-CSF, NF-GM-CSF and mock transfected fibroblasts were
then amplified with GM-CSF specific primers. GM-CSF mRNA was detected in fibroblasts
which had been transfected with pEGFP-Nl containing GM-CSF, but not fibroblasts which
had been mock transfected or transfected with the plasmid containing the NF version of the
gene (Figure 3.2). In addition, cDNA samples obtained from IL-3, NF-IL-3 and mock
transfected fibroblasts were amplified with IL-3 specific primers. IL-3 mRNA was detected
in fibroblasts which had been transfected with pEGFP-Nl containing IL-3, but not in
fibroblasts which had been mock transfected or transfected with NF-IL-3 (Figure 3.3).
Figure 3.1 GAPDH RT-PCR performed with cDNA samples obtained after in vitro
transfection of ovine fibroblasts. 1pg of total RNA was reverse transcribed. cDNA samples
were then amplified with GAPDH-specific primers (Table 2.5) for 30 cycles at 55°C. ~366bp
fragments are evident from each cDNA sample. Control (-RT) reactions were also prepared
from each RNA sample to assess genomic contamination (lanes 8-13), no bands can be
observed.
Lane 1 kb Molecular weight marker
Lane 2 pGM-CSF transfected fibroblasts (+RT)
Lane 3 NF-GM-CSF transfected fibroblasts (+RT)
Lane 4 plL-3 transfected fibroblasts (+RT)
Lane 5 NF-IL-3 transfected fibroblasts (+RT)
Lane 6 mock transfected fibroblasts (+RT)
Lane 7 mock transfected fibroblasts (+RT)
Lane 8 pGM-CSF transfected fibroblasts (-RT)
Lane 9 NF-GM-CSF transfected fibroblasts (-RT)
Lane 10 plL-3 transfected fibroblasts (-RT)
Lane 11 NF-IL-3 transfected fibroblasts (-RT)
Lane 12 mock transfected fibroblasts (-RT)
Lane 13 mock transfected fibroblasts (-RT)
Lane 14 negative control (molecular grade water)
Lane 15 positive control (1:1000 dilution of plasmid DNA containing GAPDH insert)





Figure 3.2 PCR-amplified GM-CSF cDNA from pGM-CSF, NF-GM-CSF and mock
transfected fibroblasts. RNA was extracted from cells 48 hours after transfection and reverse
transcribed. PCR amplification was carried out for 30 cycles. GM-CSF transcripts can only
be detected in pGM-CSF transfected fibroblasts (~300bp product is evident).
Lane 1 positive control (1:1000 dilution of 1° PCR product)
Lane 2 NF-transfected (-RT)
Lane 3 mock (-RT)
Lane 4 pGM-CSF transfected (-RT)
Lane 5 NF-transfected (+RT)
Lane 6 pGM-CSF transfected (+RT)
Lane 7 mock transfected (-RT)
Lane 8 negative control (nuclease-free water)
Lane 9 1 kb Molecular weight marker
Figure 3.3 PCR-amplified IL-3 cDNA from plL-3, NF-IL-3 and mock transfected fibroblasts.
RNA was extracted from fibroblasts 48 hours after transfection and reverse transcribed. PCR
amplification was carried out for 30 cycles. IL-3 mRNA is only detected in plL-3 transfected
fibroblasts (<250bp product is evident, expected size of amplicon is 192bp).
Lane 1 1kb ladder
Lane 2 mock (-RT)
Lane 3 NF-IL-3 (-RT)
Lane 4 plL-3 (-RT)
Lane 5 mock (+RT)
Lane 6 NF-IL-3 (+RT)
Lane 7 plL-3 transfected (+RT)
Lane 9 positive control (diluted plL-3 1:5000)
Lane 11 negative control (nuclease-free water)
Lane 14 1kb ladder
107
3.3.3 Detection of recombinant GM-CSF by ELISA
Supernatants and cell pellets were collected 48 hours post-transfection and subjected to SDS-
PAGE followed by staining with Coomassie Blue in order to detect recombinant GM-CSF
(and IL-3). No bands at the expected molecular weight (15-25 kDa) were observed (data not
shown) and more sensitive detection systems were therefore required. Supernatants from
cells transfected with GM-CSF and NF-GM-CSF constructs were concentrated under
vacuum (approximately 4 x) and tested for the presence of recombinant GM-CSF by ELISA
(Entrican et al, 1996) with reagents supplied by Moredun Research Institute. Using this more
sensitive assay, it was evident that transfection of fibroblasts with pGM-CSF resulted in both
expression and secretion of recombinant GM-CSF into the extracellular milieu (Table 3.1).
The concentration of GM-CSF in the supernatant of fibroblasts transfected with pGM-CSF
was approximately 400 pg/ml (calculated from a standard curve generated from known
standards of recombinant GM-CSF) (Figure 3.4). The concentration of GM-CSF in mock
transfected cells and cells transfected with NF-GM-CSF could not be quantified as the
absorbance readings were below the level of quantification of the assay.
Table 3.1 Mean absorbance values of supernatants analysed by GM-CSF ELISA.
Supernatants were collected 48 hours after transfection of fibroblasts with pGM-CSF, NF-
GM-CSF or mock transfected (no DNA). A standard curve was constructed with diluted




Figure 3.4 Representative standard curve for GM-CSF ELISA. Recombinant GM-CSF was
diluted in assay buffer. Recombinant GM-CSF was kindly supplied by Dr. G. Entrican
(Moredun Research Insitute). The solid line is the line of best-fit and dashed lines represent
95% confidence intervals.
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3.3.4 Detection of recombinant IL-3
3.3.4.1 Western Blotting
Western Blotting was used to detect recombinant IL-3 using a panel of murine anti-IL-3
mAb and recombinant IL-3 derived from transfected Chinese Hamster Ovary (CHO) cell
supernatant from Moredun Research Institute. IL-3 was not detected in supernatants obtained
from transfected fibroblasts as assessed by Western blots developed with the substrate
chromagen DAB (Figure 3.5). In addition, no bands were observed in lanes where
supernatant from transfected CHO cell supernatant ("positive control") was loaded (lanes 3,
4, 6 and 7), although no information was available with regard to the outcome of the
transfection experiment (for example, results obtained from RT-PCR/Western blotting). In
lanes 2 and 10, recombinant IL-3 mAb were loaded into the acrylamide gel to confirm that
antibody was indeed present in the supplied aliquots and to validate that the SDS-PAGE and
transfer procedures were carried out satisfactorily; both heavy chains (-50 kDa) and light








Figure 3.5 Western blot of recombinant IL-3. Blots were incubated for 2 hours at rt with
either (a) mAb 3F7 (diluted 1: 200) or (b) mAb 2H11 (diluted 1:200).
Lane 1 Biorad low-range molecular marker
Lanes 2 & 10 10pl anti-IL-3 mAb 3F7 and 2H11 (1:200)
Lanes 3 and 4, 6 and 7 recombinant IL-3 (diluted 1:2, supplied by Dr G. Entrican)
Lanes 5 & 8 supernatant from plL-3 transfected fibroblasts (diluted 1:2)
In order to enhance the sensitivity of the detection system, enhanced chemo luminescence
(ECL) reagents (Amersham) were employed; however, it was still not possible to detect
recombinant IL-3 from either transfected cell line, even when additional anti-IL-3 mAb were
tested for reactivity (data not shown).
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3.3.4.2 Detection of IL-3 by immunofluorescent staining
After several unsuccessful attempts to detect recombinant IL-3 by Western blotting, an
alternative method was performed using immunofluorescent staining to detect intracellular
recombinant IL-3. Cells were harvested approximately 16 hours post-transfection and fixed
in ice-cold acetone and methanol and spotted onto a multiwell slide. After extensive
blocking of non-specific antigens, staining was carried out with a panel of IL-3 mAb
(Section 2.2.3.5) followed by TRITC-conjugated goat anti-murine IgG. Recombinant IL-3
was only detected by 2H11 mAb in cells transfected with pIL-3 (Figure 3.6) and not in mock
transfected fibroblasts. Attempts to repeat this experiment (and to include the NF-control
transfected cells) were however unsuccessful.
(a) (b)
Figure 3.6 Immunofluorescent staining of plL-3-transfected fibroblasts. Fibroblasts were
either (a) transfected with pIL-3 or (b) mock transfected (no DNA). 16 hours after
transfection, cells were fixed, blocked and stained with a panel of mAb raised against ovine
IL-3. (a) shows possible staining of cytoplasmic protein with mAb 2H11 in pIL-3 transfected
cells, (b) image has been lightened to show background (non-specific) staining
3.4 Gene-gun administration of cytokine gene adjuvants
in vivo over 7 days
The first part of the project addressed the histological events after gene-gun bombardment
with pGM-CSF, pIL-3 and pEGFP-Nl. The aim of this experiment was to crudely ascertain
the in vivo effects of GM-CSF and IL-3 in ovine skin in comparison to a control plasmid
(pEGFP-Nl). In particular, it was necessary to determine if indeed DC were recruited to the
skin and therefore be equipped to plan future experiments which included the appropriate
time-points. A previous study in murine muscle demonstrated maximal infiltration of DC
approximately 7 days after intramuscular administration of pGM-CSF (Bowne et al, 1999).
In addition, Haig and colleagues (1995) reported maximal infiltration of DC 5 days into
ovine skin after administration of recombinant GM-CSF in combination with TNF-a. The
preliminary biopsy experiment was therefore carried out over 7 days so as to provide ample
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opportunity to identify if indeed DC were recruited to the skin after gene-gun vaccination
with pGM-CSF (and pIL-3).
An overview of the preliminary biopsy experiment ("biopsy experiment A") is shown in
Figure 3.7. Briefly, pIL-3, pGM-CSF and pEGFP-Nl were administered in triplicate by
gene-gun into the skin of two clinically normal sheep at daily intervals for seven days. NF-
GM-CSF and NF-IL-3 were not available at this point in the study and pEGFP-Nl therefore
served as an appropriate control. Plasmid DNA coated particles were targeted towards the
epidermal/dermal junction using a previously optimised technique (Watkins et al, 1999). At
this point in the study the IL-3 construct also contained the gene encoding GFP. Neither
sheep had previous contact with GFP, nor had been used for any DNA vaccination work.
Skin samples were removed immediately at post-mortem by punch biopsy (day 7 of the
experiment) and were fixed in zinc acetate fixative, processed and stained with H & E or
used for immunohistochemistry.
Ill
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Figure 3.7 Overview of biopsy experiment A. Two sheep were each vaccinated with plL-3,
pGM-CSF and pEGFP-N1 over seven days. Skin was prepared by clipping and shaving the
flank of each animal, followed by washing the area with HIBI scrub and 100% ethanol
(Section 2.4). Triplicate shots of each plasmid were delivered. At post-mortem, samples
were removed by punch biopsy and immediately placed into ZSF for subsequent H & E
staining and for immunohistochemistry. Note that the day 2 time-point was omitted from
sheep 1 (top) whereas the day 3 time-point was omitted from sheep 2 (bottom).
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3.4.1 Effects of pGM-CSF administration in skin over 7 days
Whilst the overall magnitude of the inflammatory reaction was grossly similar after gene-
gun administration of cytokine genes in both animals, some differences were apparent.
Presentation of representative data for both animals at each of the time-points investigated is
therefore problematic. In addition, time-points of days 3 and 2 post-vaccination (p/v) were
only available for animals 1 and 2, respectively (Figure 3.7). Representative images for each
animal are shown and the main findings are summarised in Table 3.2 (animal 1) and Table
3.3 (animal 2). Figure 3.8 is representative of H & E stained sections obtained from normal
(non-vaccinated) skin from each of the two animals used in the study. An epidermal layer of
4-6 cells is evident and relatively few leukocytes are located within the dermis.
Figure 3.8 H & E stained sections from normal (non-vaccinated) skin from sheep 1 (a) and
sheep 2 (b). (Scale bar = 250pm.)
(i) outer keratin layer
(ii) epidermis






3.4.1.1 Histological analysis of pGM-CSF vaccinated skin
It was evident that gene-gun administration of pEGFP-Nl induced an inflammatory response
in both animals (Figure 3.9 and Figure 3.10). This may be a result of physical damage from
the vaccination procedure in combination with the introduction of stimulatory CpG motifs
into the skin; the relative contribution of each of these stimuli was not investigated in this
study. In both animals, the inflammatory response induced after administration of pEGFP-
N1 was characterised by an increase in dermal cellularity by 24 hours, and by 48 hours an
epidermal neutrophilic pustule had formed. The dermal infiltrate after administration of
pEGFP-Nl was generally mixed in composition; neutrophils, eosinophils, lymphocytes,
macrophages and monocytes were observed throughout the time-course of the experiment,
with the exception of 4 days p/v in both animals, where the infiltrate was composed largely
ofmononuclear cells.
It was evident that the magnitude of the reaction induced after gene-gun delivery of pGM-
CSF was substantially more severe than observed with pEGFP-Nl (Figure 3.9 and Figure
3.10). An acute inflammatory reaction had taken place in both animals by 24 hours,
characterised by an influx of neutrophils, resulting in the formation of a large epidermal
pustule ("microabscess'V'crust"). Massive exocytosis was still evident 24 hours after pGM-
CSF administration and focal disruption of the epidermal-dermal junction due to cell
trafficking was evident in all sections examined. The extent of the epidermal and dermal
reaction was however slightly more pronounced in sheep 1 than in sheep 2, 24 hours p/v. An
inflammatory reaction was also evident underneath the basal membrane (superficial dermal
reaction), which was mixed in composition; approximately 50% of the infiltrate was
composed of eosinophils and some monocytes and macrophages were also observed. Little
inflammation was apparent deeper within the dermis at this time-point, although cells could
be observed in and around the blood vessels suggestive of active recruitment of cells to the
site. Whereas much of the inflammatory reaction appeared to have taken place 48 hours after
pEGFP-Nl administration, as indicated by minimal exocytosis and the presence of a
confluent pustule, exocytosis was still pronounced 48 hours after pGM-CSF administration.
The severity of the reaction elicited by pGM-CSF did not increase over the time-course of
the experiment but instead appeared to resolve, as shown by the degeneration of the
microabscess approximately 4—5 days p/v. The peak inflammatory reaction therefore
appeared to have taken place within the first 24 hours after gene-gun delivery of pGM-CSF.
Interestingly, early time-points (24-48 hours) were largely characterised by the recruitment
of PMN (neutrophils and eosinophils), whereas mononuclear cells were the predominant
infiltrating cells at later time-points; the infiltrate was composed of >90% mononuclear cells
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3 days p/v in sheep 1 (Table 3.2) and 4 days p/v in sheep 2 (Table 3.3), consistent with a
slightly more delayed reaction in this animal. Between 5-6 days after pGM-CSF
administration, healing of the skin was apparent as the crust began to resolve and epidermal
thickening (acanthosis) was evident. By 6-7 days after gene-gun delivery of pGM-CSF,
many of the pustules had sloughed off, and the epidermal layer was renewed, although




Figure 3.9 Comparison of the inflammatory events induced in the skin after gene-gun
administration of pGM-CSF and pEGFP-N1 (sheep 1). Skin biopsies were removed
immediately at post-mortem, fixed in ZSF and stained with H & E. Representative images
from each of the time-points are shown. (Scale bar = 250pm.)
(i) gold bullets in outer epidermal layer
(ii) pustule (composed predominantly of neutrophils)
(iii) dermal infiltrate (predominantly eosinophils)
(iv) mononuclear infiltrate










Figure 3.10 Comparison of the inflammatory events induced in the skin after gene-gun
administration of pGM-CSF and pEGFP-N1 (sheep 2). Skin biopsies were removed
immediately at post-mortem, fixed in ZSF and stained with H & E. Representative images











3.4.1.2 Immunohistological analysis of pGM-CSF vaccinated skin
In order to further investigate the histopathological changes after gene-gun administration of
the plasmid constructs, mAb reactive with various immune cell populations were required. In
order to obtain a panel of mAb for subsequent staining of ovine skin biopsies, lymph nodes
were removed from sheep during routine cannulation surgery and fixed in ZSF. Gonzalez
and colleagues (Gonzalez et al, 2001) have successfully identified a number of antibodies
capable of staining ovine immune cells in lymph nodes previously fixed in ZSF. This method
confers several advantages over conventional aldehyde-based fixatives; not only is the
morphology of the cells maintained, but also antigen-retrieval steps are not required. A panel
of approximately 20 mAb (shown to be reactive by flow cytometry) was tested on lymph
node sections based on this method.
Whilst many of the mAb successfully identified cell populations within lymph node sections
(results not shown), staining of resident cell populations within the skin was more
problematic. In mammalian skin there are two major populations of DC, which differ in their
anatomical localisation, phenotype and function. LC are located in the epidermis, whereas
dermal DC are generally associated with dermal structures including blood vessels, hair
follicles and sweat glands. Both populations express high levels ofMHC class II with most
cells also expressing the CD1 antigen (Townsend et al., 1997). mAb reactive with ovine
CD lb (IAH-CC20 and IAH-CC14) and pan-CD 1 (clone SBU-T6) identified DC when
applied to paraffin wax-embedded lymph node sections; however, mAb did not successfully
stain epidermal LC or dermal DC, even after extended incubation periods. Various antigen
retrieval methods were attempted using normal skin sections fixed in paraformaldehyde with
little success (results not shown). For this reason, identification of DC relied on MHC class
II staining in combination with morphological assessment.
Immunoperoxidase staining of MHC class II+ cells
Due to the problems encountered with identifying ovine LC and dermal DC by
immunohistochemistry using a range of anti-CD 1 mAb, VPM 54 (anti MHC class II DRa)
was applied to skin sections in order to identify if indeed DC infiltrated the skin after gene-
gun administration of pGM-CSF or pEGFP-Nl; however, MHC class II is not only
constitutively expressed on DC but on all professional APC (monocytes, macrophages and B
cells) (Puri et al., 1987). In addition, its expression can be induced in activated T cells in
sheep (Dutia et al., 1993a). Observations must therefore be interpreted with some degree of
caution. In addition, only qualitative observations were made; no quantitative analysis of
immunostained sections was carried out in this study.
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Staining with mAb VPM 54 revealed a slight increase in MHC class II+ cells in the skin 24
hours after administration of both pGM-CSF and pEGFP-Nl in sheep 1 (Figure 3.11). In
contrast, a more pronounced accumulation of MHC class 1I+ cells was evident 24 hours in
pGM-CSF vaccinated biopsies than in control-vaccinated biopsies in sheep 2 (Figure 3.12);
foci of MHC class II+ cells were evident both at epidermal sites and also deep within the
dermis and surrounding blood vessels, suggestive of active recruitment rather than
proliferation of resident cells in this animal. Such observations are indeed consistent with the
H & E stained sections evaluated by Dr Susan Rhind, where monocytes and macrophages
were observed in and around the blood vessels in this animal 24 hours after pGM-CSF
administration (Table 3.3), consistent with the observation that cells are being recruited to
the site. A modest increase in MHC class II+ cells in the dermis was also observed in
pEGFP-N 1 vaccinated skin of this animal; however, this was not as pronounced an increase
as elicited after pGM-CSF administration and indeed the majority (>80%) of the dermal
infiltrate was comprised of eosinophils.
Foci ofMHC class II+ cells within the dermis were evident in both the control and pGM-CSF
vaccinated skin approximately 2 days after gene-gun bombardment in sheep 2; however at
this time-point, no marked difference was apparent between pEGFP-Nl or pGM-CSF
vaccinated skin. The most striking observation in this animal (sheep 2), occurred 4 days after
pGM-CSF administration; at this time-point large foci of MHC class II+ cells were evident
particularly in and around blood vessels and deep within the dermis. This increase in MHC
class II+ cells was also in accord with the findings from the H & E stained skin sections
(Table 3.3), where more than 90% of cells within the dermis were described as mononuclear.
High magnification images of MHC class II+ infiltrates are shown in Figure 3.12b. Upon
closer examination, cells with the morphological appearance of DC can be observed;
dendrites, an indented nucleus and high MHC class II expression are evident. This dramatic
increase in MHC class II+ cells was not observed in pEGFP-N1 vaccinated skin sites.
Perhaps consistent with a more acute inflammatory reaction in sheep 1 was an infiltration of
MHC class II+ DC 3 days after administration of pGM-CSF in this animal (as compared with
an infiltration of DC 4 days after administration, as observed with sheep 2). Infiltrates were
evident both within the epidermis and the superficial dermis. Such intense foci of DC were
not observed 4 days after administration in this animal, although more MHC class II+ cells
were present than in the control pEGFP-Nl vaccinated site. Such discrepancies between the
two animals are again in agreement with the earlier observations made from the H & E
stained sections, where although the overall reaction in both sheep was of a similar
magnitude, the cellular kinetics in sheep 2 were slightly delayed. In both animals,
comparatively more MHC class II+ cells were evident in pGM-CSF vaccinated skin biopsies
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than in control pEGFP-Nl vaccinated skin 5-6 days p/v; however, infiltration was less
pronounced than observed 3-4 days p/v. By 7 days p/v, numbers ofMHC class If cells were
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Figure 3.11 pGM-CSF enhances DC recruitment to the skin (sheep 1). Immunolabelling of
skin sections with mAb VPM 54 (anti-MHC class II DRa) after gene-gun bombardment with
pGM-CSF (right panels) and pEGFP-N1 (left panels). Sections were counterstained with
haematoxylin. An increase in epidermal MHC class II DR+ cells with the morphological






Figure 3.12 Recruitment of DC into skin 4 days after DNA vaccination with pGM-CSF (sheep
2). Immunolabelling of skin sections was carried out with mAb VPM 54 (anti-MHC class II
DRa) after gene-gun bombardment with pGM-CSF (part (a), right panels) and pEGFP-N1
(part (a), left panels). Sections were counterstained with haematoxylin. Note that low power
views (original magnification, *80) have been used for all of the sections with the exception
of day 4 after DNA vaccination with pGM-CSF (original magnification, *250). Note the
infiltration of dermal DC 4 days after pGM-CSF administration in this animal, (b) High






Immunoperoxidase staining of CD45RA+ lymphocytes
CD45RA is a surface marker of ovine B cells and a T cell subset (Mackay et al., 1990). In a
previous study with pGM-CSF, an infiltration of lymphocytes was observed several days
after both intramuscular and intradermal delivery (Perales et al, 2002). Immunostaining with
a mAb that recognises CD45RA (mAb 73B (Dutia et al., 1993c)) revealed a slight increase
in the number of CD45RA+ lymphocytes in the skin approximately 24 hours after gene-gun
administration of both pGM-CSF and pEGFP-Nl constructs (Figure 3.13). A further increase
in CD45RA+ lymphocytes was evident 3^1 days after gene-gun delivery of pGM-CSF (data
are shown for sheep 1 only); however serial sections stained with mAb 73B and VPM 54
revealed that MHC class II+ infiltrates were not CD45RA+ lymphocytes since MHC class II+
infiltrates were localised within and in close proximity to the epidermis (Figure 3.11),
whereas CD45RA+ lymphocytes were present deeper within the dermis (Figure 3.13). Since
there are very few naive (CD45RA+) T cells in afferent lymph (Mackay et al, 1990), these
cells are likely to be B cells.
MHC class II+ infiltrates may contain macrophages as well as DC. Unfortunately, attempts to
stain for monocytes and macrophages with mAb specific for ovine CD 14 and CD lib (and
therefore enable discrimination ofmonocytes and macrophages from DC) were unsuccessful.
It was interesting to observe that foci of CD45RA+ lymphocytes were present 5-6 days after
pGM-CSF administration, but not after bombardment with the pEGFP-Nl in any of the skin
biopsies evaluated. Serial sections immunolabelled with mAb 73B and VPM 54 (anti MHC
class II DRa) revealed a similar pattern of staining at later time-points (5-6 days after DNA
vaccination with pGM-CSF), where CD45RA+ MHC class II+ cells (possibly B cells) were





Figure 3.13 Infiltration of CD45RA+ cells after pGM-CSF administration (sheep 1). Ovine
skin sections were immunolabelled with mAb 73B (anti CD45FJA) after gene-gun
bombardment with pGM-CSF (right-hand side panels) and pEGFP-N1 (left panels). Sections
were counterstained with haematoxylin. An infiltration of CD45RA+ lymphocytes is evident in
the dermis 3 days after pGM-CSF delivery (whereas MHC class ll+ cells were located near to
the epidermis in this animal; Figure 3.11). Infiltration of CD45RA+ lymphocytes is also
evident 5-6 days after pGM-CSF delivery. (Scale bar = 250pm.)
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Immunoperoxidase staining of 78 T cells
Ruminant 78 T cells are concentrated at epithelial surfaces (Mackay and Hein, 1989) and
share many common features with mice and human 78 T cells, although the latter species
contain relatively few yS+ T cells in the epithelium. Human 78 T cells have been reported to
induce DC maturation (Ismaili et al., 2002) and thus an increase in 78 cell numbers could
have implications in terms of DC activation. In mice, epidermal 7S+ T cells found in murine
skin have been proposed to be related to resident DC in the skin (Bergstresser et al., 1983;
Tschachler et al., 1983) and 78 DC are known to present antigen (Welsh and Kripke, 1990).
Indeed, ovine 78 DC isolated from lymph have ultrastructural features characteristic of DC
(Dandie et al., 2001).
A mAb specific for sheep WC1 that reacts with all 78 T cells (IAH-CC15) identified
numerous cells in normal (non-vaccinated) skin sections (Figure 3.14). An increase in the
number of 78 T cells in skin relative to those identified in normal skin was evident after
gene-gun bombardment with both pGM-CSF and pEGFP-Nl constructs 24 hours in both
animals (Figure 3.14 and Figure 3.15). Two days after plasmid administration (sheep 2 only),
the number of 78 T cells had declined in the control vaccinated skin, but remained slightly
elevated in the pGM-CSF vaccinated skin biopsies, whereas by 3^1 days p/v numbers of 78
T cells appeared comparable to those observed in normal skin. Of interest was an infiltration
of 78 T cells 5 days after pGM-CSF in sheep 1 (Figure 3.14), particularly around wool
follicles and this was also observed, but to a lesser extent in pEGFP-Nl vaccinated skin
biopsies, where 78 T cells were also observed in and near to the epidermis. Six days after
pGM-CSF and pEGFP-Nl administration (Figure 3.15), a slight increase in 78 T cells was
identified in the skin of sheep 2, again consistent with the more delayed cellular kinetics in
this animal. By day 7, the relative numbers of 78 T cells in skin vaccinated with either
plasmid appeared similar to those identified in normal skin, although 78 T cells were more
commonly observed in the epidermis of gene-gun vaccinated sections. In addition, some 78





Figure 3.14 Infiltration of y5 T cells in skin after gene-gun vaccination (sheep 1).
Immunolabelling of WC-1 epitopes was carried out with mAb IAH-CC15 (anti-y5 T cells) after
gene-gun bombardment of the skin with pGM-CSF (right panels) and pEGFP-N1 (left
panels). A representative image of normal skin from both animals stained with mAb IAH-




Figure 3.15 Infiltration of y5 T cells in skin after gene-gun vaccination (sheep 2).
Immunolabelling of WC-1 epitopes with mAb IAH-CC15 (anti- y5 T cells) after gene-gun
bombardment of the skin with pGM-CSF and pEGFP-N1. Slides were counterstained with
haematoxylin. (Scale bar = 250pm.)
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3.4.2 Effects of plL-3 administration in skin over 7 days
3.4.2.1 Histological analysis of plL-3 vaccinated skin
Representative images are shown for each animal after gene-gun bombardment with pIL-3
and pEGFP-Nl (Figure 3.16 and Figure 3.17). The extent of the inflammatory reaction after
gene-gun delivery of pIL-3 was greater than observed with pEGFP-Nl; however, the
magnitude of the reaction was less severe in association with pIL-3 than with pGM-CSF. In
addition, there appeared to be less consistent alterations in association with pIL-3, although
the process of active exocytosis appeared to last longer than that observed after pGM-CSF
administration. Again, a more pronounced reaction was observed in sheep 1 by 24 hours. As
can be observed in Figure 3.16, pronounced exocytosis is evident and epidermal pustules
(neutrophil exudates) had already formed by 24 hours in this animal, whereas pustules were
still developing in sheep 2 up to 48 hours after pIL-3 administration (Figure 3.17). Indeed
massive exocytosis and disruption of the epidermis was evident 2 days after gene-gun
administration of pIL-3 in this animal. The early inflammatory response (24 hours) after
gene-gun bombardment of the skin with pIL-3 was composed predominantly of eosinophils
in both animals, although it should be noted that eosinophils were also the major cell type
infiltrating the skin after DNA vaccination with pEGFP-Nl in sheep 2. At later time-points
the inflammatory reaction was mixed, with the exception of day 5 in sheep 1, where many
eosinophils were observed, particularly around vessels deep within the dermis.
Epidermal thickening was evident as early as 3 days after pIL-3 administration in sheep 1
and by 5 days in sheep 2. By 6-7 days after gene-gun bombardment, pustules had started to
resolve and slough off in both animals and the keratin layer was returning to normal, as
illustrated by the underlying "basketweave" of keratin. Minimal inflammation was evident




Figure 3.16 Comparison of the inflammatory events induced in the skin after gene-gun
administration of plL-3 and pEGFP-N1 (sheep 1). Skin biopsies were removed immediately
at post-mortem, fixed in ZSF and stained with H & E. Representative images from each of
the time-points are shown. (Scale bar = 250pm.)
(i) pustule formation by 24 hours








Figure 3.17 Comparison of the inflammatory events induced in the skin after gene-gun
administration of plL-3 and pEGFP-N1 (sheep 2). Skin biopsies were removed immediately
at post mortem, fixed in ZSF and stained with H & E. Representative images from each of





(v) aggregates of gold beads
(vi) "basket weave" of keratin (healing epidermis)
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controls IL-3
Table 3.2 Overview of the inflammatory reaction after gene-gun vaccination with pGM-CSF,
plL-3 and pEGFP-N1 (sheep 1). Note that the plasmid containing IL-3 still contained the GFP
gene at this stage. (MO, macrophages; L, lymphocytes; eos, eosinophils; monos,
mononuclear cells; +, mild; ++, moderate; +++, severe; ++++, extremely severe (beyond
"normal" levels).)
days













































































pIL-3 superficial mixed ++
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Table 3.2 (Cont.)








































































Table 3.3 Overview of the inflammatory reaction following vaccination with pGM-CSF, plL-3
and pEGFP-N1 (sheep 2). Note that the plasmid containing IL-3 still contained the GFP gene
at this stage. (MO, macrophages; L, lymphocytes; eos, eosinophils; monos, mononuclear
cells; +,mild; ++, moderate; +++, severe; ++++, extremely severe (beyond "normal" levels).)
days
p/v construct location cell type
severity
(dermal) epidermis other comments






pGM-CSF mainly mid mixed, 30 +++/I I I I developing focal disruption
to 50% eos. pustules, massive of epidermis and
superficial exocytosis d/e junction.
monos & MOs in
and around blood
vessels
pIL-3 deep >70% eos ++/+++ developing
adnexal to pustules,
superficial exocytosis




pGM-CSF deep mixed ~50% ++ massive pustule,
adnexal to eos. trafficking/
superficial, exocytosis still in
mainly progress
perivascular



































5 pEGFP-N 1 mainly
superficial



























































3.4.2.2 Immunohistological analysis of pIL-3 vaccinated skin
Immunoperoxidase staining of MHC class II+ cells
pIL-3 vaccinated skin biopsies were immunolabelled with mAb VPM 54 (anti-MHC class II
DRa) and representative images from both animals are shown in Figure 3.18 (sheep 1) and
Figure 3.19 (sheep 2). The initial immunohistological changes caused by pIL-3 vaccination
were subtle. The numbers of MHC class II+ cells were slightly elevated 24 hours after pIL-3
administration when compared to pEGFP-Nl vaccinated skin in sheep 1 (Figure 3.18),
whereas no difference was apparent in pIL-3 and pEGFP-N1 vaccinated skin sites in sheep 2
(Figure 3.19). By 2 days, slightly more MHC class II+ cells had infiltrated pIL-3 vaccinated
skin; immunolabelled cells were small, round and mononuclear (possibly monocytes/B
cells), but this did not differ markedly from the control (pEGFP-Nl) vaccinated skin
sections. No difference in the number of MHC class II+ cells was apparent 3—4 days after
administration of either pIL-3 or pEGFP-N 1. Some infiltrates of MHC class II+ cells were
however evident in the dermis (sheep 2) and near to the epidermis (sheep 1) 6-7 days after




Figure 3.18 Identification of MHC class ll+ cells in skin vaccinated with plL-3 and pEGFP-N1
(sheep 1). Skin sections were immunolabelled with mAb VPM 54 (MHC class II DRa) after
gene-gun bombardment with plL-3 (right-hand side panels) and pEGFP-N1 (left panels).








Figure 3.19 Identification of MHC class ll+ cells in skin vaccinated with plL-3 and pEGFP-N1
(sheep 2). Skin sections were immunolabelled with mAb VPM 54 (MHC class II DRa) after
gene-gun bombardment with plL-3 (right panels) and pEGFP-N1 (left panels). Sections were
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Immunoperoxidase staining of CD45RA+ cells
Generally more CD45RA+ lymphocytes were present in skin 24 hours after pIL-3
administration than observed in control-vaccinated skin (Figure 3.20a,b). Importantly, serial
sections stained with VPM 54 and 73B mAb showed a similar pattern of staining; MHC
class II+ CD45RA+ cells (possibly B cells) were generally present deep within the dermis. In
addition, slightly more CD45RA+ lymphocytes were present in the control-vaccinated skin
than in non-vaccinated skin, indicating that an influx of CD45RA+ lymphocytes is a result of
the damage elicited to the skin during the gene-gunning procedure and/or administration of
prokaryotic DNA. From 3-6 days, similar numbers of CD45RA+ cells were apparent in pIL-
3 vaccinated skin sections, although numbers were slightly elevated when compared to those
in normal (non-vaccinated) skin sections (data not shown).
Immunoperoxidase staining of yd T cells
Trafficking of y8 T cells into the skin was evident in both animals with both pIL-3 and
pEGFP-Nl at the 24 hour time-point (Figure 3.20c,d). A modest increase in the numbers of
y5 T cells was also evident in pIL-3 vaccinated skin biopsies approximately 5 days after
gene-gun delivery when sections were compared with both pEGFP-Nl vaccinated biopsies
and normal skin sections (data not shown). By day 7, the prevalence of y5 T cells in skin
vaccinated with either plasmid appeared similar to those observed in normal skin.
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Figure 3.20 Immunolabelling of CD45RA+ leukocytes and y5 T cells in skin after DNA
vaccination with plL-3 and pEGFP-N1. (a, b) Immunolabelling of CD45RA epitopes with mAb
73B (sheep 1); (c, d) immunolabelling of WC-1 epitopes with mAb CC15 24 hours after
gene-gun delivery of pEGFP-N1 and plL-3 (sheep 2). (Scale bar = 250pm.)
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3.4.3 Summary of findings from biopsy experiment A
• pGM-CSF caused mass inflammation by 24 hours as shown by extensive pustule
formation and dermal: epidermal effacing
• The early time-points (24-48 hours) revealed an infiltration of largely PMN after
pGM-CSF administration, whereas mononuclear cells were the predominant cell
type recruited at later time-points
• The most striking observation was the appearance ofMHC class II+ cells with the
morphology of DC 72-96 hour after DNA vaccination with pGM-CSF
• Less consistent alterations to the skin were apparent after pIL-3 administration.
pIL-3 caused less pathology than pGM-CSF, although the process of active
exocytosis appeared to last longer
• Biopsies removed 24 hours after pIL-3 administration contained predominantly
eosinophils (approximately 70-80% of the infiltrate). In addition, small
mononuclear MHC class II DRa+ CD45RA+ cells were present 24 hours p/v
• With the possible exception of later timepoints (6-7 days p/v), a pronounced
infiltration ofMHC class II+ cells with the morphological appearance ofDC was
not observed after pIL-3 administration
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3.5 Gene-gun administration of cytokine gene adjuvants
over 24 hours
The results from biopsy experiment A (Section 3.4) necessitated a closer investigation into
the histological events that take place within the first 24 hours, particularly since the peak
inflammatory reaction appeared to have already taken place by 24 hours with pGM-CSF;
earlier time-points were thus required to dissect the inflammatory events in more detail. It
was also evident that the magnitude of the inflammatory reaction was greater with pGM-CSF
than with pIL-3. At this point in the study, pIL-3 also contained the GFP gene and it was
speculated that the fusion protein may have had more limited effects in vivo. The GFP gene
was therefore removed from the IL-3 construct for future experiments. It was also imperative
to include the NF cytokine constructs to ensure that the results from biopsy experiment A
were indeed due to the biological activities of each cytokine and not due to any stimulatory
sequences (CpG motifs) within each cytokine gene. NF-GM-CSF and NF-IL-3 (herein
referred to as NF-controls) were employed for all subsequent experiments. Further
experiments were needed to confirm the findings ofbiopsy experiment A and to correlate the
histological findings with the kinetics of plasmid gene expression and expression of
proinflammatory cytokines (IL-ip, TNF-a and IL-18).
This part of the study investigated the course of local inflammation in ovine skin 1-24 hours
after DNA vaccination with pGM-CSF, pIL-3 and NF-controls. Two clinically healthy sheep
were vaccinated over 24 hours (biopsy experiments B and E) as illustrated in Figure 3.21.
Details of biopsy experiments are listed in Chapter 2 (Table 2.8). For these experiments (and
those that followed), the GFP gene was removed from the IL-3 construct, which was
sequenced to confirm that no alterations to the IL-3 gene had occurred. In vitro mRNA
expression was again validated by RT-PCR (data not shown). For consistency, the GFP gene
was also removed from both NF-controls. Each plasmid construct was administered in
triplicate at each time-point. Immediately at post-mortem one half of each biopsy was fixed
(either in ZSF or paraformaldehyde) for immunohistochemistry and H & E staining, and the









Figure 3.21 A representative example of a biopsy experiment carried out over 24 hours
(biopsy experiments B and E, Table 2.8). In this experiment, two animals were vaccinated
three times with each of the four plasmid constructs (pGM-CSF, plL-3 and the NF-controls)
by gene-gun administration over 24 hours (outlined in chapter 2). Sheep were sacrificed and
biopsies were immediately removed and bisected. Biopsies used for RNA extraction and
subsequent quantitative RT-PCR analysis were immediately placed into RNAlater™.
3.5.1 Effects of pGM-CSF in skin 1-24 hours after administration
3.5.1.1 Skin histopathology after gene-gun vaccination with pGM-CSF
A histological examination of tissue sections was performed at intervals after gene-gun
delivery of both pGM-CSF and the NF-control. The NF-control vaccinated biopsies revealed
a slight increase in dermal cellularity at all time points investigated when compared to
normal non-vaccinated skin biopsies (Figure 3.22); an increase in cellularity was evident as
early as 1 hour after plasmid administration, where neutrophils were the predominant
infiltrate. Neutrophils continued to be recruited over the time-course and accumulated in the
dermis after DNA vaccination with the NF-control plasmid. There was however no pustule
formation nor effacing of the dermal: epidermal junction 24 hours after gene-gun
bombardment.
In accord with biopsy experiment A, gene-gun vaccination with pGM-CSF caused a severe
inflammatory reaction by 24 hours, again characterised by pustule formation and epidermal-
dermal junction separation due to en masse neutrophilic trafficking (Figure 3.22).
Histopathologically, the first change in the skin after pGM-CSF delivery was the presence of
marginating PMN within the dermal blood vessels, as was observed after delivery of the NF
control. The infiltration of PMN was however substantially more pronounced after pGM-
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CSF administration than after administration of the NF control; increased numbers were
evident as early as 2 hours, but invariably by 4 hours and PMN tended to accumulate under
the keratin layer. At this time, the epidermal layer was still recognisable, although changes in
some of the epidermal cells were apparent. Between 4 and 6 hours p/v, large numbers of
neutrophils continued to migrate to the site, and the development of a microabscess was
apparent as PMN continued to accumulate under the keratin layer. By 24 hours the epidermal
layer was not readily recognisable, due to a universal florid epidermal reaction involving
PMN. As observed in biopsy experiment A, a mixed dermal reaction was also apparent by
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Figure 3.22 Comparison of the inflammatory events induced in the skin from 1-24 hours
after gene-gun administration of pGM-CSF and the NF-control. Skin biopsies were removed
immediately at post mortem, fixed in ZSF and stained with H & E. Representative images
from each of the time-points are shown. After pGM-CSF delivery, many neutrophils have
accumulated under the keratin layer and pustule formation is evident by approximately 4












3.5.1.2 Immunohistological analysis of pGM-CSF vaccinated skin
The biopsies were bisected and stained with mAb in order to attempt to identify cell
populations recruited to the skin over the time-course.
Immunoperoxidase staining ofMHC class II+ cells
Immunoperoxidase staining was carried with mAb VPM 54 (anti MHC class II DRa) on skin
sections removed from pGM-CSF and NF-control sites and compared with normal (non-
vaccinated skin) Representative images from each time-point are shown (Figure 3.23).
Qualitative assessment of the sections obtained from NF-control vaccinated skin indicated a
slight increase in the number of DR+ cells when compared to normal skin at 6 and 24 hours
p/v, whereas numbers of DR+ cells were slightly elevated at all time-points (1-24 hours)
after pGM-CSF administration. In addition, staining of endothelial cells and cells within the
dermis (near to blood vessels) was evident as early as 1 hour after pGM-CSF administration.
By 2-A hours, DR+ cells were identified amongst the infiltrating PMN population which had
accumulated near to the epidermis and in the superficial dermis. At 6 hours, little difference
was observed after administration of either of the plasmids; however, by 24 hours, a more
pronounced infiltration of DR+ cells was apparent in pGM-CSF vaccinated skin than in NF-
control vaccinated skin.
Immunoperoxidase staining of CD45RA+ lymphocytes and 78 T cells
Staining with mAb 73B was carried out in order to identify CD45RA+ lymphocytes in skin
before and after DNA vaccination with pGM-CSF and the NF-control. At 1, 2 and 4 hours
after administration of either plasmid, no changes in the number of CD45RA+ cells were
evident when sections were compared to normal skin. At 6 and 24 hours p/v, a slight
increase inCD45RA+ lymphocytes was observed after administration of both pGM-CSF and
NF-control. No changes in the number of 78 T cells (data not shown) were evident in any of
the skin sections screened. Immunostaining with anti-CD4 and CD8 mAb showed that skin
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Figure 3.23 Immunolabelling of MHC class ll+ cells in skin 1-24 hours after gene-gun
administration of pGM-CSF and the NF-control. Skin sections were immunoperoxidase
labelled with mAb VPM 54 (MHC class II DRa). Representative images are shown after
administration of pGM-CSF (right panels) and the NF-control (left panels). Sections were






3.5.1.3 Cytokine mRNA expression in skin after gene-gun delivery
of pGM-CSF
Quantitative RT-PCR was used to measure the kinetics of GM-CSF mRNA expression in
skin 1-24 hours p/v. Since proinflammatory cytokines are well documented to be involved in
the maturation of DC and in the migration of DC (as outlined in the Introduction), IL-ip,
TNF-a and IL-18 mRNA transcripts were also quantified. Each plasmid construct was
administered by gene-gun vaccination three times to the skin on the flank of two sheep over
24 hours. Immediately at post-mortem each biopsy was removed using a sterile biopsy punch
and bisected. Half of each biopsy was placed into RNAlater™ (to stabilise RNA species).
Biopsies were stored at -80°C until RNA extraction was performed. Occasionally gold dust
was not observed after gene-gun delivery; such "miss-fires" were noted at the time of the
experiment and RNA was not extracted from these biopsies.
GM-CSF mRNA expression
It was evident that plasmid DNA from the original vaccination procedure was not completely
degraded by the DNase step included in the RNA extraction procedure (Section 2.6). It was
imperative that a method was developed that ensured that residual plasmid DNA was
removed in order to accurately assess the kinetics ofGM-CSF (and IL-3) mRNA expression.
A method to degrade plasmid DNA was developed and optimised using RNA spiked with
pGM-CSF and pIL-3. This involved retreating RNA samples in solution with DNase in
combination with Pst-1 or Hinf-1 in order to degrade plasmids containing either pGM-CSF
or pIL-3 respectively (Section 2.6). Prior to the evaluation of cDNA samples by quantitative
RT-PCR, control (-RT) samples were first amplified with GM-CSF or IL-3 specific primers
on the LightCycler®. Specific product was confirmed by melting curve analysis in
combination with gel electrophoresis. If specific product was detected in any of the control
(-RT) samples the cDNA was not used for analysis. Instead, further treatment of the RNA
was carried out, or, if insufficient material was available, treatment of the original RNA
sample was again performed. In either case, specific product was verified to be absent in the
control (-RT) samples by amplification of these samples on the LightCycler* with GM-CSF
or IL-3 primers.
Due to problems with eliminating residual plasmid DNA contained within the RNA samples
early on in the study (biopsy experiments B (and C)), triplicate cDNA samples for each time-
point were not initially available. Due to low yields of RNA after complete removal of
contaminating plasmid DNA, RNA samples from sheep 3 (biopsy experiment B) were
initially pooled. Figure 3.24 is representative of data obtained from cDNA samples analysed
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on three separate occasions on the LightCycler® with GM-CSF specific primers and
illustrates the reproducibility of the experiment.
hours post-vaccination
Figure 3.24 GM-CSF mRNA expression in skin 1-24 hours after gene-gun delivery of pGM-
CSF and the NF-control. Representative of three independent LightCycler® experiments
where cDNA samples from each time-point (from sheep 3, biopsy experiment B) were
pooled. GM-CSF mRNA expression was normalised for the expression of GAPDH mRNA.
Data are presented as mean + SEM. pGM-CSF induced significantly more GM-CSF mRNA
than the NF-control over 24 hours (p < 0.02, unpaired Student t-test).
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When suitable methods to eradicate plasmid DNA were employed, more cDNA samples
became available from biopsy experiment B as illustrated in Figure 3.25a. Figure 3.25b
illustrates expression of GM-CSF mRNA in sheep 4 (biopsy experiment E), where triplicate
biological samples were available for each of the time-points (1-24 hours) and analysed
alongside cDNA derived from normal skin.
GM-CSF mRNA was detected in normal skin in both animals and is represented as a solid
line on Figure 3.25a. Endogenous expression of GM-CSF mRNA was only just within the
limit of quantification of the assay in sheep 4; (0.65 normalised units) and is not represented
on Figure 3.25b. In both animals, an increase in GM-CSF mRNA was evident after gene-gun
bombardment with the NF-control and expression peaked approximately 6 hours p/v; a 16
fold increase in GM-CSF mRNA was observed in sheep 3. In contrast, administration of
pGM-CSF resulted in a more pronounced linear increase in GM-CSF mRNA in both
animals, peaking at approximately 4 hours. Relative to levels induced by administration of
the NF control, a 22 fold increase in GM-CSF mRNA was observed in sheep 3 and a 12-fold
increase was observed in sheep 4 at this time-point. From 4-24 hours p/v, GM-CSF mRNA
expression then declined in an almost linear fashion. Expression of GM-CSF transcripts was
significantly higher in pGM-CSF vaccinated skin compared to skin which had been
vaccinated with the NF-control over the entire time-course in sheep 3 (p < 0.002) and a
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Figure 3.25 GM-CSF mRNA expression in skin 1-24 hours after gene-gun delivery of pGM-
CSF and the NF-control. (a) Sheep 3 (biopsy experiment B; n = 2-3 biopsy samples for each
time-point); (b) sheep 4 (biopsy experiment E; n = 3 biopsy samples for each time-point).
Data are presented as mean + SEM. Endogenous GM-CSF expression is represented as a
solid line in (a). Endogenous GM-CSF mRNA expression was also detected in normal skin in
sheep 4 (0.65 normalised units) and cannot be represented on this figure.
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IL-ip mRNA expression
IL-ip mRNA was detected in normal skin in both animals and is represented as a solid line
in Figure 3.26a (sheep 3). Administration of the NF-control and pGM-CSF induced a similar
(approximately 2-fold) increase in IL-lp mRNA expression 1 hour after gene-gun delivery in
this animal. Endogenous IL-ip mRNA expression in skin isolated from sheep 4 was only just
within the limit of detection of the assay and is not represented on Figure 3.26b; however, a
marked increase was also evident one hour after gene-gun administration of either plasmid in
this animal (Figure 3.26c). Expression of IL-113 mRNA peaked 4 hours after administration
of the NF-control in both animals.
In marked contrast, gene-gun bombardment of skin with pGM-CSF caused a much more
pronounced increase in IL-1 (3 mRNA. Expression of IL-1 p mRNA followed a similar trend
in both animals, where levels of IL-1 p increased in an almost linear fashion over the first 24
hours after pGM-CSF administration. By 24 hours, a 200 fold increase in IL-1 p mRNA was
evident in sheep 3 (relative to IL-1 p transcripts in NF-control vaccinated skin) and a 350 fold
increase was evident in sheep 4. Moreover, where levels of IL-1 p mRNA are compared after
administration of either pGM-CSF or the NF-control in sheep 3, the difference is statistically
significant over the entire time-course (p < 0.02, unpaired Student t-test). A statistically









































Figure 3.26 IL-1p mRNA expression in pGM-CSF and NF-control vaccinated skin from 1-24
hours, (a) Sheep 3, biopsy experiment B (n = 2-3 biological replicates; p < 0.02, unpaired
Student t-test); (b) sheep 4, biopsy experiment E; n = 3 biological samples; (c) induction of
IL-1 p expression 1 hour after DNA vaccination with both pGM-CSF and the NF-control in




Expression of IL-18 mRNA was similar following gene-gun delivery of either plasmid in
sheep 3 (biopsy experiment B) (Figure 3.27a); indeed no statistically significant difference
was apparent in skin samples where pGM-CSF had been administered when compared to
NF-control vaccinated skin (p > 0.05). Endogenous IL-18 expression was also analysed in
this LightCycler® assay and perhaps surprisingly, higher levels of IL-18 mRNA were
observed in normal skin (represented as a solid line in Figure 3.27a) than in skin vaccinated
with either pGM-CSF or with the NF-control. Endogenous expression of IL-18 was
reanalysed in another experiment alongside cDNA samples obtained from NF-control
vaccinated skin removed one hour after gene-gun vaccination (Figure 3.27b); a 5 fold
reduction in IL-18 mRNA expression was again observed in gene-gun vaccinated skin.
In agreement with the findings from biopsy experiment B, there was no statistically
significant difference in IL-18 transcripts in pGM-CSF or NF-control vaccinated skin in
sheep 4 (p > 0.05). A decrease in IL-18 mRNA was also apparent after delivery of both
plasmids in this animal from 1-6 hours and a further reduction was evident 24 hours p/v
when levels are compared to normal skin (Figure 3.27c). Quantitative RT-PCR was repeated
using two cDNA samples (derived from two biopsies) one hour after DNA vaccination with
the NF-control or pGM-CSF. Samples were analysed alongside cDNA obtained from normal
skin (n = 2). A similar (approximately 2-fold) decrease in IL-18 mRNA was again evident










































Figure 3.27 IL-18 mRNA expression in skin 1-24 hours after gene-gun vaccination with
pGM-CSF and the NF-control. (a) Sheep 3 (biopsy experiment B, n = 2 biological samples);
(b) sheep 3, expression of IL-18 in normal (non-vaccinated skin, n = 3) was analysed again
alongside skin cDNA samples obtained 1 hour after administration of the NF-control. (c)
Sheep 4 (biopsy experiment E, n = 3 biological samples); (d) sheep 4, analysis of IL-18
mRNA expression in normal skin and cDNA samples obtained from skin biopsies vaccinated
with pGM-CSF and the NF-control (n = 2 biological samples). Endogenous expression is















TNF-a mRNA expression was highly variable in the skin after gene-gun delivery of pGM-
CSF and the NF-control. This was evident even in skin vaccinated with the same plasmid
and harvested at the same time-points (Figure 3.28a,b). It was evident that gene-gun
bombardment with the NF-control plasmid resulted in increased expression of TNF-a
transcripts in the skin, which is illustrated in Figure 3.28b, where a 4—5 fold increase in TNF-
a expression can be observed as early as 1 hour p/v (compared to endogenous TNF-a
expression, which is illustrated as a solid line). From 1-6 hours p/v, TNF-a mRNA
expression was variable and there was generally little difference between pGM-CSF or NF-
control vaccinated skin in either animal. Conversely, by 24 hours, TNF-a transcripts were
more abundant in pGM-CSF vaccinated skin than in NF-control vaccinated skin; a 2.5 fold
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Figure 3.28 TNF-a mRNA expression in skin 1-24 hours after gene-gun administration of
pGM-CSF and the NF-control. (a) Sheep 3 (biopsy experiment B); (b) sheep 4 (biopsy
experiment E). Data are presented as mean ± SEM. Endogenous expression of TNF-a was
not analysed in sheep 3.
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IL-12p40 mRNA expression
LC-derived IL-12 plays a pivotal role in the initiation of contact hypersensitivity, a Thl
immune response in the skin. An increase in IL-12 protein was reported in a previous study
after pGM-CSF administration in both murine skin and muscle (Perales et al, 2002). Due to
the expense of quantitative RT-PCR using the LightCycler®, IL-12p40 mRNA expression
was initially evaluated by conventional RT-PCR. Undiluted cDNA samples from each of the
pGM-CSF vaccinated skin biopsies from sheep 4 (biopsy experiment E) were subjected to 40
cycles of amplification using an already optimised method with IL-12p40-specific primers.
mRNAs encoding IL-12p40 were only detected in one out of the three pGM-CSF vaccinated
biopsy samples from the 6 hour time-point and in one out of three samples obtained 24 hours
p/v (Figure 3.29a), where an amplicon of approximately 250bp can be observed (expected
size of amplicon is 243bp, Table 2.11). IL-12p40 mRNA expression was detected in normal
skin and was subjected to further analysis by quantitative real-time RT-PCR (sheep 4, biopsy
experiment E) (Section 3.6.1.3); however, no IL-12p40 transcripts were detected using this
method where a 1:10 dilution of the cDNA was used.
IL-10 mRNA expression
Expression of the anti-inflammatory cytokine IL-10 was analysed by conventional RT-PCR
essentially as described above. IL-10 transcripts were detected in all of the pGM-CSF
vaccinated skin samples and also in normal skin obtained from the same animal (Figure
3.29b). No quantification of IL-10 was carried out using quantitative RT-PCR due to time
constraints. Furthermore, although IL-10 transcripts were detected in normal skin by
conventional RT-PCR, no specific product was detected on the LightCycler® after 40 cycles
of amplification, where 1:10 dilutions of cDNA were used (Section 3.6.1.3). Undiluted
cDNA samples require further analysis by quantitative RT-PCR.
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Figure 3.29 IL-12p40 (a) and IL-10 (b) mRNA expression in normal skin and in biopsies
removed from pGM-CSF vaccinated skin sites. Amplification was carried out for 40 cycles.
IL-12p40 mRNA expression is evident in normal (non-vaccinated) skin and also in one of the
three skin samples removed 6 and 24 hours after administration of pGM-CSF. A ~250bp
amplicon (expected size of amplicon is 243bp) can be observed in these samples. IL-10
mRNA expression is evident in all skin samples analysed.
Lanes 1 and 20, 100bp marker
Lanes 2-4, 1 hour p/v
Lanes 5-7, 2 hours p/v
Lanes 8-10, 4 hours p/v
Lanes 11-13, 6 hours p/v
Lanes 14-16, 24 hours p/v
Lane 17, normal skin
Lane 18, negative control (nuclease-free water)
Lane 19, positive control (1:1000 dilution of 1° PCR product)
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3.5.1.4 Expression of TLR9 mRNA in normal skin and in plasmid DNA-
vaccinated skin
A recent study reported that although TLR9 mRNA is not detected in normal murine skin, its
expression can be induced by intradermal injection of either normal saline or CpG motifs
(Liu et al, 2003). A similar experiment was carried out using cDNA obtained from skin
biopsies removed from non-vaccinated skin sites and also using cDNA from pGM-CSF and
NF-control vaccinated skin from biopsy experiment E (1-24 hours). Importantly, and in
contrast to murine skin, TLR9 mRNA was detected in normal ovine skin from three different
animals (Figure 3.30a). In all of the RT reactions, lpg of total RNA was reverse transcribed.
PCR amplification was carried out at 55°C for 40 cycles and all 50pl of each PCR reaction
were loaded onto an agarose gel. TLR9 transcripts could only just be detected in some the
vaccinated biopsies; biopsies obtained 4 hours after pGM-CSF delivery and 6 hours after
delivery of the NF-control (Figure 3.30a,b); however, there did not appear to be any change
in the relative intensity of any of the bands when visualised by UV when compared with
normal skin samples, suggesting that CpG motifs/physical trauma does not cause TLR9
upregulation in sheep; however, this observation is merely qualitative and quantitative RT-
PCR method should be employed to clarify this preliminary finding.
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Figure 3.30 TLR9 mRNA expression in normal skin and after gene-gun delivery of pGM-
CSF and the NF-control. 1pg of RNA was reverse transcribed from each skin biopsy. cDNA
samples were amplified with ovine-specific TLR9 primers for 40 cycles and all 50pl of the
PCR reaction were loaded onto an agarose gel (2%).
Lanes 1 & 20, 100bp marker
Lanes 2^4, normal skin obtained from biopsy experiments E, C and D
Lane 5 nuclease-free water
Lanes 7-9, 1 hour after NF-control
Lanes 10-12, 2 hours after NF-control
Lanes 13-15, 4 hours after NF-control
Lanes 16-18, 6 hours after NF-control
Lane 19, 24 hours after NF-control
Lane 1, 100bp marker
Lanes 2-3, 24 hours after NF-control
Lanes 5-7, 1 hour after pGM-CSF
Lanes 8-10, 2 hours after pGM-CSF
Lanes 11-13, 4 hours after pGM-CSF
Lanes 14-16, 6 hours after pGM-CSF
Lane 17-19 24 hours after pGM-CSF




3.5.2 Effects of plL-3 in skin 1-24 hours after administration
3.5.2.1 Skin histopathology after gene-gun vaccination with plL-3
Microscopic evaluation revealed that gene-gun bombardment with pIL-3 caused severe
pathological changes to the skin by 24 hours, whereas comparatively little inflammation was
induced after gene-gun vaccination with the NF-control (Figure 3.31). Moreover, the kinetics
of cellular infiltration were similar to that observed after gene-gun delivery of pGM-CSF,
notably that at 1 hour after delivery of pIL-3 and the NF-control, little difference in
cellularity was apparent, whereas at 2 hours significantly more PMN were evident in pIL-3
vaccinated skin sections, particularly associated with the epidermis. This accumulation of
PMN in pIL-3 vaccinated sites was even more marked by 4 hours and continued to
dramatically increase over the next couple of hours and by 24 hours pustule formation had
occurred; effacing of the dermal: epidermal junction had taken place. In addition, an
overlying epidermal oedema was evident 24 hours after pIL-3 administration in some of the
sections screened. This was not observed in the previous experiment (biopsy experiment A).
The dermal infiltrate was mixed and comprised predominantly of eosinophils after delivery
of pIL-3. Mononuclear cells were also more prevalent within the dermis when sections were
compared with normal and control-vaccinated skin sections, as was documented in the





Figure 3.31 Comparison of the inflammatory events induced in the skin 1-24 hours after
gene-gun administration of plL-3 and the NF-control. Skin biopsies were removed
immediately at post mortem, fixed in ZSF and stained with H & E. Representative images







3.5.2.2 Immunohistological analysis of pll_-3 vaccinated skin
Skin sections were immunolabelled to identity cell populations recruited to skin 1-24 hours
after pIL-3 administration. mAb VPM 54 (anti-MHC class II DRa) was applied to skin
sections as previously described. There was little change in the prevalence of DR+ cells
within the skin 1-2 hours after gene-gun delivery of either pIL-3 or the NF-control (Figure
3.32), whereas from 4-24 hours, a slightly more pronounced infiltration was evident in pIL-3
vaccinated skin. DR+ cells appeared to accumulate beneath the developing pustule.
Staining was also carried out with mAb 73B (anti-CD45RA). No difference in the number of
CD45RA+ cells was apparent 1-6 hours p/v in DNA vaccinated skin (pIL-3 and NF-control)
when compared to normal skin (Figure 3.33); however, 24 hours after gene-gun delivery of
the NF-control, a slight increase in CD45RA+ lymphocytes was apparent and an even more
marked infiltration was apparent after pIL-3 administration, particularly within the
superficial dermis. In addition, immunoperoxidase staining was carried out with mAb IAH-
CC15, which showed there was no change in yd T cell numbers after gene-gun vaccination




Figure 3.32 Infiltration of MHC class ll+ cells in skin 1-24 hours after gene-gun delivery of
plL-3. Sections were processed from skin vaccinated with plL-3 (right-hand side panels) and
the NF-control (left panels) and were immunolabelled with mAb VPM 54 (MHC class II DRa).
Infiltrating DR+ cells can be observed beneath the developing pustule 24 hours after plL-3




Figure 3.33 Immunolabelling of CD45RA+ lymphocytes in plL-3 and NF-control vaccinated
skin 1-24 hours after gene-gun delivery. Skin biopsies were immunolabelled with mAb 73B
(CD45RA). Representative images are shown from each time-point; plL-3 (right-hand side
panels) and the NF-control (left panels). Slight infiltration of CD45RA+ cells is evident 24
hours after DNA vaccination with plL-3. Sections were counterstained with haematoxylin.
(Scale bar = 250pm.)
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3.5.2.3 Cytokine mRNA expression in skin after gene-gun delivery of plL-3
The kinetics of IL-3 mRNA expression and the expression of proinflammatory cytokines
was investigated by quantitative RT-PCR. As discussed in Section 2.6, residual plasmid was
a consistent problem after standard DNase treatment included in the protocol. RNA samples
were therefore incubated again with DNase in combination with Hinf-1 in solution in order
to degrade pIL-3. Prior to the evaluation of cDNA samples by quantitative real-time RT-
PCR, control (-RT) samples were first amplified with IL-3 specific primers and validated to
be free of residual pIL-3 (results not shown).
IL-3 mRNA expression
IL-3 mRNA was not detected in normal skin nor in samples obtained from control
vaccinated skin (Figure 3.34), although this may be due to the lack of specificity of the
primers, since extensive accumulation of non-specific product (melting temperature of 90°C
compared to the specific IL-3 amplicon which melted at 88°C) was a consistent problem with
this particular set of primers and occurred before 30 cycles of amplification. Due to the small
size of the IL-3 insert, problems were encountered when designing primers since stringent
parameters are required when the SYBR green method of quantification is employed.
IL-3 mRNA was detected in skin biopsies as early as 1 hour after gene-gun administration of
pIL-3 in both animals (Figure 3.35). Levels of IL-3 mRNA increased in a linear fashion,
peaking at 4 hours in sheep 3 and at 6 hours in sheep 4. From 4-24 hours, IL-3 mRNA
declined in a linear fashion in sheep 3, whereas a more marked decrease was evident in
sheep 4 after 6 hours.
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1 46 1 NF IL-31 hOUfE
2 48 1 NF IL-3 2 hours E
3 51 1 NF IL-3 4 hours E
4 54 1 NF IL-3 6 hours E
5 37 1 NF IL-31 day
6 39 1 NF IL-3 2 days
7 31 1 1 hour IL-3 E
8 32 1 1 hour IL-3 E
9 331 1 hour IL-3 E
10 34.1 2 hours IL-3 E
11 351 2 hours IL-3 E
12 36.1 2 hours IL-3E
13 37.1 4 hours IL-3 E
14 38 1 4 hours IL-3 E
15 391 4 hours IL-3E
16 401 6 hours IL-3 E
17 41 1 6 hours IL-3 E
18 421 6 hours IL-3 E
19 431 24 hours IL-3E
20 44 1 24 hours IL-3 E























10 18 20 22 24 20 28 30 32 34 30 38 40
cycle number (°C)
1 461 NF IL-31 hOurE
2 48 1 NF IL-3 2 hours E
3 51 1 NF IL-3 4 hours E
4 54 1 NF IL-3 6 hours E
5 37 1 NF IL-3 1 day
6 39 1 NF IL-3 2 days
7 31 1 1 hour IL-3 E
8 321 1 hour IL-3 E
9 331 1 hour IL-3 E
10 34 1 2 hours IL-3 E
11 351 2 hours IL-3 E
12 36 1 2 hours IL-3 E
13 371 4 hours IL-3 E
14 38 1 4 hours IL-3E
15 39 1 4 hours IL-3 E
16 401 6 hours IL-3E
17 41 1 6 hours IL-3 E
18 42 1 6 hours IL-3 E
19 43 1 24 hours IL-3E
20 44.1 24 hours IL-3E




Figure 3.34 Specific IL-3 transcripts are detected in skin samples after gene-gun delivery of
plL-3 and not in normal skin or after delivery of the NF-control. Amplification of IL-3
transcripts in cDNA samples can be observed from approximately 22-26 cycles (a). An
increase in fluorescence at approximately 30 cycles of amplification in both NF-control cDNA
samples and the negative control (nuclease-free water) is evident (1). (b) Melting curve
analysis shows specific product (2) is present in skin biopsies vaccinated with plL-3 (melting
at the same temperature (88°C) as the positive control sample). In contrast, (3) shows non¬
specific product (melting at 90°C) which has accumulated after 30 cycles of amplification
with IL-3 primers in the negative control (water) and also in cDNA samples obtained from
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hours post-vaccination
Figure 3.35 IL-3 mRNA expression in skin 1-24 hours after gene-gun vaccination with plL-3.
IL-3 mRNA in normal ovine skin or in NF control-vaccinated skin could not be quantified, (a)
Sheep 3, biopsy experiment B; (b) sheep 4, biopsy experiment E. Data are presented as
mean ± SEM and n = 3.
181
IL-ip mRNA expression
Endogenous expression of IF-ip mRNA was analysed alongside cDNA samples obtained
from pIL-3 and NF-control vaccinated skin. An increase in IF-ip transcripts was observed in
NF-control vaccinated skin and mRNA levels peaked at approximately 4 hours p/v in both
animals (Figure 3.36). A more dramatic increase was apparent after gene-gun vaccination
with pIF-3. It is of interest to note that in sheep 3, IL-ip mRNA expression mirrored the
kinetics of IF-3 mRNA expression, again reaching maximal levels 4 hours p/v. A 6.5 fold
increase in IF-ip mRNA (relative to levels induced after administration of the NF-control)
was evident 4 hours p/v in sheep 3. Furthermore, this difference was statistically significant
over the time-course of the experiment (p < 0.02). A similar trend was observed in sheep 4
where peak IL-ip mRNA expression was also observed 4 hours after pIL-3 administration; a
4 fold increase relative to expression in NF-control vaccinated skin was observed in this
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Figure 3.36 IL-1p mRNA expression in skin 1-24 hours after gene-gun administration of pIL-
3 and the NF-control. (a) Sheep 3, (b) sheep 4. Data are presented as mean ± SEM.
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IL-18 mRNA expression
Figure 3.37 shows expression of IL-18 mRNA before and after gene-gun delivery of pIL-3
and the NF-control in two animals over 24 hours. There was no significant difference in IL-
18 mRNA expression in skin vaccinated with pIL-3 compared to skin vaccinated with the
NF-control (p > 0.05), with the exception of the 24 hour time-point (sheep 3), where levels
of IL-18 were approximately 3 fold higher in NF-control vaccinated skin than in pIL-3
vaccinated skin. In accord with earlier data obtained with normal skin and skin vaccinated
with pGM-CSF or NF-control, IL-18 mRNA expression was approximately 5 fold higher in
normal skin biopsies than in skin vaccinated with either of the plasmids in sheep 3 (Figure
3.37a) and approximately 3 fold higher in sheep 4 (Figure 3.37b). Since only two biopsies
were removed from normal skin and this RNA was pooled prior to the RT reaction, no
statistical analysis can be performed in order to compare this apparent reduction of IL-18
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Figure 3.37 IL-18 mRNA expression in skin 1-24 hours after gene-gun delivery of plL-3 and
the NF-control in sheep 3 (a) and in sheep 4 (b). Endogenous expression of IL-18 is
represented as a solid line. Data are presented as mean ± SEM.
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TNF-a mRNA expression
TNF-a mRNA expression was highly variable in the skin of both animals over the time-
course (1-24 hours) after administration of both pIL-3 and the NF-control. This variability
was even apparent in biopsies where plasmids were administered at (approximately) the
same time (Figure 3.38). Notably, administration of both plasmids resulted in increased
TNF-a mRNA expression as early as one hour p/v (relative to transcripts quantified in
normal skin). In general, there was little difference in abundance of TNF-a transcripts
between NF-control or pIL-3 vaccinated skin samples over the time-course of the experiment
(p > 0.05, sheep 3 and 4), with the exception of the 24 hour time-point after gene-gun
delivery of pIL-3 in sheep 4, where a 3 fold increase in TNF-a mRNA expression was
apparent.
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Figure 3.38 TNF-a mRNA expression in skin 1-24 hours after gene-gun vaccination with
plL-3 and the NF-control in sheep 3 (a) and in sheep 4 (b). Data are presented as mean ±
SEM.
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3.6 Gene-gun administration of cytokine gene adjuvants
over 4 days
Biopsy experiment A identified a pronounced infiltration of MHC class II DR+ cells with the
morphology of DC 3^1 days after pGM-CSF administration. Notably this was not observed
after administration of the control plasmid (pEGFP-Nl). It was imperative to confirm the
findings of biopsy experiment A and also to correlate the immunohistological findings with
the expression of proinflammatory cytokines (IL-1(3, TNF-a and IL-18). It was also
necessary to investigate the effects of the NF-controls over a longer time period (>24 hours).
In addition, no apparent infiltration ofDC was observed after pIL-3 administration; although
a slight increase in MHC class II+ CD45RA+ cells was observed 24 hours p/v. Further
analysis was required to determine the in vivo effects of pIL-3 where the GFP gene had been
removed from the construct, since expression of a fusion protein (as employed in biopsy
experiment A) may have limited the in vivo effects ofpIL-3.
Two sheep (animals 5 & 6) were prepared as described previously and vaccinated in
triplicate over 4 days with pGM-CSF, pIL-3 and NF-controls (biopsy experiments C and D).
The experiments are summarised in Figure 3.39. Note that the 16 hour time-point was
omitted in the biopsy experiment D (sheep 6). Biopsies were removed immediately at post¬
mortem. Half of each biopsy was submerged into RNA/a/er™ for subsequent quantitative
RT-PCR analysis. The remaining biopsy fragments were fixed in either ZSF or PFA,











Figure 3.39 DNA vaccination over 4 days (biopsy experiments C and D) with pGM-CSF, pIL-
3 and NF-controls. The 16-hour time-point was omitted in biopsy experiment D (sheep 6).
3.6.1 Effects of pGM-CSF in skin
3.6.1.1 Histological analysis of pGM-CSF vaccinated skin
Representative images from both sheep are shown in Figure 3.40. Importantly,
comparatively little inflammation was induced after gene-gun administration of the NF-
control plasmid over the time-course. Some minor changes to the epidermis were observed,
but importantly (and in contrast with the previous experiments where pEGFP-Nl was used
as a control), there was no pustule formation. Furthermore, the number of PMN did not
increase over the 4 days; indeed little dermal infiltration was evident 2—4 days after gene-gun
delivery of the NF-control plasmid.
In stark contrast with the effects ofNF-control, but in keeping with biopsy experiments A, B
and E, was the development of a severe inflammatory reaction in both animals 24 hours after
delivery of pGM-CSF. Again, the peak reaction appeared to have taken place within the first
24 hours and is likely to have taken place from 16-24 hours in sheep 5 (biopsy experiment
C). PMN (mostly neutrophils) again represented the predominant population from 16-24
hours, although a slight increase in mononuclear cells was observed by 24 hours. After the
first 24 hours, thickening of the crust was evident and dermal-epidermal separation had taken
place. The kinetics of the cellular response appeared almost identical in both animals. At 48-
96 hours p/v there was a reduction in the level of infiltrating PMN and an increase in the




Figure 3.40 Comparison of the inflammatory events induced in the skin from 16-96 hours
after gene-gun administration of pGM-CSF and the NF-control. Skin biopsies were removed
immediately at post mortem, fixed in ZSF and stained with H & E. Representative images









3.6.1.2 Immunohistological analysis of pGM-CSF vaccinated skin
Skin sections were immunolabcllcd to identify cell populations recruited to the skin up to 4
days after administration of pGM-CSF and the NF-control. Figure 3.41 shows representative
images taken from biopsy experiments C and D. A slight increase in MHC class II+ cells was
observed after administration of the NF-control plasmid when compared to normal skin 16-
48 hours after gene-gun bombardment; however, by 3—4 days p/v, numbers ofMHC class II+
cells were comparable to those observed in normal skin. In contrast, MHC class II DR+ cells
were more prevalent in pGM-CSF vaccinated skin than in NF-control skin at all time-points
investigated and in both animals. Small MHC class II+ mononuclear cells infiltrated the
dermis and some staining was evident in the epidermal layer 16 hours p/v. Further
infiltration of DR+ cells was observed 3 days after delivery of pGM-CSF; cells were
particularly prevalent under the pustule. The most striking observation in both animals, was
the pronounced infiltration ofMHC class 11 DR+ cells with the morphological appearance of
DC 4 days p/v.
Staining with anti-CD45RA (mAb 73B) revealed a modest increase in CD45RA+ cells in
biopsies removed from pGM-CSF vaccinated skin 16 hours after administration (Figure
3.42), whereas few CD45RA+ positive cells were present in the NF-control vaccinated skin
sites. At all of the other time-points investigated there did not appear to be any difference in
CD45RA+ cells after administration of pGM-CSF or NF-control; numbers were comparable
to those observed in normal non-vaccinated skin, which suggests that the MHC class II+ cells
infiltrating the skin 4 days after pGM-CSF vaccination were not B cells (Mackay et al,
1990). Sections were also stained with IAH-CC15 and this revealed a slight increase in y5 T
cells relative to normal skin, 24 hours after gene-gun vaccination with pGM-CSF. It was
interesting to note that there appeared to be an infiltration of y8 T cells, particularly near to
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Figure 3.41 Infiltration of MHC class ll+ DC in skin 4 days after gene-gun delivery of pGM-
CSF. Immunolabelling of skin biopsies was carried out with mAb VPM 54 (MHC class II
DRa) obtained from sheep vaccinated from 16-96 hours with pGM-CSF (right-hand side
panels) and the NF-control (left panels). Representative images are shown form both biopsy
experiments (C and D), with the exception of the 16-hour time-point, where sections were
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Figure 3.42 Immunohistochemical staining of CD45RA+ lymphocytes 16 and 96 hours after
gene-gun delivery of pGM-CSF and the NF-control. Note that 96 hours after pGM-CSF
administration there are relatively few CD45FRA+ lymphocytes. Sections have been




Figure 3.43 Immunohistochemical staining of T cells in skin sections obtained 72 and 96
hours after gene-gun vaccination with pGM-CSF and the NF-control. Note the slight increase
in T cells 72 hours (NF-control) and 96 hours (pGM-CSF) after administration. (Scale bar
= 250pm.)
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3.6.1.3 Cytokine mRNA expression in skin after gene-gun delivery of pGM-
CSF
Quantitative RT-PCR was next employed to investigate the kinetics of GM-CSF mRNA
expression and the expression of proinflammatory cytokines in the skin up to 96 hours after
gene-gun delivery ofpGM-CSF (and the NF-control).
GM-CSF mRNA expression
In both animals, the level of GM-CSF transcripts declined in an almost linear fashion over
the 4 days after administration of both pGM-CSF and the NF-control (Figure 3.44). GM-CSF
mRNA was only just within the quantification limit of the assay 48-96 hours after delivery
of the NF-control (sheep 5) and could not be accurately quantified in several cDNA samples
in sheep 6 (at 72-96 hour time-points). In contrast, GM-CSF mRNA was still detectable up
to 96 hours after administration of the functional version of the plasmid. No statistically
significant difference in GM-CSF mRNA expression was however evident after
administration of pGM-CSF when compared to the NF-control vaccinated skin (where mean
values for each time-point have been calculated and compared; p > 0.05, sheep 5 and 6,
unpaired Student t-test). In addition, although specific GM-CSF product was detected in
normal skin from both animals by quantitative RT-PCR, levels were below the limit of
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Figure 3.44 GM-CSF mRNA expression in skin over 96 hours after gene-gun administration
of pGM-CSF and the NF-control. (a) Sheep 5 (biopsy experiment C), (b) sheep 6 (biopsy
experiment D). Endogenous expression of GM-CSF mRNA could not be quantified in either
LightCycler® experiment carried out, although specific product was detected (data not
shown). GM-CSF mRNA was also below the level of quantification in several of the NF-




IL-ip mRNA expression was highly elevated in skin up to 96 hours after gene-gun delivery
of pGM-CSF (Figure 3.45a,b). Importantly, a statistically significant difference is apparent
when mRNA levels of IL-ip are compared to those induced after NF-control delivery over
the entire time-course of the experiment (p < 0.02 sheep 5 and p < 0.002 sheep 6; unpaired
Student t-test). IL-ip transcripts were approximately 70 fold higher (range 22.4—156.6) in
skin after gene-gun vaccination with pGM-CSF than in NF-control vaccinated skin in sheep
5, and 46 fold higher (range 25-67.5) in sheep 6. Maximal expression of IL-ip mRNA was
evident 72 hours after pGM-CSF administration in both animals (mean 157 fold difference
(sheep 5) and 68 fold difference (sheep 6)). When IL-ip mRNA expression in pGM-CSF
vaccinated skin is compared to endogenous IL-ip expression, a -200 fold induction is
apparent (range 173-234; sheep 6) over the first 72 hours. Moreover, expression was still
100 fold higher than endogenous levels up to 96 hours after gene-gun delivery.
IL-ip mRNA was detected at low levels in normal skin in both animals and is also
represented in Figure 3.45. IL-ip mRNA expression was elevated in NF-control vaccinated
skin 16 hours p/v in sheep 5. Levels thereafter were comparable to endogenous IL-ip mRNA
expression. In sheep 6, administration of the NF-control plasmid caused (approximately) a 5
fold increase in IL-ip transcripts over the first 72 hours, although some variability is evident
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hours post-vaccination
Figure 3.45 IL-1 (B mRNA expression in skin over 96 hours after gene-gun delivery of pGM-
CSF and the NF-control. (a) Sheep 5 (biopsy experiment C); (b) and (c) sheep 6 (biopsy
experiment D). Endogenous expression of IL-113 mRNA is represented as a solid line in (a); n
= 2-3 biological samples (data are presented as mean ± SEM); p < 0.02 (0.012, unpaired
Student t-test). In (b), n=3 biological samples and p < 0.002 (0.0017), unpaired Student t-
test. Endogenous expression of IL-1 p mRNA is too low to be represented in (b), and is


















The kinetics of IL-18 mRNA expression over 96 hours was investigated after administration
of both pGM-CSF and the NF-control (Figure 3.46). In both animals, no statistically
significant difference was evident in skin vaccinated with pGM-CSF when compared to
biopsies vaccinated with NF-control at any of the time-points investigated (p > 0.05, sheep 5
and 6). Endogenous expression of IL-18 mRNA was approximately 2 fold higher than in
skin vaccinated with either plasmid from 24-96 hours p/v-in sheep 5 (Figure 3.46a) and
expression remained at a similar level in all biopsies evaluated over the time-course in this
animal. Gene-gun administration of both plasmids also resulted in decreased IL-18 mRNA
expression in sheep 6 from 24—72 hours, although by 96 hours p/v, IL-18 mRNA expression




































24 48 72 96
hours post-vaccination
Figure 3.46 IL-18 mRNA expression in skin over 96 hours after gene-gun vaccination with
pGM-CSF and the NF-control. (a) Sheep 5 (biopsy experiment C), (b) sheep 6 (biopsy
experiment D). Endogenous IL-18 mRNA expression is represented as a solid line. Data are
presented as mean ± SEM.
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TNF-a mRNA expression
In both animals, expression of TNF-a mRNA was consistently higher after pGM-CSF
administration than after administration of the NF-control plasmid at all of the time-points
investigated (Figure 3.47). Furthermore, this difference in TNF-a mRNA expression was
statistically significant (p < 0.003, sheep 5; p < 0.002, sheep 6). Variability in the expression
of TNF-a was however evident in biopsies from the same time-points. Expression of TNF-a
mRNA was also analysed in normal skin obtained from sheep 6 (b). This revealed that there
was a mean 3 fold increase (range 2.9-3.4) in TNF-a mRNA expression up to 72 hours after
vaccination with the NF-control. Expression of TNF-a then declined to levels expressed in
normal skin. Conversely, expression of TNF-a was still highly elevated in the pGM-CSF
vaccinated skin biopsies up to 96 hours p/v (mean 7.8 fold increase, range 3.0-15.3).
203
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hours post-vaccination
Figure 3.47 TNF-a mRNA expression in skin over 96 hours after gene-gun delivery of pGM-
CSF and the NF-control. (a) Sheep 5, (b) sheep 6. Expression of TNF-a was significantly
higher in pGM-CSF vaccinated biopsies than in NF-control vaccinated skin in both animals
(p < 0.003, sheep 5; p < 0.002, sheep 6, unpaired Student t-test). Endogenous expression
was also analysed and is represented by the solid line. Data are presented as mean ± SEM.
204
IL-12p40 mRNA expression
Expression of IL-12p40 mRNA was analysed by quantitative real-time RT-PCR. IL-12p40
transcripts were not detected in any of the samples obtained from pGM-CSF or NF-control
vaccinated skin biopsies. In addition, IL-12p40 was undetectable in normal skin removed
from two different animals (animals 4 and 6; biopsy experiments E and D, respectively).
Only non-specific product accumulated during the amplification stage, whereas specific
product was detected in the positive control sample (diluted 1° PCR product) and is shown in
Figure 3.48.
IL-10 mRNA expression
IL-10 mRNA expression was also analysed by quantitative RT-PCR. IL-10 transcripts were
not detected in any of the biopsy samples evaluated from sheep 6 (biopsy experiment D), or
indeed in sheep 4 (biopsy experiment E) after gene-gun delivery of pGM-CSF or the NF-
control. Furthermore, IL-10 transcripts could not be detected in normal skin. Results are
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Figure 3.48 IL-12p40 and IL-10 transcripts are not detected in normal skin, pGM-CSF
vaccinated or NF-control vaccinated skin, (a) Amplification plot of cDNA samples amplified
with IL-12p40 and IL-10-specific primers, (b and c) Only non-specific products have
accumulated since amplicons do not melt at the same temperature as the IL-12p40 (1) or IL-
10 (2) standards (diluted 1° PCR products).
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3.6.2 Effects of plL-3 in skin over 4 days
3.6.2.1 Histological analysis of plL-3 vaccinated skin
Gene-gun vaccination with pIL-3 (without the GFP gene) caused severe inflammation over
the time-course in all biopsy sections evaluated from both animals. Comparatively little
inflammation was induced after administration of the NF-control in most of the sections
screened (Figure 3.49). Inflammation was however observed in some of the skin sections
where the NF-control was administered in sheep 5 (data not shown) from 16-24 hours,
whereas only low-grade inflammation was observed in sheep 6 (biopsy experiment D).
By 24 hours, a pronounced eosinophilic infiltration in both the epidermis and dermis was
apparent after gene-gun administration of pIL-3. Neutrophils were also present within the
developing pustule and small mononuclear cells had also accumulated in the upper part of
the dermis by 24 hours. The reaction did not appear to increase in severity over the time-
course, and it is likely that the peak inflammatory reaction occurred within the first 24 hours.
Perhaps the most striking observation after pIL-3 administration in both animals was an
overlying epidermal oedema which started to form approximately 48 hours p/v and was still
evident up to 4 days p/v. This fluid filled pustule was evident by eye (Figure 3.50) and in
some of the sections measured up to 800 pm. The H & E stained skin sections also revealed
a pronounced infiltration of mononuclear cells in the dermis 3 days p/v in sheep 5 (biopsy
experiment C) and 4 days p/v in sheep 6 (biopsy experiment D).
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controls IL-3
Figure 3.49 Comparison of the inflammatory events induced in the skin 16-96 hours after
gene-gun administration of plL-3 and the NF-control. Skin biopsies were removed
immediately at post mortem, fixed in ZSF and stained with H & E. Representative images





Figure 3.50 Development of erythematic reaction 4 days after gene-gun administration with
four plasmid constructs. DNA vaccination was carried out on adjacent skin sites with the
following plasmids: NF-GM-CSF (sites 1-3), pGM-CSF (sites 4-6), NF-IL-3 (sites 7-9) and
plL-3 (sites 10-12). Note the severe inflammatory reaction (pustule formation) caused by
gene-gun vaccination with pGM-CSF and plL-3. Gold dust is still clearly visible on skin where
NF constructs have been delivered and little swelling is evident.
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3.6.2.2 Immunohistological analysis of plL-3 vaccinated skin
MHC class II DRa+ cells infiltrated skin approximately 16-24 hours after gene-gun
vaccination with pIL-3 (Figure 3.51). MHC class II DRa+ cells accumulated just under the
epidermis and high magnification revealed that these cells possessed a small and round
morphology (Figure 3.52a). Some infiltration of DR+ cells was observed in the NF-control
vaccinated site but this was not nearly as pronounced as observed after pIL-3 delivery. DR+
cells appeared to continue to traffick into the skin up to 2 days after pIL-3 administration and
cells were evident in the deeper regions of the dermis. The most striking observation in this 4
day experiment was a pronounced accumulation of DR+ cells 3 days p/v (sheep 5, Figure
3.51) and 4 days p/v (sheep 6; data not shown). On closer examination, some of the cells had
a dendritic morphology. In addition, MHC class II+ cells with the appearance of fibroblasts
were present in the deeper regions of the dermis in skin removed 3 days p/v with pIL-3
(Figure 3.52b). This was not observed in any of the NF-control vaccinated skin sections.
An increase in CD45RA+ cells was also evident 24 hours p/v with pIL-3 (Figure 3.53), but
not after vaccination with the NF-control. Serial sections again showed a similar pattern of
staining with mAbs VPM 54 and 73B. CD45RA+ cells continued to traffic over the next 24
hours and could be observed deep within the dermis and surrounding blood vessels and
numbers remained slightly elevated up to 4 days p/v. With the exception of the 24 hour time-
point p/v with pIL-3 (where numbers of yS T cells were slightly increased relative to normal
skin) there was little change in the prevalence of these cells over the time-course of the




Figure 3.51 Infiltration of MHC class ll+ cells in plL-3 vaccinated skin. Immunolabelling of
MHC class II DRa+ cells was carried out with mAb VPM 54. Representative images are
shown after staining plL-3 vaccinated skin section (right panels) and NF-control vaccinated
skin sections (left panels). Note the infiltration of small, round DR+ cells 24 hours after plL-3
administration and infiltration of DR+ cells with a dendritic morphology 48 hours later.
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Figure 3.52 High power magnification of skin sections immunolabelled with mAb VPM 54
(anti MHC class II DRa). (a) 24 hours p/v; note the small MHC class ll+ mononuclear cells
infiltrating the superficial dermis, (b) 72 hours p/v; note MHC class ll+ cells with the





Figure 3.53 Immunostaining of CD45RA+ lymphocytes in plL-3 and NF-control vaccinated
skin with mAb 73B. An increase in CD45RA+ cells (B cells and naive T cells) is evident 24




Figure 3.52 (cont.) (Scale bar = 200|jm.)
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3.6.2.3 Cytokine mRNA expression in skin after gene-gun delivery
of plL-3
Quantitative RT-PCR was employed to assess the kinetics of IL-3 mRNA expression in the
skin from 16-96 hours and the kinetics of proinflammatory cytokine mRNA expression.
RNA samples were treated as already described (Section 3.5.2.3) and validated to remove
residual plasmid prior to the evaluation of samples by quantitative real-time RT-PCR (data
not shown). Unfortunately, only two biopsies were available for the 48-96 hour time-points
after pIL-3 administration in sheep 5 (biopsy experiment C), due to problems encountered
with plasmid delivery in this experiment.
IL-3 mRNA expression
IL-3 mRNA expression remained at an almost constant level 16-24 hours after gene-gun
bombardment with pIL-3 in sheep 5 (Figure 3.54a). Expression of IL-3 mRNA dropped
markedly by 48 hours and remained at a similar level until the last sampling time-point (96
hours p/v). In sheep 6, expression of IL-3 mRNA declined in an almost linear fashion from
24 to 96 hours (Figure 3.54b). Expression of IL-3 mRNA was again undetectable in normal
skin sections and in skin sections where the NF-control had been administered (data not
shown), possibly as a result of the lack of specificity of the IL-3 primers employed in the
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hours p/v
Figure 3.54 IL-3 mRNA expression in skin over 96 hours after gene-gun vaccination with
plL-3. (a) Sheep 5, (b) sheep 6. Data are presented as mean ± SEM.
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IL-lji mRNA expression
Expression of IL-ip mRNA was consistently higher in pIL-3 vaccinated skin when
compared to NF-control vaccinated skin (and normal skin) at all time points investigated in
sheep 5. Furthermore, this difference was statistically significant (p < 0.005), where mean
values for each time-point have been calculated and values obtained after pIL-3 vaccination
compared with values obtained after NF-control vaccination (Figure 3.55a). There was
however considerable variation in IL-1(3 expression in different skin sites vaccinated with
pIL-3 at the 16 hour and 96 hour time-points. In addition, only one cDNA sample from the
48 hour time-point was available for analysis in this LightCycler® experiment. In sheep 6
(Figure 3.55b), IL-lp transcripts were highly elevated in pIL-3 vaccinated skin biopsies
when compared to transcripts measured in normal skin and in NF-control vaccinated skin at
3 of the 4 time-points investigated. Furthermore, this difference was highly significant 48












































24 48 72 96
hours post-vaccination
Figure 3.55 IL-1 (3 mRNA expression in skin over 96 hours after gene-gun vaccination with
plL-3 and the NF-control. (a) sheep 5, (b) sheep 6. Note that only one biopsy cDNA sample
from the 48 hour time-point was available from sheep 5 for analysis in this LightCycler®
experiment. Data are presented as mean ± SEM.
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IL-18 mRNA expression
As demonstrated in the previous experiments carried out in this study, IL-18 mRNA
expression was lower in skin vaccinated with either plasmid (cytokine construct or the NF-
control) than expressed in normal skin. A 2-3 fold reduction in IL-18 transcripts was
apparent after administration of both plasmids 24 hours p/v. This was evident in both
animals in this part of the study. In addition, expression of IL-18 mRNA was higher in the
NF-control vaccinated skin biopsies harvested at 24, 72 and 96 hours than in those
vaccinated with pIL-3 in sheep 5 (Figure 3.56a). Furthermore, this difference in IL-18
expression was statistically significant (p < 0.03). In contrast, IL-18 transcripts were
comparable in skin after administration of either pIL-3 or the NF-control plasmid in sheep 6
(Figure 3.56b) with the exception of the 72 hour time-point, where levels were higher in the
NF-control vaccinated skin biopsies. No statistically significant difference was apparent over





































24 48 72 96
hours post-vaccination
Figure 3.56 IL-18 mRNA expression in skin 24-96 hours after gene-gun vaccination with
plL-3 and the NF-control in sheep 5 (a) and in sheep 6 (b). Endogenous IL-18 expression is
represented as a solid line. Data are presented as mean ± SEM.
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TNF-a mRNA expression
The kinetics of TNF-a mRNA expression was also investigated after DNA vaccination with
pIL-3 and the NF-control. Data are shown from both animals in Figure 3.57. TNF-a mRNA
was expressed at higher levels from 24—96 hours in the pIL-3 vaccinated biopsies than in
NF-control vaccinated skin in both sheep. In addition, administration of the NF-control
plasmid resulted in an upregulation of TNF-a mRNA at most of the time-points investigated
when compared to endogenous TNF-a expression (Figure 3.57a); however, it is evident in
this experiment that the expression of TNF-a mRNA was significantly higher in biopsies
obtained from pIL-3 vaccinated skin (sheep 6) than in NF-control vaccinated biopsies (p <
0.002). Although increased expression of TNF-a mRNA was evident after gene-gun delivery
of pIL-3 when compared to NF-control vaccinated skin in sheep 5, this was not statistically
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hours post-vaccination
Figure 3.57 Expression of TNF-a mRNA in skin over 96 hours after gene-gun vaccination
with plL-3 and the NF-control. (a) Sheep 5, (b) sheep 6. Endogenous expression of TNF-a is
represented as a solid line. Data are presented as mean ± SEM.
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3.7 Discussion
3.7.1 Immunopathology of pGM-CSF vaccinated skin
3.7.1.1 Biopsy experiment A (1 -7 days)
It was evident from biopsy experiment A that pGM-CSF caused a severe inflammatory
reaction in the skin 24 hours after gene-gun delivery. This was characterised by the
formation of epidermal microabscesses which were composed predominantly of neutrophils.
In contrast, the dermal infiltrate was composed of some mononuclear cells and a large
number of eosinophils 24 hours p/v. GM-CSF is indeed a chemoattractant for eosinophils
(Warringa et al., 1991) and this early recruitment is in agreement with observations by Haig
and colleagues (Haig et al, 1995a) following intradermal administration of recombinant GM-
CSF. At later time-points the dermal infiltrate became largely composed of mononuclear
cells and an infiltration ofMHC class II+ cells with the morphological appearance ofDC was
apparent 3-4 days after pGM-CSF administration. Whilst an inflammatory response was also
induced after administration of control plasmid pEGFP-N1 (characterised by a mixed dermal
infiltrate over the time-course), large foci of MHC class II DR+ DC were not observed.
Immunohistochemical staining revealed an infiltration of CD45RA+ lymphocytes (expressed
by both naive T cells and B cells) at later time-points (5-6 days) after pGM-CSF
administration. Since there are essentially no CD45RA+ T cells in afferent lymph draining
skin (Mackay et al, 1990), these cells are most likely to be B cells. Another interesting
finding from this experiment was an apparent increase in y5 T cells 24 hours after
administration of all of the plasmids.
3.7.1.2 Gene-gun delivery of NF-(GM-CSF) control induces mild
inflammatory changes in ovine skin
To further understand the adjuvant mechanisms of GM-CSF DNA, an examination into the
early events (1-24 hours) was required in order to assess the earlier events (i.e. before the
peak inflammatory reaction had taken place). In addition, later time-points (up to 4 days p/v)
were required in order to confirm DC infiltration and also to correlate the histological
findings with cytokine expression in the skin. It was evident that the NF-control induced a
mild inflammatory response in the first 24 hours; the biopsies taken from the NF-control
vaccinated sites exhibited low-grade infiltration of neutrophils at the earlier time-points (2—
24 hours), however no pustule formation was evident over the 4 days as was observed after
pEGFP-N 1 administration. Unfortunately, no direct comparison of the inflammatory effects
induced after delivery of either pEGFP-N 1 or the NF-control was made in this study.
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Neutrophilic recruitment and pustule formation was documented by Braun and colleagues
(Braun et al, 1999) and occurred regardless of the presence of plasmid on the gold beads,
suggesting that the response was due to the delivery of gold, and not a response to bacterial
DNA. The lesions were composed largely of neutrophils following vaccination with both
pGM-CSF and pEGFP-Nl and it is likely that neutrophils represent the first cell population
to be recruited to the vaccination site. The results from this study are in agreement with
previous studies indicating that granulocytes are the first cells migrating into the tissue
during inflammation (Braun et al, 1999; Van Der et al., 2001).
Keratinocytes, which comprise 95% of the cells in the epidermis, form the first line of
defence in skin and alert the host to danger by the production of a number of cytokines
(including GM-CSF, IL-ip and TNF-a; (Kimber et al., 2000). In accord with a mild
inflammatory response was an increase in GM-CSF mRNA in NF-control vaccinated skin
biopsies, possibly as a result of the damage elicited to the keratin layer by the gene-gun
procedure. An increase in TNF-a and IL-ip transcripts was apparent as early as one hour
after delivery of the control plasmid and levels were slightly elevated (when compared to
endogenous levels) for up to 96 hours in some of the biopsies. Thereafter, levels of TNF-a
and IL-ip declined to baseline levels. A slight increase in MHC class II+ staining was
evident at some of the early time-points (16-24 hours) and may be due to activation of
resident skin cells and even endothelial cells; however, a pronounced infiltration of DC-like
cells was not observed in any of the sections analysed.
3.7.1.3 pGM-CSF recruits neutrophils into the skin
In marked contrast to the effects elicited by the NF-control plasmid, was a pronounced
infiltration of neutrophils as early as 2—4 hours after pGM-CSF delivery. The histological
findings correlated well with the expression ofGM-CSF mRNA, where transcripts peaked at
approximately 4 hours in both animals. At this time-point neutrophils accumulated under the
keratin layer and development of a micro abscess was evident as early as 6 hours p/v. GM-
CSF mRNA progressively declined but was still slightly elevated at the 96 hour time-point,
consistent with the sloughing of the epidermal layer. Quantification of TNF-a and IL-ip
transcripts revealed differential expression patterns over time. TNF-a expression did not
differ markedly from NF-control vaccinated skin biopsies at early time-points (1-6 hours)
after pGM-CSF delivery; however, at later time-points (24—96 hours), TNF-a mRNA
expression was elevated in skin vaccinated with pGM-CSF, consistent with a more
pronounced inflammatory reaction. Perhaps the most striking observation with regard to
cytokine expression in this study was the highly pronounced increase in IL-ip transcripts
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after pGM-CSF administration, where levels increased in a linear fashion over the first 24
hours and remained highly elevated up to 4 days p/v. Expression of IL-1 p mRNA was 200-
300 fold higher in pGM-CSF vaccinated biopsies than in normal skin. Moreover, IL-ip
transcripts remained sustained over the 4 days after pGM-CSF delivery, whereas levels had
returned to those measured in normal skin 48 hours after delivery of the NF-control plasmid.
It is interesting to speculate which cells are the major source of IL-ip transcripts. IL-ip is
produced almost exclusively by LC in murine epidermis (Heufler et al, 1992; Schreiber et al,
1992) however, IL-1 (3 is also an inducible product of human keratinocytes (Kupper et al.,
1986). GM-CSF has indeed been reported to promote the transcription and synthesis of IL-
ip in mouse dendritic cell clones (Granucci et al., 1994) and human monocytes (Smith et al.,
1990). Furthermore, GM-CSF induces IL-ip message accumulation in PMN (Fernandez et
al., 1996) and is a well-known survival factor for PMN (Brach et al., 1992; Colotta et al.,
1992). PMN are now known to play an important role in inflammation, immune responses,
and tissue repair by secreting IL-ip (reviewed in Yamashiro et al., 2001). In this study, a
pronounced accumulation of neutrophils was evident as early as 4 hours and it is possible
that neutrophils are responsible for such high levels of IL-1 p transcripts. In situ hybridisation
in combination with immunohistochemistry would help to address the source of IL-ip.
3.7.1.4 pGM-CSF recruits DC into the skin
In agreement with biopsy experiment A, a pronounced infiltration of MHC class II+ cells 4
days after pGM-CSF administration was evident in both animals. Unfortunately, attempts to
further characterise MHC class II+ infiltrates proved difficult; staining with anti-CD 14 mAb
in order to differentiate infiltrating macrophages from DC was unsuccessful. Staining with
anti-CD lb was also unsuccessful and whilst mAb successfully stained cells in cytospins
(results not shown), the morphology of the cells and tissue was poor. Further analysis of
MHC class II+ infiltrates is imperative to confirm that these cells are indeed DC.
It could be envisaged that GM-CSF is first chemotactic for PMN resulting in their early
recruitment into the skin. PMN start to accumulate where abundant GM-CSF protein is
present which in turn induces IL-lp expression in PMN, thereby amplifying the acute
inflammatory responses by recruiting additional PMN into inflammatory sites. Recently, it
has been reported that defensins and other peptides pre-stored in PMN granules attract
monocytes, dendritic cells and T cells, leading to the hypothesis that the release of PMN
granular peptides may link innate and adaptive immunity (Yamashiro et al, 2001). It is now
coming to light that there is first a requirement for "priming" of PMN by cytokines to induce
the delayed expression of monocyte chemoattractant protein-1 (MCP-1), which is a signal
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for mononuclear cells (Rand et al., 1996). As a result of the chemokines and cytokines
expressed by infiltrating PMN and the increased permeability of endothelium, recruitment of
DC takes place. In line with this was an upregulation of MCP-1 protein which coincided
with maximal DC infiltration after DNA vaccination with pGM-CSF (Perales et al, 2002).
3.7.2 Immunopathology of plL-3 vaccinated skin
In the first study conducted, the histological effects elicited after pIL-3 administration were
not nearly as pronounced as the histological changes induced by pGM-CSF. Indeed, at some
of the time-points investigated, the effects of pIL-3 were only slightly more pronounced than
observed with pEGFP-Nl (control plasmid). Consistent with the known in vivo effects of
pIL-3 was an increase in the number of eosinophils, particularly within the first 48 hours
(Warringa et al, 1991). Immunohistochemical staining revealed a modest increase in small
MHC class II+ mononuclear cells by approximately 24 hours. Serial sections were compared
after staining with mAb specific for both MHC class II and CD45RA and a similar staining
pattern was apparent. It is likely that these MHC class II+ CD45RA+ cells were B cells (as
discussed in 3.7.1.1). It is known that IL-3 receptors are expressed at low levels on the
majority of peripheral blood B-lymphocytes (Macardle et al., 1996) and perhaps B cells are
recruited from the blood to the skin after pIL-3 administration. Further analysis is required in
order to confirm this preliminary finding. No apparent infiltration of DC was observed after
pIL-3 administration in biopsy experiment A.
For subsequent analysis of pIL-3 effects, the GFP gene was removed from the construct.
Since no comparison was made using the same animals with pIL-3 containing the GFP gene
and the construct where GFP had been removed, it is impossible to confirm if removal of
GFP gene had any effect; however, in all subsequent experiments a more pronounced
inflammatory reaction was evident after pIL-3 (-GFP gene) than observed in biopsy
experiment A. In addition a more pronounced infiltration of eosinophils and mononuclear
cells was apparent by 24 hours, when compared to biopsy experiment A. Furthermore, large
infiltrates of MHC class II+ cells were identified 3^1 days after pIL-3 administration. It
remains to be determined if the cells expressing MHC class II 3 days after pIL-3
administration were indeed DC.
The kinetics of pIL-3 mRNA expression followed a similar trend observed after pGM-CSF
administration, notably where peak expression was observed approximately 4 hours after
administration and declined thereafter. IL-3 transcripts were detected up to 96 hours p/v,
whereas IL-3 transcripts could not be detected in normal skin or in the NF-control vaccinated
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skin biopsies. Consistent with a pronounced inflammatory reaction was a marked increase in
TNF-a and IL-lp transcripts over the time-course. It should however be acknowledged that
attempts to detect recombinant IL-3 were largely unsuccessful. If further work is to be
carried out with this cytokine, it is imperative that functional protein is demonstrated to be
expressed. Since problems were encountered using the anti-IL-3 mAb, an alternative is to
measure the in vitro stimulatory capacity of supernatants collected from IL-3-transfected
cells using bone marrow cultures.
3.7.3 IL-18 mRNA decreases after gene-gun vaccination
In this study, gene-gun bombardment with all plasmids caused a decrease in IL-18
transcripts in skin (relative to endogenous expression). IL-18 is expressed by both
keratinocytes and LC (Stoll et al., 1997; Stoll et ah, 1998) and gene-gun vaccination with
pGM-CSF has been documented to result in an increase in IL-18 protein (Perales et al,
2002). This present study relied on the quantification ofmRNA transcripts to assess changes
in gene expression after DNA vaccination. Whilst quantitative RT-PCR is a powerful
method and gave some insight into the changes induced in tissues after adjuvant
administration, some caution in the interpretation of the data is imperative. What this study
fails to show is how mRNA expression is related to protein expression and secretion, and so
in the case of IL-18 expression, the number of relative transcripts may be less shortly after
DNA vaccination, but levels of protein could indeed be higher. In addition, it has been
reported that cells harbour high levels of IL-18 mRNA which is rapidly translated upon
stimulation, thus the level ofmRNA may not correlate with the level of protein expression. It
would therefore be more informative if this study had also included some evaluation of
protein expression.
IL-12p40 transcripts are reported to be expressed at low levels in normal skin (Scarozza et
al., 1998) and purified LC are known to spontaneously produce IL-12p40 (Tada et al., 2000).
Since IL-12 promotes the accessory cell function of epidermal LC (Suemoto et al., 1998),
expression of this cytokine after pGM-CSF administration was analysed. In this study,
mRNAs encoding IL-12p40 were detected in normal skin (by conventional RT-PCR), but
rarely after pGM-CSF vaccination which is in line with the observation that GM-CSF
inhibits IL-12p40 production by stimulated LC (Tada et al, 2000). In contrast, Perales and
colleagues detected IL-12 protein within 24-48 hours in skin following gene-gun vaccination
with pGM-CSF (Perales et al, 2002). In addition, IL-10 transcripts could not be detected by
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quantitative RT-PCR in this study; however, conventional RT-PCR using undiluted cDNA
samples revealed that IL-10 was indeed expressed in normal skin and in all of the pGM-CSF
vaccinated samples. Quantification of this anti-inflammatory cytokine merits further
investigation; in particular it would be of interest to determine if IL-10 expression is
upregulated when expression ofproinflammatory genes is at maximal levels.
3.7.4 DC migration and maturation
During infection, microbial components provide signals that alert the immune system to
danger and promote the generation of immunity by stimulating DC to mature so that they can
present foreign antigens and stimulate T cells. In the absence of danger signals, there is often
no immune response or tolerance may develop. This has led to the concept that the immune
system responds only to antigens perceived to be associated with a dangerous situation such
as infection. GM-CSF is not only a growth factor of DC but is thought to exert its adjuvant
activity by acting as a danger signal. In agreement with this latter statement, a pronounced
upregulation of IL-ip and TNF-a was induced after gene-gun delivery of pGM-CSf (and
pIL-3) and levels remained elevated over 4 days. Both of these cytokines are pivotal in DC
maturation and migration. Moreover, GM-CSF and IL-ip mediate the maturation of murine
epidermal LC into potent immunostimulatory DC (Heufler et al., 1988). DC were observed
to enter the skin 3 -4 days after pGM-CSF delivery and accumulated in the dermis and then
disappeared, presumably having migrated to the DLN. Isolation of DC after gene-gun
delivery of pGM-CSF or pIL-3 was therefore the next logical step to take, since
hyperelevated levels of IL-1(3 in the skin 3-4 days after pGM-CSF administration may cause
maturation and migration ofDC.
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4 Effects of pGM-CSF on ALDC draining the
site of gene gun delivery
4.1 Introduction
Recent studies indicate that the nature of maturation stimuli and the kinetics of activation
have a quantitative and qualitative impact on T cell stimulation. Understanding how DC
interpret different stimuli is pivotal to our understanding of the generation of immune
responses following infection and vaccination. Interest in GM-CSF as a molecular adjuvant
is due to its dual role as a growth factor for DC and as an inducer of inflammation or
"danger", resulting in the activation and maturation of DC. Indeed, enhancement of humoral
and cell-mediated immune responses has been well documented after vaccination with
plasmids encoding poorly immunogenic antigens in combination with GM-CSF in mice.
This enhancement has been attributed to the recruitment of DC to the site of vaccination.
Some enhancement of immune response has also been documented in outbred species;
however, further optimisation is still required if GM-CSF is to be successfully employed in
vaccination procedures.
The mechanisms by which GM-CSF enhances the immune response are not fully
understood. Studies in mice and humans have focused on the administration of large
quantities of recombinant GM-CSF and the preferential expansion and activation of myeloid
DC has been reported in both species (reviewed in Chapter 1). Attempts to directly isolate
and study ex vivo DC after DNA vaccination with pGM-CSF are currently lacking and
would further our understanding of the mechanisms by which this adjuvant works in vivo.
Alterations in the type and quantity of cytokines expressed by DC are likely to be a major
influence in T cell sub-population activation. In addition, changes in the expression of
antigen presentation molecules and costimulatory markers (CD80 and CD86) need to be
further addressed after DNA vaccination with pGM-CSF, since upregulation of these
markers would equip DC with a greater capacity to stimulate T cells. If GM-CSF is to be
fully exploited as a molecular adjuvant, it is essential to understand both the changes in DC
subpopulation balance and the characteristics of expanded DC relative to those of steady-
state DC after vaccination with pGM-CSF.
Experiments on the physiology of DC require access to DC closest to their native, non-
activated form. Human and mouse systems rely on complex and lengthy cultures or isolation
of DC from tissues and it is therefore difficult to equate DC to physiological conditions.
Cannulation of the pseudoafferent lymphatics in sheep provides an efficient method to
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directly access unmanipulated DC closest to their natural form as they traffic from the skin to
the lymph node. This technique is performed by first removing the DLN and allowing
anastomosis of the afferent vessels with the remaining efferent duct. Approximately eight
weeks later, the "efferent" vessel can be cannulated and afferent lymph obtained for periods
sometimes in excess of 2 months. Although this technique is feasible in both rats and in
cattle, only intestinal lymph is available in the former and in both species cannulations
remain patent for only a few days (John Hopkins, personal communication). By
pseudoafferent lymphatic cannulation of sheep, it is possible to monitor phenotypic and
functional changes in DC draining from the skin after DNA vaccination with pGM-CSF over
a longer time-period. This is therefore a potentially useful model in order to further
investigate the biology of DC which infiltrate the skin approximately 4 days after DNA
vaccination with pGM-CSF in sheep (chapter 3). A further advantage of the ruminant model
is that it enables collection of large numbers of cells for more detailed analysis throughout
the duration of any response.
Two ALDC subpopulations have been well characterised in both cattle (Howard et al, 1997)
and in rats (Liu et al, 1998c) and appear to have different roles in vivo. Bovine SlRPa+
ALDC are more effective at stimulating proliferative responses in allogeneic CD4+ and
CD8+ T cells (Howard et al, 1997). Differences in function of bovine ALDC have been
related to differences in constitutive cytokine expression by the two populations as defined
by the expression of SIRPa and not due to a difference in expression of costimulatory
markers (Stephens et al, 2003). Bovine SIRPu ALDC constitutively express high levels of
IL-12p40, whereas IL-10 transcripts are rare or absent in this subpopulation. Conversely,
SIRPa+ ALDC express low levels of IL-12p40 but constitutively express high levels of pro¬
inflammatory IL-6, IL-la and IL-ip and occasionally, low levels of IL-10. Moreover, the
induction of strong CD8+ T cell responses by SIRPa+ ALDC is related to the high level of
expression of IL-la (Hope et al, 2001).
Cytokine profiles of rat ALDC have not as yet been ascertained; however, rat splenic CD4
/SIRPa- DC were reported to produce large quantities of IL-12 and TNF-a and induced Thl
responses in allogeneic CD4+ T cells, whereas CD4+/SIRPa+ DC produced low amounts of
IL-12 and no TNF-a, but induced both Thl and Th2 responses (Voisine et al, 2002). As
described in cattle, rat splenic and afferent lymph SIRPa+ DC are highly immunostimulatory,
whereas CD4 /SIRPa DC exhibit a poor CD8+ T cell stimulatory capacity (Liu et al, 1998c;
Voisine et al, 2002). Furthermore, a recent study indicates that SIRPa- ALDC transport
material from apoptotic enterocytes to T cell areas of mesenteric lymph nodes and a role in
the maintenance of tolerance has thus been proposed (Huang et al, 2000).
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Ovine ALDC subpopulations have been partially characterised (Bailey, 2003); however, the
cytokine profiles of steady-state ovine ALDC have not as yet been determined. Further
characterisation of the two subpopulations was therefore essential in order to ascertain any
changes in cytokine expression after DNA vaccination with pGM-CSF and also to further
our understanding of ovine ALDC based on expression of the SIRPa molecule.
4.2 Aims
The aims of this part of the study were to isolate ovine ALDC based on the expression of
SIRPa and to:
Characterise ovine SIRPa+ andSIRPa ALDC subpopulations in the steady-statefluxfrom
the skin
(i) Characterise the morphology and cell-surface marker expression
(ii) Quantify expression of cytokine transcripts (IL-12p40, IL-18, IL-10, TNF-a
and IL-ip)
(iii) Investigate TLR expression and LC-specific transcripts
Characterise SIRPa+ and SIRPa DC subpopulations afterpGM-CSF administration
(i) Quantify cytokine mRNA expression in SIRPa+ and SIRPa-ALDC at
intervals after gene-gun vaccination with pGM-CSF
(ii) Determine if GM-CSF causes expansion of SIRPa+ and SIRPa-ALDC
(iii) Determine changes in cell-surface markers on MHC class II+ ALDC
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4.3 Phenotypic characterisation of ALDC
4.3.1 Isolation of SIRPa+and SIRPcf subpopulations of ALDC by
cell sorting
ALDC were obtained by cannulation of afferent lymphatics as described in chapter 2
(Section 2.2.4.1). This technique allows the collection of lymph with a cellular composition
identical to true afferent fluid. Experiments were not started until at least seven days after
cannulation to guarantee access to cells unaffected by surgical trauma. A typical 24-hour
collection of 100ml of lymph contains approximately 1 x 106 cells/ml of which 1-10% are
non-lymphoid MHC class II+ DC (Hopkins et al, 1989). A 24 hour collection of lymph may
therefore contain between 106 and 107 DC. There is no single surface marker that is both
specific for DC and is expressed by all DC; therefore it is imperative that attempts to isolate
DC are not based solely on the expression of a single marker. There are several "pan"-DC
surface markers for which there are antibodies available for sheep (Table 4.1) and one such
marker is MHC class II. Constitutive expression of MHC class II is usually restricted to
professional APC (Puri et al, 1987), although in sheep afferent lymph the majority of CD4+,
CD8+ and y8 T cells express both DQ and DR molecules (Dutia et al, 1993a). In addition,
MHC class II expression is inducible in (human) neutrophils (Radsak et al., 2000). MHC
class II is however expressed at significantly higher levels on ALDC than expressed on other
cell types, including both macrophages (Santin et al., 1999) and B cells (Hopkins et al,
1986); indeed the level of MHC class II expression on ALDC is 3-10 greater than on resting
B cells.
ALDC were enriched to approximately 60% (when examined by light microscopy) using the
density-gradient medium, OptiPrep™, as outlined in chapter 2 (Section 2.2.4.6). OptiPrep™
was used to enrich for DC as it does not appear to cause activation of APC unlike Percoll
gradients which cause activation following ingestion of silica particles (Graziani-Bowering
et al, 1997). ALDC were double immunolabelled using IL-A24 mAb that recognises the
SIRPa molecule (Brooke et al, 1998; Ellis et al., 1988) followed by a biotinylated mAb
(SW73.2) that is specific for a nonpolymorphic determinant on sheep class II (MHC class II
DR DQP) (Hopkins et al, 1986) since this combination of mAb resulted in clearly defined
populations of ALDC (Section 2.2.4.7).
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Table 4.1 Cell surface markers expressed by ALDC and available ruminant-specific mAb.
The table also lists potential uses and/or limitations in using the listed mAb in cell sorting of
ALDC populations.
surface marker mAb(s)
cell types expressing uses/limitations for
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(ii) stains majority of
DC. Weak reactivity
with granulocytes










cells (Gliddon et al,
2004)
Gupta et al (1993)








DC express higher Hopkins et al
MHC class II than on (1986)
other cells, including
B cells and m<j)s
For subsequent cell sorting, DC were defined by:
(i) High FSC and SSC (due to their large size and granularity)
(ii) High MHC class II (channel number > 103)
100% of ALDC express high levels (channel number >103) of surface MHC class II.
Individual gates were therefore positioned around the MHC class IIhl SIRPa+ and MHC
Class IIhl SIRPa populations. A representative experiment illustrating the gate criteria for
cell sorting is shown in Figure 4.1. The SIRPa+ population is the larger of the two
populations of ovine ALDC; approximately 80% (range 71-86%) of ovine ALDC express
SIRPa (Table 4.2), as was reported with bovine ALDC (Brooke et al, 1998). This is also in
agreement with an earlier study, where the SIRPa molecule was expressed on the majority
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(approximately 58%) of ovine ALDC using an immunoperoxidase staining method (Haig et
al., 1995b).
It was then deemed necessary to confirm that ALDC purified by FACS were indeed DC,
since MHC class II expression is not restricted to these cells. In addition, the SIRPa
molecule is expressed on bovine monocytes as well as DC (Brooke et al, 1998). Expression
of SIRPa by a subset of ovine lymphocytes is evident in Figure 4.2. It was therefore vital
that purified ALDC populations were analysed by employing a variety of different
techniques to confirm that cells displayed characteristics typical of DC prior to carrying out
further work. It was also of interest to compare morphological characteristics of SIRPa' and
SIRPa" ALDC subpopulations with those already described in cattle and rats.
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Figure 4.1 Two-colour flow cytometry of ALDC. (a) ALDC were gated based on high FSC
and SSC (gate R1). (b) DC were immunolabelled with mAb IL-A24 (anti-SIRPa) followed by
the biotinylated mAb SW73.2 (anti-MHC class II p). To isolate the two populations of ALDC,
gates (R2 and R3) were positioned around cells, which express high MHC class II (channel
number > 103).
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Figure 4.2 ALC stained with mAb IL-A24 (anti-SIRPa). (a) Flow cytometry analysis of ALC
stained with mAb IL-A24 (detected with a FITC-conjugated mAb). (i) FSC and SSC profiles
of ALC. For FACS analysis, gates were routinely set to exclude dead cells and discriminate
between two regions containing predominantly APC and large blasts (R1) or small
lymphocytes (R2). (ii) Two populations of cells (SIRPa+ and SIRPcf) are evident in R1 (pink).
A small population of cells in the lymphocyte-gate (R2) are also SIRPa+ (green), (b) DC-
enriched fraction (fraction 1 after centrifugation with OptiPrep™) immunolabelled with mAb
IL-A24 (detected with a peroxidase-conjugated mAb) and counterstained with haematoxylin.
Most ALDC react with mAb IL-A24 (large veiled brown cells). Smaller mononuclear cells
(black arrows) also react with this mAb.
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Table 4.2 Cell sorting experiments carried out with the DC-enriched fraction obtained from
"resting" lymph. The percentages of SIRPa+/~ ALDC are derived from the number of cells
recorded in each gate (R2 and R3) upon initial analysis and not from the total numbers of
each FACS-sorted population isolated. Approximately 80% (range 71-86%) of ALDC
express the SIRPa antigen. The table also lists the total number of SIRPa+ and SIRPcf
ALDC obtained from each cell sort. Cell sorting experiments 5.0-10.0; cell sorts after DNA
vaccination with pGM-CSF (Section 4.6) are omitted. (NA, not assessed; *, no further work

















1.0 JH1 85 15 56,511 9891 95 96
2.0 JH1 79 21 446, 651 114, 442 99 96
3.0 JH2 75 25 343, 137 160, 165 96 NA
4.0 JH2 71 29 640, 223 313,367 99 NA
11.0 JH3 79 21 401, 816 362, 824 93 *42
12.0 JH3 71 29 564, 372 159,526 95 90
13.0 JH3 77 23 140, 000 40, 000 96 95
14.0 JH4 77 23 648, 952 156, 993 97 97
15.0 JH4 79 21 258, 962 78, 401 95 90
16.0 JH5 86 16 2.69 x 106 326, 607 100 96
17.0 JH6 80 20 158, 742 29,671 NA NA
18.0 JH6 78 22 233,398 54, 346 98 97
19.0 JH6 82 18 122, 881 24, 992 NA NA
20.0 JH6 77 23 NA NA 96 95
237
4.3.2 Morphological characterisation of SIRPa+ and SIRPa ALDC
Experiments were then undertaken in order to compare the morphology of the purified
SIRPa+ and SIRPa ALDC. Immediately after cell sorting, cytospins were prepared from
each collection (Section 2.2.2.3). Cells were fixed in ice-cold acetone and either stained with
Giemsa, or were restained with mAb IL-A24 and counterstained with haematoxylin.
Representative images are shown in Figure 4.3. DC were defined by reported criteria,
notably that they are typically large mononuclear cells with round or indented nuclei with
prominent dendritic processes (Steinman, 1991). Both populations of cells have typical
features ofDC, as illustrated by their large size (>10pm) and prominent nuclei. Furthermore,
both populations show pronounced protrusions and microvillous projections of their plasma
membrane typical ofDC (Drexhage et al., 1979).
Differences in morphology are apparent between the two populations. SIRPa+ ALDC
contain large nuclei with relatively sparse cytoplasm and multiple blunt processes
(pseudopodia) (Figure 4.3a). In contrast, many SIRPa" ALDC display a frilly or veiled
appearance, which is particularly evident in Figure 4.3f. In addition, SIRPa" ALDC appear to
be a relatively homogeneous population of cells, in contrast to the heterogeneous SIRPa+
ALDC subpopulation. When viewed by light microscopy, SIRPa" cells are slightly larger
than SIRPa+ ALDC and this difference is confirmed by analysis of light scatter profiles by
flow cytometry (Figure 4.4). These morphological distinctions are not absolute, and DC with












Figure 4.3 Morphology of SIRPa+ and SIRPa" ALDC. FACS-sorted ALDC were
cytocentrifuged and either stained with Giemsa or re-immunolabelled with IL-A24 and
counterstained with haematoxylin. SIRPa+ (a, c & e) and SIRPa" (b, d & f) ALDC were then
examined by light microscopy.
(a) SIRPa+ ALDC stained with Giemsa (original magnification, *80)
(b) SIRPa" ALDC stained with Giemsa (original magnification, x80)
(c) SIRPa+ ALDC stained with Giemsa (original magnification, *250)
(d) SIRPa" ALDC stained with Giemsa (original magnification, *250)
(e) SIRPa+ ALDC stained with IL-A24 (original magnification, *250)










Figure 4.4 Comparison of SIRPa+ and SIRPa ALDC populations for light scatter
characteristics.
(a) FSC and SSC profiles of unfractionated lymph cells
(b) Unfractionated lymph cells stained using mAb IL-A24 (SIRPa) and biotinylated
SW73.2 (MHC class II p)
(c) back-gated FSC x SSC profiles for SIRPa+ DC defined by R1 (a) and R2 (b)






4.3.3 Ultrastructural characterisation of ALDC
Transmission Electron Microscopy (TEM) was next employed in order to determine
ultrastructural characteristics of isolated SIRPa+ and SIRPa ALDC. Purified ALDC were
fixed in glutaraldehyde immediately after cell sorting. In addition, unfractionated lymph was
washed and fixed for TEM. Overall, SIRPa+ and SIRPa ALDC show some ultrastructural
features characteristic of DC (Figure 4.5a,b). Since sorted DC were not freshly fixed (i.e.
soon after collection from the animal), it is possible that some of the ultrastructural features
may in fact be lost or induced from the experimental procedure itself. Loss of some of the
pronounced protrusions (observed previously in the Giemsa stained ALDC) is particularly
evident when sorted DC are compared with freshly fixed ALC (Figure 4.5c,d). Occasionally
many atypical mitochondria were observed in some SIRPa"1" cells; however, this may in fact
be artefact (Steven Mitchell, personal communication). Cells were also closely examined for
the presence of Birbeck granules, which are characteristic of human LC (Birbeck et al.,
1961) and also for the presence of apoptotic body inclusions, since rat SIRPa" ALDC have
been reported to contain apoptotic DNA (Huang et al, 2000). Due to low cell yields after the
sorting procedure, few SIRPa" ALDC were present on the cut sections; however,
intracellular vesicles which resembled apoptotic bodies were observed in two SIRPa" cells
(Figure 4.5b (V)). The main observations for both ALDC populations are:
(i) A large diameter (when compared to lymph-derived lymphocytes),
(ii) Abundant cytoplasmic vesicles were present in some of the cells (possibly
lysosomes, phagolysosomes and endocytic vacuoles),
(iii) No Birbeck granules (a unique feature of epidermal LC) were observed in
either subpopulation ofALDC,
(iv) Pleomorphic and deeply convoluted nuclei with marginated heterochromatin
characteristic of DC (Drexhage et al, 1979; Gregg et al., 1995) and
(v) Nucleoli were not obvious in either population.
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Figure 4.5 Transmission electron microscopy (TEM) of FACS-sorted DC. (a) SIRPa+ MHC
class llhl ALDC, (b) SIRPcf MHC class llhl ALDC, (c & d) lymph enriched for DC. ALDC were
separated by FACS, fixed in glutaraldehyde, and examined by TEM. SIRPcf ALDC contain
numerous electron-dense and -lucent inclusions (b, label V). Both populations contain
heterochromatic nuclei and electron-lucent cytoplasm, characteristic of DC. (DC, dendritic
cell; He, heterochromatic nuclei; L, lymphocyte; V, vesicle.)
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4.3.4 Immunostaining of purified ALDC subpopulations
To assess more specifically the phenotype of SIRPa+ and SIRPa ALDC, several mAb
directed against cell surface markers were tested for reactivity by immunochemistry. A range
of mAb was applied to cytospins prepared from sorted cells. Neither subpopulation of DC
appeared to express T- or B cell surface markers by immunochemistry (data not shown). It is
known that DC and macrophages share many cell surface antigens such as MHC class II,
CDllb, CDllc and mannose receptors including DEC-205 (CD205). However, ovine
ALDC express CD lb but very little CD14 (Hopkins and Dutia, 1991; Hopkins and Gupta,
1996), while ovine macrophages express little or no CD lb but low to high levels of CD 14
(Gupta et al., 1996; Rhind et ah, 1996a).
Humans possess five distinct CD1 genes (CD1A, B, C, D and E) which encode four protein
products, CD la, CD lb and CDlc (group 1) and CD Id (group 2); and sheep possess at least 7
CD1 genes including CD IB, D and E (Hopkins et ah, 2000). Previous studies in sheep have
shown that the majority ofmAb recognise a 46 kDa antigen with a distribution similar to that
of human CDlb (expressed by thymocytes and DC). The mAb SBU-T6 has a wider tissue
distribution (Mackay et ah, 1988b) and is considered to recognise a CDlc-like molecule or
to represent a "pan-CDl" mAb (Hopkins and Dutia, 1991). Importantly, mAb SBU-T6 stains
both LC and dermal DC in sheep, whereas VPM 5 and CC118 stain dermal DC only (Rhind,
1996). Both subpopulations stain strongly with mAb SBU-T6 (Figure 4.6), suggesting that
either population may be derived from either LC or dermal DC. Insufficient material was
available to assess reactivity of all anti-CD 1 mAb with ALDC by immunochemistry.
Cytospins were also stained with a mAb that recognises y8 T cells in ovine skin (CC15;
Table 2.1). The y5+ DC found in the skin of many rodent species were first described by
Bergstresser (Bergstresser et al, 1983) and Tschachler (Tschachler et al, 1983). y8 cells were
initially described as Thy-1+ DC and have been reported to express the yS T cell receptor and
to present antigen (Welsh and Kripke, 1990). Indeed, ovine yS DC have been isolated from
lymph and were found to have ultrastructural features characteristic of DC (Welsh and
Kripke, 1990). In my work, neither population stained with this antibody, suggesting that
neither population has arisen from this type of "DC" in the skin (data not shown).
Weak reactivity was observed with mAb VPM 65 (anti-CD14) in a small fraction of SIRPa+
ALDC by immunochemistry (Figure 4.7), as observed previously with ovine ALDC (Gupta
et al, 1996). None of the cells in the SIRPa fraction stained positive with mAb VPM 65 in














Figure 4.6 Reactivity of purified SIRPa+ and SIRPa ALDC with an anti-CD1 mAb. Cytospins
were prepared from purified ALDC and immunostaining was carried out with mAb SBU-T6
followed by counterstaining with haematoxylin. Reactivity is observed with both SIRPa+ and
SIRPa" ALDC.
(a) SIRPa" DC (original magnification, x80)
(b) SIRPa+ DC (original magnification, *80)
(c) SIRPa" DC (original magnification, *250)
(d) SIRPa+ (original magnification, *250)
(e) Positive control: lymph cells stained with SBU-T6 mAb
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Figure 4.7 Reactivity of purified SIRPa+ and SIRPa ALDC with an anti-CD14 mAb.
Cytospins were prepared from purified ALDC and immunostaining was carried out with mab
VPM 65. Reactivity is observed with some SIRPa+ ALDC.
(a) SIRPa- DC (original magnification, *80)
(b) SIRPa+ DC (original magnification, *80)
(c) SIRPa- DC (original magnification, *250)
(d) SIRPa+ (original magnification, *250)
(e) Positive control: lymphocyte-enriched fraction stained with VPM 65 mAb
(f) Negative control: sorted cells immunolabelled with secondary mAb only
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4.3.5 Flow cytometric analysis of ALDC
In order to further investigate the phenotype of SIRPa+ and SIRPof ALDC, flow cytometry
was carried out on unfractionated ALC. ALC were immunolabelled with several mAb (listed
in Table 2.2) and biotinylated IL-A24 (anti-SIRPa). Since weak reactivity was observed with
mAb VPM 65 (anti-CD 14) in a fraction of SIRPa+ ALDC when assessed by
immunochemistry (Section 4.3.4), ALDC were again evaluated for surface expression of
CD14 by flow cytometry. Figure 4.8 is representative of data obtained from three animals.
Approximately 15% (range 13-21%) of SIRPa+ ALDC express CD14 (as determined by
FL1, Figure 4.8a). Conversely, CD14 was not detected on any of the SIRPcf ALDC in any
of the animals used in this study. The phenotype of ovine SIRPa+ and SIRPcT ALDC has
been extensively characterised by flow cytometry in a previous study (Bailey, 2003). In
agreement with these findings, approximately 40% of SIRPa+ ALDC were reported to
express CD 14. Interestingly, both studies show that SIRPcf ALDC express higher levels of
CD45RA than SIRPof ALDC (Figure 4.8b), whereas expression of MHC class II and CD40













MHC class II (FITC)
Figure 4.8 Two-colour flow cytometry of ALDC populations. Expression of (a) CD14, (b)
CD45RA, (c) CD40 and (d) MFIC class II on SIRPa+ (R2, purple) and SIRPcf (R3, blue)
ALDC. Negative controls (NMS) are shown in black (histograms).
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4.3.6 ATPase staining of purified ALDC subpopulations
Veiled cells in lymph form a heterogeneous population, some of which have been proposed
to belong to the LC lineage based on morphological analysis (Brand et al., 1993); surface
expression of CD1 (Bujdoso et al, 1989) and possession of Birbeck granules (Hoefsmit et al.,
1982), a unique feature of LC (Birbeck et al, 1961). LC can be further differentiated by a
variety of other criteria including expression of ATPase (Steinman, 1991) or
acetylcholinesterase (Hollis and Lyne, 1972; Lyne and Chase, 1966). Acetylcholinesterase
staining has been reported to be a more reliable method of quantifying ovine LC than using
mAb which recognise MHC class II antigens or CD1 (Townsend et al, 1997). LC also
possess strong ATPase activity; this enzyme is described as being an ectoenzyme, localised
within or at the surface of the plasma membrane and not within cells, in both human
(Zelickson and Mottaz, 1968) and guinea pig epidermal LC (Wolff and Winkelmann, 1967).
In order to investigate if either sub-population of ALDC is derived from epidermal LC,
ATPase staining was carried out on cytospin preparations from FACS-sorted DC. FACS-
sorted DC were not fixed in ice-cold acetone following cytocentrifugation, but instead were
air-dried and stored at -20°C until the ATPase procedure was carried out. Sections of equine
muscle were simultaneously stained (by Neil Mclntyre, EBVC) and served as positive
controls for the staining procedure (results not shown). FACS-sorted ALDC and muscle
sections were then fixed in cacodylate buffer and ATPase staining was carried out. Faint
ATPase staining was observed in some SIRPcC ALDC (obtained from cell sorting
experiment 3.0) as indicated by the dark grey peripheral staining of DC processes (Figure










Figure 4.9 ATPase staining of highly purified ALDC populations. After sorting by FACS, cells
were cytocentrifuged and air-dried prior to storage at -20°C. ATPase staining was carried
out and cells were lightly counterstained with Giemsa. A fraction of SIRPa+ ALDC appear
ATPase positive (dark grey); staining of cell membrane and dendrites can be observed.
(a) SIRPa+ cells (original magnification, *80)
(b) SIRPa" cells (original magnification, *80)
(c) SIRPa+ cells (original magnification, x250)
(d) SIRPa" cells (original magnification, *250)
(e) SIRPa+ cells (original magnification, *250)
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4.4 Molecular analysis of purified ALDC populations
RNA was extracted from freshly sorted ALDC stored in FACS buffer supplemented with
actinomycin D in order to prevent de novo transcription. From an average 16 hour collection,
approximately 0.5pg (range 0.2-2.7pg) of RNA was extracted from purified SIRPa+ ALDC;
RNA could not be quantified in the majority of SIRPa ALDC samples. RNA was
concentrated under vacuum in order to perform a RT reaction with as much available RNA
as possible. Conventional RT-PCR was first employed using GAPDH primers to confirm
that amplifiable material was present and genomic DNA had been fully degraded.
Occasionally, no signal was observed after 40 cycles of amplification of cDNA samples with
GAPDH-specific primers (both ALDC samples obtained from sort 1.0; Figure 4.10) or only
a very weak signal (samples obtained from cell sorting experiment 13.0, results not shown)
indicating that either insufficient RNA was extracted, or that RNA had degraded during the
extraction procedure.
GAPDH transcripts were present in samples from sorting experiments 2.0 and 3.0 (Figure
4.11), and in all the samples that followed, where the cell yields were generally higher than
those obtained from the first sorting experiment. Agilent analysis of samples 2.0 and 3.0
revealed that the concentration of RNA was low and of poor quality (results not shown);




Figure 4.10 Analysis of GAPDH transcripts in purified ALDC by RT-PCR. GAPDH RT-PCR
was carried out with cDNA samples obtained from SIRPa+ and SIRPcf ALDC purified from
cell sorting experiment 1.0. No GAPDH transcripts are evident after 40 cycles of
amplification.
Lane 1 SIRPa+ ALDC (+RT)
Lane 2 SIRPcf ALDC (+RT)
Lane 5 SIRPa+ ALDC (-RT)
Lane 6 SIRPcf ALDC (-RT)
Lane 8 Negative control (nuclease-free water)
Lane 10 Positive control (1:1000 dilution of GAPDH 1° PCR product)
1 23456789 10 11
Figure 4.11 Analysis of GAPDH transcripts in purified ALDC by RT-PCR. GAPDH RT-PCR
was carried out with SIRPa+ and SIRPcf cDNA samples obtained from cell sorting
experiment 2.0. Specific transcripts are evident after 40 cycles of amplification.
Lane 1 SIRPcf (+RT)
Lane 2 SIRPa+ (+RT)
Lane 3 enriched DC fraction (+RT)
Lane 5 SIRPcf (-RT)
Lane 6 SIRPa+ (-RT)
Lane 7 enriched DC fraction (-RT)
Lane 9 Negative control (nuclease-free water)
Lane 11 Positive control (1:1000 dilution of GAPDH 1° PCR product)
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4.4.1 Reverse transcription-polymerase chain reaction (RT-PCR)
for Langerhans'-cell specific transcripts in FACS-sorted DC
Since a fraction of SIRPa+ ALDC stained weakly with ATPase (Figure 4.9), further analysis
was required to determine if cells within this population represent migratory epidermal LC.
In humans, CDla is a reliable marker of LC (Ruco et al., 1989). However, sheep CDla -
specific antibodies have not yet been defined as most seem to react with both LC and dermal
DC. Both ALDC subpopulations react with mAb SBU-T6 (pan anti-CD 1) and could
therefore contain DC derived from either lineage. CD1A has not as yet been identified in
sheep or in cattle and is completely lacking in mice, although a partial sequence for equine
CDla cDNA is now available (Steinbach and Walter 2003, unpublished data; accession
number AY376269). A molecular approach was therefore adopted to ascertain if either
ALDC population contain CDla transcripts.
CD la-specific primers were designed from available human cDNA sequences and analysed
by Premier Biosoft software (Section 2.3.5.2). Initial attempts to amplify ovine CDla used
annealing temperatures of 55°C and 52°C; however, no products were observed using cDNA
from ovine spleen, skin or from enriched DC which had been verified to contain amplifiable
material by GAPDH RT-PCR (data not shown). A source of material was thus required in
order to determine the specificity of the CDla primers. DNA extracted from human skin was
pooled with human skin-derived cDNA (a kind gift from Kirsty Newman, University of
Edinburgh) and amplified for 40 cycles at 52°C. To ensure that ovine transcripts were not a
limiting factor in this system, 5pg of RNA from the skin of two different sheep was reverse
transcribed. Specific PCR products were only observed with the human DNA/cDNA mix
(Figure 4.12). A ~1500bp amplicon (1480bp) corresponds to the amplification of the human
CDla gene and a ~400bp amplicon (384bp) corresponds to the amplification of CDla
cDNA. Two non-specific bands were observed in both ovine skin cDNA samples at
approximately 600bp and 700bp. Attempts to optimise the PCR reaction proved
unsuccessful. No further work was carried out with this set of primers.
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Figure 4.12 CD1a (RT)-PCR optimisation. Primer pairs were tested on human DNA and also
on SSk and spleen cDNA samples. Amplification was carried out for 40 cycles at 50°C.
Lane 1 100bp marker
Lane 2 Human skin-derived genomic material (DNA and RNA) amplified with CD1a-
specific primers
Lane 3 Ovine skin (from biopsy experiment D) cDNA amplified with CD1a primers
Lane 4 Ovine skin (from biopsy experiment E) cDNA amplified with CD1a primers
Lane 6 Negative control (nuclease-free water)
A molecular approach was again adopted to ascertain if either ALDC subpopulation contain
transcripts for langerin (CD207), which is expressed by both human and murine LC
(Valladeau et al., 2000; Valladeau et al., 2002). Langerin (CD207) is a novel C-type lectin
and acts as a potent inducer of Birbeck granule formation (BG) and is a nonconventional
endocytic receptor routing into these organelles in LC (Valladeau et al, 2002). Although
Birbeck granules appeared to be absent from both populations when viewed by electron
microscopy (Figure 4.5), langerin (which is the major component of Birbeck granules) may
still be expressed by ALDC. In line with this hypothesis, murine DC within lymph nodes and
spleen and also in some non-lymphoid tissues (lung, liver, heart) have been reported to
express langerin (Valladeau et al, 2002), suggesting that migrating DC may still contain
langerin transcripts.
At the time ofwriting, there were no available sequences for langerin in sheep, or indeed any
other ruminant. Human and murine langerin (CD207) sequences were therefore aligned and
consensus primers were designed from homologous regions. Murine skin (and spleen)
contain abundant mRNA transcripts of langerin (Takahara et al., 2002). In line with this
observation, RNA (and DNA) were extracted from murine spleen to serve as positive control
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material (kindly supplied by Miss Clemence Hindley, University of Edinburgh). RNA was
also extracted from (normal/non-vaccinated) skin biopsies obtained from two different sheep
(collected from biopsy experiments D and E). Langerin primers were tested on skin cDNA
samples where different amounts (l-5pg) of RNA were reverse transcribed. A 400bp
product was observed after 40 rounds of amplification with all ovine skin cDNA samples
tested and also in murine cDNA derived from spleen (Figure 4.13). The expected amplicon
size of genomic (human) langerin is 1580bp following PCR with this set of primers; a
>1000bp product was detected after amplification with human and sheep DNA and may
correspond to amplification of genomic material. Primary PCR product was then purified
and cloned into into pGEM®-T Easy (Section 2.3.7.2) and sequenced. Sequencing revealed
that ovine langerin (CD207) shares 94% homology with bovine CD207 (accession number
XM_588243; sequence submitted March 2005), and shares 85% homology with human
CD207 (accession number AJ242859) (Appendix III). RT-PCR was then carried out with
purified ALDC cDNA samples. Importantly, 400bp products were detected in two out of the
four SIRPa+ ALDC samples tested. No transcripts were detected in any of the four SIRPa
ALDC samples evaluated (Figure 4.14).
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
<—500 bp
<—400 bp
Figure 4.13 Optimisation of langerin RT-PCR. RNA was extracted from ovine skin and
spleen biopsies and reverse transcribed. Positive control material consisted of DNA and
cDNA obtained from murine spleen and human skin. cDNA was amplified for 40 cycles with
an annealing temperature of 53°C. 400bp products correspond to amplification of langerin
mRNA and can be detected in both normal ovine skin and murine spleen.
Lane 1 100bp marker
Lane 2 ovine skin (1 pg, biopsy experiment E)
Lane 3 ovine skin (5 pg biopsy experiment E)
Lane 4 ovine skin (1 pg biopsy experiment D)
Lane 5 ovine skin (5 pg biopsy experiment D)
Lane 6 ovine spleen DNA
Lane 7 human skin
Lane 8 murine spleen DNA
Lane 9 murine spleen cDNA
Lane 11 water (negative control)
Lane 15 100bp marker
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Figure 4.14 Analysis of langerin transcripts in purified ALDC by RT-PCR. RT-PCR was
carried out for 40 cycles with freshly sorted SIRPa+ and SIRPcf ALDC. Langerin transcripts
(400bp fragments) are present in two out of the four SIRPa+ ALDC populations evaluated.
Lane 1 100bp ladder
Lane 2 SIRPa+ ALDC (JH4 sort 14.0; purity: 97%)
Lane 3 SIRPa+ ALDC (JH4 sort 15.0; purity: 95%)
Lane 4 SIRPa+ ALDC (JH5 sort 16.0; purity: 100%)
Lane 5 SIRPa+ ALDC (JH6 sort 20.0; purity: 96%)
Lane 8 SIRPcf ALDC (JH4 sort 14.0; purity: 97%)
Lane 9 SIRPcf ALDC (JH4 sort 15.0; purity: 90%)
Lane 10 SIRPcf ALDC (JH5 sort 16.0; purity: 96%)
Lane 11 SIRPcf ALDC (JH6 sort 20.0; purity: 95%)
Lane 14 positive control (ovine skin)
Lane 16 negative control (nuclease-free water)
Lane 18 100bp marker
4.4.2 Expression of toll-like receptors in purified ALDC
subpopulations
Different subsets ofmurine and human DC express different TLR and consequently respond
to different PAMP. Expression of TLR family members has been investigated in human
blood CD1 lc pDC and CD1 lc+ myeloid DC (Jarrossay et al, 2001; Kadowaki et al., 2001;
Krug et al., 2001). These studies have shown that myeloid DC preferentially express TLR4,
whereas pDC uniquely express TLR9. TLR9 is involved in the recognition of CpG motifs
(Hemmi et al, 2000), which is of particular interest with regard to DNA vaccination where
CpG motifs are present within the bacterial DNA of the plasmid. Experiments were thus
undertaken in order to identify any differences in TLR expression between the two ALDC
populations, which may help to further understand their biology. Due to the availability of
(bovine) sequences, TLR3, TLR4 and TLR9 were investigated in this study.
RNA was extracted from ovine PBMC, spleen and skin obtained from clinically normal
(non-vaccinated) sheep and analysed by RT-PCR to optimise primers. TLR3, TLR4 and
TLR9 transcripts were detected in PBMC after 35 cycles of amplification (Figure 4.15).
After 40 cycles, TLR3 and TLR4 transcripts were detected in spleen samples (Figure 4.16).
Conversely, TLR9 transcripts were absent in spleen samples in this study. TLR9 mRNA was
however detected in normal skin obtained from two different sheep and where 5(ig of total




Figure 4.15 Optimisation of TLR primers with ovine PBMC and spleen cDNA. Amplification
was carried out for 35 cycles with an annealing temperature of 55°C. Expected sizes of
amplicons are as follows: ovine TLR9, 239bp; ovine TLR4, 151 bp; ovine TLR3, 139bp.
Lane 1 1kb ladder
Lane 2 spleen cDNA amplified with TLR9 primers
Lane 3 PBMC cDNA amplified with TLR9 primers
Lane 4 spleen cDNA amplified with TLR4 primers
Lane 5 PBMC cDNA amplified with TLR4 primers
Lane 6 spleen cDNA amplified with TLR3 primers
Lane 7 PBMC cDNA amplified with TLR3 primers
Lane 8 spleen cDNA amplified with murine TLR4 primers (250bp product)
Lane 9 PBMC cDNA amplified with murine TLR4 primers (250bp product)






Figure 4.16 Optimisation of TLR primers with ovine skin and spleen cDNA. Amplification
was carried out for 40 cycles with an annealing temperature of 55°C. Expected sizes of
amplicons are as follows: ovine TLR9, 239bp; ovine TLR4, 151 bp; ovine TLR3, 139bp.
Lane 1 100bp marker
Lane 2 TLR3 amplification of spleen (139bp)
Lane 4 TLR4 amplification of spleen (151 bp)
Lane 6 TLR9 amplification of spleen (239bp)
Lane 8 TLR9 amplification of skin cDNA (1pg RNA)
Lane 9 TLR9 amplification of skin cDNA (5pg RNA); biopsy experiment D
Lane 10 TLR9 amplification of skin cDNA (5pg RNA); biopsy experiment E
Lane 12 Negative control (nuclease-free water)
Lane 14 100bp marker
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4.4.2.1 TLR4 mRNA expression in purified ALDC subpopulations
TLR4 is expressed by both human and murine myeloid DC (Boonstra et al, 2003; Jarrossay
et al, 2001) and also in monocyte-derived pre-DCl (Kadowaki et al, 2001). Since a small
proportion of SIRPa+ ALDC expressed surface CD 14 (as shown by both immunochemistry
and flow cytometry analysis), it was postulated that this population may also express TLR4,
since TLR4 and CD 14 work in conjunction with one another in the recognition of LPS
(Poltorak et al, 1998), a characteristic of Gram-negative bacteria.
Primers were designed from available bovine sequences and primer pairs were first
optimised. In this set of experiments, cDNA derived from (i) enriched-DC fraction and (ii)
PBMC served as positive control material. TLR4 transcripts were detected in purified
SIRPa+ ALDC following amplification of mRNA derived from three different cell-sorted
preparations obtained from "resting" lymph from three different animals. Figure 4.17a is
representative of three independent RT-PCR experiments carried out with cDNA derived
from sorting experiments 2.0, 3.0 and 15.0. TLR4 transcripts were not detected in the SIRPof
ALDC population, even after 40-45 rounds of amplification. GAPDH RT-PCR indicated
that there was amplifiable material present within each of the SIRPcf ALDC samples chosen
(Figure 4.17b), indeed cDNA samples were chosen from cell sorting experiments with high
cell yields (Table 4.2). TLR4 PCR products were subsequently purified using a PCR clean¬
up kit (Qiagen™), cloned into pGEM®-T Easy (Section 2.3.7.2) and sequenced by Mr. Ian
Bennett (Appendix III). Ovine TLR4 shares 95% homology with bovine TLR4 (accession










Figure 4.17 Analysis of TLR4 transcripts in freshly isolated SIRPa+ and SIRPcf ALDC by
RT-PCR. (a) Fragments <250bp are evident after amplification of mRNA obtained from
SIRPa+ ALDC, PBMC and the DC-enriched fraction (OptiPrep™ fraction 1), but not in
SIRPcF ALDC (anticipated TLR4 product size is 151 bp; Table 2.5). ALDC subpopulations
were isolated by cell sorting to a purity of >90%. cDNAs were amplified for 40 cycles and
were separated on a 2% agarose gel containing ethidium bromide. The data shown are
representative of three independent RT-PCR experiments from three different animals. Total
RNA was extracted from 106 PBMC and 106 cells from fraction 1 (enriched DC-fraction,
Figure 2.4). (b) Amplifiable material was confirmed by GAPDH RT-PCR (b) where amplicons
of approximately 400bp are evident (expected size of amplicon is 366bp with GAPDH
specific primers, Table 2.5).
(a) TLR4 RT-PCR
Lane 1 1kb ladder
Lane 2 SIRPa+ ALDC (sort 15.0; purity 95%)
Lane 3 SIRPcf ALDC (sort 15.0; purity 90%)
Lane 4 DC-enriched fraction
Lane 5 PBMC
Lane 6 Negative control (nuclease-free water)
Lane 71kbladder
(b) GAPDH RT-PCR
Lane 1 1kb ladder
Lane 2 SIRPcf ALDC (15.0) -RT
Lane 3 SIRPa+ ALDC (15.0) -RT
Lane 4 PBMC -RT
Lane 5 DC -RT
Lane 6 SIRPcf ALDC (15.0) +RT
Lane 7 SIRPcf ALDC (15.0) +RT
Lane 8 PBMC +RT
Lane 9 DC +RT
Lane 10 positive control (1:1000 1° GAPDH PCR product)
Lane 11 negative control (water)
Lane 12 1 kb ladder
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Figure 4.18 Analysis of TLR9 transcripts in freshly isolated SIRPa+ and SIRPcf ALDC by
RT-PCR. ALDC subpopulations were isolated by cell sorting to a purity of >95%. cDNAs
were amplified for 40 cycles with an annealing temperature of 55°C. The data shown (a and
b) are representative of three experiments from three different animals. TLR9 mRNA
expression was also analysed in DC-enriched fraction and in PBMC. Fragments of
approximately 250bp are evident after PCR amplification of cDNA (expected size of TLR9 is
239bp, Table 2.5).
(a)
Lane 1 1kb ladder
Lane 2 SIRPa+ ALDC (sort 15.0)
Lane 3 SIRPcf ALDC (sort 15.0)
Lane 4 DC-enriched fraction
Lane 5 PBMC
Lane 6 Negative control (nuclease-free water)
(b)
Lane 1 1 kb ladder
Lane 2 SIRPcf ALDC (sort 3.0)
Lane 3 SIRPcf ALDC (sort 4.0)
Lane 5 SIRPa+ ALDC (sort 3.0)
Lane 6 SIRPa+ ALDC (sort 4.0)
Lane 8 DC-enriched fraction
Lane 9 PBMC
Lane 11 Negative control (nuclease-free water)
Lane 13 1 kb ladder
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4.4.2.2 TLR9 mRNA expression in purified ALDC subpopulations
Several factors are likely to influence the magnitude of the immune response generated after
DNA vaccination, including optimal gene expression and the immunogenicity of the
expressed gene. Indeed, there is compelling evidence that the immunogenicity of plasmid
DNA is influenced by CpG motifs contained within the plasmid backbone, for example
within the antibiotic resistance gene and the non-coding region of the plasmid. (Klinman et
al., 1999; Sato et al, 1996). Recently, it has been demonstrated that TLR9 is essential for
CpG-induced innate immune cell activation, since TLR9 knockout mice are refractory
(Hemmi et al, 2000). From the current literature, it appears that TLR9 is preferentially
expressed by pDC (Jarrossay et al, 2001; Kadowaki et al, 2001), although an equivalent cell
type has not yet been described in ruminants.
To further characterise the SIRPa+ and SIRPa ALDC populations in sheep, primers were
designed for TLR9 using available bovine sequences (*ovine sequences were not available at
the time of writing). The expression of TLR9 was investigated by RT-PCR on freshly
isolated, highly purified (> 90% purity) SIRPa+ and SIRPa" ALDC. TLR9 transcripts were
detected in SIRPa+ ALDC obtained from three different animals (Figure 4.18a,b). TLR9
transcripts were also present in SIRPa" ALDC obtained from cell sorting experiments 4.0
and 15.0, although only weak expression of TLR9 was evident in sample 15.0. TLR9
transcripts were absent in SIRPa ALDC obtained from cell sorting experiment 3.0. TLR9
PCR products were purified using a PCR clean-up kit (Qiagen™), cloned into pGEM®-T
Easy (Section 2.3.7.2) and sequenced by Mr. Ian Bennett (Appendix III). The selected clone
shares 98% homology with the available 'ovine TLR9 sequence (accession number
NM 00101 1555 submitted by Brownlie et al., February 2005, unpublished data) and 96%
homology with bovine TLR9 (accession number AY859726).
4.4.2.3 TLR3 mRNA expression in purified ALDC subpopulations
TLR3 is involved in the recognition of dsRNA (Alexopoulou et al, 2001) contained within
some viruses, for example, reovirus, and in the recognition of dsRNA produced during the
viral lifecycle (West Nile virus). TLR3 is expressed by both human myeloid and pDC
(outlined in the Introduction).
RT-PCR was carried out essentially as already described with cDNA derived from sorted
ALDC populations. Weak expression of TLR3 was observed in both SIRPa+ and SIRPa
ALDC and also in PBMC and enriched DC after 40 cycles of amplification. A representative






Figure 4.19 Analysis of TLR3 transcripts in SIRPa+ and SIRPcf ALDC by RT-PCR. cDNA
was amplified for 40 cycles with an annealing temperature of 58°C. Fragments <250bp are
evident after amplification of cDNA obtained from SIRPcf ALDC samples, PBMC and in the
enriched-DC fraction, (expected size of amplicon is 139bp with TLR3 primers). TLR3
transcripts are only weakly detected in SIRPcF ALDC.
Lane 1 1kb ladder
Lane 2 SIRPcf ALDC (sort 3.0)
Lane 3 SIRPcf ALDC (sort 4.0)
Lane 5 SIRPa+ ALDC (sort 3.0)
Lane 6 SIRPa+ ALDC (sort 4.0)
Lane 8 PBMC
Lane 9 DC-enriched fraction
Lane 11 Negative control (nuclease-free water)
Lane 12 1 kb ladder
4.4.3 Cytokine expression in freshly isolated ALDC populations
The purpose of this part of the study was to investigate whether differences in cytokine
production between the two ALDC subpopulations are present, which could influence the
bias of the immune response they stimulate in the steady-state flux from the skin. In addition,
characterisation of cytokine expression for each population was imperative in order to
accurately assess any change(s) in the cytokine profile after DNA vaccination with pGM-
CSF. Quantitative polymerase chain reactions were carried out to measure specific cytokine
transcripts. Although GAPDH transcripts were detected in some sort samples by
conventional RT-PCR, transcripts for some cytokines could not be quantified (for all
cytokines evaluated with sample 13.0, as transcripts were either below the level of
quantification (>40 cycles of amplification were required in order to quantify products which
was not always possible due to availability of the LightCycler® machine) or were absent
altogether. Cytokine expression was normalised against the universal housekeeping gene
GAPDH. Figures are representative of 2^4 independent experimental runs on the
LightCycler®. cDNA derived from fresh, unstimulated ALDC revealed that distinct
differences in cytokine expression were indeed evident.
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4.4.3.1 IL-12p40 mRNA expression in purified SIRPa+ and SIRPcf ALDC
For quantification of IL-12 transcripts, only the production of the p40 subunit was evaluated,
as production of p35 is generally considered to be constitutive in most cells (Schoenhaut et
al., 1992). ALDC samples were analysed on 3-4 separate occasions by quantitative RT-PCR
with the exception of ALDC samples obtained from sorting experiment 16.0, where only two
quantitative RT-PCR experiments were carried out due to time constraints. Data are
presented as mean ± SEM (arbitrary normalised units) calculated from 2^1 experiments. IL-
12p40 mRNA was detected in all ALDC samples analysed (Figure 4.20a). There was
however considerable variability in IL-12p40 expression between different animals, and may
reflect the outbred nature of this population. In addition, the level of IL-12p40 expression
varied between samples collected from the same animal but on different days (sheep JH3 and
JH9); however there was limited variation in expression of IL-12p40 in samples collected
from sheep JH2 on consecutive days (sort samples 3.0 and 4.0) and importantly this animal
was later vaccinated with pGM-CSF (Section 4.6) immediately after "resting" lymph (4.0)
was collected.
Although considerable variability in IL-12p40 mRNA expression was evident between
different animals and samples, constitutive production of IL-12p40 was consistently higher
in SIRPa ALDC than in SIRPa+ ALDC from each afferent lymph sample in all six animals
analysed (Figure 4.20a). Statistical analysis using the paired (two-tailed) Student t-test
revealed that there is a statistically significant difference in IL-12p40 expression in SIRPa-
and SIRPa+ ALDC obtained from the following cell sorting experiments: 2.0 (JH1, p <
0.02); 3.0 (JH2, p < 0.04); 4.0 (JH2, p < 0.04); 12.0 (JH2, p < 0.05); 15.0 (JH4, p < 0.03);
19.0 (JH6, p < 0.02); 20.0 (JH6, p < 0.03 ). No statistically significant difference in IL-12p40
expression is apparent between SIRPa+ and SIRPa" ALDC obtained from sorting experiment
14.0 (p > 0.05).
A way to overcome the issue of non-independence in this data set is to calculate mean values
for each ALDC sample from each animal (excluding the second set of measurements from
samples obtained from the same animal) and to compare values from all six animals (Figure
4.20b). Using this type of analysis, IL-12p40 expression is significantly higher in SIRPa
ALDC (p < 0.03, paired Student t-test; p < 0.04, Wilcoxon matched pairs test). On average,
freshly isolated SIRPa" ALDC express 24-fold more p40 transcripts than SIRPa+ ALDC
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Figure 4.20 Expression of IL-12p40 mRNA in freshly sorted ALDC subpopulations. IL-12p40
mRNA expression was analysed in six animals (a, JH1-JH6). Subscript numbers in brackets
correspond to individual cell sorting experiments. Data are presented as mean ± SEM (n =
2^4 independent quantitative RT-PCR experiments; JH1(2.0), P < 0.02; JH2(30), p < 0.04;
JH2(40), p < 0.04; JH3(i2o), p < 0.05; JH4(140), p > 0.05; JH4(150), p < 0.03; JH5(16.o), n = 2, p
cannot be determined; JH6(19.o), p < 0.02; JH6(20.o), P < 0.03.) (b) Mean values for each ALDC
sample have been calculated for each of the six animals and compared as one data set,
presented as mean ± SEM (p < 0.03, paired Student t-test; p < 0.04, Wilcoxon paired test)).
Results show that freshly sorted SIRPcT ALDC express significantly more IL-12p40
transcripts than SIRPa+ ALDC.
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4.4.3.2 IL-10 mRNA expression in purified SIRPa+ and SIRPa ALDC
Transcripts for IL-10 were undetectable in SIRPa ALDC in all six animals analysed. Figure
4.21 a,b is representative of several melting curve analyses performed after the amplification
stage and show that only non-specific products have accumulated with cDNA samples
derived from SIRPa" ALDC after 40 cycles of amplification. Conversely, constitutive
production of IL-10 mRNA was detected in the majority of SIRPa+ samples (Figure 4.21c).
In four of the six sheep analysed (SIRPa+ samples 2.0^1.0 and 14.0-16.0), specific IL-10
transcripts were consistently detected, since amplicons melt at the same temperature as IL-10
standards (diluted 1° PCR products, verified to be IL-10 amplicons by sequence analysis,
Appendix III). No IL-10 transcripts were detected in SIRPa+ samples obtained from sheep
JH3 (sorts 12.0 and 13.0) or sheep JH6 (sort 20.0) in any of the experiments undertaken.
Specific IL-10 transcripts were detected in one LightCycler® experimental run carried out
with sample 19.0 but were below the level of quantification of the assay.
Figure 4.22 shows data obtained from each SIRPa+ ALDC sample, where mean values have
been calculated from 2-3 independent experiments carried out on the LightCycler®. There
was considerable variation in IL-10 expression between different animals and even in
samples collected on different days from the same animal; considerable variation in IL-10
transcripts was apparent in SIRPa+ ALDC obtained from sheep JH4 (14.0 and 15.0). There
was however limited variation in expression of IL-10 in SIRPa+ ALDC samples collected
from sheep JH2 (SIRPa+ samples 3.0 and 4.0) 24 hours apart, which is of relevance to this
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Figure 4.21 SIRPa+ ALDC uniquely express IL-10 transcripts. Melting curve analysis
performed on amplicons generated during amplification with freshly sorted ALDC cDNA
samples. Specific IL-10 transcripts were detected in most of the SIRPa+ ALDC samples
analysed, with the exception of samples obtained from sheep JH3 (sort samples 12.0 and
13.0; (a & c)) and sheep JH6 (sort samples 19.0 and 20.0; (c)). No IL-10 transcripts were
detected in any of the SIRPa- ALDC samples tested (a & b). Note that in (a) MyD-1
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Figure 4.22 Expression levels of IL-10 mRNA in freshly sorted SIRPa+ ALDC. IL-10
transcripts were undetectable in all SIRPcf samples studied and were absent or below the
level of quantification for several SIRPa+ ALDC samples (sheep JH3 and JH6). n = 3
independent quantitative RT-PCR experiments (JH1 and JH2); n = 2 (JH4 and JH5). Data
are presented as mean ± SEM.
4.4.3.3 IL-ip mRNA expression in purified SIRPa+ and SIRPa ALDC
The expression of pro-inflammatory IL-ip was also investigated by quantitative RT-PCR.
IL-ip transcripts were evident in both ALDC subpopulations, with the exception of SIRPa"
ALDC samples obtained from sheep JH6 (sort samples 19.0 and 20.0), where transcripts
were undetectable. In general, fresh SIRPa+ ALDC produce considerably more IL-ip
transcripts than SIRPa" ALDC (Figure 4.23a). There was, however, considerable variation
between the results for different animals and values for IL-ip were substantially higher in
SIRPa+ ALDC samples obtained from sheep JH4 (samples 14.0 and 15.0) and JH5 (sample
16.0) than in SIRPa+ samples obtained from the other animals. Where data from sheep JH4
and JH5 are not presented (Figure 4.23b), a pronounced difference in IL-ip expression is
also evident with samples obtained from other animals, with the exception ofALDC samples
obtained from sheep JH2 (sort samples 3.0 and 4.0).
On average SIRPa+ ALDC produce 13 fold (range 1.2-32.5) more IL-ip transcripts than
SIRPa ALDC (Figure 4.23c) and importantly this difference is of statistical significance (p
< 0.008, Wilcoxon paired t-test). Mean fold differences have been calculated for ALDC
samples obtained from the same lymph and are presented in Table 4.3. Since IL-ip was not
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Figure 4.23 Expression of IL-1 p mRNA in freshly sorted ALDC subpopulations. (a)
Expression of IL-1 (3 mRNA in freshly sorted ALDC from six animals. Mean values have been
calculated for each ALDC population from each animal and presented as mean ± SEM. (b)
Expression of IL-1 p mRNA in freshly sorted ALDC without data obtained from animals JH4
and JH5 presented; c, SIRPa+ ALDC express significantly more IL-p transcripts than SIRPa"
ALDC. There is a statistically significant difference in IL-1 p expression by SIRPa+ and

















Table 4.3 Mean fold difference in IL-1p mRNA expression in highly purified ALDC
subpopulations. (, difference calculated from one experiment only, where IL-ip expression
in the SIRPa" ALDC subpopulation was within the quantification limit of the assay; cannot
be assessed: IL-1 p transcripts were absent in SIRPa" ALDC samples obtained from sorts




JH1 2.0 15 9.9-20.1
JH2 3.0 1.5* -
JH2 4.0 1.2* -
JH4 14.0 4.5 4.2—4.9
JH4 15.0 26.65 20.8-32.5
JH5 16.0 31.83 31.8-31.9
JH6 19.0 - -
JH6 20.0 - -
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4.4.3.4 IL-18 mRNA expression in purified SIRPa+ and SIRPa ALDC
IL-18 transcripts were detected in both ALDC subpopulations by quantitative RT-PCR in
this study. Figure 4.24a shows data obtained from three independent experimental runs on
the LightCycler®, with the exception of ALDC samples obtained from cell sorting
experiment 19.0 (n = 2 independent experiments). Data are presented as mean ± SEM. With
the exception of samples 4.0 and 16.0, where IL-18 transcripts are significantly higher in the
SIRPa+ ALDC population (p < 0.03 (4.0) and p < 0.02 (16.0)), no obvious difference in
expression of IL-18 is apparent between SIRPa+and SIRPa ALDC when data obtained from
the three independent LightCycler® runs are presented in this way.
Due to the lack of reproducibility of the quantitative RT-PCR experiments, data are also
displayed as individual plots for each of the five sheep analysed showing all of the replicate
values for each quantitative RT-PCR experiment carried out (Figure 4.24b). This better
illustrates that there is indeed a difference in IL-18 expression between SIRPa+ and SIRPa"
ALDC in four out of five animals analysed in this study; on average, SIRPa® ALDC express
2 fold more IL-18 transcripts than SIRPa" ALDC. This is particularly evident in sample 2.0
(sheep JH1), samples 3.0 and 4.0 (sheep JH2) and sample 16.0 (sheep JH6). In 2 out of 3
LightCyler® experiments, more abundant IL-18 transcripts were quantified in the SIRPa®
ALDC derived from sample 14.0; however, on the third analysis, levels of IL-18 were
approximately the same. The mean fold differences in IL-18 expression are presented in
Table 4.4 for each set of samples.
Importantly, where mean values are calculated for each SIRPa® and SIRPa- ALDC sample
for each animal and are compared as one data set, the difference in IL-18 expression between
the two ALDC populations is statistically significant (p < 0.03; Figure 4.24c).
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Figure 4.24 Expression of IL-18 mRNA in freshly sorted ALDC subpopulations. (a) Data are
presented as mean ± SEM of three independent LightCycler® experiments (JH1, JH2, JH4 &
JH5) or mean ± SEM of two experiments (JH6). (b) Normalised values for each cDNA
sample and from each LightCycler® experiment carried out (i-iv). (c) SIRPa+ ALDC express
significantly more IL-18 transcripts than SIRPcf ALDC. Mean values have been calculated
for each animal and values obtained from SIRPa+ ALDC compared with mean values
















JH1 2.0 2.0 1.6-2.8 -
JH2 3.0 2.1 1.6-2.7 -
JH2 4.0 2.5 2.0-2.9 0.03
JH4 14.0 1.46 1.3-1.73 -
JH4 15.0 1.2 1.1-1.4 -
JH5 16.0 2.1 1.9-2.3 0.01
4.4.3.5 TNF-a mRNA expression in purified SIRPa+ and SIRPa ALDC
TNF-a transcripts were detected in all ALDC samples examined, although transcripts were
below the level of quantification in samples obtained from cell sorting experiments 12.0 and
20.0. TNF-a mRNA expression was highly variable in all five animals analysed in this study
(Figure 4.25). For example, expression of TNF-a was higher in SIRPa ALDC than in
SIRPa+ ALDC isolated from sorting experiments 15.0 (sheep JH4, mean 1.6 fold difference)
and 16.0 (sheep JH6, mean 3.2 fold difference), calculated from two independent
quantitative RT-PCR experiments (Figure 4.25a). Conversely, TNF-a expression was higher
in SIRPa+ ALDC obtained from sorting experiment 3.0 (sheep JH2, mean 1.4 fold
difference; calculated from three independent LightCycler® runs) and 14.0 (sheep JH4, mean
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5 fold difference; calculated from two LightCycler® runs). With the exception of samples
obtained from sheep JH2 (sort samples 3.0 and 4.0), where levels of TNF-a mRNA remained
at a similar level in samples collected on different days, differences in the expression of
TNF-a in ALDC subsets collected from sheep JFI4 were inconsistent. Samples 14.0 and 15.0
represent 24-hour samples collected on different days from this animal, and notably, SIRPa+
ALDC contain more TNF-a transcripts from one collection, whereas SIRPa" ALDC contain
more abundant transcripts 24 hours later. In addition, differences in levels ofTNF-a between
SIRPa+ and SIRPa ALDC (from the same lymph sample) were inconsistent when analysed
on separate occasions, as illustrated in Figure 4.25b, where values obtained from individual
analyses are compared. For instance, in one quantitative RT-PCR assay, levels of TNF-a
transcripts were approximately the same in SIRPa+ and SIRPa- ALDC obtained from sheep
JH2 (sorting experiment 4.0), whereas in another assay (ii), SIRPa+ ALDC expressed 1.9
fold more TNF-a transcripts than SIRPa ALDC and in the third assay (iii), SIRPa ALDC
expressed 2.7 fold more TNF-a transcripts than SIRPa+ ALDC.
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Figure 4.25 Expression of TNF-a mRNA in freshly sorted ALDC subpopulations. (a) Data
are presented as mean ± SEM calculated from 2-3 independent experiments, (b) Data are
displayed from each individual LightCycler® experiment (experiments i-iii) carried out with
each cDNA sample.
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4.5 Discussion (part 1)
4.5.1 Morphology of SIRPa+and SIRPa ALDC
Two phenotypically distinct subpopulations of ALDC were identified in ovine afferent
lymph based on differential expression of the SIRPa molecule. Microscopy of the sorted
ALDC revealed a classical DC morphology, with many dendrites, abundant veils, prominent
nuclei and a large size (>10pm diameter). It is of interest to note that there are indeed
morphological differences between the two populations, as has been reported in studies
involving both rats (Liu et al, 1998c) and cattle (Howard et al., 2002). In all three species,
SIRPa- ALDC are larger than SIRPa+ ALDC and appear to be a homogeneous population,
whereas the SIRPa+ ALDC appear to be more heterogeneous. In addition, ovine SIRPa DC
display blunt pseudopodia and have a "spiky" appearance, whereas SIRPa- ALDC have a
more veiled or frilly appearance.
Ultrastructural analysis by TEM showed that both populations possess some ultrastructural
features common to DC of other species, including abundant cytoplasmic inclusions and
heterochromatic nuclei. MacPherson and colleagues demonstrated that OX41- ALDC
contain apoptotic DNA and have suggested a role for this subpopulation in the induction and
maintenance of peripheral tolerance (Huang et al, 2000). Structures that resemble apoptotic
bodies were identified in ovine SIRPa- ALDC; however, this observation must be interpreted
with caution as only a small number of SIRPa- DC were present on sections. Furthermore,
electron microscopy was carried out with only two available SIRPa- samples from two
animals. Staining with the fluorescent dye 4', 6-diamidino-2-phenylindole (DAPI) was also
carried out on cytospin preparations of sorted cells to attempt to identify DNA contained
within apoptotic bodies. The results from this experiment were inconclusive (data not
shown). Further analysis by TEM, TUNEL and DAPI staining would help to clarify if ovine
SIRPa- cells contain apoptotic bodies and are potentially involved in the traffic of self-
antigens from the skin to the DLN.
4.5.2 Origin of SIRPa+ and SIRPa- ALDC
It is of paramount interest to determine the origin of the SIRPa+ and SIRPa ALDC
subpopulations and to determine if expansion of a particular DC subset is required for the
generation of a type 1 or type 2 immune response following DNA vaccination. Gene-gun
vaccination targets the skin, which harbours two populations of immature DC; LC and
dermal DC. The origin ofALDC populations in sheep is not yet known, although expression
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of CD1 suggests that either population could be derived from LC and/or dermal DC. Since
DNA vaccination by gene-gun targets the skin and LC are a major target, further analysis of
ALDC populations was necessary. In cattle there is some evidence that the SIRPa+ ALDC
population contains migratory LC, since acetylcholinesterase positive cells are evident
within this population (Howard and Hope, 2000; Yirrell et al., 1991). Furthermore, cells in
the epidermis and dermis express SIRPa (Adams et al, 1998), indicating that SIRPot+ lymph
DC are derived from these locations. In this study, no staining of any cells occurred with
mAb IL-A24 on paraffin wax embedded ovine skin or lymph node tissue (results not shown)
and further studies should be carried out with frozen sections.
A unique feature of epidermal-derived LC is the presence ofBirbeck granules (Birbeck et al,
1961), which are disks of two limiting membranes, separated by leaflets with periodic
"zipper like" striations (Valladeau et al., 2003). Birbeck granules, which often described as
resembling tennis-racket like structures, could not be observed in either DC subpopulation
by electron microscopy. Ovine LC have been reported to contain fewer Birbeck granules
than other mammals (Hollis and Lyne, 1972). Furthermore, LC in lymph contain no or
markedly fewer Birbeck granules (Brand et al, 1993). ATPase staining is often employed to
identify LC in the epidermis and is also reported to be a reliable marker of epidermal LC
(Steinman, 1991). ATPase staining revealed that some SIRPof ALDC stained weakly for
ATPase. This preliminary result necessitated further analysis to determine if SIRPcf DC
possessed any other features characteristic of LC such as expression of CD la, langerin or
S100.
Immunohistochemical labelling of cytospins prepared from sorted cells revealed that an
equal proportion (approximately 80%) of both subpopulations express CD1, a surface
marker associated with both LC and dermal DC. mAbs specific for CD la are currently
lacking in the sheep system. A molecular approach was therefore adopted to investigate if
either population expressed CD la and/or langerin, both of which are exclusively expressed
by human LC. Birbeck granules were absent from both populations when viewed by electron
microscopy; however, langerin (a major component of Birbeck granules) could still be
expressed by LC-derived ALDC. Importantly, langerin transcripts were detected in two out
of the four SIRPof samples analysed, but absent in all four of the SIRPa" samples which had
been verified to contain amplifiable material by GAPDH RT-PCR. It is interesting that
transcripts were lacking in some of the SIRPa+ DC. It is possible that the PCR system was
not sufficiently sensitive even though cDNA samples chosen for RT-PCR were those derived
from sorting experiments where high cell yields/RNA were obtained. Alternatively, langerin
transcripts may be quite rare or even absent in migratory LC. Indeed, langerin is down-
regulated upon culture of mouse epidermal LC and this is in line with the notion that it
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represents a feature of immature cells (Larregina et al., 2001a; Valladeau et al., 1999). From
this preliminary analysis, it is possible that the SIRPa+ ALDC population contains a
migratory population of DC derived from epidermal LC (due to expression of both langerin
and ATPase).
Indeed the SIRPa+ population appears to be a heterogeneous group of DC, in which some
CD14 expressing cells were detected. Whilst it was not proven that the SIRPa+
subpopulation was completely devoid of monocytes and tissue macrophages, it is possible
that CD14 is expressed by (SIRPa+) ALDC as reported previously (Bailey, 2003; Gupta et
al, 1996), rather than due to adsorption of this molecule. RT-PCR using ovine-specific CD14
primers would help to clarity this matter. Although no direct comparison was made,
macrophages express higher levels of CD14 than DC (Gupta et al, 1996) and the level
expressed by the SIRPoC ALDC in this study appears to be rather low. It is of relevance to
this study that MoDC retain low-level expression of CD 14 in culture (Manna et al., 2001)
and freshly isolated LC can express low levels of CD14 (Caux et al., 1992a). Moreover,
dermal resident CD14+ cells have been shown to differentiate into LC (Larregina et al,
2001a) and in the steady-state LC have been demonstrated to be mostly derived from a skin
resident cell, rather than a blood or bone marrow precursor (Merad et al., 2002). Importantly,
langerin is also expressed by dermal LC precursors and so it is possible that this SIRPa+
ALDC population contains cells derived from dermal LC precursors and/or LC. It is
interesting that neither fresh nor cultured ALDC express coagulation factor XHIa, a marker
associated with dermal DC (Haig et al, 1995b), suggesting that LC represent the migratory
population and not dermal DC.
Alternatively, these CD14+ SIRPa+ ALDC may be directly derived from a monocyte
precursor, as the physiological factors involved in the regulation of DC differentiation are
still unknown and there appears to be a fine line between monocytes differentiating into
macrophages or DC; Randolph and colleagues (Randolph et al., 1998) first demonstrated the
ability of human endothelial cells to mature adherent peripheral blood CD14+ monocytes into
DC in a reverse transmigration assay, a process that is reminiscent of the movement of cells
from tissue into lymphatic vessels. It has also recently been demonstrated that macrophages
can differentiate into DC in vitro (Ichikawa et al., 2003), suggesting that macrophages are
not as fully differentiated as has been proposed. Both ALDC populations probably arise from
myeloid precursors, since they express myeloid markers, namely CDllc (Bailey, 2003). It
does not appear to be the case that either population is the equivalent of the pDC found in
humans, although high expression of CD45RA by SIRPa ALDC is a characteristic of pDC
(Liu et al, 2001).
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4.5.3 TLR mRNA expression in ALDC subpopulations
Since a fraction of SIRPa' DC expressed CD 14, it was postulated that this population might
also express TLR4, since CD 14 and TLR4 work in conjunction with one another in the
recognition of LPS, a component of Gram-negative bacteria (Poltorak et al, 1998). In line
with this, TLR4 transcripts were detected in SIRPa+ ALDC, whereas transcripts for this
receptor could not be detected by conventional RT-PCR in SIRPa ALDC. TLR4 is
expressed by myeloid DC in humans, and more recently, TLR4 has also been reported to be
expressed by murine LC (Mitsui et al, 2004). Bovine DC derived from blood monocytes
have also been reported to express TLR4, but at lower levels than in monocytes and
monocyte-derived macrophages (Werling et al., 2004). It is difficult to draw upon any
similarities with ex v/vo-derived cells, since Werling's group employed an in vitro system
where many factors, including cytokines could affect TLR expression. In another study
which employed xenogeneic endothelial cells to maturate DC, maturation of adherent
monocytes into DC was accompanied by an upregulation of message for TLR4 (Manna et
al., 2002).
It then became apparent that further investigation of expression of other TLR was required,
as any differences in the expression of these receptors may highlight differences in the
biology of these DC and how they are likely to respond to a pathogen or stimulus such as
CpG motifs contained within DNA vaccines. From those samples tested, both populations
were found to express TLR3 and whilst all SIRPa"1" ALDC samples analysed expressed
TLR9, weak expression was detected in only some of the SIRPa" ALDC. Due to time
constraints, no quantification of TLR was carried out and this would be a logical approach to
take, since RNA yields were typically low for the smaller SIRPa" ALDC population. High-
quality antibodies are still not available for many TLR, and are completely lacking for the
ovine system; many reports therefore rely on mRNA expression profiles. In principle, either
population could be regarded as being capable of responding to prokaryotic dsRNA or CpG
motifs. Functional studies now need to be adopted in order to assess how each DC
population would respond to these ligands.
Expression of TLR9 by myeloid DC is a contentious issue. Indeed Werling and colleagues
did not detect TLR3 or TLR9 from bovine MoDC, although transcripts for TLR2 and TLR4
were detected, albeit at lower levels than on monocytes or macrophages. Human monocytes
are believed to be unresponsive to CpG motifs because they lack expression of TLR9
(Hornung et al., 2002). The lack ofmRNA transcripts for TLR9 in bovine myeloid DC is in
accordance with several other reports. However, expression of TLR9 may not be restricted to
cells of the lymphoid origin/pDC as illustrated by work carried out by Spies and colleagues
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(2003) in which they demonstrated that plasmid DNA can activate both pDC (CD11 chl
CD45RAhi CD1 lb10) and conventional myeloid (CD1 lchi CD45RA10 CD1 lbhi) DC via TLR9.
Furthermore, freshly isolated murine LC (myeloid DC) express TLR9 (Mitsui et al, 2004).
These examples illustrate the difficulties of translating functional findings between DC
subsets in different species.
4.5.4 Cytokine mRNA expression in ALDC subpopulations
This study provides evidence that distinct quantitative differences in cytokine production
exist between two ALDC subpopulations in sheep. There was substantial variation in
cytokine mRNA levels between sheep and this may reflect the nature of an outbred
population; however, cytokine profiles of SIRPa+ and SIRPa ALDC were similar in the six
sheep analysed. Differences in cytokine expression were also observed with some samples
collected on different days from the same sheep (with the exception of samples collected
from JH2; 3.0 and 4.0). Such inconsistencies may reflect changes in the lymph after surgery,
or that there is some natural (but unknown) stimulation or perhaps insufficient prevention of
de novo transcription. Actinomycin D was added to prevent de novo transcription and
concentrations of actinomycin D had to be estimated from the volume of lymph collected 24
hours earlier and thus it was not always possible to obtain the optimal concentration.
Alternatively, although expression of the housekeeping gene GAPDH should be consistent,
changes in the expression of GAPDH have been reported (Bustin, 2000). Normalisation with
another housekeeping gene such as ribosomal 18S may help to clarity this matter.
Quantitative RT-PCR revealed that SIRPa ALDC express significantly higher levels of IL-
12p40 than SIRPa+ ALDC, which is in agreement with findings from cattle (Howard et al,
2002; Stephens et al, 2003) and rat splenic SIRPa DC (Voisine et al, 2002). IL-12 drives T
cells towards Thl-type responses (Heufler et al, 1996; Macatonia et al, 1995; Seder et al,
1993). On this basis, SIRPa" ALDC could be anticipated to polarise naive CD4+ T cells into
Thl cells. However, in this study, only the expression of the p40 subunit was quantified; no
assessment of p35 was made. In addition, IL-12 has been described as the mandatory
molecule secreted by activated DC that promotes the differentiation of naive B cells into
plasma cells (Dubois et al., 1998). Further studies must be conducted in order to determine if
indeed bioactive IL-12 is produced by both SIRPa and SIRPa+ DC, since p40 is the
common subunit of both IL-12 and IL-23 (Brombacher et al., 2003; Oppmann et al., 2000).
Currently there are no commercially available ELISAs for ovine IL-12 and hence many
studies rely on mRNA profiles. A capture ELISA for bovine IL-12 has been described (Hope
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et al., 2002); however, the mAb available do not distinguish between IL-12p40 and the IL-12
p75 heterodimer.
Polarisation of Th cells into Thl cells also depends on IL-18, which potentiates the effects of
IL-12, resulting in higher levels of JFN-y (Okamura et al., 1995). IL-18 has been
demonstrated to be constitutively expressed by human MoDC (Gardella et al., 1999). Both
ALDC populations were reported to express IL-18 in cattle, but transcripts were not
quantified (Stephens et al, 2003). In this study it was evident that both ALDC populations
constitutively express IL-18 mRNA. Levels of IL-18 expression were similar in some of the
SIRPa+ and SIRPa samples derived from the same lymph; however, in most samples
analysed, IL-18 transcripts were approximately 2 fold higher in the SIRPa+ ALDC
subpopulation. High constitutive expression of IL-12p40 in conjunction with IL-18
expression may favour the development of a Thl-type immune response by SIRPa ALDC.
It would be of interest to assess the Th types induced by means of a mixed lymphocyte
reaction, where allogeneic naive CD4+ T cells are incubated with SIRPa (/SIRPa+) ALDC
and IFN-y production is quantified. In addition the stimulatory capacity of ovine SIRPa+ and
SIRPa- ALDC requires investigation as it remains to be elucidated if SIRPa- DC, like rat
and bovine SIRPa" DC are poor at stimulating CD4+ and CD8+ T cells in comparison to the
highly immunostimulatory SIRPa+ ALDC.
Quantitative RT-PCR revealed that SIRPa+ ALDC exclusively express IL-10 whereas IL-10
transcripts were undetectable for the entire collection of SIRPa- ALDC sort samples in all
six of the animals studied. This is in agreement with work carried out in cattle, where IL-10
transcripts are more abundant in SIRPa+ ALDC than in SIRPa- ALDC (Stephens et al,
2003). The presence of both IL-10 and IL-6 during T cell stimulation has been linked to the
generation of Th2-type responses in mice (Liu et al, 1998b; Rincon et al, 1997). Conversely,
IL-10 has been demonstrated to have a down-regulatory effect in humans and in ruminants,
reducing the proliferation of both Thl- and Th2-type clones (Brown and Estes, 1997; Del
Prete et al, 1993). IL-10 is also reported to down regulate IL-12 production (D'Andrea et al.,
1993) and this could help to explain the low IL-12p40 expression by SIRPa+ ALDC. It is
also interesting to speculate that high expression of IL-10 by SIRPa+ ALDC may have an
effect on the production of IL-12p40 by SIRPa- ALDC. This could explain the difference in
IL-12p40 expression observed in SIRPa- ALDC collected on different days from sheep JH4,
where lower expression of IL-12p40 correlated with high IL-10 mRNA expression in
SIRPa+ ALDC, whereas increased expression of IL-12p40 by SIRPa- ALDC 24 hours later
correlated with a reduced number of IL-10 transcripts in SIRPa+ ALDC.
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IL-10 has also been demonstrated to act on a variety of cell types to suppress the production
of proinflammatory mediators, although the ability of IL-10 to inhibit proinflammatory
activation has been shown to be selective with respect to stimulus and effector responses
(Lisinski and Furie, 2002). It is possible that the SIRPa+ ALDC, or indeed cells within this
population have an anti-inflammatory role as has been proposed by Howard and colleagues
(Howard et al, 2002). This is an attractive theory since constitutive expression of
proinflammatory IL-1 (3 and IL-18 was significantly higher in SIRPa+ ALDC analysed in this
study. IL-18 is a member of the IL-1 family and is also commonly described as a
proinflammatory cytokine, (Sims, 2002). It is conceivable that the expression of IL-10 by
SIRPa+ ALDC exerts a regulatory effect on T cells whilst production of proinflammatory IL-
1 [1, in conjunction with high levels of IL-18, may be beneficial for an efficient host immune
response against infections. It is interesting that the cytokine profile of steady-state SIRPa+
ALDC is similar to that observed with monocytes which differentiate into TLR7 expressing
DC with potent functional activities in the presence of IFN-1 (Mohty et al., 2003), which
also secrete large amounts of IL-10, IL-1 (3, (IL-6) and IL-18, when compared with immature
and mature (IL-4 stimulated) DC. Furthermore, these DC promote a Thl response that is
independent of IL-12p70 and IL-18, but is substantially inhibited by IFN-a neutralisation.
SIRPa+ ALDC through IL-18 and other inflammatory cytokines may play an important role
in regulating the immune response, especially at the early steps of cell-mediated immunity.
Most SIRPa+ DC analysed in this study expressed IL-12p40, but at significantly lower levels
than expressed by SIRPof ALDC. It is tempting to draw upon similarities of the SIRPof
population with LC due to the possible expression of langerin and/or ATPase in this
preliminary study and the expression of acetycholinesterase demonstrated by a subset of
these cells by Howard and colleagues (Howard and Hope, 2000). LC produce constitutively
and/or inducibly, a variety of cytokines including IL-1 (3, IL-6, IL-12, IL-15 and IL-18
(Kimber et al, 2000), indeed murine LC are the major source of mRNA for IL-1 p among
unstimulated epidermal cells (Cumberbatch et al., 1996). Constitutive expression of IL-12
mRNA by CDla+ ALDC (proposed to be LC) isolated from humans has been reported
(Yawalkar et al., 1996), however, this study made no comparison of IL-12 mRNA
expression in other DC-types (for instance, in lymph or in blood) and IL-12 transcripts were
detected in only 4 out of the 10 samples by nested PCR.
Recent studies have generated considerable debate as to how DC regulate distinct types of T
cell responses. An evolutionary theory suggests that DC lineages or subsets can induce Thl
or Th2 immune responses. However, several studies have demonstrated that a given DC
subset can demonstrate a remarkable functional plasticity and induce either Thl or Th2
immune responses depending on the types of stimulation (Kalinski et al., 1999b; Kalinski et
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al., 1999a; Liu et al., 2000). However, the expression of limited sets of pattern recognition
receptors on human pDC and myeloid DC suggest that neither can respond to all microbial
antigens, and do not therefore have unrestricted functional plasticity. It would be interesting
to expose ALDC subpopulations to various PAMP and quantify the cytokines produced
before and after stimulation. For instance, functional in vitro studies would determine if
exposure of SIRPa+ ALDC to LPS resulted in an upregulation of bioactive IL-12 and indeed,
if both populations respond "equally" to CpG motifs and dsRNA by producing similar
cytokine profiles, thereby demonstrating the plasticity of DC. For instance, can PAMP
interaction with PRR change a SIRPcf ALDC into a DC that stimulates a Th2 response, as a
result of IL-10 expression? Such studies could also be extended to address if Thl or Th2
cells are always stimulated by one subpopulation rather than the other in the steady-state, and
if this is still evident after exposure to microbial stimuli.
Whether SIRPa+ and SIRPa ALDC represent distinct lineages of DC or different
maturational/developmental stages is not known. In the rat model, it has been argued that
SIRPa+ and SIRPa ALDC are not precursors of each other, since CD4+ SIRPa+ and CD4
SIRPa" ALDC have similar turnover times in vivo (Liu et al, 1998c). Indeed, SIRPa+ and
SIRPa" ALDC appear to be two separate populations as they differ both phenotypically and
functionally in both rats and cattle (Howard et al, 1997). Observations from this study and
from other studies conducted with DC in other species (cattle, rats, mice and humans) are
summarised in Table 4.5. Functional studies are now required to assess how ovine SIRPa+
and SIRPa" ALDC compare with rat and bovine subpopulations.
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Table 4.5 Comparison of phenotype and cytokine expression in DC subsets in different
species. Information regarding DC subsets in sheep, cattle and rats refers to ALDC (with the
exception of cytokine profiles of rat SIRPa+ and SIRPa DC where the only information
currently available is obtained from splenic DC). Cytokine expression refers to the cytokine
profile in freshly isolated ALDC or the reported "bias" in cytokine expression (human and
murine DC subsets1), although it is now established that the cytokine expression is not fixed
and ultimately depends on the extracellular milieu/stimulus used. ND = not determined; *,
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(ii) "myeloid" splenic DC. Note that in the spleen there are at least two myeloidDCpopulations:
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4.6 DNA vaccination of cannulated sheep
Experiment 1 - vaccination with pGM-CSF
From the earlier work carried out on pGM-CSF vaccinated skin (chapter 3), it was apparent
that GM-CSF was a potent inducer of inflammation, as demonstrated by the formation of a
microabscess by approximately 6 hours and significantly elevated expression of
proinflammatory TNF-a and IL-ip mRNA. Furthermore, administration of pGM-CSF
consistently caused a pronounced infiltration of MHC class II+ DC into the skin
approximately 3—4 days p/v. For these reasons, it was decided to administer pGM-CSF to a
cannulated animal rather than with pIL-3. Sheep JH2 was used for this preliminary
experiment. Two 24-hour lymph samples were collected from this sheep prior to DNA
vaccination (sort samples 3.0 and 4.0). Lymph volumes were carefully measured as the
volume of actinomycin D was crucial to prevent de novo transcription in order to quantify
any changes in cytokine expression after DNA vaccination with pGM-CSF. The sheep was
prepared (Section 2.4) and vaccinated five times (0.5-1 .Opg of pGM-CSF per shot) in the














Figure 4.26 Gene-gun administration of pGM-CSF to a cannulated sheep. The animal was
vaccinated five times in the drainage area of the cannula and lymph was collected every 24
hours. 90% of the lymph was committed to the enrichment procedure and cell sorting. The
remaining unfractionated lymph was used for double immunolabelling and analysis of cell
surface markers.
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Approximately 24 hours p/v, 5-10ml of lymph was removed for double immunolabelling of
ALC for a variety of cell surface markers followed by staining with biotinylated SW73.2
(anti-MHC class lip). The remaining lymph (approximately 90ml) was washed and enriched
for DC and stained for sorting (as already described). After sorting, RNA was extracted and
stored at -80°C until required. The lymph continued to flow for six days after gene-gun
vaccination with pGM-CSF.
4.6.1 Expansion of ALDC subsets after pGM-CSF administration
Development of an epidermal lesion was evident after pGM-CSF administration (not
shown). Concurrent with the onset of inflammation was an increase in the total number of
leukocytes migrating through the draining afferent lymph (Table 4.6). The absolute numbers
of purified ALDC are also listed in Table 4.6. From this, it appears that gene-gun
administration of pGM-CSF expands both sub-populations ofALDC 4 days p/v. In addition,
relative percentages of purified SIRPa+ and SIRPoT ALDC (as a % of total leukocytes) have
been calculated. A 2.6 fold increase in SIRPa+ ALDC and a 1.9 fold increase in SIRPoT
ALDC was recorded 4 days after pGM-CSF administration (relative to percentages
calculated prior to DNA vaccination).
Relative percentages of SIRPa+ and SIRPa ALDC (as a % of enriched DC immunolabelled
for subsequent cell sorting) have also been calculated (Figure 4.27a,b), where an increase in
the percentage of SIRPa+ ALDC was observed 3-4 days after pGM-CSF administration and
an increase in the percentage of SIRPcT ALDC was observed at days 5-6 p/v. In addition,
the relative frequencies of PMN, lymphocytes and ALDC in afferent lymph are presented
before and after pGM-CSF administration (Figure 4.27c and Figure 2.1 for gate criteria). The
scattcrplots clearly show that the number ofPMN increased quite dramatically 24 hours after
pGM-CSF administration; the number of neutrophils represented approximately 9% of total
ALC in the steady-state and increased to approximately 21% 24 hours p/v. Changes in the
number of lymphocytes were also evident; where the proportion of lymphocytes was lower
(range 51-54%) at days 1, 5 and 6 p/v compared with the proportion of lymphocytes
observed in the steady-state (approximately 65% of lymph cells). Conversely, only small
changes were evident in the proportion of ALDC (ranged from approximately 7%—11% of
total ALC).
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Table 4.6 Total leukocyte output and absolute numbers of SIRPa+ and SIRPa ALDC












pre 1.32x10s 343,137 160,165 0.26 0.12
pre 1.55x10s 640,223 213,367 0.4 0.14
1 day p/v 2.08x10s 170,000 0.08
2 days p/v 2.36x10s 446,068 99,000 0.19 0.04
3 days p/v NA 921,820 239,552 NA NA
4 days p/v 1.96xl08 2xl06 500,000 1.02 0.26
5 days p/v 1.93x10s 1,166,700 423,440 0.6 0.22
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days post-vaccination with pGM-CSF
Figure 4.27 Expansion of SIRPa+ and SIRPa- ALDC populations after gene-gun delivery of
pGM-CSF. (a) Lymph was collected from sheep JH2 for 2 days prior to vaccination with
pGM-CSF. For each 24-hour collection, lymph was enriched for DC and double
immunolabelling was carried out with mAb IL-A24 (anti-SIRPa) and SW73.2 (anti-MFIC class
II P), where the SIRPa+ DC comprised 56-58% of enriched cells and SIRPa" DC comprised
-24% (represented in (b) as solid lines), (b) Relative percentages of SIRPa+ and SIRPa"
ALDC after administration of pGM-CSF. (c) Percentage of PMN, lymphocytes and ALDC
(calculated as a % of total ALC) before and after administration of pGM-CSF (refer to Figure
2.1 for gate criteria).
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Figure 4.27 (cont.)
4.6.2 Flow cytometric analysis of ALDC cell surface marker
expression after gene-gun delivery of pGM-CSF
In experiment 1, the expression of several surface markers on ALDC was analysed by flow
cytometry pre- and post-administration of pGM-CSF. The aim of this experiment was to
define any changes in the expression of surface markers so that future experiments could be
more carefully designed to assess changes in surface expression in SIRPa+ and SIRPa
ALDC. Furthermore, biotinylated mAb IL-A24 (anti-SIRPa) was not available at this point
in the study. Results from experiment 1 are represented in Figure 4.28—4.35 and the recorded
mean fluorescence intensities and percentage of gated cells are also listed. Unfractionated
lymph cells (1 x 107 cells/ml) were first immunolabelled with antibodies specific for ovine
CDlb, CD40, CD80, CD86, CDllc, CD2, and LFA-3. Bound antibody was detected with
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FITC-conjugated anti-mouse Ig. Lymph cells were then stained with biotinylated SW73.2
(anti-MHC class II (3) which was detected with streptavidin-PE. ALDC were electronically
gated based on high SSC and FSC (Rl) and then gated on the population of cells expressing
high MHC class II (channel number >103, R2).
4.6.2.1 Expression of antigen presentation molecules on ALDC after gene-
gun delivery of pGM-CSF
In experiment 1, a pronounced increase in the expression of several surface markers on
ALDC occurred after gene-gun vaccination with pGM-CSF. A marked increase in the
expression of surface CD lb was particularly evident from 1-6 days p/v (Figure 4.28). The
increase in expression of CDlb was similar 1—4 days p/v; however, a further shift in
fluorescence was evident 5 days p/v and levels then declined slightly by day 6 to levels
observed 1—4 days p/v. Importantly, the mAb used to detect CDlb (VPM 5) was previously
titrated and a concentration of 1:100 ofVPM 5 was shown to be at saturating levels and thus
used for all subsequent experiments (Section 2.2.4.5).
A pronounced increase in the expression of surface MHC class II was observed on ALDC
for the first 48 hours after gene-gun delivery ofpGM-CSF (Figure 4.29), whereas expression
was comparable to levels observed pre-vaccination at days 3^1 p/v. Interestingly, an increase
in MHC class II expression was again evident 5 days p/v and then declined to levels lower
than expressed on ALDC in the steady-state flux.
4.6.2.2 Expression of costimulatory molecules on ALDC after gene-gun
delivery of pGM-CSF
Expression of the costimulatory molecules CD40, CD86 and CD80 was also investigated,
since upregulation of these molecules would suggest enhanced accessory function of ALDC
in the lymph node. Expression of surface CD40 essentially mirrored surface MHC class II
expression. A slight upregulation in CD40 surface expression was observed for the first 48
hours after pGM-CSF delivery (Figure 4.30). A reduction in surface CD40 to levels observed
prior to DNA vaccination was then evident 3^1 days p/v, which was followed by an increase
in CD40 at days 5-6 p/v. Staining of cell surface CD86 revealed an increase in the expression
of this costimulatory molecule for the first 48 hours p/v (Figure 4.31). Expression of CD86
then returned to pre-vaccination levels at days 3^1. A similar shift in fluorescence was again
observed at days 5-6 and a proportion of these cells expressed CD86 at high levels (channel
number 102-103). In contrast to the expression of CD40 and CD86, there was little change in
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surface expression of CD80 on the majority of ALDC over the time-course (Figure 4.32);
high CD80 expression was however evident in a small proportion of ALDC from days 1-2
and days 5-6 following pGM-CSF administration.
LFA-3 expression remained unchanged over the time-course of the experiment, with the
exception of the 5-day time-point, where LFA-3 expression increased slightly (Figure 4.33).
Levels of LFA-3 were not assessed at the 4 days p/v time-point in this experiment. ALDC
have been reported to express CD2 on their cell surface (Bujdoso et al, 1989), a ligand for
LFA-3 (Selvaraj et al., 1987), although it is possible that this may be due to adsorption of the
CD2 molecules as a consequence of the high level of LFA-3 shown by afferent DC (Bujdoso
et al, 1989), rather than due to expression of a CD2 gene. No change in CD2 expression was
observed at any of the time-points investigated (Figure 4.34). Conversely, a marked increase
in the expression of the integrin CD1 lc was observed (detected with mAb OM1) at days 1-2










% gated M1 56.79
day 1
MFI 51.54
% gated M1 60.68
day 2
MFI 56.81
% gated M1 70.04
day 3
MFI 37.25
% gated M1 50.27
day 4
MFI 39.82
% gated M1 50.51
day 5
MFI 90.01
% gated M1 72.75
day 6
MFI 63.50
% gated M1 63.24
Figure 4.28 Cell-surface expression of CD1b on ALDC before and after gene-gun
vaccination with pGM-CSF. Non-specific staining with NMS (negative control) is shown (blue
histogram); expression of CD1b at that time-point (red histogram) and expression of CD1b
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MHC class II expression
Figure 4.29 Cell-surface expression of MFIC class II DRa on ALDC before and after gene-
gun vaccination with pGM-CSF. Non-specific staining with NMS (negative control) is shown
(blue histogram); expression of MFIC class II at that time-point (red histogram) and
expression of MHC class II prior to vaccination is represented again at each time-point after
DNA vaccination with pGM-CSF (yellow histograms).
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CD40 expression
Figure 4.30 Cell-surface expression of CD40 on ALDC before and after gene-gun
vaccination with pGM-CSF. Non-specific staining with NMS (negative control) is shown (blue
histogram); expression of CD40 at that time-point (red histogram) and expression of CD40
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CD86 expression
Figure 4.31 Cell-surface expression of CD86 on ALDC before and after gene-gun
vaccination with pGM-CSF. Non-specific staining with NMS (negative control) is shown (blue
histogram); expression of CD86 at that time-point (red histogram) and expression of CD86

































% gated (M1) 30.67
CD80 expression
Figure 4.32 Cell-surface expression of CD80 on ALDC before and after gene-gun
vaccination with pGM-CSF. Non-specific staining with NMS (negative control) is shown (blue
histogram); expression of CD80 at that time-point (red histogram) and expression of CD80
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LFA-3 expression
Figure 4.33 Cell-surface expression of LFA-3 on ALDC before and after gene-gun
vaccination with pGM-CSF. Non-specific staining with NMS (negative control) is shown (blue
histogram); expression of LFA-3 at that time-point (red histogram) and expression of LFA-3
prior to vaccination is represented again at each time-point after DNA vaccination with pGM-
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Figure 4.34 Cell-surface expression of CD2 on ALDC before and after gene-gun vaccination
with pGM-CSF. Non-specific staining with NMS (negative control) is shown (blue histogram);
expression of CD2 at that time-point (red histogram) and expression of CD2 prior to
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Figure 4.35 Cell-surface expression of CD11c on ALDC before and after gene-gun
vaccination with pGM-CSF. Non-specific staining with NMS (negative control) is shown (blue
histogram); expression of CD11c at that time-point (red histogram) and expression of CD11c
prior to vaccination is represented again at each time-point after DNA vaccination with pGM-
CSF (yellow histograms).
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4.6.3 Cytokine expression in purified ALDC subpopulations after
gene-gun delivery of pGM-CSF
Cytokine mRNA synthesis in migrating afferent DC pre- and post-pGM-CSF administration
was examined by quantitative real-time RT-PCR analysis. RNA was extracted from each
ALDC subpopulation purified from lymph collected at 24-hour intervals over the time-
course of the experiment. ALDC were purified by FACS as described previously and RNA
was concentrated under vacuum. All of the RNA was committed to the reverse transcription
reaction. Prior to quantitative analysis conventional GAPDFI RT-PCR was carried out to
ensure that genomic DNA was fully degraded and that amplifiable material was present in
each sample (Figure 4.36). The purities of each collection are listed in Table 4.7.
Importantly, there was little variation in expression of transcripts in purified ALDC
populations collected on two separate occasions (48 and 24 hours prior to vaccination with
pGM-CSF, Section 4.4.3), therefore a suitable "baseline" was established for comparison of
cytokine transcripts in each ALDC population after pGM-CSF vaccination.
Table 4.7 Purity of each cell-sorted ALDC population. Immediately after cell sorting a sample
from each collection was analysed by flow cytometry. This is expressed as a % of cells
which fall into the correct (previously defined) gate (either the MHC class llhl SIRPa+ gate or
the MHC class llhl SIRPcT gate).
Time-point SIRPa purity SIRPa+ purity
day 1 97% 100%
day 2 99% 97%
day 3 99% 99%
day 4 100% 99%
day 5 99% 99%
day 6 97% 99%
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Figure 4.36 Analysis of GAPDH transcripts in purified ALDC by RT-PCR. RNA was
extracted from each ALDC population after gene-gun delivery of pGM-CSF. RNA was
concentrated under vacuum and reverse transcribed both with and without reverse
transcriptase (-RT) to confirm that genomic DNA had been sufficiently degraded by the
DNase step included in the protocol. ~350bp fragments are evident after amplification of
cDNA samples obtained from SIRPa+ and SIRPa ALDC with GAPDH-specific primers
(expected amplicon size is 366bp, Table 2.12) but not in samples where the RT enzyme was
omitted, indicating that there are no genomic contaminants.
(a)
Lane 1 1kb ladder
Lanes 2-7 D1-D6 p/v -RT SIRPa+ samples
Lanes 8-13 D1-D6 p/v +RT SIRPa+ samples
Lane 14 Negative control
Lane 15 Positive control (1:1000 dilution of GAPDH 1° PCR product)
(b)
Lanes 1 & 16 1kb ladder
Lanes 2-7 D1-D6 p/v-RT SIRPa samples
Lanes 8-13 D1-D6 p/v SIRPa- samples
Lane 14 Negative control
Lane 15 Positive control (1:1000 dilution of GAPDH 1° PCR product)
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4.6.3.1 IL-12p40 mRNA expression in ALDC populations after pGM-CSF
administration
IL-12p40 transcripts were quantified in each ALDC population before and after gene-gun
delivery of pGM-CSF. Due to the number of cDNA samples obtained from this experiment,
it was not possible to analyse each cDNA sample in triplicate, therefore quantitative RT-
PCR was carried out on three separate occasions and data are presented as mean ± SEM
(Figure 4.37). In this experiment, pGM-CSF caused a 1.7 fold increase (range 1.6-1.9) in IL-
12p40 transcripts in SIRPcf ALDC 4 days after pGM-CSF administration (p < 0.03; paired
Student t-test) and a similar increase in IL-12p40 transcripts was recorded at day 6 p/v (p <
0.03; range 1.5-2.0) In addition, an increase in IL-12p40 mRNA expression was observed in
SIRPoC ALDC when compared to pre-vaccination levels. This was particularly evident at






















pre 1 2 3 4 5
days post-vaccination with GM-CSF
Figure 4.37 Expression of IL-12p40 mRNA in freshly sorted ALDC populations before and
after gene-gun vaccination with pGM-CSF. Data are presented as mean ± SEM calculated
from three independent quantitative RT-PCR experiments.
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4.6.3.2 IL-10 mRNA expression in ALDC populations after pGM-CSF
administration
IL-10 mRNA expression was also evaluated in both populations of ALDC by quantitative
RT-PCR (Figure 4.38). Three independent experiments were carried out on the LightCycler®
with each of the cDNA samples. A slight increase in IL-10 expression was observed in
SIRPa+ ALDC 3 days p/v (mean 2.4 fold increase; range 1.9-2.9) and 4 days p/v (mean 2.1
fold increase; range 1.5-2.4). Interestingly, IL-10 transcripts were also detected in SIRPa
ALDC 5 days after pGM-CSF administration and notably the purity of this sample was 99%
(Table 4.7). Specific transcripts were also detected in one out of the three assays carried out
with SIRPa" ALDC samples obtained at days 1 and 2 p/v, however, transcripts could not be
quantified as the assay was not sufficiently sensitive to be able to quantify Ct values over 40
cycles of amplification (data not shown).
pre 1 2 3 4 5 6
days after vaccination with pGM-CSF
Figure 4.38 Quantification of IL-10 transcripts in freshly sorted ALDC populations before and
after gene-gun vaccination with pGM-CSF. Data are presented as mean ± SEM.
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4.6.3.3 IL-1p mRNA expression in ALDC populations after pGM-CSF
administration
A marked increase in IL-ip mRNA expression was observed in SIRPa+ ALDC after gene-
gun administration of pGM-CSF, peaking at approximately 24 hours (mean fold increase of
22.7%). IL-ip expression remained elevated over the time-course of the experiment in
SIRPa+ ALDC and was sustained even at six days p/v, where transcripts were three times
higher than those observed prior to pGM-CSF administration. Figure 4.39 is representative
of two independent experiments carried out on the LightCycler®. It was not always possible
to quantify levels of IL-ip expressed by SIRPa ALDC (levels were below the level of
quantification of the assay), although specific transcripts were present in all samples
analysed. A 2.4 fold increase in IL-ip expression was evident in SIRPa" ALDC at days 1











pre 1 2 3 4 5
days post-vaccination with pGM-CSF
Figure 4.39 Expression of IL-1p mRNA in freshly sorted ALDC populations before and after
administration of pGM-CSF. Data are representative of two separate quantitative RT-PCR
experiments and are presented as mean ± SEM.
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4.6.3.4 IL-18 mRNA expression in ALDC populations after pGM-CSF
administration
Quantification of IL-18 transcripts in purified ALDC was also carried out. Figure 4.40a is
representative of three independent quantitative RT-PCR experiments (data are presented as
mean ± SEM). From these experiments it is apparent that IL-18 mRNA expression was
elevated in both SIRPa+ and SIRPof ALDC populations 6 days after gene-gun delivery of
pGM-CSF. However, this difference is not statistically significant and there is some
variability in the values obtained from the quantitative RT-PCR assays. To compensate for
such variability between experiments, data obtained from one experiment are presented,
where each ALDC cDNA sample has been analysed in duplicate (Figure 4.40b). It was not
possible to perform this assay with triplicates of each cDNA sample as only 32 reactions can
be carried out at any one time on the LightCycler®. The trend is similar to that obtained from
the three independent experiments (Figure 4.40a). Notably, IL-18 mRNA expression was
increased approximately two-fold in SIRPa+ ALDC (when compared to pre-vaccination
levels) isolated at days 3, 4 and 6 p/v. A two-fold increase in IL-18 mRNA expression was
also observed in the SIRPa ALDC population at all time-points investigated with the
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1 2 3 4 5
days post-vaccination with pGM-CSF
Figure 4.40 Expression of IL-18 mRNA in freshly sorted ALDC populations before and after
gene-gun delivery of pGM-CSF. (a) Representative of three independent experimental runs
on the LightCycler®. Data are presented as mean + SEM. There are no significant
differences between pre- and post-vaccination levels of IL-18 mRNA in either subpopulation.
(b) Expression of IL-18 mRNA before and after vaccination with pGM-CSF. Each cDNA
sample was analysed in duplicate on the LightCycler® and data are presented as mean ±
SEM.
306
4.6.3.5 TNF-a mRNA expression in ALDC populations after pGM-CSF
administration
TNF-a mRNA expression was analysed in each ALDC subpopulation before and after
administration of pGM-CSF and data are displayed in Figure 4.41a,b. Figure 4.41a
represents data from three independent LightCycler® experiments (data are presented as
mean ± SEM). From these experiments, it is evident that pGM-CSF resulted in increased
TNF-a mRNA expression in SIRPa ALDC 24 hours p/v (p < 0.03). Levels of TNF-a were
elevated in both ALDC populations 4 days after administration of pGM-CSF and this
increase is statistically significant (p < 0.04 (SIRPa+ ALDC); p < 0.02 (SIRPa-ALDC). Due
to the variability between quantitative RT-PCR assays, expression of TNF-a mRNA was
also assessed by analysing each cDNA sample in duplicate in the same quantitative RT-PCR
assay (Figure 4.41b), and importantly the overall pattern of TNF-a mRNA expression was
comparable to the results obtained from the three independent experiments carried out.
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pre 1 2 3 4 5 6
days post-vaccination with pGM-CSF
pre 1 2 3 4 5 6
days post-vaccination with pGM-CSF
Figure 4.41 TNF-a mRNA expression in freshly sorted ALDC populations before and after
gene-gun vaccination with pGM-CSF. (a) Data obtained from three independent experiments
using the LightCycler®. There is a statistically significant difference between TNF-a
expression between pre-vaccination samples and samples collected 4 days p/v (SIRPa+
samples, p < 0.04; SIRPa" samples, p < 0.02; paired Student t-test). There is also a
statistically significant difference 24 hours p/v in the SIRPa" population (p < 0.03); (b)
Expression of TNF-a mRNA before and after gene-gun vaccination with pGM-CSF and
where each sample was analysed in duplicate. Data are presented as mean ± SEM.
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4.6.4 DNA vaccination of cannulated sheep
Experiment 2
It was imperative that pGM-CSF was administered to other cannulated sheep to confirm the
findings from experiment 1. It was also imperative that vaccination with NF-control plasmid
was carried out in order to assess if the changes in (i) surface marker expression on MHC
class II+ ALDC and (ii) cytokine expression by the SIRPa+ and SIRPa populations are
indeed due to the biological effects of GM-CSF and not due to immunostimulatory CpG
motifs and/or the physical trauma of the vaccination procedure. CpG motifs can cause LC
migration and activation of DC (Ban et al, 2000). The trauma of the DNA vaccination
procedure itself induces some changes in the cytokine milieu of the skin, for instance, an
upregulation of TNF-a and IL-ip mRNA was documented in control-vaccinated skin sites
(discussed in chapter 3), even though there appeared to be only low-grade pathology at these
sites. Upregulation ofproinflammatory cytokines may affect the biology of resident skin DC.
Attempts to repeat the gene-gun experiment with pGM-CSF with cannulated sheep proved
difficult (Table 4.8); the lymph stopped flowing three times in the first 16-hours after gene-
gun vaccination with pGM-CSF.
Table 4.8 DNA vaccination experiments carried out on cannulated sheep.
sheep ID plasmid outcome experimental information





+ lymph flowed for 1 week
lymph stopped after DNA
vaccination
lymph stopped after DNA
vaccination
lymph stopped after DNA
vaccination
JH6 NF-control +/- lymph flowed for 5 days
(bloody lymph)
JH6 pGM-CSF +/- lymph flowed for 4 days
(bloody lymph)
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Sheep JH6 was vaccinated with the NF-control construct and lymph was collected at 24-hour
intervals over 5 days and SIRPa+ and SIRPa ALDC were purified by FACS. On the fifth
day, the animal was vaccinated with the pGM-CSF. The lymph was collected from this
sheep for the following four days. At all time-points investigated, the lymph contained many
erythrocytes and lymph volumes were low (<35ml) and stopped flowing several times over
the time-course. Due to the fact that previous experiments had been unsuccessful and due to
time constraints, heparin was administered to the animal several times to maintain the flow
of lymph.
4.6.4.1 Expression of surface markers on ALDC after gene-gun vaccination
Expression of surface markers (CD40, MHC class II, CD lb, CD80, CD86 and LFA-3) was
analysed after gene-gun vaccination with both pGM-CSF and the NF-control. Some of the
data are displayed in Figure 4.42 and Figure 4.43.
In contrast to experiment 1, where a marked increase in several surface markers (MHC class
II, CD lb, CD40, CD86 and CD1 lc) was observed on ALDC 24 hours after vaccination with
pGM-CSF, there was no change in surface expression in this experiment. Figure 4.42 shows
ALDC surface expression of CD lb, CDllc and MHC class II before and 24 hours after
administration of pGM-CSF. Although no change in the level of expression ofMHC class II
was apparent, the number of cells expressing MHC class II at lower levels (lO'-lO2 logio
fluorescence) increased p/v (this was not observed previously) and may correspond to an
increase in the number of activated lymphocytes (blasts) in the R1 (DC) gate.
Expression of surface markers remained unchanged throughout the time-course. No increase
in expression ofCD40, CD1 lc or MHC class II (Figure 4.43) or CDlb (data not shown) was
evident 4-5 days after vaccination with pGM-CSF (or NF-control), which again contrasts
markedly with experiment 1. Cytokine expression by ALDC populations was also evaluated
by quantitative RT-PCR (data not shown). mRNA expression of proinflammatory TNF-a
and IL-1 p was highly elevated in ALDC samples after administration of either plasmid (data
not shown), whereas IL-10 transcripts were rare or absent.
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CD1b expression
Figure 4.42 Representative data from vaccine experiment 2, 24 hours after vaccination with
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Figure 4.43 Representative data from vaccine experiment 2, 96 hours after gene-gun
vaccination with pGM-CSF and the NF-control. Blue histogram: negative control (NMS);
yellow histogram: pre-vaccination levels; red histogram: pGM-CSF vaccinated; light blue
histogram: NF-control vaccinated.
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4.7 Discussion (part 2)
To assess the in vivo effects of pGM-CSF on ALDC, a pseudo-afferent lymph cannulation
model was employed, enabling access to pure unmanipulated DC after gene-gun vaccination.
In this study the immunophenotype of MHC class II+ ALDC was investigated. In addition,
cytokine expression was quantified in purified SIRPof and SIRPof ALDC and compared to
levels prior to vaccination. Maintaining the lymph flow after gene-gun vaccination of
cannulated sheep proved difficult for reasons that remain to be elucidated, although it seems
likely that since GM-CSF induces acute inflammation and oedema (fibrinous exudate), one
might expect the lymph to clot. The first experiment where pGM-CSF was administered to a
cannulated sheep revealed some interesting findings. Nonetheless, these data must be
interpreted with considerable caution since this experiment was not successfully repeated,
nor was the experiment involving gene-gun administration of the NF-control carried out
successfully. Further experiments must be conducted to further define the activities of pGM-
CSF (and the effects of CpG motifs/vaccination trauma) on ALDC populations in vivo.
However, data obtained from this preliminary experiment are consistent with some
previously reported activities of recombinant GM-CSF and may therefore shed some light on
the in vivo activities of this cytokine and help to design future experiments.
4.7.1 Expression of surface molecules on ALDC after gene-gun
delivery of pGM-CSF
Several of the cell surface markers investigated in this preliminary study were upregulated
after gene-gun delivery of pGM-CSF. An increase in surface expression ofCDlb and CD1 lc
was particularly evident at all time-points investigated with the most pronounced increase
observed 5 days p/v. An increase in surface expression ofMHC class II by ALDC was also
apparent 24-48 hours after DNA vaccination. In addition, an increase in CD40 and CD86
was observed at days 1-2 and also at days 5-6 after administration of pGM-CSF, whereas
surface expression of LFA-3 was increased six days p/v. An upregulation of these molecules
would suggest that DC draining the skin after pGM-CSF administration are of a mature
phenotype and have enhanced accessory function in the lymph node.
GM-CSF is well documented to cause an increase in cell surface markers; for instance in
vitro exposure of isolated LC to GM-CSF results in upregulation of CD80, CD86 and CD40
(Salgado et al., 1999) and exposure of human monocytes and alveolar macrophages to
recombinant GM-CSF has been demonstrated to increase surface expression of CD 11c
(Rivier et al., 1994). There is also evidence from in vivo studies that GM-CSF increases the
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expression of a number of surface markers, which may explain the enhanced function of DC
after exposure to GM-CSF. Indeed preferentially expanded DC1 cells identified after in vivo
GM-CSF/IL-4 therapy were reported to express higher levels ofHLA-DR, CD1 lc and CD80
than pre-treatment DC (Kiertscher et al, 2003). Interestingly, an increase in CD Id was
reported on GM-CSF expanded DC in a study by Daro and colleagues (Daro et al, 2000) and
the authors concluded that this would enhance antigen presentation. Furthermore, an increase
in both CD Id and CD80 on expanded CD1 lc+ CD8a has also been reported by Mach and
colleagues after injection of murine tumour cells engineered to secrete GM-CSF (Mach et
al., 2000). With the exception of some CD80hl expressing ALDC 24 hours after pGM-CSF
administration, levels of CD80 expressed by ALDC remained unchanged throughout the
time-course in this study. Conversely, an increase in CD86 expression was observed and this
is of particular interest since CD86-CD28 interaction plays a critical role during the
activation of naive T cells. In addition, an upregulation of LFA-3 on ALDC would suggest
that interaction with T cells may be enhanced.
Upregulation of CD lb and MHC class II is suggestive of an enhanced antigen-presenting
activity of ALDC, providing a mechanism by which pGM-CSF could boost immune
responses. An increase in costimulatory marker expression would be anticipated to further
enhance the immune response. Upregulation ofCD1 lc was also observed in this experiment.
Importantly, CD1 lc is an integrin on DC, macrophages and neutrophils and is a member of a
family of surface glycoproteins that is essential for adhesion-dependent functions. CDllc
binds to cell-adhesion molecules and extracellular matrix (fibrinogen). It is possible that the
observed increase in the level of surface expression of CDllc may aid trafficking of DC to
the lymph node.
The STAT6 signalling pathway is constitutively activated in immature DC (iDC), whereas
STAT1 signalling is most robust in mature DC and optimal activation of STAT1 during DC
maturation requires both IL-4 and GM-CSF (Jackson et al., 2004). Analyses of STATU7" DC
reveal a role for STAT1 in repressing CD86 expression in pre-DC and up-regulating CD40
and CDllc expression in mature DC. It would be of interest to this study to evaluate the
effects ofpGM-CSF on STAT6 and STAT1 signalling pathways.
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4.7.2 Cytokine mRNA expression in purified SIRPa+ and SIRPa
ALDC populations after pGM-CSF delivery
A modest increase in IL-10 and IL-12p40 mRNA expression was observed in SIRPa+ and
SIRPa ALDC respectively, approximately 4 days after pGM-CSF administration. A further
increase in IL-12p40 was observed 6 days p/v. It was particularly interesting that IL-10
transcripts were detected at low levels in highly purified (>98%) SIRPa- ALDC 5 days after
gene-gun vaccination with pGM-CSF. Analysis of SIRPa- ALDC in the steady-state flux
showed that IL-10 was not expressed by this subset. Perhaps IL-10 is upregulated in SIRPa-
ALDC to dampen down proinflammatory cytokine production. It is also possible that this
induction of IL-10 in SIRPa- ALDC is responsible for the marked decrease in IL-12p40 in
this DC subset 5 days after pGM-CSF vaccination, since IL-10 downregulates IL-12
expression (Murphy et al., 1994). The observed increase in IL-12p40, IL-10 and TNF-a
transcripts in ALDC 4 days p/v with pGM-CSF may correspond to activated DC recruited
into the skin approximately 4 days after pGM-CSF administration. This is interesting since
no upregulation of surface MHC class II, CD40, CD80 or CD86 was observed 4 days p/v,
yet increased expression of these surface molecules was observed 5-6 days p/v. For future
studies, it would be of interest to remove biopsies and confirm the infiltration ofDC into the
skin by immunostaining in order to correlate the findings obtained with ALDC with the
kinetics of DC infiltration into the skin.
It is particularly interesting to note that mRNA expression of IL-ip was highly elevated in
SIRPa+ ALDC isolated 24 hours after pGM-CSF administration. From the earlier part of this
study (sections 4.3.6 and 4.4.1) and studies conducted by others (Adams et al, 1998; Howard
and Hope, 2000; Yirrell et al, 1991), it seems likely that SIRPa+ ALDC contain a subset of
migratory LC and that this highly elevated expression of 1L-1 [1 is due to activated LC
migrating to the lymph node as a consequence of inflammation in the skin (discussed in
chapter 3). Indeed, LC are the major source of IL-ip in murine skin (Heufler et al, 1992;
Schreiber et al, 1992). Although levels of IL-ip mRNA remained slightly elevated in both
ALDC subpopulations over the first four days p/v, transcripts were considerably lower in
SIRPa ALDC than in SIRPa+ ALDC at the 24 hour time-point. In addition, whilst an
increase in IL-ip transcripts was observed in SIRPa- ALDC, a pronounced difference
between the two populations was still evident as observed prior to administration of pGM-
CSF. TNF-a and IL-18 transcripts were also elevated in both ALDC populations at all time-
points investigated when compared to pre-vaccination levels. It is interesting to observe that
pGM-CSF administration does not appear to skew the cytokines produced by either DC
subset (with the possible exception of low-level IL-10 expression in SIRPa- ALDC 5 days
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p/v), but perhaps by activating these cells (by acting as a "danger signal"), expression of
these constitutively produced cytokines is enhanced.
In agreement with these findings, administration of recombinant GM-CSF in mice resulted in
increased production of IL-10 in murine myeloid DC, whereas IL-12p40 expression was
increased in the lymphoid DC subset (Parajuli et al, 2001). The increase in cytokine
production was however more pronounced in Parajuli's study; however, this could be due to
the route of administration, differences in the biological activities of GM-CSF or even the
concentration of GM-CSF. In the latter study, high concentrations of recombinant GM-CSF
were administered systemically to mice (6pg/kg/day ofGM-CSF). In this study, DNA coated
on bullets was quantified in each batch and ranged from 0.25-1.0pg of pGM-CSF per shot.
No assessment of the concentration of GM-CSF after gene-gun vaccination of ovine
fibroblasts was made in this study and so it is difficult to compare the findings. Turner and
colleagues reported that normal human skin fibroblasts transfected by the gene-gun produce
high levels of human recombinant GM-CSF (250ng/106 cells/24 hours) (Turner et al., 1998),
suggesting that gene-gun vaccination is an efficient method to deliver cytokine genes. GM-
CSF has been shown to inhibit IL-12 production of murine LC (Tada et al, 2000), but no
inhibition of IL-12p40 was evident in this nor in Pulendran's study.
Kiertscher and colleagues demonstrated a preferential expansion of myeloid HLA-
DR+/CDllc+ DC1 cells (IL-12 producing) after GM-CSF administration in humans
(Kiertscher et al, 2003) and argue that expansion of the DC1 subset may augment cell
mediated immune responses, where Thl polarisation is required. In this study, whilst an
increase in both SIRPa+ and SIRPcf ALDC was evident 4 days after vaccination with pGM-
CSF, (which is of interest since DC were previously identified in the skin at this time-point
(chapter 3)), SIRPa+ ALDC were still the predominant population. It would therefore be of
interest to determine the overall bias of the immune response and compare findings with
observations in humans and in mice.
4.7.3 Gene-gun vaccination with the NF-(GM-CSF)-control
It is necessary to determine to what extent the vaccination procedure itself and CpG motifs
contained in the plasmid are responsible for upregulation of surface markers on DC draining
from the skin. It was concluded from earlier work conducted (chapter 3), that pGM-CSF is
expressed in the skin within 2 hours after gene-gun administration (mRNA levels peaking at
4 hours p/v). It is interesting that surface expression of CD lb, MHC class II and CDllc was
increased (in comparison to pre-vaccination levels) on ALDC collected 24 hours p/v,
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suggesting that GM-CSF (and/or CpG motifs) causes maturation and migration of skin
resident cells such as LC and dermal DC. CpG sequences are present in plasmids and might
contribute to the immune response generated by DNA vaccination. Ban and co-workers
demonstrated that intradermal injection of lOpg of CpG-containing oligonucleotides into
murine skin induced the local depletion of LC within 2 hours of exposure. In addition, in
vitro unmethylated CpG motifs were found to directly activate splenocytes, monocytes,
macrophages and DC to secrete a variety of cytokines such as IFN, IL-ip, TNF-a, IL-18 and
IL-12 and activate B cells for IL-5 secretion and proliferation (Ban et al, 2000). Therefore it
was essential that gene-gun administration of the NF-control plasmid was carried out.
The only other animal, which remained patent after DNA vaccination was sheep JH6.
However, lymph volumes were low and the lymph contained both erythrocytes and PMN.
Due to time constraints, the NF-control was administered to this animal and lymph was
collected over 5 days. Gene-gun administration of pGM-CSF was then carried out on the
fifth day. No changes in cell surface markers were observed in ALDC obtained from the
control experiment or in the repeat of the pGM-CSF experiment. The data for this set of
experiments must be interpreted with caution. Lymph that contains blood is not normally
used for experiments, as this implies that surgical trauma has occurred, resulting in
conditions which would not reflect the physiological conditions and indeed such conditions
may cause activation of DC. Indeed, for all other experiments, lymph was analysed for PMN
and erythrocytes prior to usage. Heparin was used several times throughout the course of the
experiment and heparin itself is known to cause changes in DC. For instance, heparin
induces differentiation of CDla+ DC from monocytes and heparin-treatcd DC respond to
LPS or LPS plus IFN-y with higher IL-10 and less IL-12 production than heparin-untreated
DC (Xia and Kao, 2002). In addition, LC migration is modulated by N-sulphated
glucosamine moieties in heparin (O'Sullivan et al., 2000).
Further studies are therefore required to compare the adjuvant effects of pGM-CSF with the
effects of vector backbone DNA. These preliminary findings do, however, reveal the ability
ofpGM-CSF to enhance the function of DC in vivo and further studies using the cannulation
model should now be conducted.
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5 Final Discussion
One method to enhance the immunogenicity of DNA vaccines is to employ cytokines as
molecular adjuvants. Studies have shown that GM-CSF and IL-3 are implicated in DC
development/ontogeny and both cytokines have been documented to cause expansion of DC
with enhanced accessory function (Section 1.3.3.3). pGM-CSF has been extensively
investigated as a molecular adjuvant and shown to augment both CTL and antibody
responses in a number of animal models, whereas pIL-3 has received little attention. The
mechanisms by which pGM-CSF exerts its effects in vivo have not been fully characterised,
although recruitment and activation of DC have been demonstrated and are believed to be
responsible. Recent studies have demonstrated the remarkable flexibility of DC and that
inflammatory signals in the periphery (danger signals) may have important consequences in
terms of DC phenotype and function. GM-CSF is not only a growth factor of DC but is
thought to exert its adjuvant activity by causing inflammation, thus acting as a danger signal.
Understanding the inflammatory events in the skin after gene-gun administration of pGM-
CSF and pIL-3 may further our understanding of the adjuvant effects of these cytokines.
The initial experiments described in this thesis were designed to extend our knowledge of the
inflammatory response in the skin after administration of pGM-CSF and pIL-3 (chapter 3).
These experiments were aimed at determining when cells of the immune system were
recruited in relation to expression of plasmid DNA and proinflammatory cytokines (TNF-a,
IL-ip and IL-18), which are implicated in DC migration and maturation. Subsequent studies
involved further characterisation of DC draining from the skin using the pseudo-afferent
lymph model, in order to compare the phenotype of steady-state DC with those after
administration of a cytokine gene (chapter 4). This final chapter will attempt to bring
together the main findings of this thesis.
Both pGM-CSF and pIL-3 caused a severe inflammatory reaction in ovine skin,
characterised by the formation of large pustules by 24 hours, composed predominantly of
neutrophils. Whilst some infiltration of neutrophils was also apparent in NF-control
vaccinated skin, the inflammatory reaction was substantially less severe than those
associated with either pGM-CSF or pIL-3. Peak expression of GM-CSF and IL-3 transcripts
was observed approximately 4 hours after gene-gun vaccination which correlated with the
kinetics of neutrophil infiltration; pronounced trafficking of neutrophils was evident as early
as 2^1 hours p/v. Interestingly, IL-ip expression mirrored the pattern of IL-3 expression,
peaking at approximately 4 hours, yet remaining elevated up to 4 days p/v. TNF-a transcripts
were elevated in pIL-3 vaccinated skin from 24-96 hours. Infiltration of B cells was evident
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by 24 hours whereas eosinophils continued to traffic into the skin for up to 48 hours after
vaccination with pIL-3, consistent with known in vivo effects of this cytokine. B cell
infiltration was also evident in pGM-CSF vaccinated skin sections at later time-points (> 3-6
days).
Perhaps the most striking observation with regard to cytokine expression in the early study
was the highly pronounced increase in IL-ip transcripts after pGM-CSF administration,
where levels increased in a linear fashion over the first 24 hours and remained highly
elevated up to 4 days (200-300 fold higher than in normal skin). TNF-a mRNA expression
was also highly elevated from 1-4 days p/v. This is consistent with the hypothesis that GM-
CSF causes maturation and migration of DC by inducing the release of proinflammatory
cytokines (danger signals) from other cells. Interestingly, MHC class II+ DC entered the skin
at later time points; on average 4 days after gene-gun vaccination with pGM-CSF and 3-4
days after pIL-3 (where GFP had been removed from constructs), indicating that the
inflammatory milieu in the skin at these time-points is chemotactic for DC. Since TNF-a and
IL-ip transcripts were still elevated when DC entered the skin, it seems logical to assume
that infiltrating DC would be highly activated, responding as if an infection was taking place
within the skin, resulting in an increase in costimulatory molecules and antigen presentation
molecules.
From these studies it appears that both GM-CSF and IL-3 are first chemotactic for PMN
(predominantly neutrophils) and that GM-CSF (and to a lesser extent IL-3) induces IL-ip
mRNA expression in PMN, thereby amplifying the acute inflammatory response. It is a
plausible theory that defensins and other peptides pre-stored in PMN granules attract DC, in
agreement with the hypothesis that the release ofPMN granular peptides may link innate and
adaptive immunity (Yamashiro et al, 2001). Such "priming" of PMN by GM-CSF/IL-3 may
then induce the delayed expression of MCP-1, a signal for mononuclear cells (Rand et al,
1996). An analysis of the expression of IL-8 (an inflammatory cytokine produced by
neutrophils) in combination with the chemokines MCP-1 and CCR6, both of which are
highly chemotactic for DC, may well reveal more about the mechanisms by which GM-CSF
exerts its adjuvant effects.
An investigation into steady-state ALDC was next conducted. It seems likely that SIRPa
ALDC are comparable to the CD8a+ ("lymphoid") subset described in mice. Indeed CD8a+
DC express high levels of IL-12p40 (Maldonado-Lopez et al, 1999; Pulendran et al, 1999),
as described in bovine SIRPa ALDC (Howard et al, 2002; Stephens et al, 2003), rat splenic
SIRPa" ALDC (Voisine et al, 2002) and now in ovine SIRPa" ALDC. Interestingly, murine
CD8a+ DC have a unique ability to take up apoptotic cells and to cross present cytosolic
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antigens to CD8+ T cells (den Haan et al., 2000). CD8a+ DC have also been demonstrated to
be particularly efficient at inducing antigen-specific tolerance in vivo (Liu et al., 2002).
Similarly, apoptotic bodies have been observed in rat (Huang et al, 2000) and more recently
in ovine SIRPa ALDC (Epardaud et al., 2004) and a role in the maintenance of tolerance
has been proposed. Another feature shared by SIRPa ALDC and murine CD8a+ DC is the
large size and homogeneity of these cells, and the short half-life in vitro (Liu et al, 1998c;
Voisine et al, 2002). The TLR profile of ovine SIRPa- ALDC is also similar to that
described in CD8a+ DC, where both TLR3 and TLR9 are expressed, whereas TLR4
transcripts are absent. SIRPa ALDC may have an intrinsic ability to polarise naive CD4+ T
cells into Thl cells but also appear to have a role in the maintenance of tolerance in the
steady-state. The flexibility of murine DC subsets has been well demonstrated and whilst
CD8a+ DC have an intrinsic ability to polarise CD4+ T cells into Thl cells, this capacity can
be overridden by microbial signals (Section 1.4.4.2). Whether exogenous
(microbial/inflammatory) signals can skew the cytokine profde of SIRPa- ALDC remains to
be determined and would be a logical step to take.
SIRPa+ ALDC are indeed a heterogeneous population of DC and it is this population which
appears to contain a subset of migratory LC, since a fraction of ovine SIRPa+ ALDC are
ATPase+ and langerin transcripts appear to be uniquely expressed in this subset. These
findings are also in agreement with previous studies; bovine SIRPa+ ALDC contain a
population of acetylcholinesterase positive cells (Howard and Hope, 2000; Yirrell et al,
1991) and SIRPa+ cells have been detected in the epidermis by immunohistochemistry
(Adams et al, 1998). In this study, purified ovine SIRPa+ ALDC uniquely expressed TLR4
mRNA and CD 14. These findings bear similarities with those described with murine LC;
TLR4 is expressed by murine LC (Mitsui et al, 2004) and interestingly, dermal resident
CD14 ' cells differentiate into LC, suggesting that migratory LC may continue to express low
surface CD 14 (Larregina et al, 2001a)). LC are known to produce constitutively and/or
inducibly, a variety of cytokines including IL-1 fi, IL-6, IL-12, IL-15 and IL-18 (Kimber et al,
2000), indeed murine LC are the major source of mRNA for IL-ip among unstimulated
epidermal cells (Cumberbatch et al, 1996), which is also in line with the high constitutive
expression of IL-1 p by SIRPa+ ALDC in this study. Notably, IL-10 transcripts were only
detected in SIRPa+ ALDC (in the steady-state flux). It is possible that the SIRPa+ ALDC, or
indeed cells within this population have an anti-inflammatory role as has been proposed by
Howard and co-workers (Howard et al, 2002). This is an attractive theory since SIRPa+
ALDC constitutively express high levels ofproinflammatory IL-ip and IL-18.
It seems unlikely that either population is the equivalent of the pDC found in humans and
more recently identified in mice (Asselin-Paturel et al., 2001; Nakano et al., 2001), although
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high expression of CD45RA by SIRPa ALDC is a characteristic of pDC (Liu et al, 2001).
Howard and colleagues did not however detect IFN-a/p transcripts in either population, and
suggest that neither SIRPa+ nor SIRPa ALDC are equivalent to the pDC (Howard et al,
2002; Stephens et al, 2003), which is in accord with the finding that pDC circulate in the
blood and enter the lymph nodes from the blood via the high endothelial venules (Cella et
al., 1999) and would not therefore be present in lymph. Both ALDC subsets are likely to be
derived from a myeloid progenitor, based on the myeloid-like morphology and the lack of
lymphoid-related markers. Furthermore, SIRPa is a myeloid-restricted antigen (Adams et al,
1998).
The latter part of this study partly addressed the effects of pGM-CSF on DC draining from
the vaccination site. The number of leukocytes in afferent lymph increased over the first 48
hours, consistent with an acute inflammatory reaction in the skin. Furthermore, a pronounced
upregulation of surface antigen presentation molecules (CDlb and MHC class Ila),
costimulatory molecules (CD40 and CD86) and accessory molecules, CD lie and LFA-3
was observed on ALDC draining from the vaccination area at various time-points. Notably,
CD lb and CD lie were upregulated at all time points investigated. Interestingly, an increase
in surface expression of MHC class II, CD40 and CD86 was observed at earlier time-points
(24-48 hours) and this is likely due to the activation of resident DC within the first 24 hours,
possibly due to increased expression of IL-ip and TNF-a. Upregulation of surface CD40 and
CD86 was again observed 5 days p/v, coinciding with the most pronounced increase in
surface CD lb and CDllc expression. A second "wave" of upregulation of surface markers
may correspond to DC which have infiltrated the skin (approximately 4 days p/v) and which
are activated by the highly elevated levels of IL-ip and TNF-a in the skin. Upregulation of
surface markers would suggest that DC draining the skin after pGM-CSF administration are
of a mature phenotype and have enhanced accessory function in the lymph node.
As observed by others (Section 1.3.3.3), pGM-CSF does not appear to skew the cytokine
profiles of DC subsets but rather augments cytokine production. At 4 and 6 days p/v,
increased IL-10 and IL-12p40 expression was observed in SIRPa+ and SIRPa" ALDC,
respectively. Expression of TNF-a and IL-18 mRNA was also elevated in both ALDC
populations at all time-points investigated, suggesting that both populations were activated
by pGM-CSF and/or the gene-gun procedure itself. The observed increase in IL-12p40, IL-
10 and TNF-a transcripts in ALDC 4 days after vaccination with pGM-CSF may correspond
to activated DC recruited into the skin at this time-point. Conversely, IL-1 p transcripts were
highly elevated in SIRPa+ ALDC isolated 24 hours after pGM-CSF administration and
declined from there on. Such highly elevated IL-1 p expression may be due to activation of
resident LC collected in the first 24 hours after pGM-CSF vaccination, as SIRPa"1" ALDC
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appear to contain migratory LC. Since DNA vaccination on other cannulated animals was
unsuccessful, the role of CpG and the gene-gun procedure in the activation of DC is not
known. Increased IL-ip and TNF-a transcripts were documented up to 72 hours after
administration of the NF-control, and may also result in activation and migration of resident
DC such as LC; however, an infiltration of DC was not observed 3-4 days after vaccination
with control plasmids in the previous studies and so it seems somewhat unlikely that the
observed upregulation of surface markers observed 5 days p/v and the increase in cytokine
expression (days 4 and 6) was entirely due to administration of plasmid DNA and/or the
gene gun bombardment procedure.
5.1 Future work
Future work should focus on further defining the cytokine and chemokine milieu at the time
that DC infiltrate the skin after pGM-CSF/pIL-3 administration. In particular other
proinflammatory cytokines, such as IL-6 and IL-8 should be investigated in relationship to
the expression of the DC-chemotactic chemokines, MCP-1 and CCR6. The kinetics of DC
infiltration needs to be more closely addressed in order to ascertain when SIRPa+ and
SIRPof DC are recruited into the skin and/or if there is proliferation of resident DC
population(s) within the skin. This could be achieved by quantification of double
immunolabelled DC (SIRPof and MHC class II) in conjunction with ATPase staining at
various time-points p/v. Proliferation of DC could also be addressed using immunostaining
in combination with a mAb to proliferating cell nuclear antigen (PCNA). Infiltration of B
cells after pIL-3 administration (and to a lesser extent with pGM-CSF), necessitates further
investigation. DNA vaccine-induced antibody responses in outbred species have been
problematic and the ability of IL-3 to recruit B cells may therefore be advantageous. Whilst
DC are required to activate Th2 cells which ultimately induce secretion of antibody by B
cells, perhaps creating an environment where both B cells and DC are exposed to the vaccine
encoded antigen may induce a more effective antibody response. Indeed, it has been
proposed that binding of CpG motifs through TLR9 on B cells may initiate or amplify early
T cell-independent IgG responses (He et al., 2004). The adjuvant effects of pIL-3 therefore
merit closer attention.
The cannulation model provides an excellent system in which to investigate the way in
which DC respond to various stimuli including the effects of molecular adjuvants. From the
preliminary work involving DNA vaccination of cannulatcd sheep with pGM-CSF, it
appeared that the cytokine profiles were augmented, rather than skewed with pGM-CSF,
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although activation of DC by CpG motifs could be responsible for enhanced cytokine
induction, since both populations express TLR9 and increased expression of
proinflammatory cytokines was evident in NF-control vaccinated skin. It would be extremely
valuable (and a rational approach to vaccine design) to determine the extent of plasticity of
these DC subpopulations. This could be achieved by isolating SIRPa+ and SIRPa ALDC
populations after in vivo exposure to microbial stimuli. Since, both populations express
TLR3 and TLR9, it remains to be determined if both populations respond "equally" by
expressing the same cytokine profiles if exposed to microbial stimuli alone. For instance, do
SIRPa+ ALDC respond by producing more Thl-biasing IL-12p40 after exposure to dsRNA
(poly I: C)?
The in vivo effects of pGM-CSF and pIL-3 on ALDC require further study. It is imperative
that gene-gun vaccination with NF-control plasmids is carried out to assess the effects of
administration of CpG motifs and/or the gene-gun procedure on DC draining the skin. It
would also be of interest to remove biopsies and confirm DC infiltration by immunostaining,
in order to correlate the findings obtained with ALDC with the kinetics of DC infiltration
into the skin after pGM-CSF/pIL-3 vaccination. Increased surface expression of several
surface markers on ALDC, including CD1, and CD11c was evident in this study; however,
no comparison of ALDC subsets was carried out. It would be particularly valuable to
ascertain if upregulation of cell surface markers is evident in both subpopulations. In
particular, ascertaining which costimulatory molecules are expressed by each DC subset
after administration of pGM-CSF/pIL-3 is vital, as a lack of costimulatory molecules can
ultimately lead to tolerance to the DNA vaccine encoded antigen (Steinman and
Nussenzweig, 2002).
It would be particularly valuable to investigate the functional capacity of each ALDC subset
in allogeneic reactions in vitro before and after DNA vaccination with pGM-CSF/pIL-3. The
stimulatory capacity of both ALDC subsets has been investigated in both rats (Liu et al,
1998c) and in cattle (Howard et al, 1997) and both studies revealed that the SIRPa+ ALDC
possessed superior immunostimulatory capacity compared to SIRPa ALDC. It would be
fascinating to study the responses after administration of pGM-CSF and to assess if SIRPa
ALDC have enhanced immunostimulatory capacity in comparison to those isolated from the
steady-state flux. Whilst it appears from this preliminary study and others that GM-CSF does
not skew the cytokine production produced by DC subsets, it would be of interest to
determine cytokine expression in allogeneic CD4+ T cells after in vitro stimulation with
freshly isolated ALDC before and after pGM-CSF administration. Cytokine profiles of CD4+
and CD8+ T cells isolated from afferent lymph before and after pGM-CSF vaccination would
also be particularly valuable. Knowing which DC subset has enhanced accessory function
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(upregulated antigen presentation and costimulatory molecules) and knowledge of the Th
polarising capacity of each subset could provide a basis for selective targeting of DC in vivo
after DNA vaccination with pGM-CSF.
It would also be of interest to determine if pIL-3 and pGM-CSF enhance uptake and
presentation of antigen in vivo as has been suggested by other studies (Section 1.3.3.3).
Gene-gun vaccination does not result in long lived expression of the encoded "antigen",
although in this study the fact that cytokines rather than a foreign antigen were investigated
complicates matters, since GM-CSF is constitutively expressed in the skin. In this study,
peak expression of both cytokines occurred at approximately 4 hours p/v and levels
thereafter declined and were only just detectable up to 96 hours. While further
characterisation of the cytokine and chemokine milieu is necessary, studies must also focus
on the kinetics of antigen (protein) expression. If little antigen is available for DC uptake, or
peak antigen expression has occurred, DC may well become activated and capable of
stimulating T cells, but may not actually be presenting the target antigen. Ensuring that
plasmid DNA is expressed in sufficient quantities until maximal DC infiltration ensues may
be pivotal in the optimisation ofDNA vaccines. Since the "antigen-producing factories" after
gene-gun vaccination are predominantly keratinocytes and (to a lesser extent) fibroblasts
(Section 1.2.1), ensuring antigen expression may be difficult since sloughing of the skin is
inevitable by 4 days when maximal infiltration of DC occurs with pGM-CSF. Perhaps
studies should focus on administering GM-CSF and administering a second antigen-
encoding plasmid when DC infiltration takes place, therefore maximising direct transfection
of infiltrating DC and resident LC/dermal DC. Using plasmids which promote apoptosis of
transfected keratinocytes and fibroblasts may also increase the opportunity for DC to acquire
antigen in the periphery, where the presence of danger signals will promote stimulatory DC
rather than tolerogenic DC.
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Appendix I Composition of solutions
15% acrylamide resolving gel
4.0ml of resolving gel buffer (1.5M Tris-HCl, pH 8.8, 0.4% SDS), 8ml of 30%
acrylamide/Bis solution 29:1 (Biorad) 4ml of dH20 and polymerised by adding lOOpl of 10%
ammonium persulphate and lOpl ofTEMED.
4% acrylamide stacking gel
1.25ml stacking gel buffer (0.5M Tris-HCl, pH 6.8, 0.4% SDS), 0.8ml 30% acrylamide/Bis
29:1 solution, 4ml dH20. Add 25pi of 10% ammonium persulphate and 10pi TEMED, to
polymerise.
Carbonate buffer
0.1M Na2CO3.10H2O, 0.1M NaHC03, pH 9.6.
Double strength sample buffer
4% SDS, 20% glycerol, 0.01% Bromophenol Blue and 10% 2-ME in 124mM Tris-HCl, pH
6.8.
LB media
1% bacto-tryptone, 0.5% bacto-yeast extract and 0.5% sodium chloride, pH 7.0.
PBS
137mM NaCl, 27mM KC1, 8mM Na2HP04, 15mM KH2P04, pH 7.2.
10 x running buffer
25mM Tris, 190mM glycine, 0.1% SDS, pH 8.3.
SOC media
20g/l bacto-tryptone, 5g/l bacto-yeast, 0.5g/l NaCl, 2.5mM KC1, 25mM MgCl2 and 50mM
glucose).
TAE buffer (Tris-acetate-EDTA)
40 mM Tris, 0.114% glacial acetic acid, 1 mM EDTA
357
TBS (Tris-buffered saline)
0.05M Tris HC1, 0.15M NaCl, pH 7.2-7.6.
lOx TE buffer (Tris-EDTA)
lOmM Tris-Cl, pH 8.0, ImM EDTA, pH 8.0.
Transfer buffer
48mM Tris, 39mM glycine, 0.037% (w/v) SDS, 20% methanol.
ZSF (Zinc Salts Fixative)









Bio-Rad Hemel Hempstead, UK




GraphPad Software San Diego, California, USA
Invitrogen Life Technologies Paisley, UK
Menzel-Glaser Braunschweig, Germany
MWG biotech Milton Keynes, UK
New England Biolabs Hitchin, UK







Ultraviolet Products Cambridge, UK
Vector Laboratories Peterborough, UK
Zymed Laboratories Inc. Cambridge, UK
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Appendix III pGEM®-T Easy clones














MINIM 11111111111 11111111111 111111111111111111111111111
2192 atccaggagggtttccacaaaagccgtaaggttattgtcgtggtgtcccagcacttcatc
149 cagagccgatggtgtatcttcgagtacgagattgcccagacctqqcaqtttctqaqcaqc
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I II I I I I I I I I I I
2252 cagagccgatggtgtatcttcgagtatgagattgcccagacctggcagtttctgagcagc
209 cgtgctggcatcatcttcatcgtcctgcagaagctqqaqaaqtctctcctqcqqcaqcaq
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I II I I I I I I I I II
2312 cgtgctggcatcatcttcatcgtcctgcagaagctggagaagtctctcctgcggcagcag
269 ttgagaagctcatatcgccttcatgaacaggaacacctacctqqaatqqqa
I I Mill 1111111111 III 1111II111111111111 Mill
2372 --gtggagctc-tatcgccttc-tgagcaggaacacctacctggagtggga
Aligned with human TLR4 mRNA (BC025294; 90% homology)
Clone: 29 tttcacctctgccttcactacagggactttattcctggggtggccatcgccgccaatatc
Mill 11111111111111III 11111111111 II 11IIII11 II Mill III
Human: 2024 tttcagctctgccttcactacagagactttattcccggtgtggccattgctgccaacatc
89 atccaggaaggtttccacaagagccgtaaggtgattgtcgtggtgtcccagcacttcatc
Mill 11111II1111 II Mill 11111111111 111111111111111111III
2084 atccatgaaggtttccataaaagccgaaaggtgattgttgtggtgtcccagcacttcatc
149 cagagccgatggtgtatcttcgagtacgagattgcccagacctggcagtttctgagcagc
I I I I I I I I I I I I I I I II I I II II I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I
2144 cagagccgctggtgtatctttgaatatgagattgctcagacctggcagtttctgagcagt
209 cgtgctggcatcatcttcatcgtcctgcagaagctggagaag









Aligned with ovine TLR9 (NM 001011555; 98% homology)
Clone: 19 tgctgtcctacaaccacattatcaccctggcacccgaggacctggccaatctgactgccc
Ml 11 Mill III I Mil II1111111111111111111111111II111111 M 111
Ovine: 765 tgctgtcctacaaccacatcatcaccctggcacccgaggacctggccaatctgactgccc
79 tgcgtgtgcttggtgtgggcgggaactgccqccgctgcgaccacgcccgcaacccctgca
llllllllllll IIIMM Ml Mill III Mill MM Mill Mill Mill 11III
825 tgcgtgtgcttgatgtgggcgggaactgccgccgctgcgaccacgcccgcaacccctgca
139 gggagtgcccaaagaacttccccaagctgcaccctgacaccttcagccacctgagccgcc
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I
885 gggagtgcccaaagaacttccccaagctgcaccctgacaccttcagccacctgagccgcc
199 tcgaaggcctggtgttgaaggacagttctctctacaaactagagaaagattggttccgc
lilllill Mil I Mil III IIMIIIIMI111 III I Ml I Mill! 111111111
945 tcgaaggcctggtgttgaaggacagttctctctacaaactagagaaagactggttccgc








Aligned with bovine CD207 (predicted—XM_588243; 94% homology)
Clone: 19 gtggacaacatcagctccctgagttctgagatcaagaggaacagaggtgccctggtgqca
I I I I I II I I I I I I I I I I I I I I I II I I I I I I II II I I I I I I I I I I I I I I I I I I I I I I I I I
Bovine: 469 gtggacaacatcagctccctgagttctgagatcaagaggaacagaggtggcctggtggca
79 gtgggctttcaggtccggatggtgaatgccagcttgggccgcataaqctctcaqatccqq
I! Ill lllllllllllllllllll 1111111111 II11II11 111111111111
529 gttggcattcaggtccggatggtgaacgccagcttggatcgcataagttctcagatccgg
139 aggttggaaacaggcttgaaggaagccagtgcgcagctgcatgtgctaacaagtagttgg







I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I II II I II I II I I I I II I II
709 agtgctttaaatgcaaaggtccgggaactccagagtggtttggagagtatcagcaaatt-
319 gcttcaacagcaaaatgacattctccaggtggtttctcaaggctggaagtacttcagggg
I I I I I I I I I I I I I I I I I II II I M I II I I II I II I I I I I I I I I I I I I I I I I I I Mil
768 gcttcaacagcaaaaggacattctccaggtggtttcccaaggctggaagtacttcggggg
379 gcacttctattacttttctcaaatctcaaagacctggtatagtgcc
111II11111II11II111 lllllll lllllllllll hiii
828 gcacttctattacttttctaaaatctcgaagacctggtacagtgcc
Aligned with human CD207 (AJ242859; 85% homology)
Clone: 185 taacaagtagttgggaagcagtcgatgagttaaatgcccaaatcccagggctaaaacaag
lllllll llllllllll Mil I 11II1111II1111 III11 I Mill I
Human: 466 taacaagaagttgggaagaagtcagtaccttaaatgcccaaatcccagagttaaaaagtg
245 atttggataaagccagtgctttaaatgcgaaggtccgggaactccagagcggtttggaga
lllllll llllllllllllllllll I III llllll lllllll II I lllllll
526 atttggagaaagccagtgctttaaatacaaagatccgggcactccagggcagcttggaga
305 gtatcagcaaattcgcttcaacagcaaaatgacattctccaggtggtttctcaaggctgg
III Mill II III III 11111111 Mill III111111111111111111
586 atatgagcaagtt-gctcaaacgacaaaatgatattctacaggtggtttctcaaggctgg
365 aagtacttcagggggcacttctattacttttctcaaatctcaaagacctggtatagtgcc
I I I I I I I I I I MM I I I I I I I I I I I II I I I I I II I I I I I I I I I I I I I I I I I I I I
645 aagtacttcaaggggaacttctattacttttctctcattccaaagacctggtatagtgcc
Verification of quantitative RT-PCR standards
NB: pGEM®-T Easy sequences are highlighted in red; primer sequences are highlighted in
green (see Table 2.11).



































IL-3: 98% identity with ovine IL-3 (Z18897.1)
(Original primers used, Table 2.11)
ATATGGTCGACCTGCAGGCGGCCGCGAATTCACTAGTGATTTGAAGTCTGAAGCCCAGTTCCCTCTCTGAAGCCTC
AGATCATCAGTGACAACAAACTGTCCTAAATTTCTTCGATGTTTCTCACATGGTCCAGGCCTGGAAGAATTAATTT
TCTCCTGTGGAGCCAGATGAATCGTTAATTATTTAACTCCTGATATGTGTGGCCCCCATTTGTCCTTTTGGGATTA
TGTTCTCATTTTTAATCTATTGAGACTTATTTATTTATGTATGTATTTATTTATTACCTTGTGCAAATGTGAAGGG
TATTTATTTTAGCAGGGGAGTCATGTTCTGCTCCTTCTGGACAAAACTTAAGATGGGGACTTGGGAATAATCGAAT
TCCCGCGGCCGCCATGGCGG
363
